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Abstract 
Medication misadventure has been extensively studied in adults, but has not been 
well characterised in children – in particular vulnerable children with cancer.  To 
date, little is known about medication misadventure in paediatrics and the role of 
pharmacists’ interventions in minimising the misadventure in this area. This study 
consists of four parts, aiming to evaluate the role of pharmacists’ interventions in 
minimising the occurrence of medication misadventure in children including those 
with cancer, the clinical significance of pharmacists’ active interventions (i.e. 
interventions leading to changes in drug therapy) and the involvement of medication 
misadventure detected through the active interventions, and contributing factors and 
preventive strategies relating to medication misadventure, particularly medication 
error,  in this population.  
The study was undertaken in a children’s hospital in Perth, Australia. Part One was a 
prospective study to document ward-based pharmacists’ interventions through direct 
observation by principal researcher on five study wards (General Medical Ward for 
Infants, General Medical Ward for Young Children, General Medical Ward for 
Adolescents, General Surgical Ward and the Haematology-Oncology Ward) 
representing three clinical units (general medicine, general surgery, haematology-
oncology). Pharmacists’ interventions during dispensing in the Haematology-
Oncology Pharmacy were also observed by the principal researcher and documented 
over 33 days. Part One was conducted from September 2011 through August 2012. 
The predictors for physicians’ acceptance of ward-based pharmacists’ active 
interventions were identified using multivariate logistic regression. A total of 982 
interventions were documented, related to the 16,700 medication orders reviewed on 
the five wards in the three clinical units over 35-37 non-consecutive days on each 
ward. Taking medication histories and/or patient counselling were the most common 
pharmacists’ interventions in the general settings, (n=453/787, 57.6% of all 
interventions). In contrast, on the Haematology-Oncology Ward, the data revealed 
drug therapy changes as the most common interventions (n=73/195, 37.4% of all 
interventions). Active interventions constituted less than one-quarter of all 
interventions on the general medical and surgical wards, compared to nearly half on 
the specialty Haematology-Oncology Ward. Dose adjustment was the most frequent 
active interventions in the general settings, whilst drug addition constituted the most 
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common active interventions on the Hematology-Oncology Ward. The degree of 
acceptance of pharmacists’ active interventions by physicians was high (n=223/244, 
91.4%). With respect to interventions during dispensing, a total of 359 interventions 
were performed from the 1791 medication orders reviewed and dispensed by the 
pharmacists. The rates of intervention were 21.29 per 100 medication orders 
reviewed, and 35.18 per 100 patients. Amongst these interventions, less than 10% 
were classified as ‘active’ interventions, but all of the active interventions were 
accepted by the physicians. Drug information-related consultation by pharmacists 
was the most common intervention, constituting more than three-quarters of all 
interventions. With regard to the predictors of physicians’ acceptance of ward-based 
pharmacists’ active interventions, three significant variables were identified: 
patients’ age (OR = 0.89; 95%CI 0.81, 0.98), non-high-risk medication category (OR 
= 2.80; 95% CI 1.09, 7.17), and pharmacists’ experience (OR = 1.11; 95%CI 1.03, 
1.20). This body of research supports the role of pharmacists in optimising patient 
care in a range of paediatric settings, through their active interventions either during 
pharmacy rounds or dispensing. Direct observation offers the alternative approach 
for measuring the rate and pattern of pharmacists’ interventions. 
Part Two of the study involved expert panel assessment of a sample of randomly-
selected pharmacists’ active interventions data from Part One to determine the 
clinical significance of the interventions; to identify and categorise medication 
misadventure; and to classify medication misadventure involving medication error 
according to the type of error and the severity of their consequences. A random 
sample of 42 cases (15.8%) was selected from 266 pharmacists’ active interventions 
(244 interventions during pharmacy ward rounds on the five study wards, 
supplemented by 22 interventions documented during dispensing in the 
Haematology-Oncology Pharmacy). Panel 1 consisted of two researchers and three 
independent panellists (hospital pharmacist, academic pharmacist, clinical nurse), 
and its assessment was undertaken in March-June 2013. Panel 2 consisted of the two 
researchers and two independent panellists (medication safety pharmacist, paediatric 
oncology pharmacist) and was set up in July 2014 as Panel 1 could not reach 
consensus. For the clinical significance assessment, the rating system modified by 
Dooley et al. was used, whilst the assessment of the type and severity of medication 
error were conducted using the National Coordinating Council for Medication Error 
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Reporting and Prevention Taxonomy. The most common clinical significance rating 
of the active interventions assessed by Panel 1 was ‘moderate’. Meanwhile, the 
majority (n=37/42, 88.1%) of the active interventions were deemed by Panel 2 to be 
clinically significant; although no intervention was classified as life-saving. The 
strength of agreement between all reviewers of Panel 1 was “fair” (α =0.321) 
regarding the presence of medication misadventure, and “fair” (α =0.222) regarding 
the category of medication misadventure. “Fair” agreement (α =0.351) was also 
noted when classifying the type of medication error, with “slight” agreement (α 
=0.154) for the error severity. Part Two of this study provided data supporting the 
clinical significance of the interventions documented in Part One. “Fair” agreement 
between interdisciplinary reviewers regarding the assessment of medication 
misadventure is consistent with published literature; as such, this indicates support 
by other healthcare professionals for the contribution of clinical pharmacists in 
reducing medication misadventure.  
Part Three was a retrospective study to analyse data from pharmacist interventions 
from short-term (‘snapshot’) 2009-2010 self-reports in the study hospital. 
Intervention data were compared with interventions documented during direct 
observation (Part One) to examine the pattern and representativeness of short-term 
documentation as opposed to continuous documentation using observation. 
Subsequently, a focus group discussion involving eight hospital pharmacists was 
conducted in July 2013 to gather pharmacists’ opinions on the utility of the 
alternative documentation methods. A total of 398 interventions were documented by 
pharmacists during three snapshot reporting periods, with ‘clarification of medication 
orders’ being the commonest type of intervention. The overall rate of pharmacists’ 
interventions documented during direct observation was not significantly different to 
that of the snapshots (p=0.054). However, the rate of active interventions was 
significantly higher (p=0.002) during direct observation. During the focus group 
discussion, participants reported that the snapshot reports were an inadequate 
representation of pharmacists’ clinical activities. ‘Snapshot’ data may underestimate 
the impact of pharmacists’ interventions in minimising medication misadventure 
amongst paediatric inpatients. 
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Part Four applied root cause analysis to five simulated clinical case scenarios 
involving medication errors in children. The root cause analysis was undertaken via a 
self-administered questionnaire disseminated to doctors, nurses and pharmacists at 
the study hospital in order to determine the clinical significance of the medication 
errors, the responsible health care professionals, the contributing factors and the 
preventive strategies. In addition, general estimating equation analysis was 
conducted to develop an agreement model between the participants and the principal 
researcher regarding the contributing factors. Of 111 questionnaires administered 
during the study period (August-October 2014), 25 (22.5%) were returned and 
analysed. The majority of the participants rated the medication errors involved in the 
five cases ranged from ‘moderate’ to ‘life-threatening’. In relation to the factors 
contributing to the errors, the participants’ perceptions varied across the five cases. 
However, the majority of the participants identified two major contributing factors in 
all cases: dismissal of policies/procedures or guidelines and human resources issues. 
The most frequently cited strategies in this study included improved availability and 
accessibility of hospital policies/procedures or clinical guidelines for medication use, 
adequate staffing and supervision, adequate staff education and training, and 
improved communication either between staff or between staff and patient/family. 
There were varied agreement patterns across the contributing factors. This analysis 
confirmed the findings of the previous studies regarding the contributing factors and 
strategies to prevent medication error. Pharmacists, through their clinical services, 
were again central to prevention of medication error. 
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Chapter 1 
BACKGROUND 
In this chapter information is provided on pharmacists’ interventions to minimise 
medication misadventure in children with cancer. The discussion is supported by an 
in-depth literature review on medication safety terms; the incidence and 
consequences of medication misadventure; the causes of medication misadventure; 
the risk factors of misadventure in children; pharmacists’ interventions in minimising 
medication misadventure ; and the clinical significance and economic implications of 
pharmacists’ interventions. Also discussed is the role of root-cause analysis (RCA) 
as a comprehensive and systematic approach to identify systems failure. 
Healthcare delivery involves a sequence of steps, which starts with diagnosing a 
patient’s condition through to monitoring treatment. To minimise the occurrence of 
medication misadventure during treatment, these steps need to be conducted in an 
effective, safe and timely manner. It is common for patients admitted to hospital to 
receive multiple medications; each medication administered carries the risk of 
misadventure or error.(1) According to a report from the Institute of Medicine in the 
USA, errors occurring during healthcare delivery are the major causes of morbidity 
and mortality.(2) An estimated 44,000 to 98,000 deaths in the USA were attributed to 
these errors and medication-related errors were a significant proportion. This has 
significant implications on healthcare expenditure.(2) The report also highlighted 
that patient safety should be at the forefront of medication use. In Australia, 
medication misadventure is a significant burden on the health system and accounts 
for 2.4% to 3.6% of all hospital admissions in general patients. Up to 69% of these 
medication-related admissions are potentially preventable.(3) As a consequence, 
medication misadventure may impact on community confidence in the health system 
and increase healthcare costs.(3, 4)  
To date, most investigations of adverse events related to medication use have been 
undertaken in adults. Despite the evidence that such events may be more common in 
children, there is a dearth of data on error-related events in this population.(5) The 
epidemiological characteristics of medication errors (MEs) may be different between 
children and adults.(6) Children have a unique physiology and an immature ability to 
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metabolise drugs.(7, 8) The consequences of MEs have significant ramifications in 
children with complicated medical conditions such as cancer.(9-11) Children with 
cancer receive diagnosis-specific antineoplastic drugs with narrow therapeutic 
indexes that require complex administration regimens.(7, 8) The risks associated 
with medication misadventures in paediatric oncology warrant further research. 
Besides inadequate and inconclusive information on medication misadventure in the 
paediatric population, there has been concern about the lack of strategies to minimise 
errors and maximise care in the ambulatory and inpatient settings.(12) Multiple 
studies have analysed error-prevention strategies utilising clinical pharmacists.(13-
15) Several reports have shown that ward-based clinical pharmacists reduce 
MEs.(15-17) The largest studies of clinical pharmacists’ interventions in acute care 
in Australia have demonstrated that interventions initiated and undertaken by clinical 
pharmacists have a significant positive impact on patient outcomes and hospital 
costs.(3, 18) However, the impact of clinical pharmacists in minimising medication 
misadventures in paediatric oncology has yet to be justified.  
Another concern that health services continue to face is the lack of utility of the 
medication misadventure data to support system improvement. To promote safer 
health services, systems need to identify and learn from previous incidents of 
medication misadventure.(12) The most effective way of system improvement is to 
ascertain the underlying causes of the misadventures through a well-structured 
investigation utilising RCA.(19) RCA has been implemented in many high-risk 
environments such as aviation. When applied to health systems, it is used to 
investigate retrospectively all the subsets of medication misadventures, e.g. adverse 
drug events (ADEs), adverse drug reactions (ADRs) and ‘near misses’.(19) A key 
feature of RCA is its comprehensive and systematic examination of multi-level 
factors that lead to the negative outcome of interest, e.g. medication misadventure. 
RCA has been designed to produce strategies to improve the system, not individual 
performance, and to prevent recurrence of the events.(20, 21) 
1.1 Medication Safety Terms 
Many countries have made medication safety a priority.(22-25) The 
terminology/definition used to describe medication-related events and/or medication-
related harm continue to be debated and create confusion among health professionals 
3 
and researchers.(26, 27) As patient safety initiatives are strengthened and reporting 
systems are embedded into practice, a universal definition of what constitutes 
medication-related events is imperative.(10) A universal terminology/definition for 
medication safety would: encourage research; allow comparison of medication-
related events; prevent medication misadventure; and improve patient safety.(10, 28)  
According to Manasse(29) medication misadventure is: ‘any iatrogenic hazard or 
incident associated with drug therapy’. Manasse(29) also specifies the criteria for a 
hazard or incident, i.e. events: ‘created through either omission or commission by the 
administration of a drug or drugs during which a patient is harmed, with effects 
ranging from mild discomfort to fatality; events attributable to error, immunologic 
response, or idiosyncratic response; and events where the outcome may or may not 
be independent of the pre-existing pathology or disease process’. The American 
Society of Health-System Pharmacists and researchers have adopted this definition 
of medication safety.(4, 11, 27, 30) Under the broad definition of medication 
misadventure there are three subtypes of medication safety: ADE, ADR and ME.(28) 
ADE and ME are overlapping subsets of medication misadventure. The relationship 
between these three subsets of medication misadventure is illustrated in Figure 1.1.  
 
Figure 1.1 Relationship between adverse drug event, adverse drug reaction and 
medication error(28) (Reproduced with permission.) 
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ADE accounts for the largest category of adverse events in patient safety.(31) An 
ADE is: ‘an injury resulting from a medication or lack of an intended 
medication’.(27, 32) For example, if an event resulted in patient injury it would be 
classified an ADE, which can be further subclassified based on its preventability 
(preventable and non-preventable).(28, 33) An ADE may or may not result from 
MEs (error versus non-error). ADEs that do not result from MEs are considered non-
preventable ADEs or ADRs. An example of an ADR is when a patient without a 
known history of allergy to penicillin develops an anaphylactic reaction immediately 
after receiving Timentin (ticarcillin + clavulanic acid). According to Bates et al.(34), 
the majority of ADEs due to MEs are predictable and preventable. Some instances of 
preventable ADEs due to MEs include administration of the wrong drug to the right 
patient, the right drug to the wrong patient, or the wrong route of administration. 
Bates et al.(32) have proposed a practical and straightforward definition of an ADE: 
‘an injury occurring due to medical intervention associated with medication use. The 
adverse event could include injury resulting from MEs and ADRs that happen 
without involving any errors’.(32) 
According to the National Coordinating Council for Medication Error Reporting and 
Prevention (NCCMERP) an ME is: ‘any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control of 
the health professional, patient or consumer’.(35) The Institute of Medicine defines 
MEs as: ‘particular types of errors in which the occurrence of events can be 
prevented and is likely to happen at any stage of medication use process’.(27)  
MEs are not merely the result of less competent individuals but due to failure in: 
drug distribution; systems mismanagement; communication breakdown; inadequacy 
and/or unavailability of standardisation in pharmaceutical packaging, labelling and 
nomenclature; and limited availability of information about patients.(36) Hence, it is 
crucial to detect MEs in order to uncover failures during the treatment process that 
may lead to harm if not intercepted.  
MEs range in severity from trivial errors, such as incomplete medication orders 
requiring clarification from prescribers, to life-threatening errors, such as a child 
receiving a 10-fold dose of a drug with a narrow therapeutic index.(34) Most MEs 
can be considered minor if the errors are associated with little or no potential for 
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harm, e.g. missing the dose for a non-critical medication. If an ME has potential to 
harm but does not actually cause harm/injury, the error is considered a potential ADE 
(‘near miss’).(32) That is, the harm/injury is not attributed to specific circumstances, 
chance, the patient’s ability to tolerate the error, or if the error was intercepted and 
corrected. If an ME results in harm/injury, it is considered an ADE.(33) MEs occur 
more frequently than ADEs and a miniscule percentage of MEs result in injury.(9) 
Further investigation of potential ADEs could help identify where the system is 
failing (i.e. the error), as well as the success of the system in situ.(37) An example of 
a potential ADE that does not lead to harm is a patient prescribed digoxin in a dose 
that could cause toxicities that is intercepted by the pharmacist before administration.  
According to the American Society of Health-System Pharmacists, an ADR is: ‘any 
unexpected, unintended, undesired, or excessive response to a drug, with or without 
an injury’.(27) The WHO has defined an ADR as: ‘a response to a drug that is 
noxious and unintended, and occurs at doses normally used in man for prophylaxis, 
diagnosis or therapy of a disease, or for modification of physiologic function’.(38) 
According to the WHO, an ADR does not include treatment failures, drug misuse, 
errors during administering the medicine, noncompliance with right directions for 
taking the medicine, or intentional and accidental poisonings. Therefore, all ADRs 
lead to injury, whether temporary or permanent. Allergic and idiosyncratic reactions 
are also considered ADRs.(10, 39)  
ADRs occur due to intrinsic pharmacological properties of the medicine, when taken 
alone or in combination with other medicines.(40, 41) ADRs can be prevented by 
minimising patients’ exposure to suspected medications, switching to less hazardous 
alternatives and developing new medicines.(42) MEs are considered preventable and 
associated with inappropriate medication use. If an error leads to patient injury, it 
should be considered a preventable ADE.(28) For example, cough resulting from the 
use of an angiotensin converting enzyme inhibitor (ACEI) in a patient without a 
history of ACEI-induced cough is not an ME but an ADR. It is an ME if a patient 
with a history of ACEI-induced cough is prescribed the medicine.(28) 
However, some ADRs may result from MEs.(10) Nebekker et al.(42) is opposed to 
the feature of preventability to exclude events related to errors from the definition of 
ADR. They state that harm due to a drug is always caused in part by the drug’s 
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intrinsic properties, regardless of whether an error is judged to be present. They add 
that not all errors are preventable, given the intrinsic limitations of human designed 
systems and behaviours Their assumptions have been depicted in Figure 1.2.(42) 
There is still no universally accepted definition of an ADR. The WHO definition, 
clearly states that ADRs do not include events due to errors during medication use. 
This conservative and widely used definition could underestimate ADR incidence by 
only including the events due to medications properly prescribed and 
administered.(38) The WHO definition is supported by the Institute of Medicine, 
which defines ADRs as: ‘non-preventable reactions to medications related to 
inherent pharmacologic properties of the medications themselves instead of the result 
of human mistakes or system flaws’.(2)  
 
Figure 1.2 Relationship between adverse drug event, medication error and adverse drug 
reaction (some adverse drug reactions are due to medication errors)(42) (Adapted) 
1.2 Incidence and Consequences of Medication Misadventure  
Medication misadventure is common and a significant contributor to patient 
morbidity and mortality in general practice.(43) Medication misadventure also 
negatively impacts on patients treated in hospitals and may prolong hospitalisation or 
lead to death.(44) In the USA, ADEs occur in 3.7% to 30% of hospital admissions 
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and is a significant public health concern; an estimated 28% of identified ADEs are 
preventable.(32) One study reported that the rate of ADEs was 6.5 per 100 hospital 
admissions; approximately 1% were fatal and 12% were life-threatening.(34) The 
UK Department of Health reported that adverse events associated with medication 
use in 2007 were responsible for around 10% of hospital admissions.(45) In 
Australia, ADEs are associated with 2.4% to 3.6% of hospital admissions and an 
estimated 80,000 people are hospitalised every year as a result of drug-related 
problems (DRPs).(46) Preventable errors during healthcare delivery in hospitals 
account for one-quarter of adverse events in Australia.(47) The comprehensive 
Quality in Australian Health Care Study identified that 1.8% of all admissions to 
hospitals were associated with severe complications leading to disability.(47) 
The 1999 Institute of Medicine report stated that medical errors were directly 
responsible for up to 98,000 patient deaths annually in the USA, making it the fourth 
highest cause of death. MEs accounted for the majority of all medical errors.(48) In 
2007, the UK National Patient Safety Agency reported over 86,000 incidents of ME. 
A review of hospital inpatients found MEs were involved in 7% of medication 
orders, 2% of patient-days and 50% of hospital admissions.(45) A multi-site study of 
MEs in paediatric inpatients in the UK reported that prescribing errors occurred in 
13.2% of medication orders.(49) In a study of medication misadventures in paediatric 
and adult inpatients based on concurrent medication orders and chart review, and 
errors reported by doctors, nurses and pharmacists, Kaushal et al.(50) reported an 
ADE rate of 2.3 per 100 admissions or 6.6 per 1000 patient-days. They identified 616 
MEs among 10,788 medication orders reviewed; an error rate of 5.7% of all orders. 
They ascertained that one-fifth of these errors were near-misses (potential ADEs) and 
1% resulted in patient harm. They also highlighted that potential ADEs occurred 
three times more often among paediatric patients than adults.  
Other studies have reported that MEs are common during paediatric hospitalisations 
and occur in nearly 6% of all medication orders.(9, 50) A comprehensive study on 
MEs in paediatric oncology patients, reported that 13% of errors reached patients and 
2% resulted in temporary patient harm, requiring medical intervention. The study 
also reported that errors during prescribing were responsible for over 70% of the 
incidents, while errors during administration and dispensing accounted for 13% and 
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9% of the incidents, respectively.(51) However, the study of MEs in paediatric 
patients remains in its infancy due to lack of consensus on the medications of most 
concern and the children at greatest risk.(52, 53)  
In the era of heightened fiscal constraints, the cost burden of compromised patient 
safety has received attention. The implications of medication misadventure in health 
systems are significant. Medication misadventure imposes a threat to patient safety 
and a high financial burden on the health system. Medication misadventure is costly 
with regard to human, economic and societal perspectives. From the human 
perspective, patients may experience discomfort, complications, prolonged hospital 
stay, disability or death and health professionals often experience emotional distress. 
The economic impact of the misadventure affects individuals, healthcare 
organisations, third-party payers and society.(54)  
The economic burden for all areas of health care from drug misadventure in the USA 
exceeds USD100 billion annually.(54) In addition, time spent by healthcare 
providers in researching errors can impact on time for direct patient care. In a study 
of medical liability suits over a 16-year period, the Physician Insurers Association of 
America found MEs to be the fifth most common misadventure for paediatricians. 
More than 30% of the ME cases resulted in a paid claim, with a total indemnity of 
USD14.7 million.(55) The national projections of total healthcare costs with respect 
to MEs in in USA hospitals have ranged from USD2 to 4 billion annually.(11, 44) 
Most studies have only considered costs during hospitalisation, and ignored the 
outpatient treatment of the complications of MEs, the costs of disability and lost 
work time, family implications of caregiving burden and premature death. The 
financial implications of MEs may be significantly underestimated.(11, 56) 
The consequences of the occurrence of one ADE was associated with an average 
increased length of hospital stay of 1.91 days, based on a study by Classen et al.(44) 
and 2.2 days in a study by Bates et al.(32) In another study around 2 in 100 patients 
experienced preventable ADEs during hospitalisation.(57) The researchers estimated 
that extra costs due to preventable ADEs were USD4700 per admission or USD2.8 
million annually for a 700-bed teaching hospital. If these findings are extrapolated to 
hospitals across the USA, the hospital costs for inpatients due to preventable ADEs 
would approach USD43 billion.(57) In the UK, more than 800,000 adverse events 
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occur annually in national health system hospitals, accounting for £2 billion in direct 
costs for additional hospital days; half of these events were avoidable.(58) 
Medication misadventure can also result in significant healthcare costs.(58)  
The Australian Institute of Health and Welfare data suggest that the annual 
healthcare costs associated with medication misadventures in Australian public 
hospitals in 2002 was as high as AUD380 million.(59) Based on annual data of 
hospital admissions from 2006-2007, of the 7.7 million admissions recorded, around 
190,000 were due to medication misadventure; with an associated cost of AUD660 
million.(3) Medication safety is a major challenge in the Australian health system.(3)  
The consequences of MEs have ramifications in oncology patients already burdened 
by multimodal treatment. Antineoplastic drugs are distinguished by their toxicity 
profiles. The consequences of the MEs result in prolonged hospitalisation, 
readmissions to hospital, increased cost and premature death.(44, 57) It is evident 
that reducing the occurrence of such misadventure will lead to better outcomes for 
patients, and reduce the financial burden.(59)  
There may also be great personal costs to those involved and may result in time away 
from work, low patient satisfaction and decreased public trust toward health care.(6, 
32) Staff may experience shame, guilt and depression after making a mistake, with 
litigation and complaints imposing an additional burden. Doctors and nurses whose 
confidence has been impaired will work less effectively and efficiently; at worst they 
may abandon their career.(60) 
1.3 Causes of Medication Misadventure  
Medication misadventure can occur at any step of the medication management 
process: prescribing, transcribing, dispensing, administration and monitoring. The 
American Society of Health-System Pharmacists acknowledges the myriad of factors 
and the multidisciplinary team as sources of errors in medication use.(61) Errors 
cannot be resolved without correcting underlying causes.(62) Any individual in a 
healthcare team (physicians, pharmacists, nurses and supportive staff) could commit 
errors.(61) Studies have emphasised that the two leading causes of medication 
misadventure are lack of knowledge and breakdown in communication.(34, 63-66) 
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The other causes are attributed to performance lapses and failure of hospital 
authorities to optimise the availability of data for system improvement.(67-69) 
The medication management process requires intellectual activity in combination 
with the physical act of preparing and administering medications. A study 
investigating the preparation of intravenous medications in two UK hospitals 
revealed that around 265 MEs were observed during preparation of 483 
medications.(84) The errors ranged from insignificant slips or mistakes to major 
violations. The authors concluded that 79% of the errors were caused by lack of 
knowledge and experience dealing with medications and equipments. This study 
highlighted the need for specific training because the staff who frequently made 
mistakes in selecting medications were unfamiliar with medication names.(64)  
A system analysis in the USA identified lack of drug knowledge as the major cause 
of dosing errors.(32) This finding was confirmed by Lesar et al.(65), who identified 
that the most common variables associated with errors were related to deficient 
knowledge, such as the application of knowledge about specific drug therapies (i.e. 
expected toxicities, usual route, correct drug) and the synthesis of knowledge relating 
to patient factors that influence drug therapy outcomes (i.e. allergy, physiological 
status alterations).(65) Inappropriate prescribing is possibly the most common cause 
of avoidable events and account for over half of all preventable hospital MEs.(70) 
Prescribing is associated with errors, due to its complexity and challenging nature 
that requires diagnostic skills, knowledge of medicines, awareness of risks and 
experience. It is an anomaly that hospital doctors who have the least experience are 
expected to prescribe most often.(66) The consequence of this anomaly is that junior 
doctors are implicated in approximately 90% of serious hospital MEs related to 
incorrect dose.(70)  
Another common source of error is the lack of knowledge in dose calculation, 
especially among nurses.(71) The two skills that are critical in accurate drug 
calculations are basic mathematics and the ability to conceptualise the clinical 
information presented and extract the relevant information.(71) This is of special 
significance in paediatrics where medication dosing is often based on weight and 
body surface area (BSA).(72) 
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The other major cause of medication misadventure is communication breakdown 
between healthcare providers and their patients and/or caregivers. However, there is 
little evidence that improved communication between health professionals and 
paediatric patients will prevent MEs in this population. An analysis of medication-
related incidents has postulated that improvement in communication between 
healthcare providers and patients could minimise MEs in children.(73) Other 
contributors to medication misadventure in the post-discharge period include: 
inadequate communication to patients and/or caregivers about medication-related 
changes that have occurred in hospital; errors in prescribing or transcribing at 
discharge; and unclear health professionals’ expectations of how patients should use 
their medications.(74) This situation has been associated with poor or unavailable 
written communication that can result in errors.(75) Another concern is establishing 
and maintaining communication that deals with functional health literacy of patients 
and/or their caregivers. Successful communication relies on the quality and quantity 
of information that can be absorbed by patients.(76) Functional health literacy is the 
ability to understand and apply both written and oral health-related information.(69) 
Communication in paediatric patients is complex as it may often involve three- or 
four-way conversations with patients, parents, clinicians and others (e.g. social 
workers, interpreters).(73) Information transfer is also affected by a myriad of other 
barriers. Some studies have emphasised the correlation between the ability to recall 
information and improvement in adherence and relapse reduction.(73, 77, 78) There 
is some evidence that the effect of communication goes beyond this by improving 
patients’ health status.(73, 79) Effective communication with caregivers is one of the 
six patient safety goals included in the accreditation standards of the Joint 
Commission on Accreditation of Healthcare Organization.(80)  
Communication is a crucial strategy to reduce the occurrence of errors when working 
in a team. Well-established and well-maintained communication and interactions 
between healthcare providers could minimise the occurrence of MEs.(14) Effective 
communication is important during critical situations such as patient transfer 
between care settings/institutions, e.g. post-discharge. Poor continuity of care after 
discharge and lack of communication between the hospital and community settings 
increase the chance of patients experiencing medication misadventure.(4, 74, 81) 
Kripani et al.(79) investigated communication and information transfer during and 
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after hospital discharge and reported that direct communication between hospital 
authorities and general practitioners occurred infrequently, and could contribute to 
misadventure.  
There are also problems with communication between hospitals. For a study 
undertaken in a regional hospital in Queensland (Australia) medical records were 
reviewed of patients referred to the hospital’s oncology unit.(82) These patients had 
been prescribed chemotherapy at another hospital. Around 72% of the referral 
medical records had been associated with one or more potential errors with respect to 
patients’ medicines, such as inadequate documentation to confirm the doses, poorly 
handwritten or illegible medication orders, and lack of sufficient information on the 
length of time between cycles of chemotherapy.(82) 
Another factor cited as a major cause of errors in the medication management 
process is related to performance lapses.(67) Performance lapses or deficits are 
defined as: ‘slips and/or mistakes that generally take place when there is any 
impairment of a professional’s attention that may divert human cognitive 
functions’.(83) These lapses may result in inadvertent errors. Performance lapses are 
not related to knowledge and are mainly associated with intrinsic factors, such as 
health status and ability to manage stress and focus, and extrinsic factors, such as 
non-conducive working environments, (83) e.g. excessive workload, distractions.(84) 
For critical tasks, such as preparing intravenous additives and calculating medication 
doses, distractions may have harmful consequences for patients.(83) 
Another cause of medication misadventure is the failure of hospital authorities to 
utilise their data to prioritise and support system improvements. The first step would 
involve identifying the nature and occurrence of errors, analysing and reporting their 
pattern of occurrence within delivery systems to reduce the likelihood of adverse 
events.(12) Systems should be designed and modified based on actual and potential 
errors. The American Academy of Pediatrics has included identifying and learning 
from errors as one of its three principles of patient safety.(85) Error-learning systems 
should be transparent, promote discussion of errors without blame and punitive 
actions and provide contextual and robust data about the errors.(2)  
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1.4 Risk Factors associated with Medication Misadventure in Children 
An understanding of the risk factors associated with MEs would enable improved 
monitoring of patients and medications associated with increased risk of serious 
errors.(86) Paediatric patients are at risk of DRPs for a variety of reasons, such as 
physiological factors and healthcare settings unable to accomodate the safe use of 
medications in paediatrics.(87, 88) Psychological factors pertaining to 
communication are another risk factor for the likelihood of medication misadventure 
in this population.(89) In those diagnosed with cancer, the complexity of 
chemotherapy regimens increases their risk of experiencing medication 
misadventure.(6, 11, 90) 
Children are not ‘mini adults’. They vary in size from early infancy to adolescence, 
along with profound alterations to their physiology. Weight and BSA also vary 
greatly and range from less than 500 g to over 100 kg in body weight and 0.1 to over 
2 m
2 
in BSA between premature neonates and adolescents. The relationship of body 
size with age and other clinical characteristics may impact on drug absorption, 
distribution, metabolism and excretion, especially, in neonates and infants.(91) These 
variations may lead to difficulties in clinical practice, most notably in drug dosing 
and administration. Paediatric pharmacokinetic parameters are frequently scaled 
based on body weight. This scaling approach has the advantage of being easy to 
calculate and apply to dosing of the medicines.  
Many physiological functions that affect drug clearance (i.e. renal function, cardiac 
output, hepatic blood flow) do not scale proportionally to weight. Therefore, 
estimated BSA is an alternative approach to determine drug clearance. Empirically, 
BSA correlates more closely with the clearance of drugs than weight.(92) Volume of 
distribution may not correlate as well with BSA as it does with weight. BSA 
calculation requires height measurement that can complicate the dose 
calculation.(93)  
Substantial changes in body proportions, organ systems and composition accompany 
growth and development in children. This dynamic process of growth, differentiation 
and maturation differs from adults with respect to physiological and pharmacological 
changes. The variability in organ system maturation complicates the determination of 
medication dosages for children.(88, 93) Pharmacokinetic parameters, such as 
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volume of distribution, half-life and clearance also alter during development.(92, 93) 
Many drugs doses need to be adjusted for increased body mass and compensate for 
increased clearance and short half-life due to development of hepatic and renal 
functions.(88, 92) Besides specific dosage requirements such as weight-based 
dosages, medication delivery for children is complex because of the limited 
availability of liquid oral medication formulations in different concentrations.(6, 90) 
Simplified dose administration approaches are not adequate for individualising drug 
dosages in childhood.(94) For potent drugs, when small fractions of the adult dose 
are required for children, risks of 10-fold dosing errors increase, leading to under 
dosing or overdosing.(6, 14, 90, 95) Some incidents may be fatal.(87, 96) 
Another risk factor contributing to the possibility of medication misadventure is 
healthcare settings unable to accomodate the safe use of medications in 
paediatrics.(87) Most healthcare settings are primarily built around the needs of 
adults. Data related to efficacy, tolerability of drugs, and ADR in children are often 
lacking, partly because drug regulation authorities and the pharmaceutical industry 
have ignored routine drug evaluation in this population.(97) Many settings lack 
trained staff with expertise in paediatric care protocols and safeguards, and current 
and readily accessible reference materials for medications used in paediatrics.(87, 
98) Few drugs are commercially available in ready-to-administer unit doses or dose 
forms appropriate for children.(99) Errors in dosing could result from the inability to 
deal with complex calculations and additional procedures to dilute and reformulate 
medications from adult formulations.(100-103) These manipulations may involve 
splitting or grinding tablets or dispersing or mixing drugs with food or drink. This 
practice creates opportunities for dosing errors, as the bioavailability of the drugs 
following such manipulations is often unknown and unpredictable.(104)  
Around 75% of medications prescribed for children have not been adequately studied 
in this population.(105) Current trial and error prescribing practices (off-label use) 
may be associated with therapeutic failure and increased risk of adverse events. 
Conversely, without such precribing, effective therapy would be denied to many 
children. Information or labelling on dosing, safety, efficacy and clinical use in 
paediatrics is either not available or is insufficient and off-label use occurs. Many 
drugs used in children are either not registered (unlicensed) or outside the terms of 
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their licence (off-label indications).(102, 103) Off-label prescribing is: ‘lawfully 
prescribing a drug or biologic agent for treatment regimens not specified in the 
approved labelling or package insert’.(106) The common reason for off-label 
prescribing in children is that the drug is prescribed at a different dose, for a different 
indication, through a different route of administration or for an age group for which 
the drug is not licensed.(107) A study in the USA found that off-label use accounted 
for 21% of all prescriptions for 160 common drugs.(108) Conroy et al.(107) reported 
that two-thirds of 600 children admitted to five European hospitals were prescribed 
unlicensed and/or off-label drugs during their hospitalisation. While some off-label 
uses are accepted as standard care, e.g. beta-blockers for congestive heart failure, 
many lack evidence of clinical efficacy.(108) There is little guidance to differentiate 
between off-label uses that are supported by evidence and those that are not.(106) 
Communication issues may also complicate treatment in children. Children often 
lack communication and/or cognitive capabilities to express their feelings and report 
adverse effects.(109) Young children cannot provide sufficient feedback on potential 
adverse effects or mistakes in administration.(73) Patient monitoring can also be 
challenging for health professionals when caring for children. Many children cannot 
reliably communicate complaints or effectively understand the questions from health 
professionals. They simply feel that they are not well.(6, 110, 111)  
Another risk factor, particularly for children with cancer, is associated with the 
characteristics of antineoplastic drugs. Antineoplastic drugs are among the most 
potent medications given to children, and have narrow therapeutic windows with 
high potential for toxicity. Administration of chemotherapy is error prone and even 
small errors can cause serious harm.(11, 112, 113) Analysis in the USA revealed that 
cytostatic drugs are the second most common reason for fatal MEs.(114) Protocols 
used for cancer treatment are complex and involve many medications. Chemotherapy 
dosage is unique and specific, in that dosing should be individualised and non-
standardised. Doses are prescribed on the basis of body size (e.g. weight, BSA) in 
addition to factors, such as renal and liver function, blood cell count and substance-
specific parameters, such as neurotoxicity (e.g. vincristine).(115) The dosing process 
requires patient-specific calculations, which should be reviewed regularly, since such 
factors can change during therapy and the dose should be adjusted accordingly.(96)  
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Some antineoplastic drugs are administered via different routes in variable doses 
over various periods of time (e.g. bolus, continuous infusion). Some antineoplastic 
drugs can be given safely by one route but not by another. Vincristine, for example, 
can be potentially life-threatening if administered intrathecally.(116) Most 
antineoplastic drugs require reconstitution and preparation, with several available in 
multi-dose vials in varying concentrations. Dosages are often extemporaneously 
compounded to meet the need for small doses in these patients.(96)  
Several chemotherapy and supportive drugs have sound-alike and look-alike names. 
Oral orders involving sound-alike medications may be misinterpreted or 
misunderstood, e.g. carboplatin and cisplatin, docetaxel and paclitaxel, vincristine 
and vinblastine. Doxorubicin has been confused with the antibiotic dicloxacillin and 
methotrexate has been confused with methohexital.(117) Chemotherapy protocols 
stated as acronyms (e.g. CHOP) can also cause confusion. Referring to 
chemotherapy drugs by their nickname (e.g. ‘donna’ for duanorubicin, ‘epi’ for 
epirubicin) has also caused errors.(117) Similarities in labelling and packaging of 
chemotherapy drugs also increase the risk of MEs. On labels, names of medicines 
may be in small print that is easily misread, and many medicine labels have similar 
designs and layouts.(117, 118) Some chemotherapy drugs from the same 
manufacture are packaged using similar colours and designs. Vials may appear 
similar in size and shape but contain vastly different medications.(117)  
The process from prescribing to monitoring chemotherapy involves individuals from 
multiple disciplines whose efforts must be coordinated to minimise risks.(119) All of 
the above mentioned factors have implications on clinical decision making for 
paediatric patients, and each of the stages of dose calculation, preparation and 
administration of chemotherapy has potential for error.(120) Children receiving 
chemotherapy are identified as high-risk in terms of their likelihood to suffer the 
consequences of an untoward event associated with medication misadventure.  
1.5 Pharmacists’ Interventions in Minimising Medication Misadventure 
Clinical pharmacy services aim to ensure optimal outcomes for patients. The main 
focus of clinical pharmacy practice, as stated by the Society of Hospital Pharmacists 
of Australia, is: ‘for ensuring the correct patient receives the optimum dose of the 
most appropriate medication for a specific condition via a rational dosage form and 
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regimen, over an appropriate time period’.(121) This definition also identifies the 
role of clinical pharmacists to improve patient safety and minimise any harm related 
to medication use through identification, management and prevention of ADEs and 
drug interactions. Clinical pharmacy practice is prevalent in hospital settings across 
Australia, albeit variable in the nature and extent of the service. One of the major 
outcomes of a clinical pharmacy service is to prevent or reduce drug-related harm 
and enhance the efficacy of drug treatment.(122) Clinical services that may lead to 
pharmacists’ interventions cover all aspects of patient care and include: provision of 
drug information resources and education for health professionals; development of 
treatment protocols; patient education and counselling; analysis and performance 
improvement; medication reconciliation; and other services consistent with 
pharmaceutical care.(123, 124) 
A pharmacist’s intervention is: ‘any reactive activity in response to an erroneous 
medication order and suggestion with regard to the medication order where the 
activity may involve contacting the prescriber’.(125) The Indian Health Service 
Pharmacy’s definition of pharmacist’s intervention is: ‘any action undertaken by a 
pharmacist during the prescription screening and dispensing process when 
recognising a drug-related problem in order to solve the problem’.(126) A UK study 
has defined a clinical intervention as: ‘any recommendation made by pharmacy staff 
with the purpose of changing drug treatment or its monitoring’.(127) Although the 
precise definition is still debated, in Australia, there is general consensus that a 
clinical pharmacy intervention is: ‘any action by a pharmacist that directly results in 
a change in patient management or therapy’.(128) This definition acknowledges that 
clinical pharmacy interventions occur if they have been discussed with prescribers, 
nurses and patients, i.e. no intervention can occur if the pharmacist has not been able 
to influence their behaviour.(128)  
Besides intervening to resolve/prevent actual/potential DRPs, clinical pharmacists 
perform a number of other functions that might not result in recommendations or 
direct changes in medication management. These include (but are not limited to) 
clarifying medication orders, drug use evaluations, providing education for medical 
and nursing staff, therapeutic drug monitoring and counselling patients and/or 
parents/caregivers. All of these non recommendation generating activities are 
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important in minimising drug-related harm and could be considered clinical 
pharmacy interventions.(129)  
For the purpose of this study, the term pharmacist’s intervention was adopted from 
the Society of Hospital Pharmacists of Australia and refers to any action by a clinical 
pharmacist related to patients’ management or therapy. The interventions were 
classified as either resulting in drug changes (active interventions) or not resulting in 
drug changes (passive intervention). Passive interventions are care-centred activities 
performed by clinical pharmacists in relation to interactions with doctors, nurses, 
other pharmacists, and patients. The term ‘clinical intervention’ incorporates a wide 
range of activities performed by pharmacists to promote patient safety and protect 
patients from drug-related harm. 
Pharmacists are best positioned to ensure that medications are used rationally and 
safely, increase awareness of MEs and prevent medication misadventure. The 
traditional role of pharmacists particularly in hospitals (e.g. compounding, 
dispensing and supply of medicines) has expanded to include clinical activities. This 
transition has increased the contribution of pharmacists as part of healthcare teams in 
minimising DRPs and optimising patient outcomes.(130) Pharmacists are crucial for 
successful medication misadventure reporting and are critical in error-prevention 
interventions, especially when participating in ward rounds.(131) Many critical units, 
such as neonatal critical care and oncology, have relied on pharmacists’ participation 
during ward rounds to resolve ADRs, drug interactions and MEs associated with 
complex medical conditions and medication regimens.(14, 15) Substantial savings 
can be made by maximising the competencies of pharmacists and implementing 
pharmaceutical care.(56) The economic implications of pharmacists’ interventions 
are expanded in Section 1.6.  
One type of passive intervention involves provision of drug information and 
education to other healthcare providers. Pharmacists should ensure the availability of 
current evidence-based references on the appropriate use of drugs for all those 
involved in the medication use process.(123, 132) Pharmacists need to be well 
informed in order to be able to provide medication-related information to other 
healthcare providers. This information may include: drug-specific precautionary 
warnings and adverse effects, particularly dose- and schedule-limiting effects; 
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potential interactions with other drugs, disease states, and foods; administration 
methods, including drug admixture stability and compatibility with other drugs and 
additives; dose calculation; dose recommendations for single- and multiple-treatment 
courses; medication and dose adjustment for persons with concurrent diseases and 
organ impairment, e.g. renal failure; and dosing based on pharmacokinetic 
parameters and monitoring guidelines.(133) Pharmacists should provide current 
discipline-specific educational materials about medication use to those who 
prescribe, prepare and administer medications. Pharmacists should consider both the 
sources of the materials and effective ways to deliver information so that it is easily 
interpreted and understood. When new medications are introduced, pharmacists’ 
contribution in developing educational materials on medication regimens and 
treatment protocols are paramount.(123, 132) 
Through these interventions pharmacists can ensure that the treatment protocol has 
been described clearly by using standardised language, abbreviations, content and 
units of measurement.(133) In clinical units where treatment regimens are used 
intensively (e.g. paediatric oncology), pharmacists can initiate the development of 
protocols to assist with quality and accurate prescribing, minimise misinterpretation, 
and facilitate effective and safe practices. Pharmacists should also lead initiatives to 
standardise all procedures related to drug preparation, e.g. reconstitution, dilution, 
and drug admixture. This intervention is imperative in paediatric oncology where 
treatment protocols are complex and specific to cancer type.(134) Kohler et al.(135) 
have developed explicit guidelines for outlining chemotherapy dosage schedules, 
templates to describe chemotherapy drug regimens in a clear, uniform and consistent 
manner, and standardised labels for dispensed medications.  
Pharmacists have professional responsibilities to ensure patients use their 
medications appropriately.(136) Studies conducted at the Albany Medical Center 
(New York) demonstrated that most patients did not have a clear understanding or 
possessed limited knowledge about their medications.(137) In another study, 
discrepancies between the medications prescribed and the medications taken by 
patients were reported in 76% of cases.(138) Failure to educate patients about their 
medications has also been the subject of litigation. The duty of pharmacists to 
educate and warn patients of potential problems and/or hazards related to medication 
20 
use has been tested in the courts in the USA and Australia; failure to perform this 
duty has had legal consequences for pharmacists.(1) The Institute of Medicine’s, To 
Err is Human: Building a Safer Health System, has heightened awareness on the 
necessity to increase a patient’s role in effective and safe medication use. 
Pharmacists are critical to facilitating this process through educating and counselling 
patients about their medical conditions and medications.(2)  
Medication reconciliation may trigger pharmacists’ interventions. Medication 
reconciliation is: ‘a process to consciously continue, discontinue or modify 
medication orders’.(139) This is thorough process is used to collate a complete and 
accurate list of patients’ current medications.(140) It ensures that patients receive all 
intended medications during hospitalisation. Discrepancies are discussed with the 
prescriber and reasons for changes to therapy are documented. The medication list 
should include all prescription and non-prescription medications, including dietary 
supplements and over-the-counter medicines. Medication reconciliation should be 
performed for each patient being transferred within the same institution or to other 
institutions.(141) Medication orders can be incomplete, particularly when patients 
are transferred to other units in the same hospital or to another hospital, or discharged 
from hospital.(142) Medication accuracy at transitions of care is one of five patient 
safety priorities nominated by the World Health Alliance on Patient Safety, which 
can be achieved through medication reconciliation.(140) The effectiveness of 
medication reconciliation in error reduction is well established. Around 40% of MEs 
are due to inadequate reconciliation during hospital admission, transfer and 
discharge.(143) Medication reconciliation by pharmacists could decrease MEs by 
70% to 80% and ADEs by more than 15%.(144)  
1.6 Clinical Significance and Economic Implications of Pharmacists’ 
Interventions 
Numerous studies have highlighted clinical pharmacists’ roles in ensuring safe and 
optimal medication management in the continuum of care in critical settings, 
specifically emergency departments (EDs) (145) and intensive care units (ICUs).(15, 
17, 146) A study in a metropolitan teaching hospital in Australia examined the 
impact of an ED clinical pharmacist on prescribing errors. The rate of prescription 
errors detected was 1.6 errors per patient during the control period, which decreased 
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to 0.5 errors per patient during the intervention period, when the ED clinical 
pharmacist participated in the healthcare team.(145)  
Leape et al.(15) justified the contribution of clinical pharmacists in reducing the rate 
of ADEs in an ICU. They reported a decrease in preventable ADEs in adult patients 
by 66% after the implementation of clinical pharmacy services. There were 10.4 
ADEs per 1000 patient-days before the intervention and 3.5 ADEs per 1000 patient-
days after the intervention, with no change in the control ICU. The introduction of 
clinical services including pharmacists’ interventions in a 30-bed medical ICU in a 
tertiary teaching hospital in Korea were considered essential by other members of the 
healthcare team. This one-year study also highlighted the highest need for 
pharmacists’ interventions was for severely ill patients with renal impairment and 
long length of stay.(146)  
Studies investigating the incidence of ADEs in paediatric patients are lacking. A 
prospective epidemiological study in two university hospitals found that the ADE 
rate in children was similar to adult patients. This study also highlighted that the 
potential ADE rate was three-fold higher in children.(50) A pharmacist in a 
paediatric ICU was shown to intercept MEs, as well as recognise ongoing problems 
related to medication use.(17) Clinical pharmacists in the ICU, in adult or paediatric 
settings, could also be the main source of knowledge for medical and nursing staff in 
relation to the pharmacology of medications.(17, 144, 145)  
To measure the clinical significance of pharmacists’ interventions, it is beneficial to 
establish a specific scale of measurement. Dodds et al.(147) classified pharmacists’ 
interventions as minor, moderate and major impact. Analysis of the clinical 
significance of pharmacists’ interventions revealed five distinct scales that have been 
used for rating pharmacists’ interventions. The scale by Folli et al.(148) has been 
widely used and rates the interventions into five levels: extremely significant, very 
significant, significant, somewhat significant and no significance. Hatoum et al.(149) 
published a ranking system that highlighted the value of clinical pharmacy services 
by assessing the potential impact of the interventions with regard to patient care. An 
Australian study reported the clinical significance of pharmacists’ interventions into 
five scales: no clinical significance, minor, moderate, major and life-saving.(18)  
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Pharmacists’ interventions can be classified and analysed further based on the DRPs 
addressed. Classifying DRPs is an essential component of pharmaceutical practice 
and research.(150, 151) A systematic review of DRP classification systems identified 
20 different of classification systems. As evaluation of pharmaceutical care of a wide 
range of studies requires a universal DRP classification system, the review highlights 
the need for consensus.(152) 
Many studies have evaluated the economic implications resulting from pharmacists’ 
interventions in hospitals (Table 1.1).(17, 18, 153-158) There is a wide variety of 
study settings, study duration, definition of interventions and method of cost 
assessment. A review of the economic effects of clinical pharmacy interventions 
revealed that the majority of studies were undertaken in adult patients.(159)  
1.7 Root Cause Analysis 
A common issue faced by hospitals is that medication misadventure, particularly 
MEs, does not neatly fall into defined categories. For instance, when a patient 
receives another patient’s medications, it may be assumed that this error is the result 
of inadequate patient identification. Although a reasonable assumption, this approach 
does not identify the cause(s) of the error. Possible causes in this case may be an 
incorrect patient identification wristband or a mistake during medication order entry. 
The same errors may be repeated because incident reporting systems fail to identify 
root causes. It is important, therefore, to ensure that incident reporting systems and 
data are used to fuel RCA which results in corrective action in the systems.(1)  
The concept of RCA is detailed in Section 1.7.1 and its application in health systems 
is explored in Section 1.7.2. Another major issue relating to error-reporting systems 
is misleading assumptions among pharmacists who consider errors do not need to be 
reported if they can be corrected. For example, pharmacists may not report 
prescribing errors if the errors can be corrected in the pharmacy department. They 
assume their actions are interventions instead of MEs. This leads to an under 
estimation of MEs for the organisation and a lost opportunity to learn from potential 
errors.(160) If errors and the results of RCA are only reported and disseminated 
locally, the lessons cannot be learned by other departments/institutions.(60) 
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Table 1.1 Characteristics of pharmacist intervention studies and cost assessment 
Year  Authors  Setting  Interventions  Parameters  Key findings 
August 
1998 
Dooley et 
al. (18) 
8 major public hospitals 
(361-395 beds) in Australia 
Actions that directly resulted 
in a change to patient therapy 
or management. Each hospital 
collected 200 interventions. 
Cost saving related to 
length of stay (LOS), 
readmission, drugs, 
medical procedure and 
laboratory monitoring. 
Estimated annual cost 
saving was AUD4.4 million. 
One dollar spent on the 
change recommended by a 
pharmacist could save 
AUD23. 
April 1998 
to April 
1999 
Lee et al. 
(154) 
Veteran Affairs medical 
centre in the USA: 362-bed 
teaching hospital, 120-bed 
nursing home and clinics 
When a provider applied the 
pharmacist’s knowledge to a 
patient or physician order. The 
first 600 pharmacist 
recommendations recorded in 
the electronic documentation 
system. 
Average cost 
avoidance was 
calculated if the 
recommendations 
prevented/caused 
harm.  
Overall mean cost avoidance 
per recommendation was 
USD700 and the mean total 
cost was USD420,155. 
Not stated. 
Results 
published 
in 2001 
Bond et al. 
(155) 
Data from the 1992 National 
Clinical Pharmacy Services 
in the USA for 14 clinical 
pharmacy services and 
pharmacist staffing 
14 clinical pharmacy services, 
e.g. drug use evaluation, in-
service education, drug 
counselling, admission drug 
history and medical rounds 
Relationship between 
some variables 
(mortality rates, drug 
costs, total costs of 
care and LOS). 
Clinical pharmacist staffing 
increase was associated with 
43% decrease in hospital 
deaths. This translated into 
USD320 of pharmacy salary 
cost/death averted. 
1 
September 
to 31 
December 
2003 
Lada et al. 
(156) 
100-bed ED at a 340-bed 
teaching hospital for adult 
patients in the USA 
Categories such as provision 
of drug information, dose 
adjustment, initiation/ 
discontinuation of drug 
therapy.  
Average cost, 
probability of harm 
and potential cost 
avoidance 
2150 pharmacists’ 
interventions were 
documented; cost avoidance 
was USD1,029,776. 
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February 
2000 
Van den 
Bemt et al. 
(158) 
600-bed teaching hospital 
and 300-bed non-teaching 
hospital in the Netherlands 
Over 5 consecutive days, all 
medication orders were 
screened for prescribing errors 
by pharmacy staff. 
Cost-benefit analysis 
based on direct 
medical costs. Benefit-
to-cost-ratio was 
calculated by 
considering the net 
time spent by 
pharmacy staff to 
prevent the error and 
the possible 
consequences of the 
error. 
9.9% of screened 
medication orders contained 
prescribing errors. Time 
investment of the pharmacy 
staff had net cost of 
EUR285 and estimated 
investment-related benefits 
were EUR9867. 
September 
to 
November 
2001 
Olson et al. 
(157) 
360-bed teaching hospital in 
Canada 
Interventions that prevented 
ADEs (described as very 
serious and serious by the self-
reporting pharmacists). 
Cost savings attained 
by shortening a 
planned course of drug 
therapy and cost 
avoidance achieved by 
avoiding ADEs. 
Total cost avoidance of the 
33 preventable ADEs was 
USD84,631. USD1.20 was 
saved for each USD1 spent 
on pharmacist’s salary. 
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November 
1996 to 6 
May 1997 
Krupicka et 
al. (17) 
Ten-bed paediatric ICU in a 
124-bed university-affiliated 
children’s hospital in the 
USA 
Every intervention performed 
and documented by a 
paediatric clinical pharmacist 
during rounds and private 
discussion with the physicians. 
Drug acquisition costs 
were used to calculate 
drug cost savings. 
Drug acquisition costs 
were multiplied by 2.4 
(average LOS). 
Labour, supplies and 
any other indirect costs 
were not included. 
Total cost savings for the 
24-week study period was 
USD1977. Extrapolated 
direct cost savings per year 
was USD9135. 
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1.7.1 Improvement of System Analysis to Overcome Organisational 
Failure 
Patient safety is one of the most crucial issues facing health systems across the 
globe.(161, 162) The initial step in the process of creating a safe health system is to 
promote a culture of safety within an organisation. A culture of safety is an 
environment where individuals receive adequate support to report any deviant 
incident.(163) As the blame is usually with organisational system failure, the system 
and not the individual should be evaluated.(163, 164) Systems that receive incident 
reports without investigating, analysing and acting on these reports are inadequate. 
These flawed systems also discourage frontline staff from reporting incidents, as the 
effort and time invested in reporting these incidents are undermined.(165) On the 
grounds that humans make mistakes, the goal of system analysis is to invent a system 
that will minimise and prevent errors from occurring.(164) 
Reason(166) has developed a systematic perspective on organisational failure by 
introducing the concepts of active and latent failures to describe the multi-level 
nature of incident causation. Active failure is associated with the errors and rule 
violations of front-line staff that have an immediate and apparent impact on the 
system. Latent failure implicates individuals more distant from the incident, i.e. 
individuals at the upper levels of the system (e.g. policy maker, manager) and may be 
left untouched indefinitely. Reason created the ‘Swiss cheese’ model (Figure 1.3) to 
illustrate how organisations are built with multiple layers of safeguards against error 
(active failure), yet with holes at each layer indicating weaknesses and gaps that can 
lead to latent failure. Incidents occur if the holes in all defensive layers line up 
perfectly in a constant flux to create the pathway for incidents to happen.(167) 
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Figure 1.3 James Reason’s Swiss cheese model(179) (Reproduced with permission.) 
A similar perspective is shared by the National Patient Safety Agency who proposed 
that the system is analogous to a blade, i.e. it is divided into two parts: sharp and 
blunt ends (Figure 1.4).(162) The sharp end represents the direct/immediate point 
during provision of service to customers (i.e. patients in the health system) whereas 
the blunt end encompasses a wide range of factors such as organisational policies, 
staffing, information technology systems and the physical structure of the workplace. 
In order to resolve why incidents occur at the sharp end of the system, RCA is 
necessary to examine and analyse the contributing factors at the blunt end.(168) 
Thorough examination and analysis of incidents (actual and near misses) followed by 
adequate and well-designed recommendations are key to improving patient safety 
and reliability of the system.(169) 
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Figure 1.4 Sharp and blunt ends of the system as enablers of incidents(162) (adapted) 
1.7.2 Root Cause Analysis for Improving Patient Safety in Organisations 
The RCA that follows an incident investigation identifies weaknesses and failures in 
the system, thereby preventing the likelihood of the recurrence of similar incidents. 
RCA encompasses the methods for the retrospective and structured investigation of 
adverse incidents, near misses and sentinel events (Section 1.7.1).(169) RCA can 
also be used to evaluate undesirable patterns or trends whenever there is a 
performance deviation from recognised standards.(170) RCA has been applied 
successfully to uncover latent errors that underlie incidents in high-risk industries 
such as aviation.(20) RCA was developed to analyse major industrial incidents and 
has been taken up by health systems in the USA, Australia, Canada and the UK.(20, 
162) Health service provision occurs in a complex and high-risk environment with 
even simple procedures requiring multiple steps and providers. The probabilities of 
incidents occurring in health services are high, and safety tools such as RCA are 
essential to prevent the recurrence of similar incidents.(162) In the USA, the Joint 
Commission on Accreditation of Hospitals has mandated that all hospitals use RCA 
to investigate cases associated with patient incidents or sentinel events.(170) 
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RCA is the most important development in the transformation of error management 
in healthcare delivery.(171) To effectively minimise errors, system weaknesses that 
lead to errors must be identified and the system changed to improve its 
performance.(172) RCA designed as a quality improvement tool must be able to help 
organisations determine the contributing factors and root causes resulting in an 
incident. Striving to identify and address the root or underlying causes of critical 
incidents will lead to a greater understanding of hazards/problems in the system.  
RCA is widely adopted by hospitals and healthcare organisations, and has helped to 
identify many problems and solutions.(162, 171, 173) It has become the system 
analysis tool to investigate mistakes in healthcare delivery and provides strategies for 
developing effective recommendations and action plans for system improvement.(20) 
There are many benefits in conducting RCA, e.g. building collaborative and 
professional relationships among physicians, pharmacists, nurses and other 
healthcare providers, and providing an excellent learning opportunity for those 
involved in the RCA process. The main advantage is correcting system flaws in order 
to prevent the recurrence of similar incidents in the future.(174) 
1.7.3 Conducting Root Cause Analysis 
RCA is designed to answer three questions: What happened? Why did it happen? 
What can be done to prevent it from happening again?.(168) RCA is founded on the 
principles that patients, direct healthcare providers, senior management, board 
members and representatives of key external organisations play significant roles in 
improving the system.(20, 162) For RCA to work, it requires: a non-punitive and 
confidential method for reporting adverse events; collaboration of health 
professionals; an understanding of relevant legislation and human factor engineering 
(HFE); identification of problems in the system; and strategies to improve the 
system.(161, 162, 171) There must also be timely and relevant feedback to reporters 
of events.(171)  
Contributing factors and root causes identified are either of the HFE or non-HFE 
types. HFE is ‘the scientific discipline concerned with the understanding of 
interactions among humans and other elements in a system in order to optimise 
human wellbeing and overall system performance’.(172) HFE builds on the premise 
that human performance and subsequent occurrence of errors are influenced by 
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system factors. HFE-type factors and root causes refer to interactions between 
humans and their environment, and may include policies, procedures, 
communication, training, workload, equipment and the physical 
environment/workplace. Non-HFE-type factors and root causes include patient 
behaviour and course of disease, which are more difficult, if not impossible, to 
modify with recommendations resulting from an RCA. Consequently, when patient 
behaviour or course of disease is identified as the primary root cause, this finding 
significantly lowers the possibility that any effective recommendations from RCA 
can be identified and implemented to prevent the event from recurring.(175) 
There is broad consensus that RCA represents a variety of approaches instead of a 
single method. Woloshynowych et al.(176) have described more than 40 RCA 
techniques, such as brainstorming, cause-effect charts, ‘five whys’ diagrams and 
fault trees, which provide different options of RCA analysis techniques. Although 
variations exist, the RCA process is usually organised in sequential steps. According 
to Rooney et al.(19), RCA is a four-step process involving data collection, causal 
factor charting, root cause identification, and recommendation generation and 
implementation as follows: 
1. In Step 1 information related to the incident is collected. This step is crucial 
because without a complete dataset and an understanding of the incident, the 
causal/contributing factors and root causes associated with the incident cannot be 
comprehensively identified. Inevitably, a great deal of time invested in analysing the 
incident is spent in gathering the data.  
2. Step 2, causal factor charting, can be initiated immediately. This step provides a 
structure and visual guide for investigators to organise and analyse the information 
gathered during the investigation, and to identify gaps and deficiencies in knowledge 
as the investigation progresses.(19) This step can be considered the review process to 
brainstorm why the incident happened and the possible causes that resulted in the 
incident. Causal factor charting is a sequence diagram that describes the incidents 
and the conditions surrounding these incidents, and drives the data collection process 
by identifying the need for gathering more data. Data collection continues until the 
investigators are satisfied with the thoroughness of the investigation. When the entire 
occurrence has been charted, along with the complete dataset, the investigators are in 
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a confident position to uncover the major contributing/causal factors to the incident. 
Causal factors, if eliminated, would have either prevented the occurrence of an 
incident or reduced its severity. The focus is on identifying all issues/flaws in the 
system and all possible causes that may have contributed to the adverse incident.  
3. After all the causal factors have been identified, Step 3 involves organising and 
analysing the causal factors by category in order to identify the root causes of each 
causal factor. A key aspect of this step is to understand how the causal factors relate 
to each other and ensure that the RCA has progressed far enough into the blunt end 
of the system so that root causes can be clearly defined. A root cause map can assist 
in better visualising these inter-relationships, ensure thorough review, clarify 
understanding and shift the focus away from individual performance/sharp end 
towards system performance/blunt end. Options include the Ishikawa/fishbone and 
tree diagrams.(162)  
4. Step 4 is recommendation generation and implementation. After recognising the 
root causes for each causal factor, achievable recommendations for preventing 
recurrence of the incident are generated. The recommendations should directly 
address the root causes identified from the previous step. This step also includes the 
specific timelines for fixing the problems. The final step also includes the 
development of ongoing monitoring strategies to evaluate the improvements.(170) 
1.7.4 Limitations of Root Cause Analysis 
Conducting an RCA or another retrospective investigation presents an opportunity to 
learn valuable lessons about how to redesign health systems and prevent recurrence 
of the incident/error. Nevertheless, the RCA process is not without problems. Many 
RCAs are performed incorrectly or incompletely, and therefore, cannot produce 
appropriate and usable results. In many organisations RCA is used erroneously to 
uncover the fundamental and apparent causal factor of the incident instead of ‘the 
root causes for all possible causal factors.(20) As the determination of causal factors 
is dependent on the training and experience of the analyst, the decisions on the 
causes are inherently subjective and inconclusive. The danger of drawing 
conclusions from inadequate sample sizes (i.e. incidents with remote possibilities) 
should also be recognised. If events are common across hospitals, remedial action 
should be designed at the health system rather than individual hospitals.(20, 177) 
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Another shortcoming relates to the level at which to terminate the analysis; a sensible 
stopping point is required for each RCA process.(177) While recognising the 
limitations of RCA, significant benefits can be derived with adequate and exhaustive 
processes for each step, followed by thoughtful implementation.(162) 
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Chapter 2 
AIMS 
The aims of the study were to evaluate the role of clinical pharmacists’ interventions 
in minimising medication misadventure in children with cancer; to investigate the 
clinical significance and identification of medication misadventure through these 
interventions; and to apply RCA to examine the factors contributing to medication 
misadventure. 
The study was divided into four parts. 
Part One: Clinical Pharmacists’ Interventions in a Children’s Hospital 
The objectives were to:  
 observe and document pharmacists’ interventions from three clinical units - 
general medicine, general surgery and haematology-oncology - in a children’s 
hospital 
 compare the rate and pattern of pharmacists’ interventions and pharmacists’ 
active interventions between the clinical units 
 observe and document pharmacists’ interventions during dispensing in the 
Haematology-Oncology Pharmacy 
 identify the predictors for physicians’ acceptance of pharmacists’ active 
interventions. 
Part Two: Clinical Significance of Pharmacists’ Active Interventions and 
Identification of Medication Misadventure through Pharmacists’ Active Interventions 
Using an Expert Panel  
The objectives were to: 
 determine the clinical significance of a sample of pharmacists’ active 
interventions 
 identify whether these interventions involved medication misadventure, to 
categorise medication misadventure into three subsets - ADE, ADR and ME - 
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and to classify medication misadventure involving ME according to the type 
of error and its severity. 
Part Three: Comparison of Documentation Methods used for Pharmacists’ 
Interventions  
The objectives were to: 
 analyse pharmacists’ interventions based on snapshot self-reports of 
interventions 
 examine the representativeness of the snapshot self-reports versus continuous 
documentation using direct observation 
 ascertain pharmacists' perceptions on the interventions documented through 
snapshot self-reports versus direct observation 
 identify barriers perceived by pharmacists to documenting their interventions 
during snapshot periods and to seek suggestions on how to improve the 
documentation of pharmacists’ interventions. 
Part Four: Medication Errors in Children: Root Cause Analysis Using Simulated 
Case Scenarios  
The objectives were to: 
 apply RCA in a sample of simulated cases to determine the clinical 
significance of MEs and the responsible health professional(s) 
 investigate the contributing factors for the MEs and preventive strategies to 
reduce the occurrence of MEs in children. 
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Chapter 3 
METHOD 
The entire study was conducted in three clinical units (haematology-oncology, 
general medical, general surgical) at the Princess Margaret Hospital for Children 
(Perth, Western Australia). This 220-bed public paediatric hospital has 
approximately 250,000 patient visits (inpatient and outpatient) annually. The 
haematology-oncology unit consisted of the Haematology-Oncology Ward 
(inpatient) and the Haematology-Oncology Pharmacy (inpatient and outpatient).  
For Part One clinical ward pharmacists’ interventions were prospectively 
documented across the three clinical units and the Haematology-Oncology 
Pharmacy. The non-disguised principal researcher observed the pharmacists and 
documented their interventions.  
For Part Two randomly selected pharmacists’ active interventions from Part One 
were analysed. Two of the four researchers and three independent panellists (Panel 1) 
analysed the interventions for clinical significance and identified medication 
misadventures and classified them as an ADE, ADR or ME. If the intervention 
involved an ME, the type of error and its severity were examined. As the rating of 
the clinical significance of the interventions could not be resolved through 
consensus, a second panel (researchers and two independent panellists) was set up. 
For Part Three pharmacist’s interventions from self-reports of three snapshot periods 
were analysed retrospectively. The interventions from the self-reports were 
compared with the interventions documented during direct observation in Part One to 
examine the pattern and representativeness of short-term documentation versus 
continuous documentation by an independent observer. A focus group discussion 
followed with pharmacists from the hospital to ascertain their perceptions on the in 
situ intervention documentation process and their suggestions to improve the process.  
For Part Four an RCA was conducted of five simulated clinical cases involving MEs 
in children. For the RCA self-administered questionnaires were disseminated to 
doctors, nurses and pharmacists at the study hospital. 
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3.1 Part One: Clinical Pharmacists Interventions in a Children’s Hospital 
3.1.1 Description of Study Settings 
Data were collected using prospective non-disguised observation from September 
2011 to August 2012 in three clinical units (general medicine, general surgery and 
haematology-oncology). There were three wards in the General Medical Unit - 
General Medical Ward for Infants, General Medical Ward for Young Children and 
General Medical Ward for Adolescents – one General Surgical Ward and one 
Haematology-Oncology Ward; a total of five study wards. The general medical 
wards admitted patients under general paediatrics and a range of non-oncology 
medical specialties, while the general surgical ward admitted patients under general 
surgery, opthalmology and otolaryngology.  
Ward-based clinical pharmacy services were provided Monday to Friday 0830 to 
1700 and from 0900 to 1600 during weekends/public holidays (for intravenous 
admixture services and urgent drug supplies only). Outside these hours an on-call 
pharmacist was available for urgent drug inquiries. Ward pharmacists undertook the 
pharmacy round/full ward visit once a day during weekdays, either in the morning or 
afternoon. After that, pharmacist could be contacted via pager. During pharmacy 
rounds, they reviewed patients’ medication orders prescribed on the inpatient 
medication charts and reconciled the medications by comparing the recent 
medication orders with previous orders in patients’ medical records and double-
checking with patients and/or parents and carers. Pharmacists also took patient 
medication histories, including allergy and ADR histories. If there were any 
discrepancies, pharmacists contacted the doctor to resolve the problem. 
Ward pharmacists provided drug information to medical and nursing staff and 
education and counselling to patients and/or their parents. They also monitored the 
medications stocked on the ward (‘imprest’). The imprest medications were stored in 
a drug room on each ward and organised alphabetically, based on their dose forms. If 
there were ‘non-imprest’ medication orders requiring intravenous admixture, e.g. 
intravenous antibiotics, the ward pharmacists supplied these medications to the ward. 
Nurses were responsible for preparing imprest medications, i.e. selecting the 
medications from the imprest cupboard and placing them in the patient’s drug tray. 
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There was no supervision by the pharmacist to ensure that the medications in the 
drug trays corresponded with the medication chart. Discharge medications were 
organised by pharmacists in the main pharmacy mainly in the mornings. 
The hospital has three pharmacies - main pharmacy and two satellite pharmacies 
(cardiology and neurology, and haematology-oncology). Besides their ward-based 
clinical activities, the haematology-oncology pharmacists dispensed medications, 
including cytotoxic chemotherapy and fluid therapy. For outpatients, the non-
parenteral cytotoxic chemotherapy medications and supportive care medications (i.e. 
antiemetics, prophylactic antifungals and prophylactic antibacterials) were dispensed 
from the Haematology-Oncology Pharmacy. For inpatients, nurses prepared these 
medications from the imprest. Medication orders requiring centralised intravenous 
admixture service (CIVAS), e.g. intravenous antibiotics, were prepared and 
dispensed by the pharmacists. The Haematology-Oncology Pharmacy services were 
provided Monday to Friday 0830 to 1700 and during weekends/public holidays from 
0900 to 1600 (for intravenous cytotoxic orders and urgent drug supplies only). 
Outside these hours an on-call pharmacist was available for urgent drug inquiries.  
Three to four pharmacists and one technician were on duty each weekday in the 
Haematology-Oncology Pharmacy. Although most of the pharmacists worked part-
time in this satellite pharmacy, they were permanently assigned to the facility so they 
were familiar with the workflow and patients’ chemotherapy protocols. The 
workflow in the Haematology-Oncology Pharmacy usually involved six steps: 
1. Reviewing the patients’ chemotherapy protocols and transferring the 
information onto a parenteral cytotoxic sheet (yellow sheet) and fluid therapy 
order sheet (white sheet). 
2. Creating the labels for medications to be formulated and dispensed. 
3. Setting up the chemotherapy medications and hydration fluids prior to 
formulating in the Laminar Airflow Hood. 
4. Formulating the chemotherapy medications and fluid therapy in the Vertical 
Laminar Airflow Cytotoxic Drug Safety Cabinet. 
5. Dispensing the parenteral cytotoxic medications to the nurses for 
administration.  
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6. Dispensing the non-parenteral medications and providing counselling to 
Haematology-Oncology Clinic patients and/or carers. 
Two pharmacists were usually responsible for Steps 1 and 2; one to two pharmacists 
set up the fluid therapy and parenteral cytotoxic medications, and dispensed the 
medications to nurses and non-parenteral medications to outpatients; and one 
pharmacist formulated the parenteral cytotoxic medications and fluid therapy in the 
Vertical Laminar Airflow Cytotoxic Drug Safety Cabinet. A technician processed 
outpatient prescriptions under the pharmacist’s supervision, checked the stock and 
ordered the low-stock medications from the main pharmacy. The background 
information of pharmacists’ clinical activities during ward rounds and dispensing 
was provided as to establish the study protocol.  
3.1.2 Direct Observation for Documentation of Pharmacists’ 
Interventions 
Pharmacists working on the study wards and in the Haematology-Oncology 
Pharmacy were invited to participate in the study. The principal researcher described 
the direct observation method and the ethics requirements (Section 3.1.3) of the 
study. The rationale for the direct observation approach was to ensure that the data 
collected was comprehensive and not subjected to reporting bias. Although direct 
observation has the potential to interfere in the activities of those being observed due 
to the presence of an observer (Hawthorne effect) the evidence suggests that the 
observation method has little effect on the behaviour of those being observed.(178) 
Direct observation has been used to detect MEs and ADEs, few studies have utilised 
this approach to document pharmacists’ interventions.(37, 179-182) The majority of 
studies in a range of healthcare settings have relied on self-reporting methods to 
document pharmacists’ interventions.(129, 147, 183-185) Self-reporting of 
pharmacists’ interventions are used in the study hospital. Comparison of the self-
reporting method with direct observation is described in Section 3.3. 
Twelve pharmacists agreed to participate in the study. The ward pharmacists worked 
on the General Medical Ward for Young Children, General Medical Ward for 
Adolescents and the Haematology-Oncology Ward permanently and were senior 
pharmacists with more than 10 years experience. The General Medical Ward for 
Infants and the General Surgical Ward were staffed by junior pharmacists on a 
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temporary rotation. The ward pharmacists on the general medical and general 
surgical wards reviewed medication orders and patients on more than one ward each 
weekday. The characteristics of pharmacists assigned to the Haematology-Oncology 
Pharmacy are described in Section 3.1.1. 
3.1.2.1 Ward-based Pharmacists’ Interventions 
The principal researcher (observer) shadowed pharmacists during their ward rounds 
and documented their interventions on the five study wards for a total of 35 to 37 
non-consecutive days. The observer followed one ward pharmacist for each weekday 
and collected the pharmacist’s interventions for that ward. On the following day, the 
observer went to another ward and documented another pharmacist’s interventions. 
This protocol was used to minimise fatigue in the pharmacist under observation. If, 
during direct observation, an intervention or the omission of an intervention could 
result in substantial patient discomfort or harm, the observer notified the senior 
pharmacist immediately after the ward round. For example, if an antibiotic order was 
written for a patient with a known allergy and the pharmacist did not detect the errant 
order, the observer could notify the senior pharmacist. Data collected during direct 
observation was annotated on the intervention documentation form (Appendix 1).  
For the data collected during direct observation (Table 3.1), the diagnosis on 
admission was classified using the International Statistical Classification of Diseases 
and Related Health Problems(186) for the general medical and general surgical 
wards, and the International Classification of Childhood Cancer(187) with slight 
modifications for the haematology-oncology patients. The medications involved in 
the interventions were categorised using the Australian Medicines Handbook 
(AMH).(188). The medications were also categorised based on their dose form and 
risk category.(189) The description of interventions were categorised into major type 
with further sub-categorisation as described by Condren et al.(190) with slight 
modifications to include ‘clarification of medication order’ as an additional category 
of the intervention. The intervention categories are outlined in Table 3.2. The rates of 
interventions were defined as the number of interventions per 100 medication orders 
reviewed. A medication order could have more than one intervention. The principal 
researcher divided the interventions into ‘active’ and ‘passive’, as defined 
previously. 
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3.1.2.2 Pharmacists’ Interventions during Dispensing 
The observer shadowed pharmacists in the Haematology-Oncology Pharmacy for a 
total of 33 days. Observations were conducted during weekday trading hours. In 
order to minimise fatigue of those under observation pharmacists were not observed 
continuously (Section 3.1.2.1). Data collected during direct observation was written 
on the intervention documentation form (Appendix 1). Details of the data are 
described in Table 3.1. A medication order reviewed could have more than one 
intervention. The principal researcher divided the interventions into ‘active’ and 
‘passive’, as defined previously. 
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Table 3.1 Data collected by the observer during direct observation 
Variables Source Response options 
Patient demographics 
- Age 
- Gender 
- Admitted ward 
- Length of hospitalisation 
 
Medical record 
Medical record 
Observation 
Medical record 
 
Free text (years) 
Male/female 
Free text 
Free text (days) 
Admission and discharge 
dates 
Medical record Free text 
Diagnosis on admission Medical record Free text 
Medical history Medical record Free text 
Medication history Medical record Free text 
ADR and/or allergy history Medical record Free text 
Current medication(s) Medication chart Free text 
Description of intervention Observation Free text 
Medication(s) involved in 
intervention 
Observation and medication 
chart 
Free text 
Cause of intervention Observation Prescribing/ dispensing/ 
administration/ monitoring 
Trigger of intervention Observation Doctor / nurse /other 
pharmacist inquiry/ patient 
request/ ward meeting/ 
medication chart review/ 
laboratory result/ medication 
history taking 
Intervened health personnel Observation Doctor/ nurse/ pharmacist 
Acceptance of intervention  Observation Accepted/declined 
Characteristics of intervening 
pharmacist 
- Gender 
- Year of experience 
- Highest qualification 
- Employment status 
Intervening pharmacist  
 
Male/Female 
Free text (years) 
Free text 
Full-time/part-time and 
permanent/temporary post 
Time to complete ward 
round 
Observation Free text (minutes) 
3.1.3 Ethics 
The study protocol was approved by the Princess Margaret Hospital Institutional 
Review Board No: 2923 (Appendix 2) and the Curtin University Human Ethics 
Committee No: PH-14-11 (Appendix 3). Pharmacists working on the study wards 
and in the Haematology-Oncology Pharmacy received the Participant Information 
Sheet (Appendix 4) prior to consenting to participate (Appendix 5). The method used 
was one that minimised observer effects. Coding of data from patients’ medical 
records maintained patient confidentiality. Data files are being stored on a password-
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protected computer and archived securely for at least five years. The same procedure 
for handling of data files applied to other data collected in other parts of the study. 
3.1.4 Data Management and Analysis 
Data collected during direct observation were transcribed onto Excel spread sheets. 
The data were checked several times to ensure there were no missing variables. The 
variables of date of discharge and length of hospitalisation were incomplete in some 
patients. These missing variables were retrieved using iSoft Clinical Manager via the 
hospital intranet. Demographic variables and pharmacists’ intervention-related data 
were summarised using descriptive statistics (mean ± standard deviation or median 
[range] for variables measured on a continuous scale, and frequencies and 
percentages for categorical variables). Several pharmacists’ intervention-related 
parameters were compared using the Kruskal-Wallis test. The rates of pharmacists’ 
interventions were reported as the number of interventions per 100 medication orders 
reviewed and treated as continuous variables to enable comparison to the published 
literature. The rates of all pharmacists’ interventions and active interventions on the 
five wards were compared using Poisson regression analysis. Poisson regression 
analysis was also used to determine the influence of pharmacists’ level of 
employment and the duration of pharmacy ward round on the rates of all 
pharmacists’ interventions and the active interventions. All data were analysed using 
SPSS version 22.0. 
The univariate and multivariate logistic regression for predictors of physician-
acceptance of pharmacists’ active interventions were based on a backward likelihood 
ratio method using SPSS version 22.0. The first step of logistic regression is 
selecting dependent and independent variables. ‘Acceptance’ of each intervention, as 
a binary variable, was used as the dependent variable in a logistic regression model. 
Selection of independent variables/predictors, either continuous or categorical, was 
guided by published research and the direct observation data (Table 3.1). The 
independent variables were grouped into: 
 Patient characteristics: age, gender, diagnosis on admission, clinical area 
during hospital stay, length of stay, number of medications prescribed 
 Drug characteristics: therapeutic class(188), dose form, high-risk 
category(189) 
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 Types of active interventions (Table 3.2) 
 Pharmacists’ characteristics: gender, years of experience, highest academic 
qualification, work pattern (full-time/part-time), work post 
(permanent/temporary). 
A contingency table of dependent variables (degree of acceptance) versus categorical 
independent variables was used to ensure that no cell had a zero cell count and that 
not fewer than 20% of cells had a frequency count of fewer than five, in accordance 
with best practice (Step 2). After regrouping as necessary, univariate logistic 
regression analysis was conducted for each variable selected for inclusion in the 
model (continuous and categorical) (Step 3). As the traditional p-value (0.05) often 
fails to identify variables deemed to be important,(191) any variable demonstrating 
an association with the outcome with p<0.25 was initially included in the 
multivariate regression model (Step 4). The multivariate logistic regression applied 
backward elimination (the least significant variable was progressively deleted until 
all variables remaining in the model were statistically significant at p<0.05) to 
produce Model 1. Next, all possible two-way interactions of the significant 
independent variables from Model 1 were examined (Step 5). Each interaction was 
tested in a full regression model including all significant independent variables from 
Model 1. An interaction that was not significantly associated with the outcome was 
deleted. However, every interaction term with a significant contribution (p<0.05) was 
included in the next model. For the final step, the logistic regression was repeated to 
include all significant independent variables and significant interaction variables as 
the predictors. The odds ratios, their significance levels and 95% confidence intervals 
(95%CI) were calculated for each variable. Significant variables (p<0.05) in the final 
model were considered to be the predictors of the outcome (physician-acceptance of 
pharmacists’ active intervention). 
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Table 3.2 Pharmacist intervention categories developed by Condren et al.(184) with slight 
modification  
Intervention categories Intervention subcategories 
ADE or ME occurrence Dose missing 
Illegible order 
Inappropriate rate/dilution 
Incompatibility 
Incorrect/missing route 
Known patient allergy 
Label incorrect 
MAR error 
Missing/wrong weight 
Overdose 
Scheduling error 
Under dose 
Wrong drug 
Wrong patient 
Wrong/missing direction 
Wrong/missing strength 
Drug information provision Consulted for drug information in-service 
Provided administration information 
Provided compatibility information 
Provided without consult 
Drug interaction Disease 
Drug 
Food 
Herb 
Laboratory test 
Vitamin 
Drug therapy change Antibiotic change 
Decreased dose 
Decreased dosing interval 
Dose form change/strength change 
Dose adjustment for renal/hepatic impairment 
Drug added 
Drug deleted – no indication 
Drug deleted – therapeutic duplication 
Drug deleted – impaired renal/hepatic function 
Duration of therapy change 
Increased dose 
Increased dosing interval 
Intravenous to per oral change or vice versa 
Non-formulary to formulary change 
Regular to if required or vice versa 
Laboratory monitoring Recommended deletion 
Scheduling error 
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Medication history/patient counselling Allergy/ADR clarification 
Discharge counselling 
Medication history and/or medication 
reconciliation 
Patient and/or parent education 
ADE or ME prevented Dose missing 
Illegible order 
Inappropriate rate/dilution 
Incompatibility 
Incorrect/missing route 
Label incorrect 
MAR error 
Missing/wrong weight 
Overdose 
Patient allergy/ADR history 
Scheduling error 
Under-dose 
Wrong drug 
Wrong patient 
Wrong/missing strength 
Wrong/missing frequency 
Wrong/missing duration 
Clarification of medication order on 
medication chart 
 
Other Add patient identification on medication chart 
Monitor the possibility of adverse effect 
Clarify the diagnosis/drug indication 
Cost saving 
ADE = adverse drug event, ADR = adverse drug reaction, MAR = medication administration record 
3.2 Part Two: Clinical Significance of Pharmacists’ Active Interventions and 
Identification of Medication Misadventure through Pharmacists’ Active 
Interventions Using an Expert Panel  
3.2.1 Clinical Significance of Pharmacists’ Active Interventions  
The principal researcher de-identified all of the pharmacists’ active interventions 
collected during the ward round and dispensing from Part One. Forty-two active 
interventions were randomly selected from a total of 266 active interventions 
(approximately 16% of active interventions) using a random number generator. The 
selected active interventions were presented as vignettes describing the patient-
related information (demographics, medical history, medication history, allergy/ADR 
history, presenting complaints, diagnosis on admission, current medications), 
medication-related issues and pharmacists’ interventions to solve the issues 
(Appendix 6). The two researchers (YP, JH) with clinical pharmacy experience and 
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no involvement in data collection, reviewed the clinical significance of the selected 
cases and reached consensus. Three independent panellists (hospital pharmacist, 
academic pharmacist, clinical nurse) also reviewed the cases in their own time. As 
consensus could not be reached between the researchers and the three independent 
panellists (Panel 1), a second panel was set up. Panel 2 involved the researchers (YP, 
, JH) and two independent panellists from the study hospital (medication safety 
pharmacist, paediatric oncology pharmacist). The two panellists reviewed the cases 
in their own time. For the clinical significance assessment, the rating system 
described by Dooley et al.(19) was used with modification to include an ‘unsure’ 
option (Table 3.3). A meeting was organised between the researcher (YP) and the 
two independent panellists in order to reach consensus.  
3.2.2 Identification and Assessment of Medication Misadventure 
The two researchers (YP, JH) and Panel 1 also assessed the 42 vignettes to ascertain 
whether the cases involved medication misadventure (Section 3.2.1). If the cases 
involved medication misadventure, the researchers and the panellists determined the 
type of medication misadventure (ADE, ADR, ME). If medication misadventure 
involved an ME, the researchers and panellists classified the type of ME and rated 
the severity of the consequences using the National Coordinating Council for 
Medication Error Reporting and Prevention Taxonomy (NCCMERP).(35) The 
researchers and Panel 1 could not reach consensus. Inter-rater reliability analysis for 
the assessment of medication misadventure detected through pharmacists’ active 
interventions were determined based on Krippendorff’s alpha values calculated using 
SAS version 9.2. The Krippendorff’s alpha was the extension of Cohen’s Kappa 
which was used for inter-reliability assessment for multiple raters.  
The interpretation of the Krippendorff’s alpha values (192) was as follows:  
 0.00: poor agreement  
 0.01-0.20: slight agreement  
 0.21-0.40: fair agreement 
 0.41-0.60: moderate agreement 
 0.61-0.80: substantial agreement 
 0.81-1.00: almost perfect agreement.  
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Table 3.3 Clinical significance rating of pharmacists’ interventions  
Clinical significance Definition 
Life-saving Related to a potential life- and death situation 
Major Expected to prevent or address a 'very serious' drug-related 
problem defined as >20% chance of noticed effect or >5% 
chance of harmful effect 
Moderate Expected to enhance the effectiveness of drug therapy, 
producing minor reductions in patient morbidity or a <20% 
chance of noticed effect 
Minor Adjustment and optimisation of therapy, not expected to 
significantly alter hospital stay or clinical outcome 
No clinical 
significance 
Information only 
3.3 Part Three: Comparison of Documentation Methods for Pharmacists’ 
Interventions  
3.3.1 Documentation of Pharmacists’ Interventions during Snapshot 
Periods 
In addition to the prospective direct observation of pharmacists’ interventions (Part 
One), pharmacists’ interventions documented through self-reports were also 
analysed. Snapshot intervention documentation is used by the study hospital during 
certain periods to document pharmacists’ interventions. Snapshot periods occurred 
twice yearly during March to May and September to October and were of five days 
duration. These periods were selected to enable rotational medical staff to settle into 
their new areas before monitoring their practices. During the snapshot periods, the 
interventions were documented by pharmacists in the main pharmacy, the two 
satellite pharmacies (cardiology and neurology, and haematology-oncology), 
centralised intravenous admixture services unit and all wards. Pharmacists 
documented the interventions on a standardised form (Appendix 7) and recorded the 
patient identification number, ward location, brief description of the intervention and 
medication(s). The number of medication charts reviewed, the number of patients 
seen and other clinical activities, i.e. review of treatment protocols, teaching and 
presentations to peers were also recorded. An administrative staff member 
transferred the completed intervention forms onto Excel spread sheets (snapshot 
intervention database).  
The principal researcher retrospectively analysed the documentation form of 
pharmacists’ interventions from the five study wards for three snapshot periods - 
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September 2010 (period I), April 2011 (period II), and May 2012 (period III) - to 
determine the number and type of interventions. The snapshot documentation form 
was used instead of retrieval data from the snapshot intervention database as it was 
incomplete. The type of intervention was categorised as described by Condren et 
al.(184) with slight modification (Table 3.2). The interventions were further 
classified into ‘active’ and ‘passive’ as defined previously. The rates of intervention 
were defined as the number of interventions per 100 medication charts reviewed. 
Each medication chart reviewed could have one or more interventions. Demographic 
variables and pharmacists’ intervention data were summarised using descriptive 
statistics. The rates of pharmacists’ interventions per 100 medication charts reviewed 
documented through snapshot periods and during direct observation for each ward 
(Part One) were compared using Poisson regression analysis. Data were analysed 
using SPSS version 19.0 (Chicago, USA). This study was covered by the ethics as 
described in Section 3.1.3. The data extraction from snapshot reports maintained 
patients and pharmacists confidentiality by using coding system. 
3.3.2 Focus Group Discussion 
A focus group discussion (FGD) was conducted at the study hospital. Participants 
were invited via official electronic mail by the preceptor pharmacist to all 
pharmacists in the Pharmacy Department. A Study Information Sheet (Appendix 8) 
and Consent Form (Appendix 9) were attached to the invitation; consent included 
participants’ approval for the session to be audio recorded. The study was approved 
by Princess Margaret Hospital institutional review board and Curtin University 
Human Ethics Committee No: PH-11-13 (Appendix 10). The principal researcher 
presented the pharmacists' interventions documented from snapshot reports and the 
direct observations. This was followed by a discussion conducted by an independent 
facilitator. The principal researcher took notes during the discussion for 
crosschecking. The FGD was audio recorded and transcribed verbatim for thematic 
analysis. Transcripts of the discussion were entered into qualitative data management 
software program (QSR NVivo10). Within this software the partial transcripts were 
then coded and emergent themes were linked. 
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The research questions addressed during the FGD were: 
 Pharmacists’ interventions documented during snapshots versus observation 
were different. Are the results from observation more reflective? Why do you 
think so? 
 How important is the documentation of pharmacists’ interventions? 
 How valuable are your clinical interventions? 
 Are there any problems in documenting your interventions? Why do you 
think so? 
 Are there problems with the way data are used? Why do you think so? 
 What are the benefits and limitations of the snapshot documentation? 
 Would you like to see modifications made to your current intervention 
documentation method? What are your suggestions to improve the existing 
documentation method? 
3.4 Part Four: Medication Errors in Children: Root Cause Analysis Using 
Simulated Case Scenarios 
3.4.1 Development of Simulated Case Studies and Survey Instrument 
The principal researcher developed five simulated case studies involving paediatric 
patients. Each case study represented the patient characteristic of the five study 
wards (Part One) and was associated with one ME with a different type of error - 
inappropriate dose, dispensing error, drug omission, transcribing error and 
monitoring error. Each case study was reviewed by the other researchers (YP and 
JH) for accuracy of the clinical information and its relevance with the treatment 
policy and procedure at the study hospital. The questionnaire was divided into two 
sections. Section one contained questions related to participants’ demographics (age, 
gender, type of health professional, current position, years of experience as a health 
professional, and years of experience in paediatrics). Section two presented five 
simulated case studies in children followed by questions on ME and RCA. ME-
related questions required rating of clinical significance of the error and 
identification of the health professional(s) responsible for the error.  
The RCA questions were used to identify the potential contributing factors to the 
error in each case. The RCA questions were adapted from the Clinical Incident 
Management Toolkit(193) and included only those with relevance to the case studies. 
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The adapted RCA questions consisted of seven items. Participants were asked to 
determine the potential contributing factors by selecting the options provided for 
each question and describing why the factor(s) selected contributed to the error. The 
RCA questions included:  
 specific patient issues 
 dismissal of policies/procedures/guidelines (sub-factors: patient 
misidentification, error/omission in medication reconciliation, clinical 
guidelines, coordination of care, medical record documentation, level and 
frequency of monitoring of patient) 
 human resources-related issues (sub-factors: staff workload and inadequate 
staffing, recruitment, staff training and supervision, staff supervision) 
 communication-related issues (sub-factors: miscommunication between staff, 
miscommunication between staff and patient and/or family) 
 physical environment of the health service (sub-factors: noise, lighting, 
space) 
 control/provision of medication (sub-factors: medication storage, labelling, 
documentation of administration, internal transfer of medication). 
Participants could tick the ‘unsure’ option if in doubt about selecting the contributing 
factors. Participants could also list under the ‘other’ category any extra factors that 
contributed to the errors. After all potential contributing factors were identified and 
evaluated participants were asked to give their suggestions on strategies to prevent 
the recurrence of the error in the future. 
3.4.2 Face Validity Test 
A pilot study involving three academic pharmacists (including one of the researchers, 
LE) was conducted to determine the face validity of the questionnaire. Participants 
were asked to assess the clarity of the questionnaire including the instructions, case 
studies and questions. Participants were also asked to evaluate the questionnaire 
design and layout, and to estimate the time needed to complete the questionnaire. 
Participants’ comments were used to refine the final questionnaire. 
3.4.3 Participants and Questionnaire Administration 
A total of 111 coded self-administered questionnaires (Appendix 11) were 
distributed to potential participants from mid-July 2014 to mid-August 2014. 
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Potential participants included all pharmacists (n=37) and randomly selected (20%) 
doctors (n=31, around 5-6 doctors/ward ) and nurses (n=43, around 8-9 nurses/ward) 
from the five study wards in the hospital (Part One). A Participant Information Sheet 
(Appendix 12) containing information about the study aims, confirmation that 
collected information would remain confidential and researchers’ contact details was 
attached to the questionnaire. A consent form (Appendix 13) and reply-paid envelope 
were also provided along with the questionnaire and the Participant Information 
Sheet. This study was covered by the ethics as described in Section 3.1.3. The 
principal researcher handed the questionnaires directly to the pharmacists. The 
questionnaires for doctors and nurses were disseminated either directly by the 
principal researcher under the supervision of the ward pharmacists or by the ward 
pharmacists using convenience sampling until the number of doctors/nurses recruited 
reached the predefined sample size. Participants were allowed to complete the 
questionnaires in their own time. They were asked to return the questionnaires by the 
predefined time in the envelope provided. The overall expected response rate was 
around 40%. Participation was voluntary and no incentives were offered. The first 
reminder for returning the questionnaire was sent via email to all pharmacists at the 
end of August 2014. The ward pharmacists undertook the reminders for doctors and 
nurses during ward rounds and via staff electronic mail. The second reminder was 
sent at the end of September 2014. 
3.4.4 Data Analysis 
Demographic data of the participants, and their rating of clinical significance of the 
error, identification of the responsible health professional(s) and the contributing 
factors for each case were entered into SPSS version 22.0. Data were randomly 
checked for accuracy and descriptive statistical analysis was conducted. The 
principal researcher assigned the pre-determined answers for the questions related to 
contributing factors of MEs for each case. A General Estimating Equation (GEE) 
analysis was adopted to develop an agreement model between the participants’ 
responses on the contributing factors for each case and the principal researcher’s pre-
determined answers. If the agreement model using GEE was not able to be fitted (e.g. 
due to complete agreement in some or all cases), the results was summarised more 
appropriately using descriptive statistics. Participants’ statements on the description 
of the contributing factors and their suggestions on the prevention of the error in each 
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case were entered into the qualitative data management software (QSR Nvivo 
version 10.0) for thematic analysis. Participants’ statements were coded for any 
emergent themes. This study was covered by the ethics as described in Section 3.1.3. 
Data extraction from the questionnaire maintained the participants’ confidentiality by 
using coding system.  
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Chapter 4 
PART ONE: RESULTS AND DISCUSSION 
4.1 Direct Observation and Documentation of Ward Pharmacists’ Interventions 
4.1.1 Observation and Documentation in the General Medical Unit 
There were three wards in the General Medical Unit - General Medical Ward for 
Infants, General Medical Ward for Young Children and General Medical Ward for 
Adolescents. The characteristics of patients admitted to these three wards during the 
study period (September 2011-August 2012) are summarised in Table 4.1. Patients 
ranged in age from newborn to 19 years, and females accounted for nearly two-thirds 
of the patients in the adolescent ward. There were differences in length of stay and 
number of medications across the three wards. The five most common reasons for 
admission to each ward are presented in Figure 4.1. Diseases of the respiratory 
system were the prevalent reason for admission in the wards for infants and young 
children, while mental and behavioural disorders were prevalent in the adolescent 
ward.  
Table 4.1 Characteristics of patients on the three general medical wards 
Parameters Infants Young Children Adolescents 
Age (years), median 
(range) 
0.35 (0.02-2.42) 5.83 (2.00-13.00) 15.00 (4.33-19.00) 
Gender (%) 
-Male 
-Female 
 
320 (56.7%) 
244 (43.3%) 
 
361 (55.5%) 
290 (44.5%) 
 
258 (35.8%) 
463 (64.2%) 
Median length of stay 
(days) (range) 
6.00 (1-95) 9.00 (1-73) 14.00 (1-91) 
No. of medications 
prescribed per patient  
-Oral medications, 
median (range) 
-Non-oral medications, 
median (range) 
 
 
1.00 (0-8) 
 
1.00 (0-11) 
 
 
2.00 (0-18) 
 
2.00 (0-30) 
 
 
 
4.00 (0-22) 
 
1.00 (0-19) 
 
The 35-day observation data of pharmacists’ interventions (passive and active) and 
active interventions are shown in Table 4.2 and Table 4.3, respectively. The duration 
of pharmacy rounds ranged from 15 to 137 minutes (Table 4.2). Ward pharmacists 
made 4 to 6 interventions per day, and the rates of interventions ranged from 4.38 to 
7.83 interventions per 100 medication orders reviewed on the general medical wards.  
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Figure 4.1 Top five reasons for admission to the general medical wards 
Table 4.2 Pharmacists’ interventions on the three general medical wards (direct 
observation 35 days) 
Parameters Infants Young Children Adolescents 
Duration of pharmacy round 
(minutes), mean ± SD (range) 
35.14 ± 14.21 
(15-70) 
57.60 ± 24.39 
(20-110) 
58.69 ± 22.34 
(32-137) 
No. of Pis 145 153 218 
No. of medication orders 
reviewed 
1903 3778 4813 
No. of medication charts 
reviewed 
468 500 528 
No. of patients 564 651 721 
Rate of PIs per 100 medication 
orders reviewed, mean ± SD 
7.83 ± 6.84 4.38 ± 4.17 4.77 ± 3.07 
Rate of PIs per 100 medication 
charts reviewed, mean ± SD 
32.72 ± 29.45 33.79 ± 32.49 53.62 ± 48.94 
Rate of PIs per 100 patients, 
mean ± SD 
25.75 ± 21.63 24.32 ± 22.35 30.82 ± 18.89 
Rate of PIs per day, mean ± SD 4.14 ± 3.53 4.49 ± 3.93 6.23 ± 3.71 
PIs = pharmacist’s interventions 
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Pharmacists’ active interventions constituted less than one-quarter of interventions in 
the general medical wards. Physician acceptance of the interventions was high; 90% 
or more in the wards for infants and young children. The rates of active interventions 
ranged from 0.81 to 1.15 per 100 medication orders reviewed across the medical 
wards (Table 4.3). 
Table 4.3 Pharmacists’ active interventions on the three general medical wards (direct 
observation 35 days) 
Parameters Infants Young Children Adolescents 
No. of active PIs (%)* 16 (11.0%) 28 (18.3%) 51 (23.4%) 
Physician acceptance of active PIs 
(%) 
- Yes 
- No 
 
 
15 (93.8%) 
1 (6.3%) 
 
 
26 (92.9%) 
2 (7.1%) 
 
 
40 (78.4%) 
11 (21.6%) 
Rate of active PIs per 100 
medication orders reviewed, mean 
± SD 
0.85 ± 1.35 0.81 ± 1.24 1.15 ± 1.19 
Rate of active PIs per 100 
medication charts reviewed, mean 
± SD 
3.97 ± 6.88 5.72 ± 8.31 17.34 ± 30.16 
Rate of active PIs per 100 patients, 
mean ± SD 
2.89 ± 4.76 4.35 ± 6.17 7.40 ± 7.77 
Rate of active PIs per day, mean ± 
SD 
0.46 ± 0.74 0.80 ± 1.13 1.46 ± 1.42 
*Percentage of active interventions of all pharmacists’ interventions (i.e. passive and active).  
PI = pharmacists’ interventions 
The most common interventions by clinical pharmacists on the general medical 
wards were medication histories and/or patient counselling (Figures 4.2, 4.3 and 4.4). 
These activities constituted more than half of all interventions. The proportion of 
interventions relating to drug therapy change gradually increased from younger to 
older patients on the general medical wards. On the ward for infants (Figure 4.2), 
provision of drug information to other healthcare providers was the second most 
common intervention; just over 10% of interventions. Activities associated with drug 
therapy changes constituted the second most common intervention on the ward for 
young children (Figure 4.3). 
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Figure 4.2 Pharmacists’ interventions on the general medical ward for infants 
 
Figure 4.3 Pharmacists’ interventions on the general medical ward for young children 
10.3% 6.9% 
68.3% 
4.1% 9.7% 
0.7% 
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Drug therapy changes 
Medication history and/or 
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Prevented ADE or ME 
Clarification of medication 
order 
Other 
General Medical Ward for Infants (n=145)  
0.7% 
11.8% 
13.7% 
64.1% 
3.9% 
5.2% 0.7% 
Occurrence of ADE or ME 
Provision of drug 
information to other 
providers 
Drug therapy changes 
Medication history and/or 
patient counselling 
Prevented ADE or ME 
Clarification of medication 
order 
Other 
General Medical Ward for Young Children  
                                     (n=153) 
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Figure 4.4 Pharmacists’ interventions on the general medical ward for adolescents 
The subcategory of medication history and/or medication reconciliation dominated 
the interventions (Table 4.4). The proportion of other categories and subcategories of 
the interventions varied widely across the three medical wards. 
2.3% 
11.0% 
15.6% 
50.0% 
5.0% 14.2% 
1.8% 
Occurrence of ADE or ME 
Provision of drug information 
to other providers 
Drug therapy changes 
Medication history and/or 
patient counselling 
Prevented ADE or ME 
Clarification of medication 
order 
Other 
General Medical Ward for Adolescents (n=218)  
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Table 4.4 Categories of pharmacists’ interventions on the three general medical wards 
Categories and subcategories of 
pharmacists’ interventions 
Infants 
(n=145),  
n (%) 
Young 
Children 
(n=153), n (%) 
Adolescents 
(n=218),  
n (%) 
Occurrence of ADE or ME 
- Known patient allergy 
- Overdose 
- Scheduling error 
- Under dose 
0 (0.0) 1 (0.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (0.7) 
4 (2.3) 
2 (0.9) 
0 (0.0) 
2 (1.4) 
0 (0.0) 
Provision of drug information  
- Consulted for in-service 
- Provided administration information 
- Provided compatibility information 
- Provided without consult 
15 (10.3) 
2 (1.4) 
7 (4.8) 
0 (0.0) 
6 (4.1) 
18 (11.8) 
10 (6.5) 
5 (3.3) 
2 (1.3) 
1 (0.7) 
24 (11.0) 
9 (4.1) 
8 (3.7) 
0 (0.0) 
7 (3.2) 
Medication history and/or patient 
counselling 
- Allergy/ADR clarification 
- Medication history and/or medication 
reconciliation 
- Patient and/or parent education 
99 (68.3) 
 
32 (22.1) 
66 (45.5) 
 
1 (0.7) 
98 (64.1) 
 
14 (9.2) 
66 (43.1) 
 
18 (11.8) 
110 (50.5) 
 
13 (6.0) 
82 (37.6) 
 
15 (6.9) 
Clarification of medication order 14 (9.7) 8 (5.2) 30 (13.8) 
Drug therapy changes 
- Antibiotic change 
- Decreased dose 
- Decreased dosing interval 
- Dose form change/strength change 
- Dose adjustment for renal/hepatic 
function 
- Drug added 
- Drug deleted - no indication 
- Drug deleted - therapeutic duplication 
or drug interaction 
- Duration of therapy change 
- Increased dose 
- Increased dosing interval 
- Drug deleted - impaired renal/hepatic 
function 
- Regular to if required or vice versa 
10 (6.9) 
0 (0.0) 
2 (1.4) 
0 (0.0) 
2 (1.4) 
0 (0.0) 
 
1 (0.7) 
0 (0.0) 
1 (0.7) 
 
0 (0.0) 
4 (2.8) 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
21 (13.7) 
0 (0.0) 
2 (1.3) 
1 (0.7) 
2 (1.3) 
0 (0.0) 
 
1 (0.7) 
0 (0.0) 
4 (2.6) 
 
1 (0.7) 
7 (4.6) 
3 (2.0) 
0 (0.0) 
 
0 (0.0) 
34 (15.6) 
2 (0.9) 
2 (0.9) 
2 (0.9) 
0 (0.0) 
1 (0.5) 
 
8 (3.7) 
1 (0.5) 
4 (1.8) 
 
0 (0.0) 
7 (3.2) 
3 (1.4) 
3 (1.4) 
 
1 (0.5) 
ADE or ME prevented 
- Dose missing 
- Illegible order 
- Incorrect/missing route 
- MAR error 
- Overdose 
- Scheduling error 
- Under dose 
- Wrong patient 
- Wrong/missing strength 
- Wrong/missing frequency 
6 (4.1) 
3 (2.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (0.7) 
0 (0.0) 
2 (1.4) 
6 (3.9) 
2 (1.3) 
1 (0.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
3 (2.0) 
11 (5.0) 
0 (0.0) 
0 (0.0) 
2 (0.9) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
0 (0.0) 
2 (0.9) 
4 (1.8) 
Other 1 (0.7) 1 (0.7) 4 (1.9) 
ADE = adverse drug event, ADR = adverse drug reaction, MAR = medication administration record, 
ME = medication error 
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Drug classes implicated in active interventions are listed in Table 4.5. Unadjusted for 
prescription volume, anti-infectives were the drugs most often associated with active 
interventions, followed by analgesics and gastrointestinal drugs. 
Table 4.5 Drug classes associated with active interventions (n=95) on the three general 
medical wards  
Drug classes Infants 
Young 
Children Adolescents 
Frequency* 
(%) 
Anti-infectives 3 16 13 32 (33.7) 
Analgesics 5 4 18 27 (28.4) 
Gastrointestinal  3 1 4 8 (8.4) 
Neurological  1 0 4 5 (5.3) 
Respiratory  0 4 0 4 (4.2) 
Blood and electrolytes 2 0 2 4 (4.2) 
Endocrine  1 0 2 3 (3.2) 
Anaesthetics 0 1 1 2 (2.1) 
Cardiovascular  1 1 0 2 (2.1) 
Immunomodulators/ 
antineoplastics 
0 0 2 2 (2.1) 
Obstetric/gynaecological  0 0 2 2 (2.1) 
Allergy/anaphylaxis  0 1 0 1 (1.1) 
Ear, nose, and throat  0 0 1 1 (1.1) 
Psychotropic  0 0 1 1 (1.1) 
Vaccines 0 0 1 1 (1.1) 
*Total number of medications implicated in the active interventions, not adjusted for the prescribing 
volume of medications. 
Unadjusted for prescribing volume, antibacterials were the predominant anti-
infectives involved in the interventions (just over 90% of anti-infectives related 
active interventions, n=29); the remaining involved antifungals. The most common 
antibacterials involved were aminoglycosides, vancomycin and penicillins. Dose 
adjustment (n=18) was responsible for the majority of interventions; accounting for 
more than half of interventions in this class. Another common intervention outcome 
was dose interval/frequency adjustment (n=6); nearly 19% of interventions.  
Non-opioid analgesics (n=20) were the major contributor to active interventions on 
the general medical wards; almost three-quarters of analgesics-associated active 
interventions. The interventions were documented most frequently in adolescents 
(n=18). Pharmacists performed two-thirds of the analgesics-related interventions in 
this patient population. The three major subcategories of active interventions in this 
class were: dose adjustment, dose interval/frequency adjustment, and drug deletion. 
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The most frequent trigger for pharmacists’ interventions was medication chart review 
(Table 4.6). 
Table 4.6 Triggers for pharmacists’ interventions 
Trigger for interventions 
Infants, 
n (%) 
Young Children, 
n (%) 
Adolescents, 
n (%) 
Medication chart review 135 (93.1) 114 (74.5) 180 (82.6) 
Doctor inquiry 1 (0.7) 8 (5.2) 5 (2.3) 
Patient and/or parent inquiry 1 (0.7) 7 (4.6) 11 (5.0) 
Nurse inquiry 7 (4.8) 9 (5.9) 10 (4.6) 
Laboratory result 1 (0.7) 4 (2.6) 10 (4.6) 
Medication history taking 0 (0.0) 11 (7.2) 2 (0.9) 
4.1.2 Observation and Documentation in the General Surgical Unit 
There was one ward within the general surgical unit in the study hospital. The 
characteristics of patients admitted to the general surgical ward during the study 
period (September 2011-August 2012) are summarised in Table 4.7. Patients ranged 
in age from newborn to 17 years, and there were considerably more male patients. 
The top five reasons for admission to this ward are presented in Figure 4.5. Diseases 
of the digestive system were the most common reason for admission; more than one-
quarter of all admissions in this ward. 
Table 4.7 Characteristics of patients on the general surgical ward 
Patient characteristics Value 
Age, median years (range) 6.17 (0.06-17.00) 
Gender (%) 
- Male 
- Female 
 
311 (60.5%) 
203 (39.5%) 
Length of stay, median days (range) 5.00 (1-71) 
No. of medications prescribed per patient  
- Oral medications, median (range)  
- Non-oral medications, median (range) 
 
3.00 (0-10) 
2.00 (0-13) 
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Figure 4.5 Top five reasons for admission to the general surgical ward 
Ward pharmacists spent on average 50 minutes per day to complete their ward round 
(Table 4.8). They made around seven interventions per day; 10.48 interventions per 
100 medication orders reviewed and 76.83 interventions per 100 medication charts 
reviewed. Active interventions accounted for just over 20% of pharmacists’ 
interventions, with high physician acceptance (Table 4.9). 
Table 4.8 Pharmacists’ interventions on the general surgical ward (direct observation 37 
days) 
Parameters Value 
Duration of pharmacy round in minutes per day, mean ± SD 50.70 ± 18.99 
No. of PIs 271 
No. of medication orders reviewed 2700 
No. of medication charts reviewed 422 
No. of patients 514 
No. of patients receiving PIs (%) 155 (30.2%) 
Rate of PIs per 100 medication orders reviewed, mean ± SD 10.48 ± 6.59 
Rate of PIs per 100 medication charts reviewed, mean ± SD 76.83 ± 80.31 
Rate of PIs per 100 patients, mean ± SD 54.01 ± 31.31 
Rate of PIs per day, mean ± SD 7.41 ± 4.62 
PIs = pharmacist’s interventions 
0,0 10,0 20,0 30,0 
Diseases of the digestive system 
Symptoms, signs, and abnormal findings 
Diseases of the genitourinary system 
Diseases of the respiratory system 
Diseases of the skin and subcutaneous 
tissues 
28,2 
14,4 
11,9 
9,1 
6,8 
Percentage 
Reasons for Admission (n=514) 
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Table 4.9 Pharmacists’ active interventions on the general surgical ward (direct 
observation 37 days) 
Parameters Value 
No. of active PIs (% of all interventions) 59 (21.8%) 
Physician acceptance of active PIs (%) 
- Yes 
- No 
 
50 (84.7%) 
9 (15.3%) 
Rate of active PIs per 100 medication orders reviewed, mean ± SD 2.34 ± 2.23 
Rate of active PIs per 100 medication charts reviewed, mean ± SD 24.54 ± 64.76 
Rate of active PIs per 100 patients, mean ± SD 12.39 ± 11.71 
Rate of active PIs per day, mean ± SD 1.59 ± 1.36 
PIs = pharmacist’s interventions 
Taking a medication history and/or patient counselling was the most common 
intervention in the surgical ward (Table 4.10).  
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Table 4.10 Categories of pharmacists’ interventions on the general surgical ward (n=271) 
Categories and subcategories of pharmacists’ interventions No. of cases (%) 
Occurrence of ADE or ME 0 (0.0) 
Provision of drug information to other providers 
- Consulted for drug information in-service 
- Provided administration information 
- Provided without consultation 
27 (10.0) 
8 (3.0) 
7 (2.6) 
12 (4.4) 
Drug interaction 
- Drug-drug  
1 (0.4) 
1 (0.4) 
Laboratory monitoring 
- Recommended/deletion 
1 (0.4) 
1 (0.4) 
Medication history and/or patient counselling 
- Allergy/ADR clarification 
- Discharge counselling 
- Medication history and/or medication reconciliation 
- Patient and/or parent education 
146 (53.9) 
19 (7.0) 
1 (0.4) 
104 (38.5) 
22 (8.1) 
Clarification of medication order 35 (12.9) 
Drug therapy changes 
- Antibiotic change 
- Decreased dose 
- Decreased dosing interval 
- Dose form change/strength change 
- Drug added 
- Drug deleted - no indication 
- Drug deleted - therapeutic duplication or drug interaction 
- Increased dose 
- Increased dosing interval 
- Non formulary to formulary change 
- Regular to if required or vice versa 
50 (18.5) 
2 (0.7) 
8 (3.0) 
2 (0.7) 
3 (1.1) 
8 (3.0) 
2 (0.7) 
2 (0.7) 
12 (4.4) 
2 (0.7) 
3 (1.1) 
6 (2.2) 
Prevention of ADE or ME 
- Illegible order 
- Overdose 
- Patient allergy/ADR history 
- Wrong/missing strength 
- Wrong/missing frequency 
8 (3.0) 
1 (0.4) 
1 (0.4) 
2 (0.7) 
1 (0.4) 
3 (1.1) 
Other 3 (1.1) 
ADE = adverse drug event, ADR = adverse drug reaction, ME = medication error 
Drug classes associated with pharmacists’ active interventions are outlined in Table 
4.11. Anti-infectives were the drugs most frequently associated with active 
interventions, followed by analgesics and gastrointestinal drugs. 
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Table 4.11 Drug classes associated with pharmacists’ active interventions (n=59) on the 
general surgical ward 
Drug classes No. of active interventions (%)
*
 
Anti-infectives 30 (50.8) 
Analgesics 12 (20.3) 
Gastrointestinal  9 (15.3) 
Respiratory  2 (3.4) 
Ophthalmic  1 (1.7) 
Genitourinary  1 (1.7) 
Immunomodulators/antineoplastics 1 (1.7) 
Neurological  1 (1.7) 
Psychotropic  1 (1.7) 
Other 1 (1.7) 
*Total number of medications implicated in the active interventions, not adjusted for the prescribing 
volume of medications. 
Antibiotics accounted for all cases of anti-infectives associated interventions. Dose 
adjustment was responsible for 50% of the interventions in this class, mainly to 
increase the dose (n=9). Antibiotics involved in the interventions, unadjusted for 
prescribing volume, were aminoglycosides, vancomycin and penicillins; nearly half 
of the interventions on this ward.  
Triggers to initiate interventions (passive and active) on the general surgical ward are 
listed in Table 4.12. Medication chart review was the predominant trigger of the 
interventions; more than 80%.  
Table 4.12 Triggers for pharmacists interventions on the general surgical ward (n=271) 
Trigger for intervention No. of cases (%) 
Medication chart review 234 (86.3) 
Patient and/or parent inquiry 12 (4.4) 
Nurse inquiry 9 (3.3) 
Laboratory result 8 (3.0) 
Medication history taking 7 (2.6) 
Other pharmacist inquiry 1 (0.4) 
4.1.3 Observation and Documentation on the Haematology-Oncology 
Ward 
There was one ward in the haematology-oncology unit in the study hospital during 
the study period (September 2011-August 2012). Patients ranged from infants to 
adolescents, and male patients constitued more than 60% of patients (Table 4.13). 
There was notable variation in the length of hospital stay and the number of 
medications prescribed per patient in this specialty ward.  
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Table 4.13 Characteristics of patients on the Haematology-Oncology Ward 
Patient characteristics Value 
Age in years, median (range) 6.83 (0.35-17.00) 
Gender (%) 
- Male 
- Female 
 
279 (63.3%) 
162 (36.7%) 
Median length of stay (days) (range) 7.00 (1-82) 
No. of medications for each patient  
- Oral medications, median (range) 
- Non-oral medications, median (range) 
 
4.00 (0-21) 
3.00 (0-14) 
Leukaemias, myeloproliferative diseases and malignant bone tumors were the three 
major diagnoses; nearly three-quarters of admissions in this ward (Figure 4.6). 
Data representing pharmacists’ interventions (passive and active) and active 
interventions are outlined in Table 4.14 and Table 4.15, respectively. Clinical 
pharmacists spent on average, 42 minutes undertaking their ward round, with up to 
six interventions per day (Table 4.14). Active interventions constituted nearly half of 
pharmacists’ interventions, and acceptance was common, with almost all active 
interventions accepted by physicians (Table 4.15). 
Figure 4.6 Top five diagnoses of patients (n=441) admitted to the Haematology-Oncology 
Ward during the 35-day study period 
0,0 10,0 20,0 30,0 40,0 50,0 
Leukaemias and 
myeloproliferative diseases 
Malignant bone tumors 
Neuroblastoma 
Central nervous system and 
intraspinal neoplasms 
Haematologic and immune 
diseases 
42,2 
18,6 
11,8 
7,0 
5,4 
Top 5 Diagnoses on  the Haematology-Oncology Ward  
Percentage 
 65 
Table 4.14 Pharmacists’ interventions on the Haematology-Oncology Ward (direct 
observation 35 days) 
Parameters Value 
Duration of pharmacy round in minutes per day, mean ± SD  41.71 ± 20.06 
No. of Pis 195 
No. of medication orders reviewed 3506 
No. of medication charts reviewed 357 
No. of patients 441 
No. of patients receiving PIs (%) 123 (27.9%) 
Rate of PIs per 100 medication orders reviewed, mean ± SD 5.63 ± 3.36 
Rate of PIs per 100 medication charts reviewed, mean ± SD 54.53 ± 28.17 
Rate of PIs per 100 patients, mean ± SD 42.99 ± 23.53 
Rate of PIs per day, mean ± SD 5.57 ± 3.42 
PIs = pharmacists’ interventions 
Table 4.15 Pharmacists’ active interventions on the Haematology-Oncology Ward (direct 
observation 35 days) 
Parameters Value 
No. of active PIs (%)
*
 90 (46.2%) 
Physician acceptance of active PIs (%) 
- Yes 
- No 
 
88 (97.8%) 
2 (2.2%) 
Rate of active PIs per 100 medication orders reviewed, mean ± SD 2.43 ± 1.84 
Rate of active PIs per 100 medication charts reviewed, mean ± SD 23.25 ± 17.19 
Rate of active PIs per 100 patients, mean ± SD 19.08 ± 14.06 
Rate of active PIs per day, mean ± SD 2.57 ± 2.10 
*Percentage of active interventions per pharmacists’s intervention (i.e. passive and active).  
PIs = pharmacists’ interventions 
Drug therapy changes were the most common interventions, representing over one-
third of interventions in this specialty ward (Table 4.16). Provision of drug 
information to other healthcare providers, and medication history and/or patient 
counselling were the next major interventions with both intervention types, 
contributing to just over half of the interventions. 
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Table 4.16 Categories of pharmacists’ interventions (n=195) on the Haematology-
Oncology Ward 
Categories and subcategories of pharmacists’ 
interventions No. of cases (%) 
Occurrence of ADE or ME 
- Overdose 
1 (0.5) 
1 (0.5) 
Provision of drug information to other providers 
- Consulted for drug information in-service 
- Provided administration information 
- Provided compatibility information 
- Provided without consultation 
52 (26.7) 
41 (21.1) 
7 (3.6) 
2 (1.0) 
2 (1.0) 
Medication history and/or patient counselling 
- Allergy/ADR clarification 
- Medication history and/or medication reconciliation 
- Patient and/or parent education 
48 (24.6) 
1 (0.5) 
26 (13.4) 
21 (10.8) 
Clarification of medication order 3 (1.5) 
Drug therapy changes 
- Decreased dose 
- Decreased dosing interval 
- Dose form change/strength change 
- Drug added 
- Drug deleted - therapeutic duplication or drug interaction 
- Duration of therapy change 
- Increased dose 
- Intravenous to per-oral change 
- Regular to if-required or vice versa 
73 (37.4) 
8 (4.1) 
1 (0.5) 
1 (0.5) 
36 (18.6) 
5 (2.6) 
6 (3.1) 
12 (6.2) 
1 (0.5) 
3 (1.5) 
ADE or ME prevented 
- Dose missing 
- Medication administration record error 
- Overdose 
- Scheduling error 
- Wrong drug 
- Wrong/missing frequency 
16 (8.2) 
2 (1.0) 
4 (2.1) 
1 (0.5) 
3 (1.5) 
1 (0.5) 
5 (2.6) 
Other 2 (1.0) 
ADE = adverse drug event, ADR = adverse drug reaction, ME = medication error 
Drug classes implicated in active interventions are presented in Table 4.17. Anti-
infectives were the drugs most often associated with active interventions, followed 
by gastrointestinal drugs, immunomodulators/antineoplastics and analgesics.  
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Table 4.17 Drug classes associated with pharmacists’ active interventions (n=90) on the 
Haematology-Oncology Ward 
Drug class No. of active interventions (%)* 
Anti-infectives 38 (42.2) 
Gastrointestinal  19 (21.1) 
Immunomodulators/antineoplastics 18 (20.0) 
Analgesics 7 (7.8) 
Endocrine  2 (2.2) 
Neurological  2 (2.2) 
Cardiovascular  1 (1.1) 
Ear, nose and throat  1 (1.1) 
Ophthalmic  1 (1.1) 
Psychotropic  1 (1.1) 
*Actual number of medications implicated in active interventions; not adjusted for the prescribing 
volume of medications. 
Antibacterials (n=33) were the predominant anti-infectives involved in the anti-
infectives related active interventions and the remaining due to antifungals. Dose 
adjustment (n=15) accounted for the most common interventions in relation to the 
use of anti-infectives, followed by drug addition (n=11). Antibacterials associated 
with active interventions were trimethoprim-sulfamethoxazole (n=14), vancomycin 
(n=9) and aminoglycosides (n=5). With respect to antifungals, the majority of active 
interventions were related to the azoles (e.g. fluconazole, posaconazole). 
The second major drug class involved in active interventions was for the 
gastrointestinal system. When categorised according to subclasses, antiemetics 
constituted almost 80% (n=15/19) of the interventions followed by drugs for 
dyspepsia. Drug addition was the most common intervention in this drug class 
(n=12), predominantly to add antiemetics as regular medications for patients on 
emetogenic chemotherapy. With regard to immunomodulators/antineoplastics, the 
majority of interventions were related to immunosuppressants (n=13), with the 
remaining involving antineoplastics. Drug addition (n=9) was the most common 
active intervention in this class.  
The most common trigger for interventions in the Haematology-Oncology Ward was 
medication chart review; more than half of all triggers (Table 4.18). 
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Table 4.18 Triggers for interventions (n=195) on the Haematology-Oncology Ward 
Triggers of interventions No. of cases (%) 
Medication chart review 116 (59.5) 
Doctor inquiry 30 (15.4) 
Patient and/or parent inquiry 22 (11.3) 
Nurse inquiry 11 (5.6) 
Laboratory result 10 (5.1) 
Ward meeting 3 (1.5) 
Other pharmacist inquiry 2 (1.0) 
Medication history taking 4.1 (0.5) 
4.1.4 Rates and Patterns of Pharmacists’ Interventions on the Five Study 
Wards 
During the six months of the study, eleven clinical pharmacists on the five study 
wards reviewed 2891 patients. Six pharmacists were categorised as Professional 
Level 1 (PL1), two as Professional Level 2 (PL2) and three as Professional Level 3 
(PL3) (Table 4.19). Nearly half of the pharmacists had postgraduate qualifications, 
and three-quarters worked full-time. A total of 982 interventions were observed and 
documented by the principal researcher, which arose from the 16,700 medication 
orders reviewed.  
Table 4.19 Characteristics of pharmacists (n=11) by level of employment* 
Pharmacist 
level Number 
No. with postgraduate 
qualification 
No. working 
full-time 
No. assigned in 
permanent post 
Level 1 6 2 5 1 
Level 2 2 0 1 1 
Level 3 3 3 2 2 
*Employment of clinical pharmacists in Australia starts with the pre-registration training year, 
followed by Professional Level 1 (must work under supervision), Professional Level 2 (often rotate 
among sections of the pharmacy), and Professional Level 3 (responsible to the Director of Pharmacy 
for the management and efficient performance of a specific unit or function of the hospital 
pharmacy).(194)  
Intervention rates ranged from 4.38 to 10.48 per 100 medication orders across the 
five wards (Table 4.20). Poisson regression modelling identified significant 
differences in intervention rates between the five wards (p<0.001). The highest rate 
of interventions was documented on the General Surgical Ward, followed by the 
General Medical Ward for Infants, the Haematology-Oncology Ward, the General 
Medical Ward for Adolescents, and the General Medical Ward for Young Children. 
There was no significant difference in the intervention rate between the general 
medical wards for Young Children and Adolescents. The rates of interventions were 
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significantly different across the employment level of the observed pharmacists 
(p<0.01). The PL2 pharmacists had the highest rates (8.13 interventions/100 
medication orders, SD 6.93), followed by PL1 (8.04, SD 5.82) and PL3 (4.58, SD 
3.82), respectively. No significant difference was observed in the rates of 
interventions between PL1 and PL2 pharmacists, but PL3 pharmacists were 
associated with significantly lower rates than PL1 (p<0.05) and PL2 pharmacists 
(p<0.01).  
Table 4.20 Rates of pharmacists’ interventions per 100 medication order reviews on the 
five study wards 
Parameters 
Infants 
(Ward A) 
Young 
Children 
(Ward B) 
Adolescents 
(Ward C) 
Surgical 
(Ward D) 
Haematology-
Oncology 
(Ward E) 
Mean±SD 7.83±6.84 4.38±4.17 4.77±3.07 10.48±6.59 5.63±3.36 
95% Confidence 
interval for 
mean 
5.48-10.18 2.95-5.81 3.71-5.82 8.28-12.68 4.48-6.78 
Overall p-value p<0.0001 
A = General Medical Ward for Infants, B = General Medical Ward for Young Children, C = General 
Medical Ward for Adolescents, D = General surgical Ward, E = Haematology-Oncology Ward 
Pharmacists on average spent 49 minutes (SD 22.01) on ward rounds each day. 
Longer time spent on the ward was associated with a higher rate of interventions 
(p<0.001). Pharmacists spending more than 60 minutes on rounds made 8.09 
interventions/100 medication orders (SD 6.00), while those spending 30 to 60 
minutes and less than 30 minutes made 6.42 interventions/100 medication orders (SD 
5.41) and 5.68 intervention/100 medication orders (SD 5.24), respectively. 
Rates of pharmacists’ active interventions per 100 medication orders are summarised 
in Table 4.21. The Haematology-Oncology Ward had the highest rate of active 
interventions, followed by the General Surgical Ward and the General Medical Ward 
for Adolescents. The general medical wards for Young Children and Infants had the 
lowest active intervention rates. The pair-wise differences of active intervention rates 
were not significantly different between the three general medical wards. The rate of 
active interventions on the Haematology-Oncology Ward was significantly different 
to those in general medical settings (p<0.001) but not the general surgical ward.  
Rates of active interventions were not significantly associated with pharmacists’ 
employment level (p<0.4). PL1 pharmacists had the highest rate of active 
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interventions (1.69 active interventions/100 medication orders, SD 1.99), followed 
by PL3 (1.43, SD 1.59) and PL2 (1.24, SD 1.38) pharmacists, respectively. The rates 
of active interventions were not significantly associated with the time spent on the 
ward (p<0.2).  
Table 4.21 Pharmacists’ active interventions per 100 medication orders reviewed on the 
five study wards 
Parameters 
Infants 
(Ward A) 
Young 
Children 
(Ward B) 
Adolescents 
(Ward C) 
Surgical 
(Ward D) 
Haematology
-Oncology 
(Ward E) 
Mean±SD 0.85±1.35 0.81±1.24 1.15±1.19 2.34±2.23 2.43±1.84 
95% 
Confidence 
interval for 
mean 
0.39 – 1.31 0.38 – 1.23 0.74 – 1.55 1.60 – 3.09 1.79 – 3.06 
Overall p-value p<0.001 
A = General Medical Ward for Infants, B = General Medical Ward for Young Children, C = General 
Medical Ward for Adolescents, D = General surgical Ward, E = Haematology-Oncology Ward 
The pattern of pharmacists’ interventions across the five study wards based on the 
level of pharmacists’ employment is detailed in Figure 4.7. The three most common 
interventions for pharmacists at all levels of employment were medication history 
and/or patient counselling, drug therapy changes and provision of drug information 
to other health professionals. However, PLI and PL2 pharmacists had a greater 
proportion of interventions related to taking medication history and/or patient 
counselling compared to PL3 pharmacists, but both had a lower proportion of drug 
therapy change-associated interventions. 
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Figure 4.7 Types of pharmacists’ interventions by pharmacists’ level of employment 
across the five study wards 
Active interventions constituted less than one-quarter of all interventions on the 
general medical and surgical wards, compared to 46.2% (p<0.001) on the 
Haematology-Oncology Ward. Table 4.22 shows the distribution of 244 active 
interventions by type. For all active interventions, acceptance by physicians was 
common, at around 90% (n=223/244), and ranged from 78.4% on the General 
Medical Ward for Adolescents to 97.8% on the Haematology-Oncology Ward 
(p<0.05).  
Dose adjustment was the most frequent active intervention on the general medical 
and surgical wards. In the general medical wards, adjusting the dose accounted for 
more than half of all active interventions in the infant population. The majority of 
dose adjustments related to pharmacists’ interventions to increase suboptimal doses 
of the correct medication. Other common sources of interventions were 
wrong/missing dosing interval, therapeutic duplication requiring deletion, 
wrong/missing dose form/strength, and untreated indication requiring regular 
medication. A different trend was found on the Haematology-Oncology Ward, where 
interventions to prescribe medications regularly constituted the most common active 
interventions (40.0%), followed by dose adjustment (26.7%); approximately two-
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thirds of all the active interventions in this unit. Other common active interventions 
on the Haematology-Oncology Ward were related to improper dosage 
frequency/interval, drug deletion, and adjustment of treatment duration. 
Table 4.22 Types of pharmacists’ active interventions on the five study wards 
Types of active 
interventions 
No. of active interventions (%) 
Ward A 
(n=16) 
Ward B 
(n=28) 
Ward C 
(n=51) 
Ward D 
(n=59) 
Ward E 
(n=90) 
Wrong/missing dose 9 (56.3) 12 (42.9) 15 (29.4) 21 (35.6) 24 (26.7) 
Wrong/missing dosage 
interval/frequency 
2 (12.5) 7 (25.0) 9 (17.6) 7 (11.9) 6 (6.7) 
Drug added 1 (6.3) 1 (3.6) 8 (15.7) 8 (13.6) 36 (40.0) 
Drug deleted 1 (6.3) 4 (14.3) 10 (19.6) 6 (10.2) 5 (5.6) 
Antibiotic change 0 (0.0) 0 (0.0) 2 (3.9) 2 (3.4) 0 (0.0) 
Wrong/missing duration of 
therapy 
0 (0.0) 1 (3.6) 0 (0.0) 0 (0.0) 6 (6.7) 
Wrong/missing dose form or 
strength 
2 (12.5) 2 (7.1) 2 (3.9) 4 (6.8) 1 (1.1) 
Wrong/missing route  0 (0.0) 0 (0.0) 2 (3.9) 0 (0.0) 0 (0.0) 
Wrong drug 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1) 
Scheduling error 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0) 3 (3.3) 
Non formulary to formulary 
change 
0 (0.0) 0 (0.0) 0 (0.0) 3 (5.1) 0 (0.0) 
Regular to if required or 
vice versa 
0 (0.0) 0 (0.0) 1 (1.9) 6 (10.2) 3 (3.3) 
Intravenous to per-oral 
change 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1) 
Wrong patient 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Illegible order 0 (0.0) 1 (3.6) 0 (0.0) 1 (1.7) 0 (0.0) 
Medication administration 
record error 
0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0) 4 (4.4) 
Drug interaction 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 
A = General Medical Ward for Infants, B = General Medical Ward for Young Children, C = General 
Medical Ward for Adolescents, D = General surgical Ward, E = Haematology-Oncology Ward 
Drug classes implicated in active interventions on the five study wards are presented 
in Table 4.23. Anti-infectives were most often associated with active interventions 
(n=100), followed by analgesics (n=46), gastrointestinal drugs (n=36), and 
immunomodulators/ antineoplastics (n=21). 
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Table 4.23 Drug classes associated with active pharmacists’ interventions on the five 
study wards (n=244) 
Drug classes 
No. of active interventions (% medication orders*) 
Ward A Ward B Ward C Ward D Ward E 
Anti-infectives 3(24.2) 16 (38.5) 13 (20.8) 30 (41.4) 38 (41.1) 
Analgesics 5 (16.7) 4 (9.2) 18 (29.2) 12 (27.7) 7 (5.9) 
Gastrointestinal 3 (22.8) 1 (1.8) 4 (6.5) 9 (10.3) 19 (15.7) 
Immunomodulators/ 
antineoplastics 
0 (0.0) 0 (0.1) 2 (1.4) 1 (0.1) 18 (23.2) 
Neurological  1 (4.6) 0 (6.4) 4 (5.4) 1 (4.6) 2 (2.2) 
Respiratory  0 (4.5) 4 (11.9) 0 (4.2) 2 (4.0) 0 (0.4) 
Endocrine  1 (4.6) 0 (4.6) 2 (4.8) 0 (0.7) 2 (1.6) 
Blood, electrolytes 2 (10.6) 0 (9.2) 2 (6.5) 0 (1.1) 0 (4.9) 
Cardiovascular  1 (4.6) 1 (6.4) 0 (0.9) 0 (0.6) 1 (2.8) 
Psychotropic  0 (0.0) 0 (0.0) 1 (11.6) 1 (0.1) 1 (1.1) 
Anaesthetics 0 (0.0) 1 (0.9) 1 (0.6) 0 (0.0) 0 (0.0) 
Ear, nose, and throat  0 (0.0) 0 (3.7) 1 (3.3) 0 (4.1) 1 (0.5) 
Ophthalmic  0 (0.0) 0 (2.8) 0 (0.0) 1 (2.2) 1 (0.5) 
Obstetric, Gynaecological  0 (0.0) 0 (0.0) 2 (2.9) 0 (0.0) 0 (0.0) 
Allergy and anaphylaxis 0 (1.5) 1 (1.9) 0 (1.2) 0 (0) 0 (0.0) 
Genitourinary  0 (1.5) 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 
Vaccines 0 (1.4) 0 (0.9) 1 (0.6) 0 (0.0) 0 (0.0) 
Others 0 (0.0) 0 (0.1) 0 (2.4) 1 (0.1) 0 (0.0) 
A = General Medical Ward for Infants, B = General Medical Ward for Young Children, C = General 
Medical Ward for Adolescents, D = General Surgical Ward, E = Haematology-Oncology Ward  
*Percentage of medication orders for each class during the study period. 
The top four drug classes accounted for the major classes of medications prescribed 
across all study wards. More than one-third of the anti-infectives related 
interventions took place on the Haematology-Oncology Ward, while 30% of the 
cases were from the General Surgical Ward. The percentages of active interventions 
associated with anti-infectives were similar in the general medical wards for Young 
Children and Adolescents, with the lowest percentage in the youngest patient cohort 
on the General Medical Ward for Infants. Antibacterials were the predominant anti-
infectives involved in the interventions (92% of anti-infectives related active 
interventions), with the remainder involving antifungals. Antibacterials associated 
with anti-infective related interventions were trimethoprim-sulfamethoxazole (n=20), 
vancomycin (n=17), aminoglycosides (n=15), penicillins (n=13) and metronidazole 
(8). Dose adjustment (n=48) accounted for the most common interventions in 
relation to the use of anti-infectives, followed by drug addition (n=15) and dose 
interval/frequency adjustment (n=15).  
 75 
Active interventions related to non-opioid analgesics were observed in general 
medical and surgical settings, while interventions related to opioid analgesics were 
predominant in the haematology-oncology setting. Almost 60% of analgesics-related 
interventions (n=27) occurred on general medical wards, predominantly involving 
adolescent patients, and more than one-quarter of the interventions were documented 
on the surgical ward (n=12). Drug deletion (n=11) was the most common active 
interventions associated with this class of medication. The next most common 
analgesics-related interventions were adjustment of dosage interval/frequency (n=10) 
and dose adjustment (n=9).  
The third major drug class involved in active interventions involved the 
gastrointestinal system. More than half of the gastrointestinal medication related 
active interventions (n=19) were observed in the haematology-oncology setting. 
When categorised according to drug subclasses, antiemetics were involved in around 
64% of interventions (n=23), while drugs for dyspepsia accounted for 22.2% of the 
interventions (n=8). Interventions to add medications accounted for the majority of 
active interventions related to gastrointestinal drugs (n=15), and almost three-
quarters were related to suggestions to chart antiemetics for haematology-oncology 
patients. The second major active intervention category in relation to gastrointestinal 
drugs was to change the medications from regular to if required or vice versa (n=7). 
With regard to immunomodulators/antineoplastics, more than 80% of the 
interventions (n=18) were recorded on the Haematology-Oncology Ward. When 
categorised by subclasses of medications, immunosuppresants (n=15) accounted for 
approximately 71% of the interventions, with the remainder involving 
antineoplastics. Drug addition (n=12) was the most frequent intervention, accounting 
for more than half of all active interventions related to this drug class. 
4.2 Direct Observation and Documentation of Pharmacists’ Interventions in 
the Haematology-Oncology Pharmacy 
The characteristics of patients in the Haematology-Oncology Unit admitted to the 
clinic (outpatients) or to the ward (inpatients) during the 33-day data-capture period 
(September 2011-August 2012) are summarised in Table 4.24. Patients ranged in age 
from newborn to 18 years, and more male patients were admitted than females. Just 
over half of the medications dispensed in the Haematology-Oncology Pharmacy 
were non-oral chemotherapy orders. The top five patients’ cancer diagnoses are 
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outlined in Figure 4.8. Leukaemias and myeloproliferative diseases were the most 
frequent diagnoses seen in this specialty unit. 
Table 4.24 Characteristics of patients in the Haematology-Oncology Unit 
Patients’ characteristics Value 
Total number of patients 1028 
Source of patients 
- Inpatients 
- Outpatients 
 
430 (41.8%) 
598 (58.2%) 
Age in years, median (range) 6.25 (0.35-18.00) 
Gender (%) 
- Male 
- Female 
 
635 (61.8%) 
393 (38.2%) 
Total no. of medication orders dispensed by 
pharmacists 
- Oral non-chemotherapy orders  
- Non-oral non-chemotherapy orders  
- Oral chemotherapy orders  
- Non-oral chemotherapy orders  
1791 
 
241 (13.5%) 
367 (20.5%) 
280 (15.6%) 
903 (50.4%) 
 
 
Figure 4.8 Top five cancer diagnoses (n=1028 patients) on the Haematology-Oncology 
Ward 
Data on pharmacists’ interventions (passive, active) and active interventions during 
the 33-day study period are shown in Tables 4.25 and 4.26, respectively. Pharmacists 
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made approximately eleven interventions per day and around 16% of patients 
received the interventions (Table 4.25). Less than 10% of pharmacists’ interventions 
were classified as active interventions. Physicians accepted all of the active 
interventions (Table 4.26). 
Table 4.25 Haematology-Oncology pharmacists’ interventions (direct observation 33 
days) 
Parameters Value 
No. of patients 1028 
No. of medication orders 1791 
No. of PIs 359 
Rate of PIs per 100 medication orders reviewed, mean ± SD 21.29 ± 9.95 
Rate of PIs per 100 patients, mean ± SD 35.18 ± 17.53 
Rate of PIs per day, mean ± SD 10.88 ± 4.73 
PIs = pharmacists’ interventions 
Table 4.26 Haematology-Oncology pharmacists’ active interventions (direct observation 
33 days) 
Parameters Value 
No. of active PIs (%)* 22 (6.1%) 
Physician acceptance of active PIs (%) 
 Yes 
 No 
 
22 (100.0%) 
0 (0.0%) 
No. of medication orders 1791 
No. of patients 1028 
Rate of active PIs per 100 medication orders, mean ± SD 1.22 ± 1.91 
Rate of active PIs per 100 patients, mean ± SD 2.20 ± 3.84 
Rate of active PIs per day, mean ± SD 0.67 ± 1.08 
*Percentage of active interventions of all pharmacists’ interventions (passive and active). 
PIs = pharmacist’s interventions 
Provision of drug information to other healthcare providers accounted for the 
majority of interventions (Figure 4.9). 
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Figure 4.9 Classification of Haematology-Oncology pharmacists’ interventions (n=359) 
Consultations provided by pharmacists for drug information service constituted 
almost three-quarters of the interventions (Table 4.27). In relation to prevented ADE 
or ME, interventions for correcting the medication label were seen most frequently 
during dispensing in this specialty pharmacy. 
Table 4.27 Categories of Haematology-Oncology pharmacists’ interventions  
Categories and subcategories of pharmacists’ 
interventions No. of cases (%) 
Provision of drug information 
- Consulted for drug information in-service 
- Provided administration information 
- Provided compatibility information 
- Provided without consult 
310 (86.4) 
365 (73.8) 
15 (4.2) 
6 (1.7) 
24 (6.7) 
Medication history and/or patient counselling 
- Discharge counselling 
- Medication history and/or medication reconciliation 
- Patient and/or parent education 
27 (7.5) 
2 (0.6) 
4 (1.1) 
21 (5.8) 
Drug therapy changes 
- Decreased dose 
- Dose form change/strength change 
- Drug added 
- Increased dose 
14 (3.9) 
6 (1.7) 
1 (0.3) 
6 (1.7) 
1 (0.3) 
Prevented ADE or ME 
- Incorrect label 
- Scheduling error 
- Wrong/missing frequency 
8 (2.2) 
6 (1.7) 
1 (0.3) 
1 (0.3) 
ADE = adverse drug event, ME = medication error 
86.4% 
4.9% 
7.5% 2.2% 
Provision of drug 
information to other 
providers 
Drug therapy changes 
Medication history 
and/or patient 
counselling 
Prevented ADE or ME 
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Immunomodulators/antineoplastics accounted for the majority of medications 
associated with active interventions (n=18/22, 81.8%) followed by drugs for the 
gastrointestinal system (n=3) and anti-infectives (n=1). 
With respect to immunomodulators/antineoplastics, antineoplastics predominated the 
active interventions, where these medications were responsible for more than three-
quarters (n=14) of the interventions in this class and the remaining cases were due to 
drugs used with antineoplastics (n=2), non-cytotoxic antineoplastics (n=1) and 
immunosuppresants (n=1). Dosing adjustment (n=7) was the commonest intervention 
pertinent to the use of immunomodulators and antineoplastics, followed by incorrect 
label (n=6), drug addition (n=3), dose form change (n=1) and scheduling error (n=1). 
The second drug class involved in active interventions was drugs for the 
gastrointestinal system (n=3); antiemetics accounted for all interventions in this 
class. Interventions to add antiemetics for patients prior to/during treatment with 
emetogenic chemotherapy comprised all of the interventions in this class.  
Triggers to initiate interventions during the dispensing process are listed in Table 
4.28. The most common trigger was questions from other pharmacists, followed by 
questions from medical staff.  
Table 4.28 Triggers for pharmacists’ interventions (n=359) during dispensing 
Trigger of interventions No. of cases (%) 
Other pharmacist inquiry 160 (44.6) 
Doctor inquiry 83 (23.1) 
Medication order review 62 (17.3) 
Nurse inquiry 33 (9.2) 
Patient and/ parent inquiry 13 (3.6) 
Laboratory result 6 (1.7) 
Ward meeting 2 (0.6) 
4.3 Predictors of Physician-Accepted Pharmacists’ Active Interventions 
There were 244 pharmacists’ active interventions identified during direct observation 
on the five study wards. According to Miles and Shevlin(195) a sample size of 200 
with up to 20 predictors can identify a medium effect with a high level of power (i.e. 
80%). The outcome of the interventions (accepted/not accepted) was used as the 
dependent variable for multivariate logistic regression analysis. The significant 
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predictors of the outcome were determined by independent variable selection, and 
model building and interaction testing. 
4.3.1 Independent Variable Selection 
The logistic regression analysis began with selection of independent variables 
(predictors). Based on literature research and the data collected during direct 
observation, the following 15 independent variables were selected for initial 
inclusion: patients’ age and gender; study ward during hospitalisation; diagnosis on 
admission; length of stay; number of medications prescribed; therapeutic drug class; 
dose form; high-risk category of medication; type of active interventions; and 
pharmacists’ gender, experience, academic qualification, work pattern (full-
time/part-time) and term of employment (permanent post/temporary). A contingency 
table of the dependent variable (physician acceptance of pharmacists’ active 
interventions) versus each independent variable was used to ensure that no cell had a 
zero cell count and that not fewer than 20% of the cells had a frequency count of less 
than five. Five independent variables did not meet these criteria: study ward, 
diagnosis on admission, therapeutic drug class, dose form and type of active 
interventions. For the purposes of this analysis, the variable ‘study ward’ was 
collapsed from five categories to three: general medicine, general surgery and 
haematology-oncology (Table 4.29). 
Table 4.29 Contingency table of clinical units versus physicians’ acceptance of 
pharmacists’ active interventions 
Clinical units 
Physician acceptance of pharmacists’ 
active interventions 
Total, n (%) Yes, n (%) No, n (%) 
General Medicine 81 (33.2) 14 (5.7) 95 (38.9) 
General Surgery 50 (20.5) 9 (3.7) 59 (24.2) 
Haematology-Oncology 88 (36.1) 2 (0.8) 90 (36.9) 
Total 219 (89.8) 25 (10.2) 244 (100.0) 
The variable ‘diagnosis on admission’ was collapsed from 21 to two categories: 
neoplasms and others (Table 4.30).  
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Table 4.30 Contingency table of diagnosis on admission versus physicians’ acceptance of 
pharmacists’ active interventions 
Diagnosis on 
admission 
Physician acceptance of pharmacists’ 
active interventions 
Total, n (%) Yes, n (%) No, n (%) 
Neoplasms 91 (37.3) 1 (0.4) 92 (37.7) 
Others 128 (52.5) 24 (9.8) 152 (62.3) 
Total 219 (89.8) 25 (10.2) 244 (100.0) 
The variable ‘therapeutic drug class’ involved in the active interventions was 
collapsed from 20 to three categories: anti-infectives, analgesics, and others (Table 
4.31). 
Table 4.31 Contingency table of therapeutic drug class versus physicians’ acceptance of 
pharmacists’ active interventions 
Therapeutic drug class 
Physician acceptance of pharmacists’ 
active interventions 
Total, n (%) Yes, n (%) No, n (%) 
Anti-infectives 90 (36.9) 10 (4.1) 98 (41.0) 
Analgesics 37 (15.2) 9 (3.7) 46 (18.9) 
Others 92 (37.7) 6 (2.5) 100 (40.2) 
Total 219 (89.8) 25 (10.2) 244 (100.0) 
The ‘dose form’ variable was collapsed from three categories (oral, parenteral, 
others) to two categories (oral, non-oral) (Table 4.32). 
Table 4.32 Contingency table of dose form of medication versus physicians’ acceptance of 
pharmacists’ active interventions 
Dose form of medication 
Physician acceptance of pharmacists’ 
active interventions 
Total, n (%) Yes, n (%) No, n (%) 
Oral  140 (57.4) 17 (7.0) 157 (64.3) 
Non-oral  79 (32.4) 8 (3.3) 87 (35.7) 
Total 219 (89.8) 25 (10.2) 244 (100.0) 
The variable ‘type of active interventions’ was collapsed from 17 (Table 4.21) to five 
categories: dose adjustment, drug addition, drug deletion, adjustment of dosage 
interval/frequency, and others (Table 4.33). 
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Table 4.33 Contingency table of type of active interventions versus physicians’ acceptance 
of the active interventions 
Type of intervention 
Physician acceptance of pharmacists’ 
active interventions 
Total, n (%) Yes, n (%) No, n (%) 
Dose adjustment 76 (31.1) 7 (2.9) 83 (34.0) 
Drug addition 52 (21.3) 2 (0.8) 54 (22.0) 
Drug deletion 17 (7.0) 5 (2.0) 22 (9.0) 
Adjustment of dosage 
interval/frequency 
28 (11.5) 4 (1.6) 32 (13.1) 
Others 46 (18.9) 7 (2.9) 53 (21.7) 
Total 219 (89.8) 25 (10.2) 244 (100.0) 
Univariate logistic regression was undertaken for each independent variable (Table 
4.34). All variables met the criteria for inclusion (p<0.25) except patients’ gender, 
length of stay, number of medications prescribed, and dose form of medication. 
These four variables were not retained for the subsequent analysis.  
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Table 4.34 Univariate logistic regression coefficients of candidate variables 
Variables SE P-value OR 
95% CI for OR 
Lower Upper 
Patient age 0.041 0.027 0.913 0.842 0.990 
Patient gender (1) 0.450 0.279 0.614 0.254 1.484 
Clinical units 
- General medicine (1) 
- General surgery (1) 
- Haematology-Oncology 
(ref) 
 
0.771 
0.802 
0.024 
0.009 
0.010 
 
0.131 
0.126 
 
0.029 
0.026 
 
0.596 
0.608 
- Diagnosis on admission 
(1) 
1.030 0.006 0.059 0.008 0.441 
Length of stay 0.009 0.733 0.997 0.980 1.015 
No. of medications 0.046 0.622 0.977 0.893 1.070 
Therapeutic class 
- Anti-infectives (ref) 
- Analgesics (1) 
- Others (1) 
 
 
0.499 
0.537 
0.057 
 
0.117 
0.321 
 
 
0.457 
1.704 
 
 
0.172 
0.594 
 
 
1.215 
4.883 
High-risk medication (1) 0.425 0.085 2.080 0.904 4.783 
Dose form (1) 0.451 0.687 1.199 0.495 2.904 
Type of active intervention 
- Dose adjustment (1) 
- Drug addition (1) 
- Drug deletion (1) 
- Adjustment of dose 
interval/frequency (1) 
- Others (ref) 
 
0.566 
0.827 
0.651 
0.671 
.173 
0.375 
0.096 
0.311 
0.925 
 
1.652 
3.957 
0.517 
1.065 
 
0.545 
0.782 
0.145 
0.286 
 
5.012 
20.008 
1.852 
3.969 
Pharmacist gender (1) 1.035 0.105 5.363 0.705 40.816 
Pharmacist experience 0.032 0.058 1.062 0.998 1.130 
Pharmacist qualification 
(1) 
0.636 0.194 2.283 0.657 7.936 
Pharmacist work pattern 
(1) 
0.752 0.031 0.197 0.045 0.861 
Pharmacist work post (1) 0.631 0.009 5.214 1.515 17.941 
Variables were coded as follows: variables with two items, the categories of interest were coded as 1; 
gender (1) for male, diagnosis on admission (1) for others, high-risk medication (1) for non-high-risk, 
dose form (1) for non-oral, pharmacists’ gender (1) for male, pharmacists’ qualification (1) for 
undergraduate with postgraduate as reference, pharmacists’ work pattern (1) for full-time, 
pharmacists’ work post (1) for permanent post.  
For variables with more than two categorical variables, the category (ref) was set as reference group, 
and category (1) indicated the group of interest. 
SE = standard error, OR = odds ratio, 95% CI for OR = 95% confidence interval for odds ratio. 
4.3.2 Model Building and Interaction Test 
All variables selected from the univariate logistic regression were included for 
testing in multivariate logistic regression Model 1. The regression analysis used the 
backward likelihood ratio (LR) method using SPSS version 22. Some variables 
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demonstrated extremely large odds ratios and standard errors, namely clinical units, 
diagnosis on admission, pharmacists’ gender, pharmacists’ work pattern, and 
pharmacists’ post (Table 4.35). The regression analysis failed to reach conclusion to 
calculate odds ratios after maximum iterations (20 iterations) had been reached, 
shown by the odds ratios of offending variables of zero. This situation indicated that 
a problem existed presumably due to the model overfitting with small samples or 
combination of discrete variables with few cases in one outcome. The offending 
variables of pharmacists’ gender, work pattern, and post were dichotomous variables. 
Collapsing the categories of these variables was not possible, so the variables were 
removed. With regard to variables of clinical unit and diagnosis on admission, the 
categories were modified as per Tables 4.29 and 4.30 in order to identify whether the 
specialty haematology-oncology unit and patients with complicated conditions (e.g. 
cancer) had an impact on the acceptance of the active interventions. Therefore, both 
variables were deleted, leaving six independent variables for testing in logistic 
regression Model 2 (Table 4.36). 
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Table 4.35 Multivariate logistic regression coefficients of variables in Model 1 
Variables SE p-value OR 
95% CI for OR 
Lower Upper 
Patients’ age 0.050 0.031 0.899 0.816 0.991 
Clinical units 
-General medicine (1) 
-General surgery (1) 
 
14.933 
14.947 
0.841 
0.762 
0.764 
 
92.370 
126.872 
 
0.000 
0.000 
 
4.753E+14 
6.705E+14 
Diagnosis on admission (1) 2.751 0.002 0.000 0.000 0.048 
Therapeutic class 
-Analgesics (1) 
-Others (1) 
 
0.608 
0.656 
0.077 
0.034 
0.807 
 
0.275 
0.852 
 
0.084 
0.236 
 
0.907 
3.081 
High-risk/non high-risk (1) 0.532 0.035 3.075 1.085 8.720 
Type of active intervention 
-Dose adjustment (1) 
-Drug addition (1) 
-Drug deletion (1) 
-Adjustment of dosage 
interval/frequency (1) 
 
0.721 
0.993 
0.797 
0.797 
0.514 
0.377 
0.687 
0.288 
0.931 
 
1.893 
1.493 
0.429 
0.934 
 
0.460 
0.213 
0.090 
0.196 
 
7.782 
10.461 
2.046 
4.453 
Pharmacist gender (1) 3.321 0.002 35.425E+3 52.773 237.799E+
5 
Pharmacist experience 0.171 0.010 0.645 0.462 0.902 
Pharmacists’ qualification (1) 0.701 0.387 1.834 0.464 7.251 
Pharmacis pattern (1) 37.186E
+3 
1.000 0.676 0.000 - 
Pharmacist post (1) 49.375E
+2 
.998 0.000 0.000 - 
Variables were coded as follows: variables with two items, the categories of interest were coded as 1; 
diagnosis on admission (1) for others, high-risk medication (1) for non-high-risk, pharmacists’ gender 
(1) for male, pharmacists’ qualification (1) for undergraduate with postgraduate as reference, 
pharmacists’ work pattern (1) for full-time, pharmacists’ work post (1) for permanent post.  
For variables with more than two categorical variables, the category (ref) was set as reference group, 
and category (1) indicated the group of interest; clinical units (ref) for haematology-oncology, 
therapeutic class of medication (ref) for anti-infectives, type of active intervention (ref) for others. 
SE = standard error, OR = odds ratio, 95% CI for OR = 95% confidence interval for odds ratio. 
Table 4.36 Multivariate logistic regression Model 2 with significant independent variables 
(predictors) 
Variables SE p-value OR 
95% CI for OR 
Lower Upper 
Patient age 0.048 0.018 0.893 0.813 0.981 
Medication  
- Non high-risk 
- High-risk 
 
0.480 
 
0.032  
2.801 
1 (ref) 
 
1.094 
 
7.169 
Pharmacist 
experience 
0.038 0.005 1.114 1.033 1.200 
Constant 0.764 0.318 2.145   
SE = standard error, OR = odds ratio, 95% CI for OR = 95% confidence interval for odds ratio. R
2
 = 
0.103 (Cox & Snell), 0.214 (Nagelkerke). 
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Testing of Model 2 revealed that three variables significantly predicted the 
physician-accepted pharmacists’ active interventions: patients’ age, high-risk 
medication and pharmacists’ experience. Removing these variables produced a 
significant difference in the log likelihood value and would have a significant effect 
on the predictive ability of the model. A test of the full model with all three 
predictors against a constant-only model was statistically significant, χ2 (3, N=244) 
= 26.6, p=0.002, indicating that the predictors, as a set, significantly distinguished 
between accepted and non-accepted pharmacists’ active interventions by physicians. 
The classification was impressive, with 99.5% of the accepted and 4.0% of the non-
accepted interventions correctly predicted for an overall success rate of 89.8% (Table 
4.37). This demonstrated that the overall predicted percentage of the physician-
acceptance of pharmacists’ active intervention was 90.2% accurate.  
The interaction test was run for these three variables, resulting in three pairs of 
possible interaction variables. Multivariate logistic regression was conducted to 
identify significant interaction variables. The regression was performed by testing 
one interaction variable at a time along with those three significant independent 
variables from Model 2. The significance levels of all possible interaction variables 
are detailed in Table 4.38. 
Table 4.37 Classification table of logistic regression Model 2 
Observed physician acceptance 
of pharmacists’ active 
interventions 
Predicted physician acceptance of pharmacists’ 
active interventions
*
 
Degree of acceptance Percentage 
correct Degree of 
acceptance 
 Yes No 
Yes 218 1 99.5 
No 24 1 4.0 
Overall percentage  89.8 
*
Probability of physician acceptance of pharmacists’ active interventions ranges from 0 to 1. Cut-off 
value is 0.500. 
Table 4.38 Significance levels of interaction variables 
Interaction variables p-value Note 
Patient age - high risk medication 0.580 Excluded 
Patient age - pharmacist experience 0.417 Excluded 
High risk medication - pharmacist experience 0.903 Excluded 
 87 
There were no significant interactions identified between variables (Table 4.38). 
Therefore, logistic regression Model 2 with three predictors (Table 4.36) is presented 
as the final model.  
The final model revealed that patients’ age significantly predicted the physicians’ 
acceptance of active interventions. The odds ratio for patients’ age when holding all 
other variables constant, for a one-year increment of patients’ age, corresponded with 
a decrease in acceptance of the intervention of 0.893. Inverting the odds ratio 
revealed that for every one year of decreasing age, the odds of the intervention being 
accepted was 1.1 times higher. In addition, the medication category (high-risk versus 
non-high-risk) significantly predicted physician acceptance of active interventions, 
with the interventions involving non-high-risk medications being nearly three times 
more likely to be accepted by the physician than those associated with high-risk 
medications. The results also uncovered that for every extra year of experience of 
pharmacists, the acceptance by physicians increased (odds ratio 1.114).  
4.4 Discussion 
4.4.1 Direct Observation and Documentation of Ward Pharmacists’ 
Interventions 
The prevalence of pharmacists’ interventions per 100 medication orders in this study 
ranged from 4.38 to 7.83 on the General Medical Wards to 10.48 on the General 
Surgical Ward, and 5.63 on the Haematology-Oncology Ward. The intervention rate 
on the General Surgical Ward was the highest compared to the other two clinical 
units (p<0.05), although the surgical unit is considered less complex 
pharmacologically than general medical, intensive care or specialty areas.(196) A 
self-reported study by Chan et al.(94) involving paediatric general and specialty 
inpatients uncovered a similar rate of active intervention (0.75 interventions per 100 
medication orders) as those documented on the general medical wards for Infants and 
Young Children in our study. However, in comparison to the rates recorded in 
general settings in our study, a higher active intervention rate (2.4/100 medication 
orders) was reported from a study assessing the impact of interventions performed by 
clinical pharmacists in reducing prescribing errors in children hospitalised in a 
maternity and children’s hospital in Spain.(197) The rate of active interventions on 
the Haematology-Oncology Ward in our study was similar to the Spanish study. The 
Spanish study did not provide further information on the nature of patients’ medical 
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conditions; presumably, active intervention rates are influenced by the complexity of 
patients’ medication regimens. This may account for the higher incidence of active 
interventions among haematology-oncology patients compared to patients in other 
settings who may have less complex conditions requiring less medication.  
Besides the number of medications prescribed, other factors need to be considered as 
predictors for pharmacists’ intervention rates. A study in ICUs involving children 
and adults found that the rate of interventions was significantly higher in patients 
with long hospital stay.(146) However, in our study lower intervention rates were 
observed in the general medical wards for Young Children and Adolescents where 
patients stayed longer than in other wards. Consistent with our study, a large 
pharmacists’ interventions study in the UK, which included paediatric and adult 
patients, found the time spent during ward round significantly predicted the rates of 
the interventions.(127)  
With respect to the pattern of pharmacists’ interventions, activities related to taking 
medication histories and/or patient counselling were the most frequent interventions 
in general wards, while drug therapy changes were responsible for the most frequent 
interventions in the haematology-oncology ward. The subcategories of taking 
medication histories and medication reconciliation activities constituted the most 
common interventions performed by clinical pharmacists on general wards. This is 
not surprising, as taking medication history and medication reconciliation are the 
initial steps in reviewing patients and assessing the appropriateness of their 
medications orders. Medication reconciliation and medication history have been 
justified as effective strategies to reduce MEs in children and adults.(139, 144, 198) 
However, these activities occurred less frequently on the Haematology-Oncology 
Ward than the general medical wards. The lower percentage might be explained by 
the availability, completeness and the ease of access to patients’ medical and 
medication history on this specialty ward. As the haematology and oncology patients 
were admitted regularly to hospital for treatment and monitoring, the healthcare 
providers (including pharmacists) were apparently familiar with the patients and their 
treatment protocols, so the pharmacists often examined the patients’ records instead 
of interviewing the patients and/or the parents.  
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The reduced incidence of this type of intervention on the general medical wards with 
patients’ increasing age may have been due to a delay between the patients’ 
admission and day of clinical pharmacist observation on the adolescent ward 
compared to the wards catering for younger children. Drug therapy change-
associated interventions on the general medical wards increased with the patients’ 
age. The larger number of medications prescribed for older children might have 
attributed to the higher incidence of this type of intervention in adolescent patients as 
compared to their younger counterparts. A paediatric study documenting 
pharmacists’ interventions associated with electronic prescription review found the 
youngest patients (under 2 years old) were associated with more interventions than 
older children.(199) 
There are limited published studies on pharmacists’ interventions in different 
paediatric settings than adult patients. Condren et al.(184) conducted a study in a 
paediatric population including general and intensive care inpatients, and ambulatory 
patients. They reported interventions performed by an academic paediatric pharmacy 
team including pharmacy students, using similar intervention categories to the 
present study. There were 4605 interventions performed for 3978 patients in a year. 
The study reported 1.15 interventions per patient, the most frequent intervention 
categories being drug therapy change, medication history and/or patient counselling, 
and providing drug information to other health professionals.(184) Under the drug 
therapy change category, drug addition and drug deletion accounted for the most 
common recommendations. Our study uncovered a different pattern of 
recommendations; dose adjustment, drug addition and adjustment of dosage interval/ 
frequency accounted for the majority of recommendations. The most common 
category of active intervention found by Condren et al.(184) was consistent with the 
pattern of active interventions in the haematology-oncology unit in our study.  
A Dutch study conducted in a range of settings, including the haematology unit in a 
paediatric hospital, implementing electronic prescribing, revealed that pharmacists 
performed 1557 interventions for 138,449 prescriptions (1.1%) over 46 months.(15) 
This study reported that interventions leading to drug changes were most frequently 
performed in the haematology unit (31.1%), similar to our study (90/244, 36.8%). In 
keeping with our study, that study also found dosing adjustment was the most 
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frequent intervention, and antibacterials were the most commonly implicated 
medications.(199) 
In a four-week study in 16 paediatric wards (nine specialist, seven general) in the 
UK, interventions to resolve improper dosing, incomplete prescriptions and wrong 
frequency were the most common interventions by pharmacists.(200) Dosing issues 
were also identified as the main concern requiring pharmacist intervention in 
hospitalised children in a Spanish study.(197) Likewise, a retrospective analysis of 
four-year self-reported pharmacists’ interventions conducted by Chan et al.(94) 
involving paediatric patients in general and specialty areas (including haematology-
oncology) also detected dosing issues as the major source of problems. Studies 
incorporating general and specialty settings have consistently shown that dosing-
associated issues were the main problem in paediatric patients.(94, 184, 197, 199, 
200) However, those studies did not provide further information on the breakdown of 
interventions, as intervention data are generally aggregated for the purpose of 
analysis rather than presented by clinical setting. Accordingly, the pattern and rate of 
interventions among different settings, in particular general versus specialty settings, 
in the child patient populations cannot be compared and analysed comprehensively. 
Maat et al.(199) report in a study associated with electronic prescription review that 
interventions were most frequently conducted in the specialty units of 
immunology/haematology and neurology compared to other units such as internal 
medicine. Kaushal et al.(201) in their study of serious MEs before and after the 
introduction of unit-based clinical pharmacists in three units (ICU, general surgery, 
general medicine) in an American paediatric hospital reported that clinical 
pharmacists’ interventions substantially decreased the rate of MEs in the ICU, while 
there was no reduction in the general settings. The investigators pointed out that the 
setting influenced the rates of ME-intercepting interventions by pharmacists, in 
particular, between general and non-general settings such as ICU.(201)  
When involving adult patients, a large study of pharmacists’ interventions in the UK 
involving a range of settings in 27 acute care hospitals also found dosing-associated 
interventions as the major type of intervention, and highlighted that ward type was 
significantly associated with the rate of pharmacists’ interventions (p<0.001). The 
highest intervention rates were reported from ICU wards, followed by paediatrics 
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and special wards (e.g. haematology, oncology, organ transplant, AIDS), and other 
type of wards (e.g. medical, surgical, geriatrics, psychiatric and obstetrics).(127)  
A multicentre study of ward pharmacists’ interventions in six French hospitals 
documented an intervention rate of 4.66 interventions per 100 medication orders in a 
range of practice settings, with dose adjustment the most common intervention 
type.(202) Details of interventions in each setting from the British and French studies 
are lacking, and it is unclear whether the inclusion of adult patients influenced the 
pattern of interventions. When comparing the interventions among specialist areas, a 
prospective study involving seven specialties (three ICUs, cardiosurgery, 
haematology, nephrology and psychiatry) in an Austrian hospital uncovered 
provision of information to other healthcare providers as the most common 
intervention type. However, it appears that there was no comparable pattern when 
evaluating the next most frequent intervention types among the specialties.(203)  
With respect to medications implicated in the active interventions, it is 
understandable that larger numbers of interventions were documented from 
antibiotics and analgesics, as these medications accounted for the major drug classes 
prescribed.(199) The majority of medications implicated in the active interventions 
were used for treating acute medical conditions with the exception of 
immunomodulators and antineoplastics on the Haematology-Oncology Ward.  
The acceptance rate of pharmacists’ active interventions was high across all settings 
in our study. This acceptance rate is similar to those found in other paediatric 
studies.(197, 199, 204, 205) This strengthens the established evidence supporting the 
confidence of other healthcare providers in the significant contribution of 
pharmacists to improve the quality of patient paediatric.(17, 184, 201, 206)  
To the best of our knowledge, this is the first study that compared pharmacists’ 
interventions in a range of settings in paediatrics in terms of frequency, type, degree 
of acceptance and medications implicated. Most of the early studies on pharmacists’ 
interventions were conducted using self-report by pharmacists. Self-report has been 
associated with bias and underestimation of the intervention rates due to time 
constraints and omission of interventions that the pharmacists regarded as 
insignificant or non-favourable.(207) The prospective observational approach used in 
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the current study allowed the observer to obtain actual number of interventions 
performed by the ward pharmacists to overcome aforementioned issues with self-
reporting.(183, 208)  
4.4.2 Direct Observation and Documentation of Pharmacists’ 
Interventions during Dispensing in a Haematology-Oncology 
Pharmacy 
During the data collection period, pharmacists’ interventions rates documented 
during dispensing in the Haematology-Oncology Pharmacy were 21.29 per 100 
medication orders and 35.18 per 100 patients. Based on these data, pharmacists 
undertook approximately 11 interventions each weekday. Provision of drug 
information to physicians, nurses and other pharmacists (86.4%) constituted the 
majority of the interventions followed by medication histories and/or patient 
counselling, drug therapy changes, and prevented ADE and ME. More than three-
quarters of the interventions in our study related to chemotherapy medications. 
Waddell et al.(206) also analysed the interventions performed by oncology pharmacy 
staff within inpatient and outpatient settings. During that study, pharmacists self-
documented 503 interventions over eight months, which meant that pharmacy staff 
performed around two interventions each day, a much lower rate than our study. 
Corresponding well with our study, the majority of the interventions documented 
were the provision of drug information/consultation to other healthcare providers.  
An intervention study by Wong et al.(209) in haematology-oncology clinics in 
Virginia, providing ambulatory cancer services for adults and children, demonstrated 
lower numbers of interventions per day, half as many as our study. Wong et al.(209) 
found patient counselling and therapeutic recommendations (i.e. cessation of drugs 
without clear indications, dose recommendation, drug selection) as the leading 
categories of interventions. While our study revealed that more than 80% of 
interventions were non-chemotherapy related. The disparate rate and pattern of the 
interventions between the two studies may be explained by the complexity of the 
disease states of the patients in the study by Wong et al.(209), given that the studies 
did not specifically focus on paediatric oncology patients.  
By contrast, a retrospective study by Ruder et al.(208) analysed interventions by 
oncology pharmacists over two years in an ambulatory oncology clinic for adults 
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reported a higher rate of interventions than our study. Ruder et al.(208) demonstrated 
583 clinical intervention for 199 patients, with approximately three interventions 
performed for each patient, and the most frequent interventions related to patient 
education. A similar pattern relating to intervention type has been found in American 
and Jordanian studies involving adult(28) and paediatric patients with cancer.(29) 
Both studies reported patient counselling as the most common intervention, 
accounting for more than one-quarter of all interventions.  
With regard to interventions leading to changes to patient medication management 
(active interventions), our study documented 22 active interventions (6.1% of total 
interventions), with rates of 1.2 per 100 medication orders and 2.1 per 100 patients. 
Our finding is consistent with studies undertaken in general patient settings, 
demonstrating rates of active interventions per 100 medication orders from 0.7% to 
8.5%.(18, 94, 126, 197, 210) In relation to haematology-oncology intervention 
studies, Shah et al.(211) retrospectively analysed clinical pharmacy activities in a 
haematology-oncology outpatient practice. Pharmacists documented their clinical 
activities into personal digital assistants. During the 12-month study, 308 drug-
specific interventions were performed for 423 patients (0.73 interventions for each 
outpatient). This is a much higher intervention rate than our study. Their study 
reported that supportive care issues were responsible for half of the interventions, 
predominantly for anaemia, pain, constipation/diarrhoea and nausea/vomiting. Their 
top three interventions were drug addition, drug discontinuation and dose adjustment. 
The pattern of interventions was similar to our findings, where the predominant 
active interventions resulted in interventions to add medications and adjust the dose 
(in particular, reduce the dose) of medications.(211)  
All active interventions during dispensing in the Haematology-Oncology Pharmacy 
were accepted by doctors, nurses or other pharmacists. High rates of acceptance of 
pharmacists’ interventions in this high-risk area have also been reported in other 
studies.(206, 208, 209, 212) The high acceptance rate is a positive indicator that 
pharmacists are well accepted and considered reliable sources of information by 
other healthcare providers. 
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4.4.3 Predictors of Physician-Accepted Pharmacists’ Active Interventions 
This study included an analysis of determinants of physicians’ acceptance of 
pharmacists’ active interventions. Pharmacists’ recommendations are meaningless if 
there is no acknowledgement and uptake by physicians. Some studies have reported 
that acceptance of the interventions strongly predicted the desired clinical 
outcome.(204, 213-215) It is essential to identify the determinants or factors 
affecting the acceptance of pharmacists’ interventions. Physicians’ acceptance of 
interventions may be influenced by factors such as patients’ characteristics (age, co-
medications), type of interventions, physicians’ characteristics (specialty, perception 
on the importance of the intervention), level of interaction between pharmacists and 
physicians and the clinical setting.(216-218) However, this has not, as yet, been 
validated, and well-designed studies are required for justification.  
This appears to be the first study to determine the factors that impact on physicians’ 
acceptance of the interventions across different clinical settings (general medicine, 
general surgery, haematology-oncology) in a paediatric hospital using multivariate 
modelling. The multivariate approach benefited this study, as the data comprised 
multiple observations for each pharmacist. Pharmacists subjected to more 
observations were represented in the data to a greater degree than those with fewer 
observations. Multivariate analysis can eliminate misleading confounding factors 
from univariate analysis by accounting for all independent variables concurrently and 
different number of observations from each variables.(127, 219) In the present study, 
three factors significantly and positively predicted intervention acceptance by 
physicians: patients’ younger age, non-high-risk medications and pharmacists’ 
experience. Experienced pharmacists are more likely to make confident and strong 
evidence-based interventions given their longstanding professional experience and 
knowledge to convince precribers.(127) Patient’s age and pharmacists’ years of 
experience were not strong predictors. While interventions related to non-high-risk 
medications were three times more likely to be accepted than interventions 
associated with high-risk medications. 
Little is known about the factors that influence prescribers to accept or decline 
pharmacists’ recommendations particularly in paediatrics.(199) Comparison of the 
results of the present study with similar studies is challenging for several reasons, 
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such as the differences in study settings, methods and the predictors evaluated. 
Consistent with our study, a study examining the determinants of pharmacists’ 
interventions in electronic prescriptions in a paediatric hospital in the Netherlands 
reported patients’ age as a determinant of the interventions. Younger patients were 
significanly more likely to receive interventions than older patients. Other significant 
determinants associated with an increased rate of interventions were electronic 
prescriptions (without clinical decision support) and oral dose forms.(199) However, 
that study focussed on factors associated with interventions rather than the 
acceptance of the interventions. A study in Denmark undertaken in an ED for adults 
revealed that physicians accepted 59% of pharmacists’ recommendations. The 
Danish study uncovered the determinants of accepted recommendations as patients 
admitted with medical problems (more frequently than surgical patients) and the 
recommendation category of ‘untreated indication’.(216) However, another study 
conducted in the UK demonstrated no difference in the acceptance rate between 
physicians working in medical and surgical wards.(127) Consistent with the UK 
study, the present research determined lack of association between the clinical setting 
and acceptance of the intervention.  
Multivariate analysis from a palliative care study revealed that none of the variables 
assessed (patient and pharmacist characteristics, type of intervention) were 
associated with physicians’ decisions to accept or decline pharmacists’ 
interventions.(220) A study of 27 hospitals in the UK assessed the factors predicting 
the rate of physician acceptance of interventions by pharmacists using a mixed-
model Poisson regression technique. That study identified three significant 
predictors: ward type, pharmacist grade and time spent on the ward. The ICU and 
specialty wards, including paediatrics, were associated with a higher acceptance rate 
than other wards. In addition, pharmacists employed at grade C and above (specialist 
pharmacists and pharmacy managers) and more time spent on the ward predicted the 
increased acceptance rate.(127) Consistent with our study, the British study did not 
find significant contribution from other pharmacists’ characteristics (academic 
qualification, work pattern, post). Nonetheless, the univariate approach in the UK 
study showed that interventions by more experienced pharmacists had a lower 
acceptance rate in comparison to the less experienced ones, which was not confirmed 
by our study, although this predictor failed to contribute in the final model.  
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A different result was also reported in a Swiss study analysing the factors impacting 
on neurologist acceptance of pharmacists’ interventions in collaboration with clinical 
pharmacologists when addressing the DRPs detected in a university hospital 
neurology unit.(42) That study evaluated four factors: type of prescription, type of 
DRP, cause of DRP and type of intervention, without taking into account the factors 
related to patients and intervening pharmacists. The authors reported that prescribing 
a regular medication (instead of ‘as required’ medications) was the sole determinant 
of acceptance of interventions.(221)  
A community-based study using written communication by fax to convey 
pharmacists’ interventions to the prescribers demonstrated a higher acceptance rate 
with cost-saving implications, compared to interventions for compliance with 
guidelines directed to primary care physicians compared to those directed to 
specialists.(222) 
Our study and a study by Barber et al.(127) did not observe a significant effect of 
pharmacists’ academic qualification as a factor in acceptance of interventions. It is 
premature to conclude that this factor has no effect, and that additional education is 
not effective. Barber et al.(127) presumed that pharmacists without postgraduate 
qualification tend to be assigned to wards for younger patients who are 
therapeutically less complex. The impact of pharmacists’ academic qualification 
should be evaluated further by conducting controlled studies.  
4.5 Limitations and Recommendations 
A number of limitations need to be acknowledged in this direct observational study. 
The rate of interventions directly observed during ward rounds may have been 
underestimated and the pattern of the interventions might not be reflective of broader 
practice, as the principal researcher only documented the interventions performed by 
clinical ward pharmacists during their ward rounds. Additional interventions may 
have been performed by telephone or pager at other times. This study mainly 
documented interventions associated with drug prescribing and monitoring. As ward 
pharmacists have limited time to undertake their rounds on each ward they do not 
check the medications prior to their administration to each patient. Data were 
collected on non-consecutive days to avoid pharmacist observation fatigue, which 
may have influenced the pattern of the interventions. Future studies might consider 
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employing a combination of intervention documentation methods over a period of 
time, i.e. direct observation and self-reporting.  
This study was conducted in one paediatric hospital, which diminishes the ability to 
generalise the findings. It is recommended future studies involve multiple paediatric 
institutions, i.e. other paediatric hospitals and/or paediatric wards in general 
hospitals. Also of note are difficulties in drawing accurate comparison with other 
intervention studies due to variations in settings, design, duration, size, method and 
definitions of intervention used. 
Although the results of this study are informative with respect to the analysis of 
predictors of physician-accepted active interventions, there are several limitations. 
Firstly, in line with the existing literature assessing the factors affecting physician 
acceptance of pharmacists’interventions, this study did not include the physicians’ 
characteristics as predictors.(127, 199, 220, 221) It was not feasible for a non-staff 
researcher to collect these data. The theory of physicians’ reactance, highlighted by 
De Almeida Neto et al.(223) might clarify physicians’ psychological disposition 
during decision making about recommendations proposed by pharmacists. Reactance 
is: ‘a reaction to a recommendation to take a certain course of action which is 
affected by a motivational state compelling a response in which freedom of choice is 
maintained’.(223) The perceptions of physicians on those recommendations 
addressing the significant clinical relevance issues are likely to affect reactance. It 
has also been suggested that pharmacists frame their recommendation with options 
from which physicians can choose. In this way, the physicians still hold their sense 
of freedom of choice.(223, 224)  
Secondly, evaluating the association between acceptance of the recommendations 
and impact on patient outcome was beyond the scope of the present study. It would 
be interesting to explore this issue in future studies, in order to evaluate pharmacists’ 
recommendations to patient care. Previous studies have shown that implementation 
of accepted recommendations contributed to improved patients’ clinical 
outcome.(146, 204, 214, 215, 220)  
Thirdly, other factors (predictors) were not associated with significant contributions 
to the accepted interventions in the final model, even though they were demonstrated 
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as significant predictors during univariate analysis. This may be due to the sample 
size having insufficient power to detect the effects related to those predictors. Thus, 
escalating the sample size in future research may increase the likelihood of detecting 
other influential predictors. A follow-up study to assess the pharmacists’ attitudes 
toward interventions is warranted, as some pharmacists may intervene only on major 
issues, while others may do so for any issue. Regardless of these limitations, this 
study presents important findings to improve our understanding of the determinants 
influencing physicians’ acceptance of pharmacists’ active interventions in a range of 
paediatric settings. 
4.6 Conclusion 
Pharmacists can optimise patient care in a range of paediatric settings through their 
active interventions either during pharmacy rounds or dispensing. The rate and 
nature of pharmacists’ interventions appear to be influenced by the clinical setting. 
Specialty units, such as the haematology-oncology, had a higher active intervention 
rate where most interventions were related to drug therapy changes compared to the 
general medical and surgical units. The interventions are of value if acknowledged, 
accepted and implemented by physicians. This study found that interventions were 
more likely to be accepted by physicians for younger patients, non-high-risk 
medications, and those raised by more experienced pharmacists. 
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Chapter 5 
PART TWO: RESULTS AND DISCUSSION 
5.1 Clinical Significance of Pharmacists’ Active Interventions 
The most common significance rating following the first review of the interventions 
undertaken in March-June 2013 was ‘moderate’ (Table 5.1). The strength of 
agreement between all reviewers (α=0.265, 95%CI 0.125-0.400) was ‘fair’, and 
marginally stronger when the significance categories were collapsed into 
‘significant’ versus ‘not significant’ (α=0.394, 95%CI 0.022-0.694).  
Table 5.1 Panel 1: Clinical significance of pharmacists’ active interventions (n=42) 
Clinical 
significance 
Frequency, n (%) 
Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 4 
Not significant 2 (4.8) 2 (4.8) 6 (14.3) 5 (11.9) 
Minor 15 (35.7) 11 (26.2) 16 (38.1) 12 (28.6) 
Moderate 21 (50.0) 18 (42.9) 16 (38.1) 13 (31.0) 
Major 2 (4.8) 10 (23.8) 4 (9.5) 12 (28.6) 
Life-saving 2 (4.8) 1 (2.4) 0 (0.0) 0 (0.0) 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
Agreement between pairs of reviewers revealed the best agreement for discrete 
significance categories between Reviewers 3 and 4 (α=0.314) (Table 5.2). With 
respect to categories collapsed to ‘significant’ versus ‘not significant’, the highest 
level of agreement was evident between Reviewers 1 and 4. Reviewers 1 and 2 
demonstrated the lowest level of agreement. 
Table 5.2 Panel 1: Agreement for discrete and collapsed significance ratings 
Reviewer pairs 
Agreement for discrete 
categories (Krippendorff’s α) 
Agreement for combined 
categories (Krippendorff’s α) 
Reviewer 1 vs 2 0.121 0.475 
Reviewer 1 vs 3 0.173 0.462 
Reviewer 1 vs 4 0.211 0.540 
Reviewer 2 vs 3 0.260 0.192 
Reviewer 2 vs 4 0.106 0.234 
Reviewer 3 vs 4 0.314 0.478 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
As Panel 1 could not reach consensus, Panel 2 (medication safety pharmacist, 
paediatric oncology pharmacist) was set up (Section 3.2.1) in July 2014. Review of a 
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random sample of data by Panel 2 determined that the majority (n=37/42, 88.1%) of 
active interventions were clinically significant; no intervention was considered life-
saving (Table 5.3).  
Table 5.3 Panel 2: Clinical significance of pharmacists’ active interventions (n=42)  
Clinical significance No. per category, n (%) 
Not significant 5 (11.9) 
Minor 18 (42.9) 
Moderate 11 (26.2) 
Major 8 (19.0) 
Life-saving 0 (0.0) 
5.2 Identification and Assessment of Medication Misadventure 
Panel 1 assessed a random sample of the active interventions to determine whether 
medication misadventure was implicated; a yes/no decision. The entire Panel 1 
indicated that the majority of active interventions addressed medication misadventure 
(Table 5.4). The strength of agreement between the reviewers was ‘fair’ (α=0.321, 
95%CI 0.113-0.544). 
Table 5.4 Panel 1: Inter-rater reliability of medication misadventure detected by 
pharmacists’ active interventions (n=42) 
Medication 
misadventure? 
Frequency, n (%) 
Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 4 
Yes 31 (73.8) 35 (83.3) 26 (61.9) 31 (73.8) 
No 11 (26.2) 7 (16.7) 16 (38.1) 11 (26.2) 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
When the reviewers assigned each case into three categories of medication 
misadventure (ADE, ADR, ME), they noted ‘fair’ agreement (α=0.222, 95%CI 
0.096-0.341) (Table 5.5). Reviewers 2, 3 and 4 most commonly rated the medication 
misadventures as ME.  
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Table 5.5 Panel 1: Inter-rater reliability of type of medication misadventure detected by 
pharmacists’ active interventions (n=42) 
Type of medication 
misadventure 
Frequency, n (%) 
Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 4 
Medication error 10 (23.8) 34 (81.0) 26 (61.9) 29 (69.0) 
Adverse drug event 20 (47.6) 1 (2.4) 1 (2.4) 0 (0.0) 
Adverse drug reaction 1 (2.4) 1 (2.4) 0 (0.0) 3 (7.1) 
Not applicable 11 (26.2) 6 (14.3) 15 (35.7) 10 (23.8) 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
The reviewers further classified the MEs using the NCC MERP taxonomy.(225) The 
strength of agreement between all reviewers was ‘fair’ (α=0.351, 95%CI 0.207-
0.487) (Table 5.6). There were some similarities in the ratings by Reviewers 1 and 4, 
while Reviewers 2 and 3 demonstrated disparate ratings.  
Table 5.6 Panel 1: Inter-rater reliability of medication error type detected by pharmacists’ 
active interventions (n=42) 
Type of medication 
error 
Frequency, n (%) 
Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 4 
Improper dose 16 (38.1) 9 (21.4) 8 (19.0) 16 (38.1) 
Other  4 (9.5) 15 (35.7) 8 (19.0) 4 (9.5) 
Drug omission 2 (4.8) 2 (4.8) 5 (11.9) 7 (16.7) 
Monitoring error 5 (11.9) 2 (4.8) 0 (0.0) 0 (0.0) 
Wrong rate 0 (0.0) 7 (16.7) 0 (0.0) 0 (0.0) 
Wrong administration 
route  
1 (2.4) 1 (2.4) 2 (4.8) 1 (2.4) 
Dose omission 1 (2.4) 1 (2.4) 1 (2.4) 1 (2.4) 
Wrong patient 1 (2.4) 1 (2.4) 0 (0.0) 1 (2.4) 
Wrong strength/ 
concentration 
0 (0.0) 2 (4.8) 0 (0.0) 1 (2.4) 
Wrong duration 0 (0.0) 0 (0.0) 2 (4.8) 0 (0.0) 
Wrong drug 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.4) 
Wrong dose form 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Not applicable 11 (26.2) 2 (4.8) 16 (38.1) 10 (23.8) 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
The reviewers used the severity rating of the NCC MERP index(225) to judge the 
severity of the MEs addressed through pharmacists’ active interventions. The level of 
agreement for severity between the reviewers was ‘slight’ (α=0.154, 95%CI 0.024-
0.274) (Table 5.7).  
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Table 5.7 Panel 1: Severity of MEs detected by pharmacists’ active interventions (n=42) 
 Reviewer 
1 
Reviewer 
2 
Reviewer 
3 
Reviewer 
4 
A: Circumstances or events that have the 
capacity to cause error 
7 (16.7) 15 (35.7) 22 (52.4) 3 (7.1) 
B: An error occurred but the error did not 
reach the patient 
9 (21.4) 18 (42.9) 1 (2.4) 13 (31.0) 
C: An error occurred that reached the 
patient but did not cause patient harm 
13 (31.0) 5 (11.9) 0 (0.0) 6 (14.3) 
D: An error occurred that reached the 
patient and required monitoring to 
confirm that it resulted in no harm to the 
patient and/or required intervention to 
preclude harm 
2 (4.8) 2 (4.8) 1 (2.4) 1 (2.4) 
E: An error occurred that may have 
contributed to or resulted in temporary 
harm to the patient and required 
intervention 
0 (0.0) 1 (2.4) 0 (0.0) 9 (21.4) 
F: An error occurred that may have 
contributed to or resulted in temporary 
harm to the patient and required initial or 
prolonged hospitalisation 
0 (0.0) 1 (2.4) 1 (2.4) 0 (0.0) 
Not applicable 11 (25.6) 0 (0.0) 17 (40.5) 10 (23.8) 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
There was a notable decrease in the Krippendorff’s alpha value to 0.086 (95%CI 
0.045-0.216) when reported using collapsed categories of severity (Table 5.8). 
Reviewer 3 tended to rate the severity of the errors lower than the other reviewers.  
Table 5.8 Panel 1: Assessment of the severity of MEs (combined severity categories) 
Combined category 
of ME severity 
Frequency, n (%) 
Reviewer 1 Reviewer 2 Reviewer 3 Reviewer 4 
No error (category A) 18 (41.9) 15 (35.7) 39 (92.9) 13 (31.0) 
Error, no harm (B-D) 24 (57.1) 25 (59.5) 2 (4.8) 20 (47.6) 
Error, harm (E-H) 0 (0.0) 2 (4.8) 1 (2.4) 9 (21.4) 
Reviewer 1 = clinical nurse, Reviewer 2 = hospital pharmacist, Reviewer 3 = independent academic 
pharmacist, Reviewer 4 = consensus between two researchers 
Category A: Circumstances or events that have the capacity to cause error. 
Category B: An error occurred but the error did not reach the patient. 
Category C: An error occurred that reached the patient but did not cause patient harm. 
Category D: An error occurred that reached the patient and required monitoring to confirm that it 
resulted in no harm to the patient and/or required intervention to preclude harm. 
Category E: An error occurred that may have contributed to or resulted in temporary harm to the 
patient and required intervention. 
Category F: An error occurred that may have contributed to or resulted in temporary harm to the 
patient and required initial or prolonged hospitalisation.  
Catgeory G: An error occurred that may have contributed to or resulted in permanent patient harm. 
Category H: An error occurred that required intervention necessary to sustain  . 
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5.3 Discussion 
5.3.1 Clinical Significance of Pharmacists’ Active Interventions 
Published studies on pharmacists’ clinical interventions have used different methods. 
To date, there are no validated methods or standardised rating scales to assign 
clinical significance to pharmacists’ interventions, making it difficult to compare our 
findings. Significance assessment was initially performed by a panel comprising 
three independent experts (hospital pharmacist, academic pharmacist, clinical nurse) 
and consensus between two researchers (counted as a single reviewer). The pattern of 
agreement between the reviewers could have been different if physicians had 
participated. Studies have demonstrated that physicians tended to rate the impact of 
pharmaceutical care interventions lower than pharmacists.(226-228)  
The present study uncovered little agreement between the raters for the clinical 
significance of pharmacists’ active interventions, evidenced by low Krippendorff’s 
alpha values, α=0.265 and α=0.394 for discrete rating scales and collapsed scales, 
respectively. In accordance with our finding, low level of agreement (ϰ=0.35) was 
reported in a reliability study assessing the clinical significance of pharmacists’ 
interventions in a tertiary care hospital that included a paediatric unit. The 
assessment was conducted between the intervening pharmacists and an independent 
clinical pharmacist using six-point significance rating scale. There was no face-to-
face training in significance assessment provided to the evaluators.(203)  
A low level of agreement was also reported by Fernandez-Llamazares et al.(197) 
They evaluated the impact of pharmacists’ interventions to reduce prescribing errors 
in paediatric wards. They used a six-point rating scale (harmful, insignificant, 
somewhat significant, significant, very significant, extremely significant). The 
intervening pharmacists and an independent clinical pharmacist carried out the 
assessment.  
An American study in an integrated healthcare centre for adults found ‘slight’ 
agreement (ϰ=0.18) for the impact of pharmacists’ recommendations between two 
independent evaluators (physician, pharmacist).(154) A similar level of agreement 
(ϰ=0.20) was also reported by Bosma et al.(226) in a gastroenterology unit in a 
Dutch general hospital. A Danish study noted modest agreement (ϰ=0.25) between 
two raters (internal medicine specialist, clinical pharmacologist) for the significance 
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of pharmacists’ interventions in a clinical unit for adult patients. They employed a 
four-level significance assessment (minimal importance, moderate, significant, 
vital).(216) Better agreement was reported by Overhage et al.(227) at an American 
general hospital involving the intervening pharmacists and four independent 
reviewers (two physicians, two pharmacists).  
A meeting organised for Panel 2 (researchers and two independent panellists) to 
resolve the rating differences and reach consensus identified that the majority of the 
interventions were rated significant (45.2% moderate or major significance), leaving 
less than 12% as non-significant. An analysis of clinical pharmacists’ interventions 
by self-assessment in an Austrian hospital with a Department of Paediatric and 
Adolescence Medicine demonstrated that around three-quarters of the interventions 
were judged to be significant.(203) These findings were in accordance with a study 
by Virani et al.(204) undertaken in a Canadian paediatric mental health unit where 
86% of pharmacist-initiated recommendations had a potential positive impact on 
patient care ranging from ‘minor’ to ‘markedly significant’. However, nearly 10% of 
the recommendations had a potentially detrimental effect, compared to none in our 
study. Comparable results were also reported by a Spanish study, where more than 
three-quarters of pharmacists’ interventions rectifying prescribing errors had a 
significant impact.(197) The clinical significance of interventions documented in a 
range of paediatric healthcare settings in the USA reported more than half of the 
interventions as ‘somewhat significant’ and nearly 40% as ‘significant’.(184) A 
study conducted in a children’s hospital in the USA claimed that almost two-thirds of 
pharmacists’ interventions during medication reconcilliation were self-rated by the 
pharmacists as contributing a ‘moderate’ impact to patient care, 7% as ‘life-saving’ 
and the remaining 27% as ‘minimal impact’.(139)  
A large Australian study involving eight hospitals assessed the impact of 
pharmacists’ interventions on patients’ clinical outcomes judged by the intervening 
pharmacist and then referred to the independent panel for final assessment. Despite 
using the same significance rating scale as our study, the authors reported more than 
one-quarter of the interventions were of ‘major significance’, while ‘moderate’ and 
‘minor’ categories accounted for around 30% each.(18)  
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A different method was reported by Mogensen et al.(216) who evaluated the 
significance of interventions in an ED. They applied the highest rating from either of 
the two independent specialists as the final rating and did not seek consensus. They 
argued that the expertise of the specialists would be more relevant for the final 
assessment than consensus. They deemed around 47% of interventions to be of ‘vital 
importance’, with the remainder of ‘minor-moderate importance’.  
Sircar-Ramsewak et al.(229) retrospectively evaluated the potential impact of 
pharmacists’ interventions on addressing DRPs over one year in a general hospital in 
Trinidad. There was no clear explanation about the assessment process. More than 
two-thirds of the interventions were of ‘moderate impact’ on patient care, while 
around 30% had a ‘major impact’ and a small proportion ‘minor impact’. Although 
Sircar-Ramsewak et al.(229) used different terms to classify the value of 
pharmacists’ interventions, there were no distinct differences in defining the value. 
This means that the term ‘impact’, describing the value of the assessment, can be 
replaced by the term ‘significance’. Sircar-Ramsewak et al.(229) reported greater 
significance of pharmacists’ interventions than our study. 
A retrospective study of pharmacists’ interventions to resolve MEs during dispensing 
was conducted in a general hospital in Oman. Some challenges to the method were 
noted. Pharmacists based the intervention data on legible annotations on the 
prescriptions. The researchers did not describe their assessment processes for the 
interventions. The study revealed slightly better findings than our study, where the 
majority (72.3%) of the interventions were of ‘minor significance’, while nearly 20% 
and 7.5% were of ‘moderate significance’ and ‘major significance’, 
respectively.(230)  
Different findings were also noted in a study evaluating the impact of Doctor of 
Pharmacy students’ interventions during an internal medicine clerkship. The 
significance of the interventions were assessed by panels of two faculty members and 
10 independent pharmacists using a three-level scale (low, moderate, high). The 
differences among the panellists was resolved by a vote. Around 50% of the 
interventions were categorised as having ‘low-level significance’.(231) 
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It is evident from these studies that methods for assessing the clinical significance of 
interventions are variable. The subjectivity of the reviewers, characteristics of the 
rating scales and the accuracy of their predictions compromise all of the methods. 
Studies involving self-assessment by the intervening pharmacists may also be subject 
to bias.  
Applying actual clinical outcomes of pharmacists’ interventions would circumvent 
the subjectivity involved in theoretical estimation of significance and impact. This 
approach was attempted by McLennan et al.(232) in an assessment of pharmacists’ 
interventions in an Australian tertiary referral centre for cancer. They employed three 
classifications of patient outomes to assess the interventions (beneficial, detrimental, 
no change). The assessment was undertaken by an independent pharmacist who 
reviewed patients’ clinical status in their medical histories following the intervention 
episode until discharge, or for a maximum of seven days. McLennan et al.(232) 
claimed approximately 90% of the interventions benefitted the patient. As the study 
was conducted in a specialty setting, familiarity with the patients’ medical conditions 
may have facilitated this approach. Assessment of outcomes is expected to be more 
complex in general medical settings.  
5.3.2 Identification and Assessment of Medication Misadventure 
Analysis of medication-related events, particularly the frequency, type and severity, 
is essential to improve the quality of healthcare delivery.(233, 234) Therefore, 
reliability in the classification is vital. However, variation in judgement between 
raters may contribute to errors in reliability analysis. Variability is expected as a 
result of the raters’ clinical specialties, their awareness of best-practice management 
across a range of conditions, and their experience and familiarity with the 
classification process.(233)  
The level of agreement within Panel 1 was ‘fair’ for judgements on involvement of 
medication misadventure. Reviewers relied on concise explanations of the categories, 
without examples. Consequently, there was disagreement between the reviewers as 
to what constituted an error. Different perceptions were also noted when determining 
the presence of harm. Although the NCC MERP has created an algorithm to facilitate 
the assignment of severity to ME-related events and to minimise variability,(225) its 
utility has been questioned.(235) 
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It is challenging to compare our findings with other studies, despite widespread 
application of the NCC MERP index, for which inter-rater reliability has been 
established by a small number of studies. Forrey et al.(235) evaluated the reliability 
of the NCC MERP index among MedMARx ADE data repository users using 27 
actual ME scenarios. They reported the NCC MERP index was accurate and reliable, 
with some ability to generalise findings. However, Forrey et al.(235) proposed that 
collapsing categories E, F and H into one category, and categories C and D into 
another category, would minimise ambiguity. The present study collapsed the 
categories into four (no error, error - no harm, error - harm, error - death), as 
indicated in the NCC MERP index; paradoxically this generated a lower level of 
agreement as opposed to discrete categories. 
Little research has investigated inter-rater reliability associated with medication 
misadventure in paediatrics. Variations in definitions and categories of terms such as 
ADE, ADR and ME complicate the comparison of published research. Consistent 
with our findings, Kunac et al.(233) determined the reliability in assessment of 
paediatric inpatient medication-related events. They found low agreement ranging 
from ‘slight’ to ‘fair’ on the type and the seriousness of the event. Kunac et al.(233) 
used simulated test cases and guidelines consisting of the definitions and examples of 
the event categories to aid reviewers during the judgement process. 
Previous paediatric studies have revealed high levels of agreement for the 
classification of event type.(236, 237) ‘Substantial’ agreement was reported by King 
et al.(236); 20 randomly selected incident reports were judged by two independent 
physicians. Potts et al.(237) found ‘almost perfect’ agreement between two 
independent reviewers (physician, clinical pharmacist) who assessed a random 
sample (10%) of data relating to paediatric patients in a critical care unit. With 
respect to the severity of ME, comparison of our findings with the existing literature 
was challenged by the majority of studies evaluating the severity of all medication-
related events, not necessarily MEs. The studies also used a variety of rating scales 
resulting in distinct interpretations of the event severity. For example, two paediatric 
studies reported ‘substantial’ agreement between two independent raters for the 
severity of the event (ADEs, potential ADEs, MEs) using a four-point Likert-type 
scale.(50, 238) 
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Some differences in this concept are notable when comparing paediatric and adult 
population studies. Snyder et al.(239) modified the NCC MERP index by replacing 
the word ‘error’ in each severity category with the word ‘event’, combining 
categories B-D (error - no harm) and E-H (error - harm), and excluding categories A 
and I. They found that the level of agreement for classification of medication safety 
events ranged from ‘substantial’ to ‘almost perfect’. They also reported that the level 
of agreement for event severity among the reviewers for original discrete categories 
was substantial, and slight improvement in agreement was noted when using the 
combined categories.(239) Abdel-Qader et al.(210) conducted a study in a UK 
teaching hospital to determine the reliability of the severity of prescribing errors 
rectified by pharmacists. They found substantial agreement between intervening 
pharmacists and an independent senior pharmacist. By contrast, poor agreement was 
reported between two independent raters (hospital pharmacist, clinical 
pharmacologist) on the severity of MEs intercepted by pharmacists’ interventions in 
a specialty unit in the Netherlands.(226)  
Over three-quarters of the selected sample of pharmacists’ active interventions in our 
study addressed medication misadventure, of which over 90% involved MEs and the 
rest were due to ADRs. In line with paediatric studies,(17, 50, 99, 148, 238, 240, 
241) the researchers’ assessment demonstrated that overall, the most common type of 
MEs addressed in the active interventions during pharmacy rounds on the five wards 
and during dispensing in the Haematology-Oncology Pharmacy was related to 
inappropriate doses. A situation compounded by the limited availability of drug 
formulations for children.(242) However, the pattern of MEs on the Haematology-
Oncology Ward was slightly different, with drug omission comprising around 46% 
of the MEs. Inappropriate doses of the correct drugs were the second most frequent 
errors, contributing to 23% of the errors in this specialty unit. Half of the sampled 
MEs were not intercepted, and resulted in additional monitoring or temporary patient 
harm. A two-month study in an American paediatric teaching hospital reported a 
negligible proportion of the errors reaching patients.(243)  
Chan and Kotzin(94) described a distinct way of assessing the severity of MEs 
detected by pharmacists’ interventions. They evaluated four years of data from 
interventions in paediatric patients and found that more than half of the errors were 
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‘moderate’ in severity and just over one-fifth were ‘severe’, while the remaining 
errors were ‘minor’ and ‘unknown’ in comparable proportions. A systematic review 
of MEs in paediatric patients revealed that, MEs were moderate in severity and very 
few incidents resulted in fatal outcomes.(244) When focusing on paediatric 
chemotherapy MEs, Rinke et al.(10) assessed the five-year voluntary report of the 
US Pharmacopeia MedMARx database and found that 85% of the errors reached 
patients and 15.6% of non-intercepted errors resulted in patient monitoring or 
therapeutic interventions. The differences might be due to the researchers’ focus on 
chemotherapy instead of all medications used in oncology. Furthermore, errors 
submitted to the MedMARx ADE data repository might from all stages of 
medication-use process, which was not the case in the present study.  
5.4 Limitations and Recommendations 
There are some limitations in the study design and the results of this study. For 
convenience, only randomly selected cases of pharmacists’ active interventions were 
included in the analysis. Despite this, the findings provide some insight into 
medication misadventure in paediatrics.  
The samples used to assess the classification agreement were from a single children’s 
hospital, which might limit the generalisability of the findings. Data were gleaned 
from observations during ward rounds and dispensing. The lack of continuous 
monitoring could mean less opportunity to detect MEs during drug administration. 
Kaushal(245) has claimed that each method of error measurement detects only 
certain types of errors. The most common medication-related events, including MEs, 
occur during prescribing and administration.(3, 37, 50, 52, 179)  
The independent panellists were selected for convenience. In the selection process, it 
was deemed that the independent panellists had appropriate clinical knowledge and 
professional experience. Low levels of agreement among reviewers might be due to 
their inadequate experience in using the clinical significance rating and the NCC 
MERP index.  
Limited information provided for each case could have influenced the agreement. 
There was no formal training using simulated scenarios prior to the assessment, and 
no examples were provided for each component of assessment. The findings might 
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be different if more detailed information had been provided, along with training for 
the panellists.  
Our findings highlight that more research is needed to elucidate the rate and pattern 
of medication-related events identified through pharmacists’ active interventions in 
paediatrics. Future studies should assess all pharmacists’ active interventions 
documented within a time frame in a range of paediatric settings, and in multiple 
institutions and with actual clinical patient outcomes. Future research could also 
address the issue of selection of the independent expert panel via random selection of 
a broad group of eligible experts - doctors, nurses and pharmacists. The resulting 
data would provide a broader picture of pharmacists’ interventions in relation to their 
capacity to identify and resolve medication misadventure, and a better understanding 
of the nature of medication misadventure in children.  
5.5 Conclusion 
Most of the selected active interventions were rated as clinically significant and 
reliability of reviewers’ rating was ‘slight’ for severity of ME. Meanwhile, ‘fair’ 
agreement was achieved for the presence of medication misadventure, classification 
of medication misadventure and classification of ME. It is beneficial to implement 
approaches to improve the reliability of the assessment and generalisability of the 
findings. This study highlighted the clinical significance of pharmacists’ active 
interventions and justified the role of clinical pharmacists through their active 
interventions in paediatric settings by identifying and resolving medication 
misadventure related events, in particular ME. The medication misadventures 
detected and corrected by pharmacists provide valuable data on the pattern of the 
misadventure and subsequent direction to improve the medication use process.  
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Chapter 6 
PART THREE: RESULTS AND DISCUSSION 
This chapter comprises a published paper reproduced with permission from the 
journal: 
Hesty U Ramadaniati, Ya P Lee, Jeffery D Hughes. Snapshot versus continuous 
documentation of pharmacists’ interventions: are snapshots worthwhile? Journal of 
Pharmacy Practice and Research 2014; 44: 205-12. DOI: 10.1002/jppr.1029. 
The headings, page number, tables, figures and references have been reformatted in 
line with the thesis structure. This chapter also presents qualitative data from the 
FGD that had not been included in the paper. 
6.1 Introduction 
Clinical pharmacy services play an important role in ensuring optimal drug outcomes 
for patients.(121) Pharmacists’ interventions have been considered in some 
developed countries as one of the main parameters in evaluating the importance of 
clinical pharmacy services for improving safety and efficacy of medication use.(185, 
210, 246)
 
 Hence, the documentation of pharmacists’ clinical interventions and 
activities are of paramount importance in providing evidence that clinical 
pharmacists play an integral role in preventing medication misadventure, improving 
overall patient care and justifying their value within the healthcare system.(247, 248)  
A national survey was conducted in Australia to evaluate the extent of clinical 
services provision and their level of documentation. The survey indicated that 
clinical pharmacy services are common in hospital settings across Australia and that 
the level of documentation varied amongst institutions.(248) Likewise, a national 
survey by the American Society of Hospital Pharmacy demonstrated that most 
hospital pharmacists documented their interventions.(249) Nonetheless, there have 
been limited studies specifically evaluating the different approaches in documenting  
interventions, particularly in the paediatric population.(89, 184, 201) Paediatric 
patients are particularly at risk of medication misadventure for many reasons, 
including unique physiologic characteristics, inadequate healthcare settings to 
accommodate safe use of medication in paediatrics and psychological factors 
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specifically related to communication issues.(87) Thus, this study aimed to evaluate 
the nature of pharmacists’ interventions documented through self-reporting during 
snapshot periods in comparison to interventions documented during direct 
observation. Further, it sought to gather pharmacists’ opinions on the utility of the 
different documentation methods. 
6.2 Method  
6.2.1 Documentation of Pharmacists’ Interventions during Snapshot 
Periods 
This study was conducted in a 220-bed paediatric teaching hospital in Perth, Western 
Australia. This hospital has an in-house method for documenting pharmacists’ 
interventions during snapshot periods. Snapshot periods occur twice a year around 
March to May and September to October and are of five days’ duration. The 
interventions are self-reported manually by all pharmacists using a specific form 
(Appendix 7). The principal researcher retrospectively analysed ward-based 
pharmacists’ interventions from the five study wards (General Medical Ward for 
Infants, General Medical Ward for Young Children, General Medical Ward for 
Adolescents, General Surgical Ward and Haematology-Oncology Ward) for three 
snapshot periods, namely September 2010, April 2011 and May 2012. The snapshot 
reports from the study periods were evaluated to determine the number and type of 
the interventions. The type of intervention was categorised as described by Condren 
et al.(184) with slight modification. In addition, the interventions were divided into 
active and passive interventions. An active intervention was defined as any activity 
by a pharmacist that directly leads to a change in a patient’s drug management or 
therapy.(121) All other care-centred activities not resulting in medication changes 
were considered as passive interventions. The medications involved in the 
interventions were categorised using the AMH.(188) The results of the snapshot 
reports were then compared to interventions documented during direct observation. 
6.2.2 Documentation of Pharmacists’ Interventions during Direct 
Observation 
The principal researcher shadowed pharmacists during their ward rounds and 
documented all interventions undertaken by the pharmacists in the five study wards. 
This observation was made between 35 and 37 non-consecutive days per ward. The 
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type of data collected during direct observation can be seen in the data collection 
form (Appendix 1). 
6.2.3 Focus Group Discussion 
The principal researcher presented the results of pharmacists' intervention 
documentation from direct observation and snapshot reports to the pharmacy staff. A 
focus group discussion was conducted after the presentation by an independent 
facilitator to gather the pharmacists' perceptions and comments on the results. The 
barriers to effective documentation of pharmacists' interventions and their 
suggestions to improve the established intervention documentation system were also 
sought.  The discussion was audio recorded and transcribed verbatim for thematic 
analysis.  
6.2.4 Data Analysis 
Demographic variables and pharmacists’ intervention data were summarised using 
descriptive statistics. Data were analysed using SPSS version 19.0 (Chicago, IL, 
USA). The rates of pharmacists’ interventions per 100 medication charts reviewed, 
documented through direct observation and  during snapshot periods for each ward, 
were compared using Poisson regression using  SAS version 9.2 (SAS Institute Inc., 
Cary, NC, USA). Transcripts of the discussion were entered into a qualitative 
analysis software program (QSR NVivo 10) to code and link emergent themes. 
6.3 Results 
6.3.1 Pharmacists’ Interventions Documented during Snapshot versus 
Observation Periods 
A total of 398 interventions were documented and 1022 medication charts were 
reviewed by pharmacists during three snapshot periods in 2009 and 2010 (I, II, III). 
Complete snapshot reports from the five study wards were available for snapshot 
period II, while only reports from three wards were submitted during periods I and 
III. Of all interventions, approximately 18% (n=70/398) were considered active 
interventions. The characteristics and rates of all interventions and the active 
interventions documented by pharmacists during snapshot periods are shown in 
Table 6.1, and the types of interventions during snapshot periods are described in 
Figure 6.1. The highest rates of intervention per 100 medication charts reviewed was 
recorded in the General Surgical Ward, followed by the General Medical Ward for 
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Infants and the Haematology-Oncology Ward, respectively (Table 6.1). However, 
the analysis of active interventions revealed a different trend with the Haematology-
Oncology Ward showing the highest rate followed by the General Surgical Ward and 
the General Medical Ward for Adolescents, respectively. A total of 982 pharmacists’ 
interventions were observed and documented, and 2275 medication charts were 
reviewed in the five study wards during the direct observation. The characteristics 
and rates of pharmacists’ interventions from each ward are summarised in Table 6.2 
and the types of interventions performed by ward-based pharmacists in the study 
wards are described in Figure 6.2. As detailed in Table 6.2, the General Surgical 
Ward had the highest intervention rate per 100 medication charts reviewed. It was 
followed by the Haematology-Oncology Ward and the General Medical Ward for 
Adolescents. In terms of active interventions, the Haematology-Oncology Ward 
ranked first, followed by the General Surgical Ward and the General Medical Ward 
for Adolescents. It is interesting to note that the pattern of active interventions during 
observation was similar to that of the snapshots. 
Comparison of the rates of interventions during the snapshot periods and direct 
observation were undertaken using a Poisson regression model.  This model showed 
no significant difference in the interventions rates of the two documentation 
methods; snapshot 37.4 (95%CI 27.4–47.4) per 100 medication charts reviewed 
versus observation 50.6 (95%CI 43.1–58.1) per 100 medication charts reviewed, p = 
0.054. A similar statistical analysis was undertaken to compare the rates of active 
interventions between snapshot and observation periods. The analysis revealed that 
the rate of documentation of active interventions during the direct observation period 
was significantly higher compared to that of the snapshots (snapshot 6.7 [95%CI 
4.3–9.2] per 100 medication charts reviewed versus observation 15.1 [95%CI 10.0–
20.2] per 100 medication charts reviewed, p = 0.002). 
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Table 6.1 Characteristics and rates of pharmacists’ interventions (PIs) on the five study wards during snapshot periods 
Parameters 
Medical Ward for 
Infants 
Medical Ward for 
Young Children 
Medical Ward for 
Adolescents Surgical Ward 
Haematology-
Oncology Ward 
Duration of data collection (days) 15 10 10 9 10 
No. of PIs 141 11 42 150 54 
No. of active PIs (%)* 9 (6.4) 4 (36.4) 19 (45.2) 17 (11.3) 21 (38.9) 
No. of  medication charts reviewed 278 179 219 194 152 
Rate of PIs per 100 medication 
charts reviewed 
50.72 6.15 19.18 77.32 35.52 
Rate of active PIs per 100 
medication charts reviewed 
3.24 2.23 8.68 8.76 13.82 
*Percentage of active interventions per number of interventions on each ward. 
 
 
 
 
 
 
 
 
 
 116 
Table 6.2 Characteristics and rates of pharmacists’ interventions (PIs) on the five study wards during direct observation 
Parameters 
Medical Ward for 
Infants 
Medical Ward for 
Young Children 
Medical Ward for 
Adolescents Surgical Ward 
Haematology-
Oncology Ward 
Duration of data collection (days) 35 35 35 37 35 
No. of PIs 145 153 218 271 195 
No. of active PIs (%)* 16 (11.0) 28 (18.3) 51 (23.4) 59 (21.8) 90 (46.2) 
No. of medication charts reviewed 468 500 528 422 357 
Rate of PIs per 100 medication 
charts reviewed 
30.98 30.60 41.29 64.22 54.62 
Rate of  active PIs per 100 
medication charts reviewed 
3.42 5.60 9.66 13.98 25.21 
*Percentage of active interventions per number of interventions on each ward. 
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Figure 6.1 Types of pharmacists’ interventions performed and documented by clinical pharmacists on the five study wards during snapshot       
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Figure 6.2 Types of pharmacists’ interventions performed by clinical pharmacists and documented by observation on the five study wards 
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In terms of the types of interventions, clarification of medication orders (Figure 6.1) 
was the commonest type of intervention documented by pharmacists during 
snapshots across all settings. Clarification of medication orders arose as a result of 
activities performed by the pharmacists in annotating additional information for 
specific medications on the medication charts. As shown in Figure 6.2, taking 
medication histories and/or patient counselling were responsible for the most 
common interventions performed by clinical pharmacists in the general medical and 
surgical settings during the direct observation period. These types of interventions 
accounted for 50% or more of all interventions recorded in these settings. However, a 
different pattern was seen in the Haematology-Oncology Ward, where drug therapy 
changes constituted the most common intervention type. When comparing the pattern 
of all interventions during the direct observation period with that of snapshot reports, 
it can be clearly seen that the interventions across the study wards were not 
comparable. 
6.3.2 Characteristics of Pharmacists’ Active Interventions and Implicated 
Medications during Snapshot versus Observation Periods 
In terms of  active interventions self-reported (n=70) by pharmacists across the five 
study wards during the snapshot periods, the highest proportion of active 
interventions was found in the Haematology-Oncology Ward, followed by the 
General Surgical Ward and the General Medical Ward for Adolescents, respectively. 
Interestingly, the proportion of active interventions increased as the patients’ age 
went up in the general medical setting. In all General Medical Wards, except the 
Ward for Infants, dosing associated interventions were the most common active 
intervention type. Similarly, dose adjustment accounted for the most common active 
interventions in Haematology-Oncology. Meanwhile, the General Medical Ward for 
Infants and the General Surgical Ward shared the same pattern of most frequent 
active intervention, namely recommendation to clarify wrong/missing dosing 
interval/frequency of medication orders.  
Active interventions (n=244) contributed less than a quarter of all interventions in 
each General Ward during the direct observation. However, the Haematology-
Oncology Ward revealed a different pattern with a considerably higher proportion of 
active interventions (46.2%). Adjusting the dose was the most frequent active 
interventions in general settings; however, in the Haematology-Oncology Ward, 
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recommendations to prescribe regular medications constituted the most common 
active interventions and dosing adjustment ranked second, which differed from the 
snapshot reports. When compared with snapshot reports, active interventions during 
direct observation showed a different pattern. Nonetheless, dosing-associated 
interventions during snapshot periods and direct observation were the most common 
active interventions in almost all general medical wards. Drug addition and dosing-
associated recommendations in the Haematology-Oncology Ward accounted for two 
thirds of active interventions.  
With respect to the classes of medications implicated in active interventions during 
snapshot periods, analgesics (n=25, 35.7%) were the most common drug class 
implicated. It was found that almost half of analgesics-associated recommendations 
occurred in the General Medical Ward for Adolescents. Dosage interval/frequency 
adjustment (n=12, 48.0%) accounted for the most frequent recommendations in 
relation to the use of analgesics. Anti-infectives (n=20, 28.6%) were the second 
major class of medications associated with active interventions. Sixty-five percent of 
anti-infectives-related interventions were reported in the Haematology-Oncology 
Ward. Dosing adjustment (n=10) constituted exactly half of the interventions in this 
class. Antibacterials (n=17/20) were implicated in the majority of the active 
interventions related to anti-infectives. Drugs for the gastrointestinal system (n=12, 
17.1%) were the third major class of medications associated with active 
interventions. Half of the interventions related to this class were documented in the 
General Surgical Ward. When categorised according to subclasses of medications, 
50% of recommendations in this class were related to the use of antiemetics. The 
most frequent active intervention in this class of medication was dose adjustment.  
Meanwhile, anti-infectives were the drugs most often associated with active 
interventions (n=100, 41.0%), followed by analgesics (n=46, 18.9%), gastrointestinal 
drugs (n=36, 14.8%) and immunomodulators and antineoplastics (n=21, 8.6%), 
respectively, during the observation study. Antibacterials were the predominant anti-
infectives associated with active recommendations. In terms of the use of analgesics, 
almost 40% of analgesic-related recommendations occurred in general medical 
wards. Drug deletion (n=11/46, 23.9%) was the most common active interventions in 
this class of medications. The third major class of medications involved in active 
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interventions was drugs for the gastrointestinal system. More than half of the 
recommendations related to this medication class occurred in the haematology-
oncology setting. When categorised according to subclasses of medications, 
antiemetics were involved in around 63% of interventions associated with this class. 
Recommendations to add medications accounted for the major active interventions 
involving gastrointestinal drugs (n=15/36; 41.7%). With regard to 
immunomodulators and antineoplastics, not surprisingly, more than 80% of the 
recommendations were recorded in the Haematology-Oncology Ward.  Drug 
addition was the most frequent recommendation accounting for more than half of all 
active interventions associated with this class of medications. 
6.3.3 Some Examples of Pharmacists’ Active Interventions 
A five-month-old female patient with a brain tumor was admitted to the oncology 
ward.  During medication history taking, the parents told the ward pharmacist that 
the patient took 2.5 mL (0.1 mg) of clonazepam twice daily. When reviewing the 
medication chart, the pharmacist found clonazepam was prescribed 2.5 mg twice 
daily. The doctor confused ‘microlitre’ and ‘microgram’, and the patient almost 
received the dose that was 25 times higher than intended. The doctor reduced the 
dose to 2.5 mL twice daily on the pharmacist’s recommendation.   
A 17-year old female patient was hospitalised due to congenital right leg oedema. 
During hospitalisation, the patient was prescribed pregabalin 25 mg twice daily. The 
order written on the medication chart was slightly illegible. The ‘25 mg bd’ looked 
like ‘250 mg bd’ so the nurse assumed the dose was 250 mg and administered the 
wrong dose. The patient received 10-fold higher dose in the morning and she felt 
very drowsy afterwards. In the afternoon, the pharmacist noticed the error and asked 
the doctor to rewrite the medication order more clearly.  
6.3.4 Barriers in Documenting Pharmacists’ Interventions and 
Suggestions in Improving the Documentation 
The pharmacists who participated in the focus group discussion conducted in July 
2013 identified a number of barriers to documenting their interventions continuously 
including time constraints, fatigue, heavy workload and staffing deficiencies. The 
quotations below illustrate many of these issues:  
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“...And the reason that we moved from that [continuous recording] to snapshot 
recording, was because of the sort of things that we’re hearing now, about recording 
fatigue, about it taking up so much time that you’ve spent an enormous amount of 
time collecting data, and that is then impacting on how much time you had to 
actually do your work...” PA3 
“...And many other tertiary and hospital pharmacists are routinely documenting in 
the patient’s inpatient progress notes, but because of those particular staffing or 
resourcing differences between our hospital and other tertiary hospitals, we mightn’t 
necessarily have time  to individually document a swag of interventions...” PA5 
The majority of pharmacists thought that the snapshot report was inadequate to 
reflect their actual contribution to patient care and their workload. They suggested 
that modification of the timing of snapshot so it was undertaken during a busy period 
rather than a downtime as usual would be worthwhile (see quotations below). 
“Because we do try and do it during quiet periods, even if you do, like, rather than 
doing a week of snapshot, do a day during a busy period, and you’ll get some data 
and it’ll be more reflective of what your day-to-day life is going to be like...” PA6   
The pharmacists also proposed a hybrid system with continuous recording of 
interventions during certain periods of time by an independent observer in addition to 
existing snapshot documentation (see quotations below). 
“...that another model that we could use would be rather than the ward pharmacist 
doing the documentation, you could have, as I said, we have a medication safety 
pharmacist starting soon. One of the roles, perhaps, of the medication safety 
pharmacist could be to do a, once or twice   a year for every ward pharmacist, to 
actually go around and shadow them...” PA3 
6.4 Discussion 
It is the evident that the majority of previous studies in a range of healthcare settings 
relied on self-reporting methods to document pharmacists’ interventions.(178, 183, 
247) This method may lead to bias and under-reported findings, since documentation 
is influenced by pharmacists’ perceptions and preferences on whether or not to report 
their interventions. The direct observation approach, in combination with 
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retrospective analysis of self-reporting documentation, allows this study to determine 
the actual rate of pharmacists’ interventions as a reflection of the pharmacists’ daily 
workload. The direct observation approach is expected to be effective in resolving 
the issue of potential under-reporting associated with self-documenting intervention 
studies.(178) When comparing pharmacists’ interventions across the study wards 
between both documentation approaches, direct observation uncovered higher rates 
of active interventions than the snapshot method. Furthermore, the pattern of 
interventions reported during the snapshots did not mirror that documented during 
direct observation. However, it is not feasible to adopt direct observation as a routine 
practice since this method is time and labour intensive. Nonetheless, this study raised 
questions about the value of documenting pharmacists’ interventions during certain 
periods using only self-reporting methods. Routine self-documentation of 
pharmacists’ interventions is common amongst hospitals in the USA, Australia, and 
New Zealand (196, 246, 250); however, our study raises questions about the worth of 
this practice.   
An appropriate documentation system should accurately reflect the nature of the 
activities provided, must be able to provide information on the factors that influence 
the pattern of interventions and showcase the value of pharmacists’ 
contribution.(247) Although the interventions occur every day, it is not feasible to 
accurately quantify their impact on patient care if there is no adequate documentation 
on a day-to-day basis.(18, 246) Our findings indicated that the information recorded 
on the intervention form during snapshots was not sufficient to provide meaningful 
description of the interventions, particularly to assess the clinical significance of the 
interventions. Furthermore, there was no standardised definition and classification of 
pharmacists’ interventions to guide the pharmacists when documenting their 
interventions.(248, 250) Dooley et al.(251) suggested a national  standard for the 
documentation of clinical pharmacy practices to provide new opportunity to quantify 
clinical pharmacists’ contribution to patient care and benchmark clinical services.  
The benefits of pharmacists’ intervention documentation have been justified in a 
number of studies,(131, 197, 252, 253) where these activities promote medication 
safety and ensure optimal outcomes for patients. In line with other studies, limited 
time, limited staff and heavy workload have been identified by pharmacists in our 
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study as the main barriers to documenting their interventions.(247, 251) This under-
reporting of interventions leads to an underestimation of pharmacists’ clinical 
contribution and loss of opportunities to improve clinical services and patient care. 
This underlines the necessity to improve the documentation process of pharmacists’ 
interventions by employing innovative tools (e.g. applications on smartphones or 
tablets).(121, 253-255) Additionally, staff motivation is crucial to improving 
documentation. This may be enhanced by providing incentives to pharmacists and/or 
by making intervention documentation compulsory.(247, 253) It has been reported 
that an improved utilisation of intervention reports can considerably motivate 
pharmacists to document their interventions.(246, 248, 250)  
In summary, the self-reported pharmacists’ interventions during snapshot periods 
was not representative of the interventions documented during direct observation. 
This raises the question of the value of this documentation method, and suggests the 
need for efficient means by which pharmacists document their interventions as part 
of day-to-day practice.  
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6.6 Additional Qualitative Results 
For brevity, the following data were not reported in the published paper. These data 
represented the participants’ comments on the other questions posed during FDG, but 
not reported in the paper. 
6.6.1 Pharmacists’ comments on the results of pharmacist’s interventions 
documented during observation vs snapshot reports   
Participants were given the opportunity to comment on the differences between 
pharmacists’ interventions documented in snapshot reports and those documented 
during observation. Even though some participants did not expect these differences, 
they thought the interventions documented during observation were valid and more 
reflective than snapshot reports to describe their routine practice (see quotations 
below). 
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“...the difference in snapshot versus observation stuff is, we are really bad, we do not 
record when we do our snapshot...So, I know when we do snapshot, we’re supposed 
to record what comes into the office, but we’re very poor at doing it.” PA3 
“…although it’s different to what I expected to see, I still think it’s valid, it’s not like 
the data is incorrect … I think the 3B [Haematology-Oncology] stuff’s pretty true.” 
PA4 
“Oh, absolutely, yes. Especially for the long time periods … you were very thorough 
in recording what we actually did.” PA4 
6.6.2 How important is the documentation of pharmacists’ interventions? 
Participants in the focus group were asked to provide their opinion on the importance 
of documentation of pharmacists’ interventions. Their responses supported 
documentation as a data source for justification of staffing, medical and legal 
reasons, and pharmacy practice improvement. These issues are reflected in following 
quotations from participants: 
“That, in itself, is also very, something that is, perhaps, is staffing to justify extra 
staff.” PA3 
“And also for medical and legal reasons too, to cover your self in the future if 
something, you know is shown to have gone wrong.” PA4 
 “…some of the … preliminary data showed how good potentially a satellite 
pharmacy is, and 3B [Haematology-Oncology] is a satellite pharmacy, our only 
satellite pharmacy in the hospital ... it could provide, I guess, cases for satellite 
pharmacies in new children’s hospital.” PA5 
In addition, they perceived that the documentation of pharmacists’ interventions was 
important for quantification of pharmacists’ contribution to patient care, 
identification of problems during the healthcare process in hospital, and quality 
assurance (see quotations below). 
“You need to be able to, you know, show what we do, to quantify what we do.” PA2 
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“...then looking at common occurrences throughout the ward, because everyone’s 
covering different places, and to see and go, oh PA7 picked up an interaction, oh 
PA5 has done that same thing. Oh, look PA2 done that there, as well. Wow! That 
must be a real issue in the hospital...” PA7 
“...just with the focus on health and safety … hospitals also need to be reassured that 
the right things are done.” PA3 
6.6.3 How valuable do you think are your clinical interventions? 
When the participants were asked to assess the value of their interventions, they 
agreed that their interventions were valuable, but varied perspectives were evident in 
defining the value. They argued that the interventions can be considered valuable 
because the interventions can  minimise patient harm. Further, they perceived that 
the values were dependent of the nature and/or the timeframe of the interventions 
after identifying the harm-related problems. These themes are reflected in the 
following quotations. 
“I think there’s a full scale of it. You comment on with the things that have minimal 
value, such as writing, with food on ibuprofen at normal doses, right up to 
identifying a medication error and taking it further. So there’s a range of how 
valuable they might be.” PA1 
“But then if you’ve got the minimal intervention things that are picked up early, you 
pick that up when they first started in hospital, but then if they continue for the next 
six months to take that ibuprofen without food, it becomes more and more valuable 
that you’ve picked it up early ...”PA6 
In addition, the participants mentioned the value of pharmacists’ interventions for 
hospital accreditation and staff compliance during clinical trial (see quotations 
below). 
“Yes. It’s valuable toward process in the hospital. If it doesn’t, if it assists us in 
getting accredited as a hospital, that’s massively valuable in the whole health 
system, because you want all your hospitals to be accredited.” PA6 
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“I think it’s also valuable with the clinical trial stuff to pick it up and document it as 
well … [it] helps staff compliance, where you do really well when you get audited on 
that...” PA4 
6.6.4 Do you think there are problems with the way data are used? Why 
do you think so? 
In terms of the use of intervention documentation during snapshots, participants 
revealed some issues, including inaccesibility of snapshot data, lack of feedback for 
reporting pharmacists, and underutilisation of the reports. The following quotations 
reflect these issues. 
“…our continuous intervention system we had before was, [the data] were pretty 
well inaccesible, you know, we handed in the sheets to [administrator]. She entered 
them in a database, but … in the six or seven years it was running while I was here, I 
never went back and looked at the database at anything. I’m not sure anyone 
actually did.” PA4 
“I’ve been here six and a half years. I’ve never seen any feedback.” PA6 
“Down here, we’re doing it for higher up, basically, to keep them satisfied … we 
never see the results.” PA4 
6.7 Discussion of Additional Qualitative Results 
The practice of pharmacy in hospital settings has transformed considerably, and the 
documentation of the clinical interventions of pharmacists has become increasingly 
important.(256) Understandably, professional and regulatory bodies in some 
countries have recommended that pharmacists record their interventions.(121, 250, 
257, 258) The American Society of Health-System Pharmacists mandates 
pharmacists to document their recommendations.(257) The Joint Commission on 
Accreditation of Healthcare Organizations in the USA even stresses the importance 
of pharmacists’ intervention documentation as the clinical indicators of medication-
use system monitoring.(259) Meanwhile, the Society of Hospital Pharmacists of 
Australia strongly advises each pharmacy department to provide the policy for 
documentation of pharmacists’ interventions.(121) The Royal Pharmaceutical 
Society of Great Britain has published guidelines on the recording of pharmacists’ 
interventions.(258)  As with other studies, the participants of the FGD claimed that 
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the documentation of the clinical interventions performed by pharmacists is 
important and they argued that the documentation can be used for a range of 
purposes, including justification of staffing, identification of DRPs, quantification of 
pharmacists’ contribution, evidence of pharmacy practice improvement, source of 
information for quality assurance, clinical trial protocol compliance and medico-legal 
issues. 
It has been acknowledged in numerous studies that the documentation of 
pharmacists’ interventions can provide a great deal of information that can be used 
for assessing task workload and justifying staffing levels.(18, 184, 226, 260) Catania 
et al.(261) used documentation of clinical interventions performed by pharmacists to 
justify the cost of hiring additional hospital pharmacists. Similarly, Davydov(185) 
found that  intervention data can be used to evaluate the cost-effectiveness of hiring 
additional pharmacists. In line with other pharmacists’ intervention studies, this 
study also revealed that the documentation was beneficial for identication of DRPs. 
In addition, the analysis of the intervention involving DRPs from time to time can 
identify the trends of the problems during healthcare process. These trends can be 
monitored to evaluate the appropriateness of the solutions to correct the perceived 
problems.(147, 185) The documentation can also be employed to monitor incidents 
or near misses during the care process.(258) Furthermore, some studies proposed that 
the analysis of incident-related intervention data can be used in drug bulletin articles 
and presentations during clinical meetings to educate medical officers, pharmacists 
and other healthcare professionals.(185, 196, 226) 
As with our study, improved documentation of pharmacist interventions has been 
highlighted as the crucial component of clinical pharmacy services to quantify 
pharmacists’ contribution to patient care, and as a rich source of information for 
clarifying DRPs with prescribers.(185) Likewise, pharmacy managers participating 
in a New Zealand survey perceived that the collection of pharmacists’ intervention 
data can identify pharmacists’ impact on patient’s treatment management.(250) 
Corresponding with other studies, the pharmacists in our study have pointed out the 
importance of intervention records from a medico-legal perspective. The retrieved 
records can be the strong evidence when the decisions during care delivery are 
challenged.(257, 258) The records can also be used for quality assurance to evaluate 
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the pharmacists’ competency and ensure the quality and continuity of patient 
care.(258)  
In relation to the value of pharmacists’ clinical interventions, the participants 
generally thought that the interventions were valuable. However, the focus group 
revealed varied perspectives in defining the value of the interventions, and 
participants highlighted three points related to the value of pharmacists’ 
interventions, namely, minimisation of patient harm, hospital accreditation, and 
increased staff compliance to clinical trial protocols. Consistent with our finding, 
other studies have described the positive impact of clinical intervention of 
pharmacists on patient safety. These interventions may prevent ADEs, reduce 
mortality rates and even improve health-related quality of life.(37, 262-264) In 
addition, the recorded interventions could provide evidence of benefit to hospital 
administrators (e.g. the institutional drug and therapeutics committee), and 
subsequently for institutional accreditation, which corresponds with the responses of 
our participants.(121)  
Aside from the concerns surrounding the circumstances in documenting pharmacists’ 
interventions, there is another critical issue to be resolved: how intervention 
reporting should be taken forward to educate healthcare personnel, and subsequently 
improve patient care. During the FGD,  the predominant themes emerging from the 
data related to the shortcomings of the snapshot documentation method, including 
underutilisation of the resulting reports and lack of feedback for reporting 
pharmacists. Accepting that identification of parmacists’ intervention relies on 
documentation, the valuable documented data are frequently underutilised.(265) In a 
New Zealand study, some pharmacy managers felt intervention data were not used 
optimally, i.e. for  educational purposes.(250)  On the contrary, an American study 
reported the use of intervention data by quality assurance personnel, pharmacy 
directors and/or hospital administrators in healthcare institutions.(246) Similarly to 
suggestions in our study, intervention data have been used for peer review and 
feedback.(196, 266) With respect to the accessibility of the intervention data, Nurgat 
et al.(267) demonstrated the improved accesibility of the intervention documentation 
after implementation of web-based tool.  
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6.8 Overall Limitations and Recommendations 
There are some limitations to be acknowledged in this study. Firstly, this study 
involved pharmacists’ intervention reports collected during three snapshot periods 
only from the five study wards in a children’s hospital. A greater number of reporting 
periods would increase the opportunities to reveal the pattern of the interventions 
more representatively. Although the three snapshot periods were identified with the 
most complete set of intervention reports, the reports were largely incomplete. The 
manually-completed forms completed during snapshot documentation periods were 
not validated using patients’ medical records. Furthermore, it is recommended to data 
collection within multiple paediatric institutions for greater generalisability. It is 
possible to expand this study to include adult settings.  
FGD was chosen as the method to identify barriers and improvements regarding 
documentation of interventions. Even with skilled facilitation, this method may not 
adequately extract dissenting opinions from participants. Nonetheless, this method 
was deemed suitable for the small group of participants to collect qualitative data on 
this topic of interest.(268, 269) The method enables the investigators to understand 
issues in depth,(270) is highly flexible, and allows researchers to assess views and 
opinions directly and efficiently.(268) Future studies might consider undertaking 
further FGD research or employing other method (e.g. in-depth interview) to increase 
the likelihood of more pharmacists participating, and to obtain more insights from 
each pharmacist.  
6.9 Overall Conclusions 
To summarise, self-report by pharmacists of their interventions during snapshot 
recording periods was not representative of the interventions documented during 
direct observation. This raises the question of the value of self-documentation, and 
suggests the need for an efficient means by which pharmacists can document their 
interventions in routine practice. Meanwhile, the findings from the FGD confirmed 
previous studies regarding the barriers to documentation of pharmacists’ 
interventions, which included time constraints, limited staffing, workload and lack of 
standardisation of the documentation. The pharmacists also raised concerns around 
underutilisation of the intervention reports and lack of feedback from their employer. 
The focus group data offered clear directions for improving the existing intervention 
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documentation. The suggestions may include standardisation of intervention 
documentation, improvement in the utilisation of collated intervention data, and 
implementation of a hybrid system combining snapshot and observational reporting. 
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Chapter 7 
PART FOUR: RESULTS AND DISCUSSION 
Few studies have been conducted on medication misadventure including MEs in 
paediatrics compared to adult patients. There are lacks of strategies to prevent MEs. 
As established in Section 1.7.2, RCA was applied to identify the contributors to MEs 
and preventive strategies. An RCA was conducted using a questionnaire depicting 
five simulated case scenarios with a cohort of health professionals (doctors, nurses, 
pharmacists) at the study hospital. 
7.1 Results 
Of the 111 RCA questionnaires administered to doctors, nurses and pharmacists 
during the study period (August-October 2014), six (19.4%), 11 (25.6%) and eight 
(21.6%) were returned, respectively. All of the returned questionnaires were included 
in the analysis. The overall response rate was 22.5%. Most participants were aged 31 
to 40 years, and the majority were female (Table 7.1). Three of the doctors were 
registrars and three were consultants/specialists. Six participants were registered 
nurses/midwives, four were clinical nurses/clinical midwives/clinical development 
nurses and one was a clinical nurse/midwife consultant. Four of the pharmacists were 
not assigned a clinical pharmacist position; two were junior clinical pharmacists; one 
was a senior clinical pharmacist; and one was in a senior leadership position 
(Pharmacy Director/Deputy Director). With regard to overall years of experience as 
health professionals, each group showed a similar pattern, with most participants 
having worked for more than 10 years.  
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Table 7.1 Demographics of participants returning the RCA questionnaire 
Characteristics 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Age (years) 
21-30  
31-40  
41-50  
>50  
 
1 (16.7) 
4 (66.7) 
0 (0.0) 
1 (16.7) 
 
3 (27.3) 
4 (36.4) 
2 (18.2) 
2 (18.2) 
 
0 (0.0) 
5 (62.5) 
1 (12.5) 
2 (25.0) 
Gender 
Male 
Female 
 
2 (33.3) 
4 (66.7) 
 
1 (9.1) 
10 (90.9) 
 
1 (12.5) 
7 (87.5) 
Overall experience 
(years)  
<5  
5-10  
11-20  
>20  
 
 
0 (0.0) 
2 (33.3) 
3 (50.0) 
1 (16.7) 
 
 
2 (18.2) 
2 (18.2) 
4 (36.4) 
3 (27.3) 
 
 
0 (0.0) 
2 (25.0) 
3 (37.5) 
3 (37.5) 
Paediatric experience 
(years) 
<5  
5-10  
11-20  
>20  
 
 
0 (0.0) 
2 (33.3) 
3 (50.0) 
1 (16.7) 
 
 
2 (18.2) 
4 (36.4) 
4 (36.4) 
1 (9.1) 
 
 
2 (25.0) 
4 (50.0) 
2 (25.0) 
0 (0.0) 
As explained in Section 3.4.1, the participants were presented with five simulated 
case studies followed by two ME-related questions and seven RCA questions for 
identifying the contributing factor of ME in each case. The participants were also 
asked to give their suggestions for preventing the MEs. The results comprised six 
sections, the first five sections related to the simulated case studies, and the last 
section described the RCA assessment on the contributing factors of each case and 
the agreement of the participants’ responses. 
7.1.1 Case Study 1 (Inappropriate Dose) 
The first case was designed to highlight a prescribing error involving the high-risk 
drug digoxin in a six-month-old baby (Appendix 11). The physician wrote the 
digoxin dose inappropriately (not including a leading zero before the full stop), 
resulting in the patient receiving a 100-fold higher dose. The patient died after 
receiving the digoxin overdose.  
All participants except one pharmacist rated the error as life threatening. All doctors 
and pharmacists perceived all three health professionals (doctor, nurse, pharmacist) 
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accountable for the error. Nine of the 11 nurses agreed, with the remaining two 
nurses pointed to their own profession as responsible for the error.  
The majority of doctors and pharmacists thought patient-specific issues contributed 
to the error (Table 7.2).  
Two main themes emerged on patient-specific issues. Participants viewed the 
complexity of the patient’s medical condition in part as a contributing factor. 
‘Unwell, pneumonia, underlying cardiac condition.’ (Doctor 59) 
‘Had open heart surgery so dosage should have been checked – cardiac 
abnormalities.’ (Nurse 98) 
In addition, some participants noted the patient’s young age as the issue in this case: 
‘Young age.’ (doctor 60) 
‘Young age with severe consequence of overdose of a drug...’ (Pharmacist 39) 
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Table 7.2 Participants’ perceptions on the factors contributing to the ME (Case 1) 
Contributing factors and 
sub-factors 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Patient specific issues 4 (66.7) 3 (37.3) 6 (75.0) 
Dismissal of policies/ 
procedures or guidelines 
- Error/omission in 
medication reconciliation 
- Clinical guidelines 
- Coordination of care 
- Medical record 
documentation 
- Level and frequency of 
monitoring of patient 
6 (100.0) 
 
3 (50.0) 
 
2 (33.3) 
1 (16.7) 
3 (50.0) 
 
0 (0.0) 
11 (100.0) 
 
5 (45.5) 
 
8 (72.7) 
5 (45.5) 
6 (54.5) 
 
5 (45.5) 
7 (87.5) 
 
0 (0.0) 
 
5 (62.5) 
3 (37.5) 
6 (75.0) 
 
2 (25.0) 
Human resources issues 
- Staff workload and 
inadequate staffing 
- Staff training and 
competencies 
- Staff supervision 
5 (83.3) 
2 (33.3) 
 
5 (83.3) 
 
4 (66.7) 
10 (90.9) 
3 (27.3) 
 
8 (72.7) 
 
4 (36.4) 
7 (87.5) 
5 (62.5) 
 
7 (87.5) 
 
6 (75.0) 
Miscommunication 
- Miscommunication 
between staff 
- Miscommunication 
between staff and patient 
and/or family 
5 (83.3) 
5 (83.3) 
 
0 (0.0) 
 
5 (45.5) 
5 (45.5) 
 
2 (18.2) 
3 (37.5) 
3 (37.5) 
 
0 (0.0) 
Physical environment of the 
health service 
0 (0.0) 1 (9.1) 0 (0.0) 
Control/provision of 
medication 
- Medication storage 
- Labelling 
- Documentation of 
administration 
- Internal transfer of 
medication 
4 (66.7) 
 
1 (16.7) 
1 (16.7) 
2 (33.3) 
 
0 (0.0) 
4 (36.4) 
 
0 (0.0) 
0 (0.0) 
1 (9.1) 
 
2 (18.2) 
3 (37.5) 
 
0 (0.0) 
0 (0.0) 
2 (25.0) 
 
1 (12.5) 
‘Other’  2 (33.3) 4 (36.4) 3 (37.5) 
Participants proposed how the subsets of dismissal of policies/procedures or 
guidelines could have contributed to the error. Four themes were identified from the 
analysis of participants’ descriptions: dismissal of clinical guidelines or hospital 
policy/protocol, no/inadequate coordination of care, no/inadequate 
medical/medication record documentation and no/inadequate patient monitoring. 
Dismissal of clinical guidelines or hospital policy/protocol and no/inadequate 
coordination of care are exemplified by the following: 
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‘Dose wasn’t written correctly, mg instead of micogram, used decimal with no 0.’ 
(Doctor 36) 
‘Nurse did not double check prior to giving cardiac meds [medications]. Should be 
checked by two nurses.’ (Nurse 94) 
‘Resident should have contacted child registrar or consultant.’ (Nurse 95) 
No/inadequate medical/medication record documentation and no/inadequate patient 
monitoring is supported by: 
‘The dose in mg/kg has not been entered on the chart and therefore not easily 
checked by nurse and pharmacist.’ (Pharmacist 19) 
‘Pulse and rate/minute should be checked before giving it.’ (Nurse 95) 
‘ No evidence of pt [patient] monitoring.’ (Nurse 103) 
With regard to human resources issues as the contributing factors, comments 
highlighted problems surrounding staff training and competencies. Some participants 
argued that the error could be associated with staff workload and inadequate staffing, 
and deficiency in staff supervision: 
‘Resident just started and did not want to bother busy registrar.’ (Pharmacist 9) 
‘Registrar was busy and did not have time to adequately supervise new resident.’ 
(Pharmacist 19) 
Participants also mentioned lack of staff training and competencies as an enabler of 
the error.  
‘First week in paediatrics, but unaware of seriousness of error consequence and 
guidelines.’ (Pharmacist 17) 
‘Lack of training in correct documentation of medication.’(Doctor 61) 
Miscommunication between staff comprised all but one of the comments; 
miscommunication between staff and patient and/or family was mentioned by only 
one participant.  
‘Lack of communication between resident and senior health staff assumption that 
every party had checked dosing. Nursing belief that dosing correct instead of 
checking.’ (Doctor 61) 
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‘The nurse thought dosage had been checked by pharmacist and doctor, but did not 
make sure.’ (Nurse 96) 
Regarding control/provision of medication as the contributing factors, participants 
identified documentation of administration and internal transfer of medication as 
relevant issues. 
‘Only one nurse signed, high-risk drug – not double checked and amount given not 
written. No mg/kg in dosing box for nurse or pharmacist to check.’ (Pharmacist 17) 
‘Potentially no information given on strength digoxin given to ward to administer 
dose.’ (Nurse 98) 
With regards ‘Other’ as a contributing factor, two identified themes included the 
high-risk drug and fear of senior staff by the junior staff: 
‘Digoxin has a very low therapeutic window, and overdose can occur more readily 
than with other drugs.’ (Pharmacist 31) 
‘Fear of RMO [Resident Medical Officer] letting registrar [check the medication 
order].’ (Doctor 60) 
The last RCA question asked participants to give their suggestions on how to prevent  
recurrence of the error. Four themes emerged: firstly, improved availability and 
accessibility of clinical guidelines and strict hospital policies/protocols for high-risk 
drugs. The guidelines and the policies/protocols should cover all stages of 
medication use from prescribing through to monitoring. Secondly, all staff should be 
aware of, and comply with, the guidelines and the policies/protocols. 
‘Clinical guidelines and clear protocol and easy access for prescribing staff and 
nursing and pharmacy staff.’ (Pharmacist 17) 
‘Doctor, pharmacist and nurse should all check the prescribed dose is correct with 
AMH or other guidelines before administration and not assume correct.’ (Doctor 59) 
‘Additional restriction on who can chart dangerous/high risk drug such as digoxin.’ 
(Doctor 37) 
Thirdly, the participants proposed adequate staff supervision would prevent the 
identified error. 
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‘Close supervision of new residents and easy access to ask questions, especially 
when just starting out.’ (Doctor 59) 
‘RMO [Resident Medical Officer] being adequately supported.’ (Nurse 50) 
Fourthly, participants suggested adequate staff education and training/competencies 
can improve practice and subsequently prevent MEs. 
‘Competency of all involved, knowledge of drug, dosage and paediatric dosage 
especially.’ (Nurse 100) 
‘Ensure adequate education around high-risk drugs with prescribing, with 
dispensing, with administration.’ (Pharmacist 10) 
7.1.2 Case Study 2 (Dispensing Error) 
Case study 2 (Appendix 11) illustrated a dispensing error where a locum pharmacist 
with poor vision and inadequate supervision filled the medication orders for seizure 
patient. The drugs in the dispensary were arranged alphabetically by generic name 
and the locum dispensed prednisolone instead of primidone.  
All nurses and pharmacists rated the error in the range of major to life threatening 
(Table 7.3). The majority of the doctors offered similar assessment; one doctor rated 
the error as moderate in significance. 
Table 7.3 Participants’ ratings of the clinical significance of the ME (Case 2) 
Clinical significance of ME 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Life-threatening 1 (16.7) 5 (45.5) 4 (50.0) 
Major 4 (66.7) 6 (54.5) 4 (50.0) 
Moderate 1 (16.7) 0 (0.0) 0 (0.0) 
The majority of the participants identified two health professionals as responsible: 
nurse and pharmacist (Table 7.4). 
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Table 7.4 Participants’ responses on the responsible health professional(s)  
(Case 2) 
Health professional(s) 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Nurse 0 (0.0) 1 (9.1) 0 (0.0) 
Pharmacist 0 (0.0) 0 (0.0) 2 (25.0) 
Nurse and pharmacist 4 (66.7) 9 (81.8) 6 (75.0) 
Doctor and nurse and 
pharmacist 
2 (33.3) 1 (9.1) 0 (0.0) 
Specific patient issues were identified by only one participant as a contributor, while 
the majority of responses pointed to dismissal of policies/procedures or guidelines 
(Table 7.5). 
Three themes emerged in comments relating to the dismissal of policies/procedures 
or guidelines: omission/dismissal of medication reconciliation, dismissal of clinical 
guidelines or hospital policy/protocol, and no/inadequate coordination of care. 
 ‘Medication was not reconciled to chart.’ (Nurse 96) 
‘Lack of medication reconciliation at discharge. Did patient have a list of current 
medications? If so, this may have helped the error to be noted.’ (Pharmacist 9) 
 ‘Pharmacist not checking with another before dispensing as per guidelines.’ (Nurse 
98) 
‘If there was a discharge procedure requiring nurses to double check the medication 
prior to discharge, then it should have been followed. This process may have 
detected the dispensing error.’ (Pharmacist 19) 
‘Pharmacy/nurse not coordinating discharge medications.’ (Nurse 96) 
Participants’ responses on human resources issues uncovered three themes: staff 
workload and inadequate staffing, staff training and competencies, and staff 
supervision.  
‘Adequate cover for lunch time.’ (Pharmacist 9) 
‘Locum pharmacist and adequacy of orientation.’ (Doctor 37) 
‘Locum pharmacist in dispensary over lunch, not supported by experienced 
pharmacist in normal checking procedure.’ (Pharmacist 31) 
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  Table 7.5 Participants’ perceptions on the factors contributing to the ME (Case 2) 
Contributing factors and 
sub-factors 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Patient specific issues 1 (16.7) 0 (0.0) 0 (0.0) 
Dismissal of policies/ 
procedures or guidelines 
- Error/omission in 
medication reconciliation 
- Clinical guidelines 
- Coordination of care 
- Medical record 
documentation 
6 (100.0) 
 
4 (66.7) 
 
3 (50.0) 
3 (50.0) 
0 (0.0) 
11 (100.0) 
 
6 (54.5) 
 
10 (90.9) 
4 (36.4) 
1 (9.1) 
8 (100.0) 
 
4 (50.0) 
 
2 (25.0) 
4 (50.0) 
0 (0.0) 
Human resources issues 
- Staff workload and 
inadequate staffing 
- Recruitment 
- Staff training and 
competencies 
- Staff supervision 
6 (100.0) 
5 (83.3) 
 
1 (16.7) 
2 (33.3) 
 
4 (66.7) 
10 (90.9) 
7 (63.6) 
 
0 (0.0) 
6 (54.5) 
 
7 (63.6) 
8 (100.0) 
7 (87.5) 
 
1 (12.5) 
6 (75.0) 
 
3 (37.5) 
Miscommunication 
- Miscommunication 
between staff 
- Miscommunication 
between staff and patient 
and/or family 
2 (33.3) 
2 (33.3) 
 
0 (0.0) 
4 (36.4) 
1 (9.1) 
 
3 (27.3) 
2 (25.0) 
2 (25.0) 
 
2 (25.0) 
Physical environment of the 
health service 
- Lighting 
- Space 
4 (66.7) 
 
5 (83.3) 
1 (16.7) 
11 (100.0) 
 
11 (100.0) 
4 (36.4) 
8 (100.0) 
 
7 (87.5) 
1 (12.5) 
Control/provision of 
medication 
- Medication storage 
- Labelling 
- Documentation of 
administration 
- Internal transfer of 
medication 
5 (83.3) 
 
4 (66.7) 
1 (16.7) 
1 (16.7) 
 
1 (16.7) 
9 (81.8) 
 
7 (63.6) 
5 (45.5) 
0 (0.0) 
 
4 (36.4) 
6 (75.0) 
 
3 (37.5) 
3 (37.5) 
0 (0.0) 
 
1 (12.5) 
‘Other’ 3 (50.0) 7 (63.6) 4 (50.0) 
Participants’ comments on miscommunication revealed two themes: 
miscommunication between staff, and miscommunication between staff and patient 
and/or family. 
‘Miscommunication between requirements of dispensing discharge medications.’ 
(Pharmacist 10) 
‘Nurses should have checked every medication with family prior to D/C 
[discharge].’ (Nurse 87) 
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Participants’ comments on the physical environment of the health service revealed 
two themes. The first related to poor lighting: 
‘Inadequate lighting in this case may have contributed to the selection of the wrong 
medication.’ (Pharmacist 19) 
One-quarter of participants highlighted space as the other contributor. 
‘Medication stocked closely together.’ (Nurse 105) 
Comments relating to control or provision of medicines identified medication 
storage, labelling and internal transfer of medication as concerns. 
‘Medication stored in alphabetical order so easier to confuse.’ (Doctor 59) 
‘Label may have covered original package or drug may have been repacked making 
checking by nurse/parent difficult.’ (Pharmacist 3) 
‘No check (second time) in Pharmacy and no check by nurse when reviewing.’ 
(Pharmacist 17) 
At least half of the participants in each group nominated ‘other’ factor(s); some were 
related to the factors listed above (Table 7.5). One new theme emerged from the 
participants’ comments: staff health, in particular the pharmacist’s impaired vision: 
‘Pharmacist’s vision should have been corrected when noticed.’ (Nurse 87) 
‘Locum pharmacist in dispensing should have proper glasses when he is working in 
a responsible role. He should have been able to read label on the bottle.’ 
(Pharmacist 31) 
Suggestions to prevent the recurrence of the error encompassed six themes. The 
participants thought a policy for checking discharge medications by at least two staff 
should exist and be followed by all staff providing patient care. 
‘Nurse to check medications dispensed against chart and prescription.’ (Nurse 96) 
‘There is no harm in checking the correct dose is given to the correct patient. Every 
person that handles the medication between Pharmacy and the patient should check.’ 
(Pharmacist 19) 
Three further themes emerged related to improved staffing and supervision, adequate 
staff education, and adequate staff health requirement. 
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‘Dispensing manager should ensure staffing is adequate, so full dispensing checking 
procedures are followed at all times.’ (Pharmacist 31) 
 ‘Educating staff and consistently refreshing staff about current practices and 
protocols.’ (Nurse 87) 
‘Supervisor noting cracked glasses and asking staff to attend to these before 
working.’ (Doctor 59) 
Adequate discharge counselling was also proposed by the participants to avoid the 
recurrence of the error. 
‘Parents could have been better informed about meds [medications] prior to 
discharge and have noted absence of anticonvulsants.’ (Doctor 44) 
‘Ward pharmacist to counsel patients on discharge regarding medications.’ 
(Pharmacist 9) 
Lastly, the participants suggested improving the physical environment of the 
pharmacy. 
‘Lighting in a dispensary should be fixed.’ (Pharmacist 31) 
‘Change the way meds [medications] are stored in Pharmacy so that similar 
sounding/looking drugs aren’t adjacent.’ (Doctor 37) 
‘Storage of meds [medications] by therapeutic class.’ (Pharmacist 9) 
7.1.3 Case Study 3 (Drug Omission) 
Case study 3 described a patient with history of asthma and seizures who was 
admitted due to asthma exacerbation(Appendix 11). As one of the anticonvulsants 
(levetiracetam) was out of stock, the patient was not given levetiracetam for five 
doses, triggering a seizure.  
All doctors and pharmacists rated the error as major, while just over half of the 
nurses shared the same view (Table 7.6). 
Table 7.6 Participants’ ratings of the clinical significance of the ME (Case 3) 
Clinical significance of ME 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Life-threatening 6 (100.0) 6 (54.5) 8 (100.0) 
Major 0 (0.0) 4 (36.4) 0 (0.0) 
Unsure 0 (0.0) 1 (9.1) 0 (0.0) 
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There was little consensus between the groups on the responsible health professional 
(Table 7.7). The majority of the doctors thought all health professionals (doctor, 
nurse, pharmacist) contributed to the error, while the majority of the pharmacists 
suggested both nurse and pharmacist were responsible for the error. In the case of 
nurses, nearly half blamed their own profession alone. 
Table 7.7 Participants’ responses on the responsible health professional(s)  
(Case 3) 
Health professional(s) 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Nurse 0 (0.0) 5 (45.5) 0 (0.0) 
Nurse and pharmacist 2 (33.3) 5 (45.5) 7 (87.5) 
Doctor and nurse and 
pharmacist 
4 (66.7) 1 (16.7) 1 (12.5) 
Not more than half of the participants in each group considered specific patient 
issues as contributing factors (Table 7.8). 
Participants’ comments on patient issues uncovered two themes: patient’s medical 
condition and patient’s lack of drug knowledge: 
‘Dual diagnosis i.e. management of acute illness [asthma] taking priority over 
chronic illness/epilepsy.’ (Doctor 59) 
‘15-year-old patient could have reminded nurse about missing meds [medications], 
as at that age, would have some involvement in compliance.’ (Pharmacist 3) 
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Table 7.8 Participants’ perceptions on the factors contributing to the ME (Case 3)  
Contributing factors and 
sub-factors 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Patient specific issues 3 (50.0) 2 (18.2) 3 (37.5) 
Dismissal of policies/ 
procedures or guidelines 
- Error/omision in 
medication reconciliation 
- Clinical guidelines 
- Coordination of care 
- Medical record 
documentation 
- Level and frequency of 
monitoring of patient 
5 (83.3) 
 
3 (50.0) 
 
2 (33.3) 
4 (66.7) 
0 (0.0) 
 
1 (16.7) 
11 (100.0) 
 
8 (72.7) 
 
5 (45.5) 
9 (81.8) 
1 (9.1) 
 
2 (18.2) 
7 (87.5) 
 
4 (50.0) 
 
1 (12.5) 
6 (75.0) 
1 (12.5) 
 
1 (12.5) 
Human resources issues 
- Staff workload and 
inadequate staffing 
- Recruitment 
- Staff training and 
competencies 
- Staff supervision 
6 (100.0) 
4 (66.7) 
 
0 (0.0) 
3 (50.0) 
 
3 (50.0) 
9 (81.8) 
7 (63.6) 
 
1 (9.1) 
6 (54.5) 
 
4 (36.4) 
8 (100.0) 
4 (50.0) 
 
0 (0.0) 
6 (75.0) 
 
0 (0.0) 
Miscommunication 
- Miscommunication 
between staff 
- Miscommunication 
between staff and patient 
and/or family 
6 (100.0) 
6 (100.0) 
 
2 (33.3) 
10 (90.9) 
10 (90.9) 
 
4 (36.4) 
6 (75.0) 
6 (75.0) 
 
1 (12.5) 
Control/provision of 
medication 
- Medication storage 
- Labelling 
- Documentation of 
administration 
- Internal transfer of 
medication 
4 (66.7) 
 
1 (16.7) 
1 (16.7) 
2 (33.3) 
 
2 (33.3) 
11 (100.0) 
 
1 (9.1) 
0 (0.0) 
1 (9.1) 
 
9 (81.8) 
6 (75.0) 
 
2 (25.0) 
0 (0.0) 
0 (0.0) 
 
6 (75.0) 
‘Other’ 1 (16.7) 4 (36.4) 1 (12.5) 
Three emergent themes were associated with the participants’ comments on the 
dismissal of policies/procedures or guidelines. The participants perceived the error 
happened due to dismissal of clinical guidelines or hospital policies/protocols for 
supply of imprest medications. 
‘Levetiracetam was written on drug chart and should have been given on 2/5 [2 
May[ and 3/5 [3 May]. Nurses and ward pharmacist should have taken more care 
and followed through on low stock.’ (Pharmacist 31) 
They also indicated inadequate coordination of care and inadequate level and 
frequency of patient monitoring. 
145 
‘Lack of coordination between nursing staff and pharmacist to arrange stock of 
medication.’ (Pharmacist 28) 
‘All three health professionals not reviewed or paid attention to missed dosing.’ 
(Pharmacist 17) 
There were two emergent themes in relation to human resources: staff workload and 
inadequate staffing, and inadequate staff training and competencies.  
‘Pharmacist too busy and forgot to tell assistant to restock.’ (Doctor 59) 
 ‘Nursing staff should be made aware of which medications not be withheld (not 
given) without endangering the patient and what steps to take to obtain the 
medication or inform the doctor so that an alternative can be prescribed.’ 
(Pharmacist 19) 
‘Staff did not follow necessary steps to prevent this error and should be re-trained on 
importance of all aspects of their job.’ (Pharmacist 31) 
Participants’ comments on miscommunication indicated two themes: 
miscommunication between staff, and miscommunication between staff and patient 
and/or family.  
‘Pharmacist not informing pharmacist assistant, nurses not informing other staff of 
lack of meds [medication], doctors not being informed of medication not being 
given.’ (Nurse 98) 
‘Patient not told of omission, may have had own supply available.’ (Nurse 95) 
The issue of control/provision of medication gave rise to one theme: poor internal 
transfer of medication. 
‘Better process not followed for supply of drug to patient from Pharmacy.’ 
(Pharmacist 17) 
‘Not having medication being restock when low. Nursing not aware of how to obtain 
more stock.’ (Nurse 98) 
Participants’ comments on ‘other’ factor(s) revealed no new themes. These were 
classified under the contributors of miscommunication and control/provision of 
medication. 
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Suggestions on how to prevent recurrence of the error mapped to seven themes. 
Firstly, the participants identified the need for a hospital policy on the use of imprest 
medications. 
‘Clear process and protocol to follow if medicine not available from Pharmacy.’ 
(Pharmacist 17) 
‘Policy of an after-hours imprest list so nurse staff can source medications from 
other wards after-hours.’ (Pharmacist 9) 
The participants also indicated adequate staffing, and adequate staff education and 
training, as the other two ways to avoid recurrence of the error: 
‘Increase staffing to decrease workload.’ (Doctor 61) 
‘Re-education regarding obtaining meds [medications] rather than annotating chart 
with N
1
.’ (Pharmacist 3) 
Two further themes related to patient education and monitoring. 
‘Empower patients to be partners in their own health and medications.’ (Pharmacist 
10) 
‘Medical team checking medication chart daily.’ (Doctors 59) 
Some participants deemed the use of technologies to monitor the stock level of 
medications a promising solution.  
‘Pharmacist to have a reminder note, electronic paper so they can tick off jobs 
completed for day.’ (Nurse 105) 
‘Computer alerts to restock meds [medications].’ (Doctor 59) 
Good communication between staff was also suggested by most of the participants as 
a preventive measure. 
‘Clear route communication between ward nurses and ward pharmacist.’ (Doctor 
37) 
‘Nurse to inform shift coordinator of missing medication so it can be sourced and 
given as soon as available.’ (Nurse 105) 
‘Night nurse should have read drug chart and called on-call pharmacist on evening 
on 2/5 [2 May] and get more levetiracetam.’ (Pharmacist 31) 
                                                 
1
On the National Inpatient Medication Chart ‘N’ equated ‘Not Available’ in the study hospital. 
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7.1.4 Case Study 4 (Monitoring Error – Documented Allergy) 
Case study 4 was developed to illustrate inadequate communication and 
documentation resulting in an anaphylactic reaction in a patient with history of 
penicillin allergy (Appendix 11). At least half of the participants across the three 
groups assessed the error in this case as life threatening (Table 7.9). 
Table 7.9 Participants’ ratings of the clinical significance of the ME (Case 4) 
Clinical significance of 
ME 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Life-threatening 4 (66.7) 6 (54.5) 7 (87.5) 
Major 2 (33.3) 4 (36.4) 0 (0.0) 
Moderate 0 (0.0) 0 (0.0) 1 (12.5) 
Unsure 0 (0.0) 1 (9.1) 0 (0.0) 
There were varied perspectives among the three groups in assigning responsibility 
for the error. The doctors perceived at least two health professionals should take 
responsibility, while the majority of pharmacists thought the doctor with another 
health professional(s) was responsible (nurse, pharmacist) (Table 7.10). 
Table 7.10 Participants’ responses on the responsible health professional(s) 
 (Case 4) 
Health professional(s) 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Doctor 0 (0.0) 1 (9.1) 1 (12.5) 
Nurse 0 (0.0) 1 (9.1) 0 (0.0) 
Doctor and nurse 2 (33.3) 3 (27.3) 1 (12.5) 
Doctor and pharmacist 1 (16.7) 0 (0.0) 3 (37.5) 
Doctor and nurse and 
pharmacist 
3 (50.0) 3 (27.3) 2 (25.0) 
None of the above 0 (0.0) 3 (27.3) 1 (12.5) 
The participants’ perceptions about the contributing factors revealed patient-related 
factors and miscommunication as the key issues (Table 7.11).  
Explanation of patient-related factors was associated with one theme, the patient’s 
drug allergy. 
‘Patient has an allergy/anaphylaxis.’ (Doctor 59) 
‘Patient allergic to penicillin.’ (Pharmacist 3) 
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Comments relating to the language barrier were assigned to miscommunication 
rather than a patient-related issue.  
Table 7.11 Participants’ perceptions on the factors contributing to the ME (Case 4)  
Contributing factors and 
sub-factors 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Patient specific issues 6 (100.0) 8 (72.7) 8 (100.0) 
Dismissal of policies/ 
procedures or guidelines 
- Error/omission in 
medication reconciliation 
- Coordination of care 
- Medical record 
documentation 
- Level and frequency of 
monitoring of patient 
3 (50.0) 
 
1 (16.7) 
 
2 (33.3) 
1 (16.7) 
 
1 (16.7) 
9 (81.8) 
 
2 (18.2) 
 
5 (45.5) 
4 (36.4) 
 
0 (0.0) 
8 (100.0) 
 
1 (12.5) 
 
5 (62.5) 
7 (87.5) 
 
1 (12.5) 
Human resources issues 
- Staff workload and 
inadequate staffing 
- Recruitment 
- Staff training and 
competencies 
- Staff supervision 
3 (50.0) 
1 (16.7) 
 
0 (0.0) 
3 (50.0) 
 
1 (16.7) 
8 (72.7) 
1 (9.1) 
 
1 (9.1) 
5 (45.5) 
 
0 (0.0) 
5 (62.5) 
0 (0.0) 
 
0 (0.0) 
4 (50.0) 
 
0 (0.0) 
Miscommunication 
- Miscommunication 
between staff 
- Miscommunication 
between staff and patient 
and/or family 
6 (100.0) 
3 (50.0) 
 
5 (83.3) 
10 (90.9) 
7 (63.6) 
 
8 (72.7) 
8 (100.0) 
5 (62.5) 
 
7 (87.5) 
Control/provision of 
medication 
- Labeling 
- Documentation of 
administration 
1 (16.7) 
 
0 (0.0) 
0 (0.0) 
1 (9.1) 
 
1 (9.1) 
0 (0.0) 
1 (12.5) 
 
0 (0.0) 
1 (12.5) 
‘Other’ 1 (16.7) 3 (27.3) 0 (0.0) 
Dismissal of policies/procedures or guidelines revealed four themes. The first was 
dismissal of clinical guidelines or hospital policy/protocol. 
‘I presume hospital guidelines say no cephalosporins if likelihood of penicillin 
anaphylaxis exist. If so, they were not followed.’ (Doctor 44) 
‘Pen [penicillin] with allergy policy not followed.’ (Nurse 50) 
Some participants also indicated error/omission in medication reconciliation and 
no/inadequate coordination of care as contributing factors. 
‘Medication reconciliation not complete for allergies.’ (Pharmacist 10) 
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‘Breakdown in communication between pharmacy and doctor.’ (Nurse 50) 
No/inadequate medical or medication record documentation was also identified. 
‘Ward pharmacist did not write that penicillin allergy severity was still to be 
checked.’ (Pharmacist 31) 
‘The GP [general practitioner] should have also provided some specific information 
in the letter.’ (Pharmacist 19) 
Analysis of participants’ comments uncovered two themes related to human 
resources: staff workload and inadequate staffing, and staff training and 
competencies.  
‘GP being busy and not returning pharmacist phone call.’ (Nurse 98) 
‘Training what to prescribe in the event of anaphylactic penicillin allergy.’ (Nurse 
95) 
Two themes emerged in association with miscommunication issues. Participants 
perceived the error could be avoided with better communication between staff. 
Participants also highlighted miscommunication between staff and the patient and/or 
family contributed to the error.  
‘Pharmacist didn’t notify doctor/nurses that they were waiting for a phone call from 
the GP.’ (Nurse 87) 
‘Hospital doctor assumed pharmacist had checked degree of allergy.’ (Pharmacist 
31) 
‘Unable to communicate effectively with the family due to language barrier.’ 
(Pharmacist 10) 
There was one emergent theme associated with control/provision of medication, i.e. 
inadequate documentation of allergy was responsible for the error. 
‘Degree of severity of penicillin allergy not noted on medication chart.’ (Pharmacist 
31) 
‘Inadequate documentation of allergy.’ (Nurse 98) 
Preventive strategies were described in three themes relating to the need for clnical 
guidelines and clear hospital policies for antibiotics particularly dealing with allergy 
issues, with compliance by all staff. 
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‘Following hospital guidelines. TGA [Therapeutics Goods Administration] 
antibiotics for prescribing in context of peniciliin allergy.’ (Doctor 59) 
‘Adhere or review policies/guidelines in regards to allergies.’ (Nurse 87) 
Participants also highlighted the importance of staff education and training to prevent 
such errors. 
‘Improve education of staff in allergies, and that cephalosporin can cause allergic 
reaction if allergic to penicillin.’ (Nurse 98) 
‘Proper staff training including checking properly.’ (Pharmacist 17) 
Improved communication between staff, and between staff and the patient and/or 
family, was proposed as another solution: 
‘Ward pharmacist should have noted that the severity of the penicillin allergy had 
not been clarified, so prescriber could have tried again to call GP [general 
practitioner].’ (Pharmacist 31) 
‘Nurse giving the cephalosporin should have checked by calling doctor or ward 
pharmacist to see why it had been prescribed when medication chart had an allergy 
sticker applied.’ (Pharmacist 9) 
‘Use an interpreter to overcome language problems between this patient and staff.’ 
(Nurse 100) 
7.1.5 Case Study 5 (Transcribing Error) 
The fifth case study was developed to highlight the consequences of a transcribing 
error, where an antifungal was not recharted for a newly diagnosed oncology patient 
(Appendix 11). A non-oncology nurse was deployed to this ward, and was unable to 
identify the error.  
More than half of the nurses and the pharmacists rated the error as major in 
significance (Table 7.12). 
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Table 7.12 Participants’ ratings of the clinical significance of the ME (Case 5) 
Clinical significance of ME 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Life-threatening 1 (16.7) 2 (18.2) 2 (25.0) 
Major  2 (33.3) 6 (54.5) 5 (62.5) 
Moderate 3 (50.0) 3 (27.3) 1 (12.5) 
The majority of respondents felt that the doctor alone or in combination with other 
health professionals was responsible for the error (Table 7.13). 
Table 7.13 Participants’ responses on the responsible health professional(s)  
(Case 5) 
Health professional(s) 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Doctor 3 (50.0) 4 (36.4) 5 (62.5) 
Doctor and nurse 0 (0.0) 4 (36.4) 1 (12.5) 
Doctor and pharmacist 0 (0.0) 2 (18.2) 1 (12.5) 
Doctor and nurse and 
pharmacist 
3 (50.0) 1 (9.1) 1 (12.5) 
With respect to contributing factors, half of the doctors and the pharmacists 
perceived a specific patient issue(s) had contributed to the error (Table 7.14).  
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Table 7.14 Participants’ perceptions on the factors contributing to the ME (Case 5)  
Contributing factors and 
sub-factors 
Number (%) 
Doctors (n=6) Nurses (n=11) Pharmacists (n=8) 
Patient specific issues 3 (50.0) 4 (36.4) 4 (50.0) 
Dismissal of policies/ 
procedures or guidelines 
- Error/omission in 
medication reconciliation 
- Clinical guidelines 
- Coordination of care 
- Medical record 
documentation 
- Level and frequency of 
monitoring of patient 
3 (50.0) 
 
2 (33.3) 
 
1 (16.7) 
1 (16.7) 
0 (0.0) 
 
1 (16.7) 
11 (100.0) 
 
8 (72.7) 
 
2 (18.2) 
1 (9.1) 
4 (36.4) 
 
0 (0.0) 
 
6 (75.0) 
 
5 (62.5) 
 
0 (0.0) 
1 (12.5) 
3 (37.5) 
 
0 (0.0) 
Human resources issues 
- Staff workload and 
inadequate staffing 
- Recruitment 
- Staff training and 
competencies 
- Staff supervision 
5 (83.3) 
5 (83.3) 
 
1 (16.7) 
2 (33.3) 
 
1 (16.7) 
11 (100.0) 
11 (100.0) 
 
1 (9.1) 
4 (36.4) 
 
4 (36.4) 
8 (100.0) 
8 (100.0) 
 
2 (25.0) 
3 (37.5) 
 
1 (12.5) 
Miscommunication 
- Miscommunication 
between staff 
- Miscommunication 
between staff and patient 
and/or family 
2 (33.3) 
2 (33.3) 
 
1 (16.7) 
6 (54.5) 
5 (45.5) 
 
5 (45.5) 
1 (12.5) 
1 (12.5) 
 
0 (0.0) 
Control/provision of 
medication 
- Documentation of 
administration 
0 (0.0) 
 
0 (0.0) 
7 (63.6) 
 
7 (63.6) 
2 (25.0) 
 
2 (25.0) 
‘Other’ 3 (50.0) 5 (45.5) 2 (25.0) 
Analysis of the participants’ comments on the specific patient issue(s) revealed two 
themes: new diagnosis and complex medical condition with multiple medications. 
‘Recent diagnoses – parent not aware of meds [medications] he would usually be 
on.’ (Nurse 94) 
‘Complex medical condition and being on multiple medications.’ (Doctor 30) 
Four emergent themes were associated with the participants’ comments on the 
dismissal of policies/procedures or guidelines. Firstly, the participants perceived that 
the error was associated, at least in part, with dismissal of clinical guidelines or 
hospital policies/protocols. 
‘Transcribing policy not followed.’ (Nurse 50) 
‘Need to check protocol.’ (Nurse 105) 
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Secondly, the participants highlighted an error/omission in medication reconciliation 
as contributing to the error. 
‘Medication reconciliation should be completed across charts throughout the 
admission.’ (Pharmacist 10) 
‘Drug charts not reconciled.’ (Doctor 37) 
No/inadequate coordination of care and no/inadequate medical or medication record 
documentation were perceived by the participants as the other two contributing 
factors. 
‘Doctors omitted [medication order] but not picked up by nurse.’ (Nurse 105) 
‘The doctors didn’t transcribe 100% of the medication chart.’ (Nurse 87) 
Regarding human resources issues, staff workload and inadequate staffing were 
commonly highlighted. 
‘Doctor overworked, not enough doctors, nurses, pharmacists.’ (Nurse 100) 
‘Fatigue, inadequate staffing over public holidays.’ (Doctor 61) 
Participants also indicated staff training and competencies, and staff supervision as 
the other two factors accounting for the error. 
‘A nurse familiar with the treatment may have noticed the error, but staffing 
necessitated fill-ins who couldn’t provide the same level of care.’ (Nurse 85) 
‘Oncology is highly specialised field, and all staff working in the area should be 
suitably trained. If locum staff are required, the close supervision is needed.’ 
(Pharmacist 19) 
Participants’ comments on miscommunication issues indicated two themes: 
miscommunication between staff, and miscommunication between staff and the 
patient and/or family. 
‘Doctor intended to chart all medications but failed to do so - miscommunication 
with nurse.’ (Doctor 44) 
‘Staff not clarifying orders when transcribing medications.’ (Nurse 98) 
‘Staff not being familiar with the patient.’ (Nurse 87) 
‘Family not being aware of regular medication child is taking.’ (Nurse 105) 
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Analysis of the participants’ comments on the control/provision of medication as a 
contributing factor uncovered one theme: documentation of administration. 
‘Medication not given as not documented.’ (Nurse 96) 
‘Checking of administration times across charts.’ (Pharmacist 10) 
Comments relating to prevention of the error revealed four themes. Firstly, the need 
for hospital policy to ensure accuracy of transcribing of medication charts. 
‘Mandatory check new versus old medication charts with two staff members to 
ensure everything transcribed correctly and old medication orders ceased if 
appropriate.’ (Doctor 37) 
‘A procedure should be implemented to ensure that medications are correctly 
transcribed when new charts are written, e.g. a nurse/pharmacist/doctor could 
double check the new chart against the old chart, deliberately cancel each item on 
the old chart when it has been written onto the new chart.’ (Pharmacist 19) 
Secondly, some participants also proposed electronic prescriptions to prevent 
transcribing errors. 
‘Computerised prescriptions would overcome the dilemma of fatigue rewriting 
medication charts, missed medications.’ (Doctor 59) 
‘An electronic prescription system would avoid need for manual transcribing.’ 
(Doctor 60) 
Thirdly, the participants also underlined the need for adequate staffing of 
experienced staff particularly in the specialty area of oncology. 
‘Ensure wards are adequately staffed with experienced nurses in the particular 
specialty.’ (Nurse 87) 
‘Oncology ward nurse manager should endeavour to have ward staffed by nurses 
trained in Oncology who may have noticed that an anti-fungal drug should be given.’ 
(Pharmacist 31) 
Lastly, the need for improved communication between staff and patient and/or 
family was suggested. 
‘Nurse checking bedside with family of drug and dose to be given.’ (Nurse 105) 
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‘Check with patient along with patient’s own supply to prompt if a medication has 
accidentally not been charted.’ (Pharmacist 9) 
7.1.6 RCA of the Contributing Factors in the Simulated Cases: 
Interpretation by the Principal Researcher 
The principal researcher perceived three factors as contributing to MEs in all five 
cases: dismissal of policies/procedures or guidelines, human resources, and 
miscommunication (Table 7.15). 
Table 7.15 Principal researcher’s interpretation of the factors contributing to the MEs 
Contributing factors  Case 1 Case 2 Case 3 Case 4 Case 5 
Patient specific issues Y N Y Y Y 
Dismissal of policies/procedures or 
guidelines 
Y Y Y Y Y 
Human resources Y Y Y Y Y 
Miscommunication Y Y Y Y Y 
Physical environment of the health 
service 
N Y N N N 
Control/provision of medication Y Y Y N N 
‘Other’ N N N N N 
Y = contributing factor, N = non-contributing factor. 
Agreement between the principal researcher and the participants on each contributing 
factor in each case was presented using simple descriptive statistics. General 
Estimating Equation (GEE) analysis was applied to model the contributing factors.  
Table 7.16 shows the agreement between the principal researcher and the participants 
regarding patient specific issues as the contributing factor. High agreement was 
identified in Cases 2 and 5, and across all participants’ roles except the nurses (Table 
7.16). 
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Table 7.16 Agreement between the principal researcher and participants on patient-
specific issues as a contributing factor  
Variables 
Agreement between 
researcher and participant, 
n (%) 
Disagreement between 
researcher and participant, 
n  (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
13 (52.0) 
24 (96.0) 
8 (32.0) 
22 (88.0) 
11 (44.0) 
 
12 (48.0) 
1 (4.0) 
17 (68.0) 
3 (12.0) 
14 (56.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
21 (70.0) 
 
29 (50.9) 
 
29 (72.5) 
 
9 (30.0) 
 
27 (49.1) 
 
11 (27.5) 
Table 7.17 outlines the agreement model of patient-specific issues as the contributing 
factors using GEE analysis. The dependent variable in the GEE model was 
disagreement that patient-specific issues contributed to the MEs. An odds ratio 
greater than one indicated greater disagreement than the reference, while a value less 
than one indicated greater agreement that patient-specific issues contributed to the 
MEs. In comparing the case vignettes, Case 5 was set as the reference. The analysis 
showed significantly greater agreement about the contribution of patient-specific 
issues for Cases 2 and 4 compared to Case 5. Similarly, with agreement between the 
principal researcher and the pharmacists set as a reference, the nurses showed 
significantly higher disagreement. 
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Table 7.17 Agreement model between the principal researcher and participants on 
patient-specific issues as a contributing factor using GEE analysis 
Variables Odds ratio 
95% CI 
P-value Lower Upper 
Case study 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5* 
 
0.702 
0.027 
1.748 
0.090 
1 
 
0.305 
0.002 
0.516 
0.022 
 
1.616 
0.300 
5.917 
0.369 
 
0.406 
0.003 
0.369 
0.001 
Participants’ role 
Doctor 
Nurse 
Pharmacist* 
 
1.114 
3.719 
1 
 
0.318 
1.069 
 
3.902 
12.937 
 
0.865 
0.039 
*Set as a reference 
Regarding dismissal of policies/procedures or guidelines as a contributing factor, 
agreement between the principal researcher and participants was high across all case 
studies, and across all participants’ roles, with responses from at least three-quarters 
of each profession aligning with the principal researcher. Due to a convergence 
problem arising from complete agreement in Case 2 (Table 7.18), the GEE model 
could not be fitted. Thus, the agreement was presented using descriptive statistics. 
Table 7.18 Agreement between the principal researcher and participants on dismissal of 
policies/procedures or guidelines as a contributing factor  
Variables 
Agreement between 
researcher and participant,  
n (%) 
Disagreement between 
researcher and participant,  
n (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
24 (96.0) 
25 (100.0) 
23 (92.0) 
20 (80.0) 
20 (80.0) 
 
1 (4.0) 
0 (0.0) 
2 (8.0) 
5 (20.0) 
5 (20.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
23 (76.7) 
 
53 (96.4) 
 
36 (90.0) 
 
7 (23.3) 
 
2 (3.6) 
 
4 (10.0) 
In relation to human resources issues as a contributing factor, more than 80% of 
participants’ responses were in agreement with the researcher in all cases except 
Case 4 (Table 7.19). 
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Table 7.19 Agreement between the principal researcher and participants on human 
resources issues as a contributing factor  
Variables 
Agreement between 
researcher and participant,  
n (%) 
Disagreement between 
researcher and participant, 
n (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
22 (88.0) 
24 (96.0) 
23 (92.0) 
16 (64.0) 
24 (96.0) 
 
3 (12.0) 
1 (4.0) 
2 (8.0) 
9 (36.0) 
1 (4.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
25 (83.3) 
 
48 (87.3) 
 
36 (90.0) 
 
5 (16.7) 
 
7 (12.7) 
 
4 (10.0) 
Only Case 4 showed a higher incidence of disagreement than Case 5, while all other 
cases were similar to Case 5 (Table 7.20). There appeared to be no significant 
difference in the incidence of agreement between pharmacists and doctors or nurses. 
Table 7.20 Agreement model between the principal researcher and participants on 
human resources issues as a contributing factor using GEE analysis 
Variables Odds ratio 
95% CI 
P-value Lower Upper 
Case study 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5* 
 
3.290 
1.000 
2.093 
13.744 
1 
 
0.625 
0.055 
0.165 
2.098 
 
17.319 
18.150 
26.486 
90.019 
 
0.160 
1.000 
0.568 
0.006 
Participants’ role 
Doctor 
Nurse 
Pharmacist* 
 
1.677 
1.044 
1 
 
0.320 
0.237 
 
8.787 
4.603 
 
0.541 
0.954 
*Set as a reference 
For miscommunication as a contributing factor, only Cases 3 and 4 had high 
agreement, while the doctors showed the highest agreement of all roles (Table 7.21). 
 
 
159 
Table 7.21 Agreement between the principal researcher and participants on 
miscommunication as a contributing factor  
Variables 
Agreement between 
researcher and participant, 
No.n (%) 
Disagreement between 
researcher and participant, 
No. n (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
13 (52.0) 
8 (32.0) 
22 (88.0) 
24 (96.0) 
9 (36.0) 
 
12 (48.0) 
17 (68.0) 
3 (12.0) 
1 (4.0) 
16 (64.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
21 (70.0) 
 
35 (63.6) 
 
20 (50.0) 
 
9 (30.0) 
 
20 (36.4) 
 
20 (50.0) 
After considering Case 5 as a reference, the likelihood of agreement was 
significantly higher for Case 3 (15 times) and Case 4 (50 times) (Table 7.22). 
Doctors were significantly more likely to answer consistently with the researcher 
than pharmacists, but agreement for nurses and pharmacists was similar. 
Table 7.22 Agreement model between the principal researcher and participants on 
miscommunication as a contributing factor using GEE analysis 
Variables Odds ratio  
95% CI 
P-value Lower Upper 
Case study 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5* 
 
0.501 
1.205 
0.067 
0.020 
1 
 
0.129 
0.359 
0.015 
0.002 
 
1.944 
4.051 
0.294 
0.178 
 
0.318 
0.763 
<0.001 
<0.001 
Participants’ role 
Doctor 
Nurse 
Pharmacist* 
 
0.299 
0.402 
1 
 
0.099 
0.125 
 
0.898 
1.289 
 
0.031 
0.125 
*Set as a reference 
Considering physical environment of the health service as a contributing factor, the 
agreement model using GEE could not be fitted due to complete agreement in Cases 
3, 4 and 5. The incidence of agreement was more than 90% across all cases (Table 
7.23). Similarly, the agreement with the principal researcher was very high across all 
professions. 
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Table 7.23 Agreement between the principal researcher and participants on the physical 
environment of the health service as a contributing factor  
Variables 
Agreement between 
researcher and participant, 
n o.(%) 
Disagreement between 
researcher and participant, 
no. (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
24 (96.0) 
23 (92.0) 
25 (100.0) 
25 (100.0) 
25 (100.0) 
 
1 (4.0) 
2 (8.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
28 (93.3) 
 
54 (98.2) 
 
40 (100.0) 
 
2 (6.7) 
 
1 (1.8) 
 
0 (0.0) 
With respect to control/provision of medication as the contributing factor, agreement 
between the principal researcher and the demonstrated three cases answered 
consistently at least 80% of the time, and the agreement was similar across all roles 
(Table 7.24). 
Table 7.24 Agreement between the principal researcher and participants on the 
control/provision of medication  as a contributing factor  
Variables 
Agreement between 
researcher and participant,  
n (%) 
Disagreement between 
researcher and participant, 
n (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
11 (44.0) 
20 (80.0) 
21 (84.0) 
22 (88.0) 
16 (64.0) 
 
14 (56.0) 
5 (20.0) 
4 (16.0) 
3 (12.0) 
9 (36.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
24 (80.0) 
 
38 (69.1) 
 
28 (70.0) 
 
6 (20.0) 
 
17 (30.9) 
 
12 (30.0) 
Regarding control/provision of medication as the contributing factor, the level of 
disagreement was significantly less for Case 4 than for Case 5 (Case 4 showed 
significantly greater agreement with the principal researcher) (Table 7.25). Other 
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cases showed agreement similar to Case 5. No significant difference in agreement 
appeared between pharmacists and the other professions. 
Table 7.25 Agreement model between the principal researcher and participants on the 
control/provision of medication as a contributing factor using GEE analysis 
Variables Odds ratio 
95% CI 
P-value Lower Upper 
Case study 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5
*
 
 
2.299 
0.439 
0.334 
0.238 
1 
 
0.660 
0.123 
0.080 
0.069 
 
8.006 
1.573 
1.391 
0.897 
 
0.191 
0.206 
0.132 
0.034 
Participants’ role 
Doctor 
Nurse 
Pharmacist* 
 
0.522 
1.068 
1 
 
0.121 
0.383 
 
2.247 
2.980 
 
0.382 
0.900 
*Set as a reference 
Table 7.26 describes the agreement between the principal researcher and the 
participants related to ‘other’ contributing factors. A high incidence of agreement of 
more than 70% was seen in Cases 3 and 4 only. 
Table 7.26 Agreement between the principal researcher and participants on ‘other’ 
contributing factors  
Variables 
Agreement between 
researcher and participant, 
n (%) 
Disagreement between 
researcher and participant, 
n (%) 
Case study (25 participants) 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5 
 
16 (64.0) 
11 (44.0) 
19 (76.0) 
21 (84.0) 
15 (60.0) 
 
9 (36.0) 
14 (56.0) 
6 (24.0) 
4 (16.0) 
10 (40.0) 
Participants’ role 
Doctor (6 participants x 5 
cases) 
Nurse (11 participants x 5 
cases) 
Pharmacist (8 participants x 
5 cases) 
 
20 (66.7) 
 
32 (58.2) 
 
30 (75.0) 
 
10 (33.3) 
 
23 (41.8) 
 
10 (25.0) 
The agreement model using GEE analysis demonstrated that only Case 4 had a 
stronger agreement with the principal researcher than Case 5, with other cases 
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showing similar agreement to Case 5. No difference in agreement appeared between 
pharmacists and the other professions. 
Table 7.27 Agreement model between the principal researcher and participants on ‘other’ 
contributing factors using GEE analysis 
Variables Odds ratio  
95%CI 
P-value Lower Upper 
Case study 
Case 1 
Case 2 
Case 3 
Case 4 
Case 5
*
 
 
0.840 
1.947 
0.465 
0.278 
1 
 
0.271 
0.635 
0.164 
0.077 
 
2.603 
5.970 
1.317 
1.005 
 
0.762 
0.244 
0.150 
0.051 
Participants’ role 
Doctor 
Nurse 
Pharmacist* 
 
1.504 
2.217 
1 
 
0.473 
0.845 
 
4.780 
5.819 
 
0.489 
0.106 
*Set as a reference 
7.2 Discussion   
The analysis of medication-related events, including MEs, is important for quality 
improvement in healthcare processes.(233, 234) In the present study frontline staff 
(doctors, nurses, pharmacists) assessed the MEs through simulated case studies. 
Overall, a similar perspective was revealed among the participants across the three 
roles on the clinical significance of MEs, with the majority of participants rating the 
MEs as major and life threatening, as intended in the design of the cases.  
The present findings were not consistent with prior studies assessing medication-
related events either in paediatric or adult patients. In those studies, doctors rated the 
severity of the consequences of the incidents lower than pharmacists.(226, 227, 233) 
Less variation in the assessment of this study might be due to the non-ambiguous 
statements on the consequences of the MEs to patients’ outcomes used in the case 
studies. However, there were variations in the responses to the open-ended question 
asking which health professional(s) was responsible for the occurrence of each of the 
five MEs. It has been reported that differing judgement of medication-related 
incidents between health professionals is related to factors such as their clinical 
knowledge and understanding of the standard of patient care in varied settings.(233) 
The majority of participants in this study thought the MEs were the consequence of 
action/inaction of at least two health professionals (doctor and nurse; nurse and 
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pharmacist; doctor, nurse and pharmacist). This was in agreement with the intentions 
of the researcher when developing the cases. To some extent, the findings of this 
study confirmed those of previous studies highlighting the nature of the healthcare 
process as being ‘tightly coupled’ and ‘interdependent’, whereby deviations during 
the process were likely due to the results of interactions among the care providers 
rather than a single person.(2, 271)  
In the present setting, the varied responses on the contributing factors indicated 
making such judgements is no easy task. Understandably, similar agreement between 
the principal researcher and participants were noted in three contributing factors only 
in the majority of the cases. However, two contributing factors were frequently 
identified by participants in all five cases: dismissal of policies/procedures or 
guidelines, and human resources. Miscommunication was mentioned as a 
contributing factor in three cases, while patient-specific issue(s) and 
control/provision of medication were contributing factors in two cases, and physical 
environment a contributing factor in one case. As with this study, RCA of 17 critical 
incidents in a children’s hospital in the Netherlands found task and team factors were 
the most frequent contributing factors. The task factors were associated with 
awareness among the staff regarding the existence of clinical guidelines and/or 
hospital protocols, and the implementation of the guidelines/protocols. Team factors 
referred to issues that can be resolved through training of team-based human 
resources, i.e. supervision, communication and situational awareness. The authors 
identified an average of five factors contributing to each incident.(271)  
A report on incident management (including medication-related incidents) in the 
New South Wales public health system during 2005-2006 was in accordance with 
this study’s findings.(272) That study found issues related to policy and procedures 
as a major contributing factor to the incidents, and included failure of staff in 
following guidelines, standards and regulations, and inadequate policies for 
supporting the safety and quality of clinical care. Communication was also a major 
contributing factor to the incidents, particularly deficiencies in patient handover 
between teams and facilities in the same institution or between institutions.(272)  
Communication is also critical during patient admission and discharge, as transition 
of patient care is particularly hazardous for introducing MEs.(273) Other 
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contributing factors reported in the Australian study included issues related to staff 
knowledge, skills and competence; work environment and staff scheduling; 
equipment; safety mechanism; and patient factors.(272)  
Consistent with this study, RCA reports on ADEs submitted to the Veteran Affairs 
National Center for Patient Safety in the USA in the fiscal year 2004 uncovered 
problems with policies or procedures, staff training and education, communication, 
and equipment as the common factors contributing to ADEs.(274) Meanwhile, 
analysis of ME reports submitted to MedMARx (US national medication error 
reporting program) revealed workplace distractions, staffing issues (e.g. shift 
changes and locum staff) and workload increases as the most fequently cited 
contributing factors related to MEs during hospitalisation.(275)  
Interestingly, some RCA studies focused on the proximal causes only, without 
accounting for the contributing factors of medication-related incidents.(271, 272, 
274) Memory lapses were the most frequent  proximal causes of error (23.8%) across 
all stages, reaching nearly 50% during administration in an observational study to 
detect MEs and ADEs in a paediatric ICU.(276) The major leading system failures 
identified and responsible for MEs and ADEs in that study were drug knowledge, 
standardisation of procedures, dose and identity checking, and order 
transcription.(276) Likewise, a ME study in general medicine and specialty units in a 
major US hospital reported most MEs identified were detected during prescribing, 
and the root causes were related to deficits in pharmacotherapy knowledge 
(particularly about appropriate drug dosing and drug selection) or with failure to 
consider critical patient information (e.g. laboratory test results). Furthermore, MEs 
during dispensing and administration were mostly due to performance deficits (74%, 
e.g. accidental slips and lapses).(277) A brief analysis of clinical pharmacists’ 
interventions addressing DRP in an Australian hospital found that deficiencies in 
knowledge accounted for less than 25% of all DRP cases.(129) In the oncology 
setting, the most common cause of chemotherapy-related MEs have been reported as 
performance deficits (41.3%), equipment and medication delivery devices (12.4%), 
communication (8.8%), knowledge deficit (6.8%) and written order errors 
(5.5%).(10) It is beneficial to note that before proceeding to RCA, the majority of 
ME studies relied on manual reports of ME incidents, which were under-
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reported.(271, 272, 274, 277) A recent study promoted the use of an electronic 
system of ME reporting, along with automatically mining data from the system, to 
provide comprehensive data relating to ME.(278) 
As the contributing factors of MEs are numerous, evidence underlines the need for 
multiple strategies for ME prevention.(279) Analysis of the common themes of 
strategies proposed by participants in this study identified the need for five strategies 
to prevent each ME. The most frequently cited strategies included improved 
availability and accessibility of hospital policies or clinical guidelines, adequate 
staffing and supervision, adequate staff education and training, and improved 
communication either between staff or between staff and patient/family. The less 
frequently cited strategies were the implementation of technology (e.g. electronic 
prescribing and drug stock alert), adequate patient counselling and improved physical 
environment (e.g. arranging the medications in the dispensary by therapeutic class 
and proper lighting). In line with this study, RCA of serious cases in the 
aforementioned Dutch paediatric hospital reported an average of five 
recommendations per analysis; most recommendations related to task factors (36%), 
and required providing and/or adjusting hospital protocols or guidelines. The other 
recommendations were associated with team-based staff training and technical 
adjustment to improve the work environment (e.g. quiet area for medication 
preparation unit).(271) In addition, the findings in the current study corresponded 
well with the strategies for ME prevention in paediatrics recommended by the 
American Academy of Pediatrics Committee on Drugs and the Committee on 
Hospital Care(280) and the Pediatric Pharmacy Advocacy Group.(281) The 
strategies cited in this study also confirmed those reported by Kruk et al.(272) 
Although their RCA evaluated the broad spectrum of health incidents, and not 
necessarily focusing on medication-related incidents.  
Few participants in this study mentioned the use of information technology (IT) as 
the solution to prevent MEs. One of the most developed and widely disseminated IT 
products is computerised physician order entry (CPOE). A systematic review of MEs 
in paediatrics found that the most common type of MEs were dosing-related errors, 
which can be minimised by CPOE.(99) Some studies have justified the use of CPOE 
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to decrease MEs in paediatric patients.(53, 237, 282, 283) A similar efficacy of 
CPOE can also be seen in adult patients.(284, 285)  
Despite success at reducing MEs, IT-based interventions require considerable 
financial investment, health professional training, and system maintenance.(284) 
Electronic prescribing system support can facilitate the introduction of new types of 
prescribing errors, especially during the initial stage of technology deployment and 
dissemination.(210, 286)  
Clinical pharmacy services is an important adjunct to IT strategies, including in 
paediatric settings.(181, 197, 199) Unit-based pharmacists’ active participation 
during ward rounds is able to provide real-time information needed by physicians, 
just as CPOE provides real-time computerised decision support.(197, 201, 287) In 
addition to their role in preventing MEs during prescribing, pharmacists can also 
intercept MEs by reviewing medication orders.(207) Their presence can also 
facilitate communication between healthcare staff and the pharmacy, assisting nurses 
in drug preparation, monitoring drug storage, organising education programs for 
other staff and developing drug therapy protocols.(50, 201) Unit-based clinical 
pharmacists are generally less costly than most IT-based patient safety 
interventions.(288) These pharmacists’ roles were the premise for the observational 
and self-documentation pharmacists’ interventions studies reported in Chapter 4 and 
Chapter 6, respectively. 
As suggested by this study and other RCA, education for healthcare staff is an 
important component of ME reduction.(279, 289) According to some studies, staff 
with the least training made the most errors.(210, 243, 289) It has been strongly 
recommended that staff in paediatric settings, particularly new and junior staff, 
receive continuous education and adequate training in the use of paediatric 
medications. Regular testing of their knowledge and ability to handle peadiatric 
medications should be undertaken to enable review of the training.(242) Pharmacists 
with their knowledge and expertise in medication have been known for their role as 
educators for other health professionals and their educator role has been justified as 
effective ME prevention measures in a range of patient populations.(133, 280) 
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Modification of staff behaviour toward patient safety culture has been regarded as an 
essential predictor of safety performance.(290) Major investment in patient safety 
reform through education has been conducted in numerous countries. Despite this, 
little improvement has been reported. The authors cited a flawed assumption that 
knowledge of safety will cause staff to change their behaviour.(290, 291) Wakefield 
et al.(290) claimed that behaviour change strategies required influential clinical 
leaders to be assigned at unit levels as role models and teachers for implementing 
patient safety.  
Aside from educating health professionals, it has been recognised that empowering 
the patient is a valuable strategy for ME prevention. Healthcare staff should educate 
patients to improve their health literacy regarding information on their medical 
conditions, medications and healthy lifestyles. Healthcare staff can also encourage 
patients to actively participate in their health care by asking questions and expressing 
concerns about their health, and review their level of understanding.(27) In the case 
of paediatric patients, the involvement of their parents/guardians is important.(73, 
292) The participants in the current RCA also underlined the contribution of well-
informed parents/guardians to minimise the occurrence of MEs in most case studies. 
The current study also underlined the contribution of pharmacists in educating the 
patients along with their parents/guardians about appropriate use of medicines. 
Improved communication has also been identified as a valuable solution to minimise 
MEs.(271, 274, 293) It is important that all members of the healthcare team, 
including pharmacists, are effective communicators with other team members and in 
their contact with patients. With respect to supporting clear communication among 
health professionals, initiatives have been proposed through improved networking 
between hospitals and assignment of the medical position of ‘hospitalist’. 
Hospitalists are qualified doctors with additional training to coordinate care for 
patients across different departments and manage the transfer of care to other 
institutions.(272) These initiatives are important given the critical nature of accurate 
patient handover within the same and/or different institutions.(198)  
One common issue among healthcare staff is their lack of awareness of hospital 
policies and procedures. In the current RCA, it has been suggested that pharmacists 
are able to contribute not only to develop policies in medication use (e.g. high-risk 
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drugs, discharge medications), but also to communicate these policies to other staff. 
The current study also confirmed the findings of previous RCA studies that identified 
the necessity of adequate communication between staff and patients and their 
families. Some studies underlined common barriers experienced by the healthcare 
staff in communicating with their patients, e.g. language, medical problems and 
psychological issues.(79, 84, 294) These barriers in communication, particularly 
relating to language and the complexity of patients’ medical conditions, were also 
raised by the majority of the RCA participants in the current study. The barriers 
should be identified and resolved by pharmacists and other frontline health 
professionals, as these barriers will impede the overall quality of patient care, 
including increasing the risk of MEs.(271)   
7.3 Limitations and Recommendations 
There are several limitations to this study. The response rate was low, possibly due to 
the perceived time requirement to complete the task, and the study involved a single 
institution. A larger number of participants and involvement of other institutions may 
reveal different trends in the data on the clinical significance of the MEs, the 
contributing factors and participants’ suggestions for ME prevention. Additionally, 
the use of simulated case studies and presentation of pre-determined options could 
bias the results. The cases were not randomised, and each case was prepared with 
different amounts of information. In an authentic RCA, the participants would be 
able to obtain additional information to assist their analysis, but it was impossible to 
apply a similar process in this study. The assignment of pre-determined answers was 
influenced by the researcher’s clinical knowledge and experience, and others may 
give different assessments.  
Future research could trial a number of RCA approaches (e.g. in-depth interview, 
focus group discussion) with frontline staff and hospital managers in order to gather 
diverse perceptions about the contributing factors and ‘strong’ strategies to minimise 
ME.  
Additionally, the RCA framework to prevent ME and improve patient safety should 
be validated by comparing it with other analysis tools such as the Commercial 
Aviation Safety Team (CAST) and Failure and Mode Effect Analysis.(295, 296) The 
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implementation of the CAST framework in particular will enable future research to 
prioritise the findings of the contributing factors. 
7.4 Conclusions 
Consistent with other RCA studies, the most common contributing factors perceived 
by participants were the dismissal of hospital policies/procedures/clinical guidelines 
and human resources-related issues. Meanwhile, strategies related to development of 
policy/procedures/guidelines, staff education/training, staffing and communication 
were the most commonly cited preventive actions, in line with the majority of other 
studies. Indeed, pharmacists through their clinical services are an important strategy 
for preventing the occurrence of ME. 
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Chapter 8 
OVERALL DISCUSSION 
This chapter comprises three sections. The major findings presented in Chapters 4, 5, 
6 and 7 are summarised in Section 8.1, with a global discussion of the study in 
Section 8.2. The limitations of this study, along with recommendations for future 
research, are described in Section 8.3. 
8.1 Synthesis of Major Findings 
In Part One of the study, a total of 982 interventions were observed and documented 
by the principal researcher, which arose from the 16,700 medication orders reviewed 
by the clinical pharmacists on the five study wards. The intervention rates ranged 
from 4.38 to 10.48 interventions per 100 medication orders reviewed across the 
wards.  The intervention rates in this study were higher than reported by other 
paediatric intervention studies conducted in a range of settings using self-
documentation.(94, 184, 199, 201) Poisson regression modelling identified 
significant differences in intervention rates between the wards (p<0.001). The 
highest rate of interventions was documented on the General Surgical Ward, 
followed by the General Medical Ward for Infants, the Haematology-Oncology 
Ward, the General Medical Ward for Adolescents and the General Medical Ward for 
Young Children. The model also showed that the rates of interventions significantly 
differed according to the employment level of the observed pharmacists (p<0.01), 
and longer time spent on the ward was associated with a higher rate of interventions 
(p<0.001). Taking medication histories and/or patient counselling were the most 
common interventions performed by the clinical pharmacists on the general medical 
and surgical wards, with these activities constituting more than half of all 
interventions. While on the Haematology-Oncology Ward here, drug therapy 
changes were the most common interventions; around 37% of all interventions. 
Active interventions were defined as interventions resulting in drug changes. The 
rate of active interventions on the Haematology-Oncology Ward was significantly 
higher than the general medical wards (p<0.001), but not the general surgical ward 
(p=0.34). Active interventions constituted less than one-quarter of all interventions 
on the general medical and surgical wards, compared to 46.2% (p<0.001) on the 
171 
Haematology-Oncology Ward. For all active interventions, the degree of acceptance 
was high, at around 90% (n=223/244). Rates of active interventions were not 
significantly associated with the pharmacists’ employment level (p<0.4) or the time 
spent on the ward (p<0.2). Adjusting the dose was the most frequent active 
interventions on both the general medical and surgical wards. A slightly different 
pattern was found on the Haematology-Oncology Ward, where interventions to 
prescribe medications regularly in place of prn constituted the most common active 
interventions (40.0%), followed by dosing adjustment (26.7%).  
As for the drug classes implicated in active interventions, anti-infectives were most 
commonly associated with active interventions (n=100, 41.0%), followed by 
analgesics (n=46, 18.9%), gastrointestinal drugs (n=36, 14.8%), and 
immunomodulators/antineoplastics (n=21, 8.6%). Three variables significantly 
predicted the acceptance of the intervention:  patients’ age (OR 0.89; 95%CI 0.81-
0.98), non-high-risk medications (OR 2.80; 95%CI 1.09-7.17) and pharmacists’ 
experience (OR 1.11; 95%CI 1.03-1.20).     
Data collection in the Haematology-Oncology Pharmacy provided an interesting 
contrast between the nature of interventions during dispensing and during ward 
rounds. There were 359 interventions observed and documented by the principal 
researcher during the dispensing of 1791 medications in the Haematology-Oncology 
Pharmacy. The rates of interventions were 21.29 per 100 medication orders reviewed 
and 35.18 per 100 patients. Less than 10% of pharmacists’ interventions were 
classified as active. All of the active interventions were accepted by the physicians. 
The rates of interventions during dispensing were higher than on the five study 
wards, presumably due to more time allocation and varied clinical services that can 
be provided during dispensing. Most commonly, the interventions involved 
pharmacists providing drug information to resolve DRPs; more than three-quarters of 
interventions. Immunomodulators/antineoplastics accounted for the majority of 
medications associated with active interventions (n=18/22, 81.8%). It is critical to 
ensure these potent drugs are prescribed and dispensed appropriately; accounted for 
the high percentage of these drugs involved in the interventions in this setting.  
A random sample of 42 (15.8%) of the 266 pharmacists’ active interventions (244 
during pharmacy ward rounds on the five study wards and 22 during dispensing in a 
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Haematology-Oncology Pharmacy) from Part One were selected for expert panel 
assessment of clinical significance and contribution to medication misadventure in 
Part Two. Review of the sample interventions revealed the majority (n=37/42, 
88.1%) of the active interventions were considered clinically significant, although no 
intervention was thought to be life saving. Panel assessment indicated that the 
majority of the active interventions were performed to address medication 
misadventure, and the strength of agreement was ‘fair’(192) (α=0.321). ‘Fair’(192) 
agreement was also noted when assigning each case medication misadventure 
category (i.e. ADE, ADR, ME) and classifying the types of ME. However, the 
strength of agreement was ‘slight’(192) (α=0.154) when the panellists judged the 
severity of ME. 
Part Three of the research stage involved comparison of two pharmacists’ 
intervention documentation methods: direct observation (Part 1) and self-reports 
using a hard-copy form. A total of 398 interventions were self-reported from 1022 
medication charts that were reviewed by pharmacists. Of all the interventions, around 
18% (n=70/398) were considered active interventions. Comparison of the rates of 
interventions during the snapshot self-report periods (Part Three) and direct 
observation (Part One) showed no significant difference in the two methods. 
However, comparison of the active interventions between snapshot and observation 
periods revealed the rate of documentation of active interventions was significantly 
higher during direct observation than snapshots (snapshot 6.7 [95%CI 4.3–9.2] per 
100 medication charts reviewed vs. observation 15.1 [95%CI 10.0–20.2] per 100 
medication charts reviewed, p=0.002). In terms of the types of interventions, 
clarification of medication orders was the most common type of intervention self-
reported by pharmacists. When the pattern of all interventions and active 
interventions during the direct observation period were compared with the self-
reports, it was apparent that the interventions across the study wards were not 
comparable. This finding will be discussed in Section 8.2. 
The reasons for differences in the nature of pharmacists’ interventions between those 
documented during direct observation and the self-reports were explored using a 
FGD involving eight pharmacists. Pharmacists identified a number of barriers to 
routinely documenting their interventions, such as time constraints, fatigue, heavy 
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workload, and staffing deficiencies. However, the majority of pharmacists thought 
self-report documentation inadequately reflected their contribution to patient care 
and their workload. They postulated that switching the of snapshot self-report 
timings to busy periods instead of hospital downtimes (as was the case) would be 
worthwhile. The pharmacists also proposed a hybrid system of continuous 
documentation during certain periods by an independent observer, plus the existing 
snapshot self-report documentation. 
An RCA was conducted in Part Four, with the distribution of 111 RCA 
questionnaires to a stratified sample of doctors, nurses and pharmacists. Each 
questionnaire comprised five simulated cases for review; responses were received 
from 22.5% of those surveyed. The simulated cases represented sentinel events based 
on authentic features of the study hospital’s policies/procedures and represented a 
range of MEs. The majority of the participants rated the clinical significance of MEs 
as moderate to life threatening. Determination of the responsible health 
professional(s) varied in each case. Similarly, the participants’ perceptions on 
contributing factors to the ME also varied across the five cases. Two common 
contributing factors emerged: dismissal of policies/procedures or guidelines, and 
human resources issues. Some common suggestions for preventive action across the 
five cases included: improving availability and accessibility of clinical guidelines; ; 
strict hospital policies/protocol for medication use during prescribing, transcribing, 
dispensing, administration and monitoring; adequate number of staff with 
appropriate education and training/competencies, along with adequate staff 
supervision; and improved communication between staff, and between staff and the 
patient and/or family.  
An agreement model on the contributing factors, between the participants and the 
principal researcher on a case-by-case basis was developed using GEE analysis. This 
model determined if the participants’ perceptions on the contributing factors 
conformed to the anticipated answer pre-determined by the researcher. The GEE 
analysis found that the same pattern of agreement was observed for human resources 
issues, control/provision of medication, and ‘other’ contributing factors. The 
participants and the principal researchers were in agreement for all of the cases 
except Case 4 (described monitoring error). Meanwhile, a different pattern of 
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agreement developed for patient-specific issues and miscommunication. While two 
contributing factors - dismissal of policies/procedures or guidelines and physical 
environment of the health service - were not able to be fitted with the model.  
8.2 Overall Discussion 
The role of clinical pharmacists in paediatric healthcare settings is well 
established,(17, 181, 197, 199, 204) and their interventions to address medication-
related issues can avert misadventure.(17, 204, 254) A number of studies support the 
role of pharmacists to avert misadventure in paediatric patients.(94, 184, 197, 201, 
207) Until the time of this study, interventions had not been researched in detail in 
this hospital, despite it being one of major referral children’s hospitals in Australia 
and providing specialist services including haematology-oncology. The hospital had 
in situ snapshot self-report documentation of pharmacists’ interventions. However, 
the interventions data had not been analysed, and no outcome and feedback had been 
provided to the reporting pharmacists.   
The current study adds to the body of knowledge by confirming the significant role 
of pharmacists in undertaking clinical interventions, especially those leading to 
change in drug therapy (active interventions) to minimise the occurrence of 
medication misadventure in paediatrics. This was achieved through a series of stages 
involving direct observation of pharmacists’ interventions during ward rounds and 
dispensing; panel assessment of clinical significance of pharmacists’ active 
interventions and medication misadventure detected through the active interventions; 
comparison of two intervention documentation methods; and RCA of simulated 
cases of ME. Collectively, this approach enabled investigation of pharmacists’ 
contribution to medication safety, especially through interventions leading to drug 
changes in a range of paediatric settings. 
This study uniquely used direct observation to measure the rate and pattern of 
pharmacists’ interventions in a range of paediatric settings. Previous studies used 
self-documentation, and recognised the limitations of this approach, such as bias and 
under-reporting. This is the first known study to analyse and compare the 
interventions between direct observation and snapshot self-documentation. The 
comparative data have been presented and discussed with the pharmacy staff and the 
Director of Pharmacy in the study hospital and has resulted in improved 
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documentation, with the medication safety pharmacist undertaking direct observation 
to validate intervention data from the existing snapshot self-documentation. In 
addition, pharmacy staff in the study hospital now organise regular meetings to 
discuss the collated intervention data from the snapshot periods.  
Pharmacists’ interventions studies have been conducted in a range of paediatric 
clinical settings.(94, 197, 199) However, the majority have combined and analysed 
the data without exploring the influence of the clinical setting on the nature of the 
interventions. The current study uncovered that the clinical settings impacted on the 
rate and pattern of the interventions between general and specialty units. The 
haematology-oncology unit produced a higher rate of active interventions than the 
general medical and surgical units. As with other paediatric studies(184, 197, 199) 
dosing-associated interventions were predominantly noted in the general units. A 
distinct pattern emerged in the haematology-oncology unit, where drug additions to 
resolve untreated indications accounted for the major active interventions. More 
active interventions and the different pattern of interventions were possibly related to 
the specialist pharmacists assigned to the haematology-oncology unit. The 
haematology-oncology pharmacists were appointed in this unit on a permanent basis. 
These specialist pharmacists were well informed about the patients’ medical 
conditions and medication regimens, including their chemotherapy protocols and 
supportive medications (e.g. antiemetics, antifungals). Thus, the haematology-
oncology pharmacists, when delivering the clinical services, were able to identify 
DRPs and intervene through drug therapy changes. 
The assessment of the sample of pharmacists’ active interventions revealed that the 
majority of the interventions were clinically significant and interceptive of 
medication misadventure. At the time of writing, as the study hospital had not 
implemented electronic prescribing, pharmacists engaging in clinical services (e.g. 
taking medication histories, medication reconciliation and review of medication 
charts) either during ward rounds or dispensing contributed even more to ensure 
medication safety for patients. As with the current study, studies have showed that 
the active interventions during ward rounds were effective in changing therapeutic 
decisions and intercepting MEs in paediatric patients.(139, 197, 201) A systematic 
review highlighted that pharmacists’ review of medication charts is crucial to 
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identification of MEs; it is possibly the most effective method of improving drug 
safety in children.(207) This evidence can be applied to ward-based pharmacy 
practice and also during dispensing. 
Pharmacists’ interventions require appropriate and adequate documentation to 
substantiate their contribution to patient care and build a body of evidence that 
clinical pharmacists play substantial roles within the medication use process. The 
direct observation approach undertaken in the current study enabled gathering of the 
number and pattern of pharmacists’ interventions during ward rounds and dispensing. 
Higher rates of active interventions were found when the ward pharmacists were 
directly observed than those self-reported during snapshot periods. The study 
hospital may consider modifying their existing intervention documentation method to 
optimise data collection.  
System breakdown can be analysed and improved by implementing RCA. Health 
system breakdown can be manifested in MEs. Implementation of RCA can identify 
the causes and contributing factors of medication misadventure, along with solutions 
to prevent recurrence of the misadventure.(12) The current study may have 
benefitted if the RCA had utilised authentic cases instead of simulated cases of 
intercepted MEs. This was not feasible due to medico-legal and ethical reasons.  
The RCA used in this study served to assess theoretically the clinical significance of 
MEs described in the simulated cases, and to explore the contribution of pharmacists 
in preventing MEs. Nearly all of the surveyed participants concurred that the MEs in 
the five cases were sentinel events. The majority of the participants also identified 
more than one profession being responsible for the MEs. This is consistent with 
published RCA studies demonstrating the need for shared responsibility among 
health professionals of different disciplines.(271, 272, 274) The RCA in this study 
did not require that participants convene a formal meeting to discuss the cases. Thus, 
the data can be considered independent, notwithstanding participants discussing and 
completing the cases with colleagues. Varied responses relating to the contributing 
factors and preventive strategies were noted among the RCA participants.  
The current study also showed that frontline health professionals are able to 
undertake RCA. Participants in this study have become familiar with RCA as a tool 
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for system improvement. The RCA provided further evidence supporting the role of 
pharmacists in provision of clinical services, e.g. development and dissemination of 
drug therapy protocols, facilitated communication between healthcare staff and the 
pharmacy, education of other healthcare professionals, and provision of counselling 
to patients and parents/guardians. Occurrences of medication misadventure  
identified in routine clinical services can be intercepted and resolved by pharmacists 
through their interventions, highlighting their role in reducing medication 
misadventure. 
8.3 Limitations and Recommendations 
This is the first study to compare pharmacists’ interventions in a range of settings in 
paediatrics in terms of frequency, type, degree of acceptance, clinical significance 
and causative medications. However, a number of limitations need to be 
acknowledged. This study was conducted in one paediatric hospital, which 
diminishes the generalisability of the findings. Another limitation is the difficulty in 
drawing accurate comparisonss with other studies due to considerable variations in 
settings, design, duration, size and method.  
During direct observation, data were collected on non-consecutive days to avoid 
pharmacist observation fatigue influencing the pattern of interventions. In relation to 
assessment of clinical significance of samples of pharmacists’ active interventions 
and identification of medication misadventure, the expert panellists were selected for 
convenience after considering their clinical knowledge and professional experience. 
Further to the limitation relating to the use of simulated RCA cases, the low response 
rate and non-randomisation of the cases may not ideally represent the responses on 
the clinical significance of MEs, the contributing factors and suggestions for ME 
prevention. 
Future studies might consider employing consecutive observation of pharmacists’ 
interventions, more clinical units and other children’s hospitals to further confirm 
variations in rates and patterns of pharmacists’ clinical interventions. It would also be 
beneficial for future studies to evaluate the association between acceptance of the 
interventions and their impact on patient outcome in order to justify the value of the 
interventions to patient care.  
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It is recommended that in future studies panellists randomly selected from eligible 
experts that represent doctors, nurses and pharmacists assess pharmacists’ active 
interventions. Therefore, the tendency of the researcher to select experts with similar 
opinions or because of convenience will be reduced, with benefits for validity of the 
research. Furthermore, use of a larger number of active interventions would allow 
comprehensive understanding of the pattern of active interventions and medication 
misadventure in paediatrics. When conducting analysis of medication misadventure, 
future studies may also consider involving the hospital management, as well as 
frontline health professionals, and applying different RCA approaches and other 
system analysis tools as described earlier. 
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Chapter 9 
CONCLUSIONS 
This study aimed to evaluate the contribution of pharmacists’ interventions to 
reduction of medication misadventure in children with cancer.  
Documentation and evaluation of clinical interventions in this study provides 
evidence that pharmacists can play an important role in optimising patient care 
through their clinical services during ward rounds and dispensing in general and 
specialty haematology-oncology settings. Direct observation of pharmacists’ 
interventions in this study offers a novel approach to recording the rate and pattern of 
the interventions witnessed by the researcher during defined periods, as an 
alternative to reliance on self-documentation by practitioners. The rate and types of 
pharmacists’ active interventions, addressing Objectives 1 and 2 in Part 1 of this 
thesis, differed between clinical settings, being most frequent in the specialty 
haematology-oncology setting. Patients’ age, type of medication (high risk/non-high 
risk) and pharmacists’ experience were identified as predictors for physicians’ 
acceptance of ward-based pharmacists’ active interventions. Furthermore, this study 
achieved the two objectives of Part 2 by systematically assessing the clinical 
significance of pharmacists’ active interventions, defined as interventions leading to 
changes in drug therapy, and the role of clinical pharmacists through their active 
interventions to identify and resolve medication misadventure-related events, in 
particular, ME. Identification of the nature of medication misadventure through 
pharmacists’ active interventions can provide direction to improvements in the 
medication use process in this patient population.  
To date, there has been a paucity of literature comparing self-report and observation 
for documentation of pharmacists’ interventions in paediatrics. Part 3 of the current 
study compared the intervention documentation approaches (direct observation 
versus short-term self-report). The current study found self-report by pharmacists 
during snapshot recording periods was not representative of the interventions 
documented during direct observation by the researcher. This questions the value of 
self-documentation and proposes a need for improved methods of documentation. 
This study also provided insight into pharmacists’ barriers to documenting their 
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interventions. Standardisation of intervention documentation, improved utilisation of 
the intervention data and modification of the existing self-documentation approach 
are suggested to improve the documentation of pharmacists’ interventions. 
The two objectives of Part 4 of this study related to exploration of the clinical 
significance, along with contributing factors and resolution, of medication-related 
errors, using five scenarios and the perspectives of three groups of health 
professionals: pharmacists, nurses and doctors. Involvement the frontline healthcare 
professionals, instead of a team of system analysis experts – as described in the 
majority of studies of RCA – to analyse the scenarios, adds value to this study. 
Through their interaction with patients during routine practice, frontline health 
professions provide insight into sectors of the healthcare system and processes that 
need to be improved to minimise ME in children. 
Pharmacists, as the medication experts and part of frontline health care professionals, 
can participate in improving medication safety through delivery of clinical services, 
including (but not limited to) ensuring hospital policies/guidelines are followed to 
ensure appropriate medication use, and by providing drug information services for 
other frontline staff and educating patients/carers. At the same time, ongoing 
documentation, analysis and review of these clinical interventions remain critical.  
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Appendix 6: Case Vignettes for Expert Panel Assessment 
The expert panel assessed 42 cases. Each case was followed by the same questions. 
For brevity, the questions were presented after Case 1 and not repeated in the other 
cases. 
GENERAL MEDICAL WARD FOR INFANTS 
Case 1  
A 27-day-old female (weight: 3.97 kg) was admitted to the emergency department 
because of fever over the last few days. The mother said that the baby was a little 
more sleepy than usual and did not drink milk well. The mother and her older sister 
had sore throats, and cousins had croup and in contact with her. She was born full-
term without any complications. Medical history: insignificant. Regular medications: 
nil. Allergy/ADR history: nil. She was initially diagnosed with sepsis. During 
hospitalisation, she was prescribed the following medications: 
Domperidone 10 mg TDS oral 
Normal saline 3 mL IV PRN 
Paracetamol 60 mg QID oral 
Gentamicin 28 mg OD IV  
Aciclovir 80 mg TDS IV 
Cefotaxime 200 mg QID IV 
Amoxycillin 20 mg QID oral 
The following day, the pharmacist reviewed the medication chart and noticed that the 
patient was prescribed domperidone 10 mg TDS and the dose was high for the 
patient (max dose 9 mg/day). The pharmacist contacted the doctor and was informed 
that the medication was for the mother’s nausea and not for the baby. However, there 
was no sticker/alert that said the medication was for the mother and not the baby. 
The pharmacist attached the alert sticker that the medication was not for the patient. 
Examination of the cerebrospinal fluid, nasopharyngeal aspirate, blood and urine 
culture was negative for the presence of bacteria and virus. The final diagnosis was 
viral illness with fever of unexplained origin. The baby improved and was discharged 
home 4 days after admission without any medications. 
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QUESTIONS 
1. From the case above, how do you rate the clinical significance of pharmacist’s 
intervention? (Please tick the most appropriate rating) 
 Unsure 
 No clinical significance 
 Minor: small adjustments and optimisation of therapy, not expected to 
significantly alter hospital stay or clinical outcome 
 Moderate: adjustments expected to enhance effectiveness of drug therapy, 
producing minor reductions in patient morbidity 
 Major: intervention is expected to prevent or address very serious drug 
related problem 
 Life saving 
2. In your opinion, does the case described above involve a medication 
misadventure? 
(Medication misadventure is any iatrogenic hazard or incident associated with drug 
therapy.) 
 Unsure 
 Yes 
 No  
3. If you answer yes to question 2, what type of medication misadventure best 
describes the case? (Please tick any that apply) 
 Adverse drug event: any injury resulting from a medication or lack of an 
intended medication 
 Adverse drug reaction: any unexpected, unintended, undesired or excessive 
response to a drug, with or without an injury  
 Medication error: any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the 
control of health professionals, patient, or consumer 
4. If the case involves medication error, what is the most appropriate category for the 
error? (Please tick one category only) 
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 Unsure 
 Drug omission (the failure to prescribe the required medication) 
 Dose omission (the failure to administer an ordered dose) 
 Improper dose (over dosage, under dosage, extra dose) 
 Wrong strength/concentration 
 Wrong drug 
 Wrong dosage form 
 Wrong techniques of administration 
 Wrong route of administration 
 Wrong rate (too fast or too slow) 
 Wrong duration 
 Wrong time 
 Wrong patient 
 Monitoring errors (includes contraindicated drugs, drug-drug interaction, 
drug-food interaction, drug-disease interaction, and documented allergy) 
 Deteriorated drug error (dispensing drug error which has expired) 
 Other (any medication error that does not fall into one of the above) 
5. How do you rate the potential severity of the error involved in the case? (Please 
tick the most appropriate category) 
 Unsure 
 Category A: circumstances or events that have the capacity to cause error 
 Category B: an error occurred, but the medication did not reach the patient 
 Category C: an error occurred that reached the patient but did not cause 
patient harm 
 Category D: an error occurred that resulted in the need for increased patient 
monitoring but no patient harm 
 Category E: an error occurred that resulted in the need for treatment or 
intervention or caused temporary patient harm 
 Category F: an error occurred that resulted in initial or prolonged 
hospitalisation and caused temporary patient harm 
 Category G: an error occurred that resulted in permanent patient harm 
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 Category H: an error occurred that resulted in a near-death event (e.g. 
anaphylaxis, cardiac arrest) 
 Category I: an error occurred that resulted in patient death 
Case 2  
A 9-month-old male was admitted to hospital because of vomiting, reduced feeding, 
fever and irritability. The family had returned from a holiday in Indonesia 2 weeks 
ago. Medical history: insignificant. Regular medications: nil. His mother had 
thalassemia minor and was diagnosed with hepatitis A one week ago. During 
hospitalisation, the baby was diagnosed with typhoid fever and received the 
following medications: 
Ceftriaxone 680 mg OD IV 
Azithromycin 180 mg OD oral 
Paracetamol 140 mg QID oral PRN 
Ibuprofen 90 mg TDS oral PRN 
Normal saline 5 mL 6-hourly IV PRN 
On Day 2 he was receiving azithromycin 180 mg once daily. According to hospital 
policy for Salmonella infection, the azithromycin dose is Day 1: 20 mg/kg and Days 
2 to 6: 10 mg/kg. As he weighed 9 kg and it was Day 2, the pharmacist 
recommended the doctor reduce the dose to 90 mg once daily until Day 6. The 
recommendation was accepted. 
Case 3  
A 1-year-old female (weight: 8.95 kg) was admitted due to cystic fibrosis-associated 
pulmonary exacerbation. She had symptoms of upper respiratory tract infection for 2 
to 3 weeks. Medical history: cystic fibrosis with pancreatic insufficiency (diagnosed 
during newborn screening program). Allergy/ADR history: nil. 
Medications on admission  
Vit ABDECK
®
 (multivitamin) ½ OD oral 
Sodium chloride 3.5 mL BD oral 
Creon
®
 (pancreatic enzyme) I oral PRN 
Augmentin Duo
®
 (amoxycillin + clavulanic acid) BD 
oral 
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Current medications 
Day 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Vit ABDECK
®
 
(multivitamin) ½ OD 
oral 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Sodium chloride 3.5 
mL BD oral 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Creon
®
 (pancreatic 
enzyme) I oral PRN 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Timentin
®
 (ticarcillin 
+ clavulanic acid) 900 
mg TDS IV 
x x x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Tobramycin 90 mg OD 
IV 
✓ ✓ ✓ ✓ x x x x x x x x x 
Tobramycin 120 mg 
OD IV 
x x x x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Augmentin Duo 180 
mg BD oral 
✓ ✓ ✓ x x x x x x x x x x 
Azithromycin 90 mg 
3x/ week on 
Mon,Wed,Fri 
✓ x ✓ x ✓ x x ✓ x ✓ x ✓ x 
Pulmozyme 2.5 mg 
neb BD pre-
physiotherapy 
x x x x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Normal saline flush 3-
5 mL IV PRN 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
During hospitalisation, she was prescribed tobramycin 90 mg once daily IV (10 
mg/kg/day). After the third dose, the AUC level was 68 mg/L/h (target range: 70-
100) and below therapeutic level. Based on tobramycin pharmacokinetic 
calculations, the pharmacist recommended the doctor increase the dose to 120 mg 
once daily IV; maximum dose for patient: 750 mg once daily IV (15 mg/kg/day). The 
recommendation was accepted. 
She was discharged 14 days after admission with discharge medications: sodium 
chloride 3.5 mL BD oral, Vit ABDECK® ½ daily oral and Augmentin Duo® 200 mg 
BD oral. She was to be reviewed at the cystic fibrosis clinic 2 weeks post-discharge. 
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GENERAL MEDICAL WARD FOR YOUNG CHILDREN 
Case 4  
An 11-year-old male was admitted because of pneumonia. His medical history was 
complicated: born premature 23/40 weeks, cerebral palsy, chronic lung disease, 
global developmental delay, epilepsy, on bilevel positive airway pressure, on 
Percutaneous Endoscopic Gastrostomy (PEG) and infusaport, severe subglottic 
stenosis, recurrent persistent Candida infection, pseudomonas colonisation, ligation 
of partial ducts, submandibular gland removal. Multiple antibiotic allergies 
(Bactrim® [trimethoprim + sulfamethoxazole], amoxycillin, cephalexin, Timentin® 
[ticarcillin + clavulanic acid], meropenem, fluconazole, penicillin, vancomycin, 
amikacin, amphotericin, ciprofloxacillin). 
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Medications on admission Current medications  
Benztropine 0.5 mg nocte PEG Benztropine 0.5 mg nocte PEG 
Melatonin 10 mg nocte PEG Melatonin 10 mg nocte PEG 
Movicol
®
 (macrogol laxative) ½ sachet OD 
PEG 
Movicol
®
 (macrogol laxative) ½ sachet OD 
PEG 
Magnesium chloride 3.7 mL BD PEG Magnesium chloride 3.7 mL BD PEG 
Nitrazepam 5 mg nocte PEG Nitrazepam 5 mg nocte PEG 
Baclofen 2.5 mg TDS PEG Baclofen 2.5 mg TDS PEG 
Clobazam 5 mg TDS PEG Clobazam 5 mg TDS PEG 
Phenobarbitone 60 mg nocte PEG Phenobarbitone 60 mg nocte PEG 
Levetiracetam 500 mg mane PEG Levetiracetam 500 mg mane PEG 
Levetiracetam 1000 mg nocte PEG Levetiracetam 1000 mg nocte PEG 
Epilim
®
 (valproate) (200 mg/mL) 12.5 mL 
BD PEG 
Epilim
®
 (valproate) (200 mg/mL) 12.5 mL 
BD PEG 
Dantrolene 4 mL BD PEG Dantrolene 4 mL BD PEG 
Aztreonam 900 mg 8-hourly IV Aztreonam 900 mg 8-hourly IV 
Teicoplanin 300 mg OD IV Teicoplanin 300 mg OD IV 
Diazepam 2 mg TDS PEG Diazepam 2 mg TDS PEG 
Centrum
®
 (multivitamin) I OD PEG Centrum® (multivitamin) I once daily PEG 
Heparin saline 5 mL TDS PRN IV Heparin saline 5 mL TDS PRN IV 
Panadol
®
 (paracetamol) 450 mg QID PRN 
PEG 
Panadol
®
 (paracetamol) 450 mg QID PRN 
PEG 
Loratadine 6 mg OD PEG Loratadine 6 mg OD PEG 
Posaconazole 5 mL BD PEG Posaconazole 5 mL BD PEG 
Inner Health Plus
®
 (probiotic) ½ tablespoon 
BD PEG 
Inner Health Plus
®
 (probiotic) ½ tablespoon 
BD PEG 
Normal saline neb 10 mL PRN Normal saline neb 10 mL PRN 
During hospitalisation, he was prescribed aztreonam 900 mg 8-hourly IV, which was 
charted twice. The pharmacist double checked with the nurse and was informed that 
one of the aztreonam orders was for the hospital-in-the-home (HITH) service. There 
were no notes on the medication chart that it was for HITH. The pharmacist attached 
the alert sticker on the other medication chart that it was for HITH. 
Case 5  
A 1-year-11-month-old (weight: 10.8 kg) was admitted due to HIV encephalopathy, 
cardiomyopathy and disseminated tuberculosis. He had experienced 10 days of fever, 
cough, vomiting, lethargy, chronic thrush and long-standing developmental 
regression. He had had several infections since he was 14 months old, e.g. thrush, ear 
infection, measles and pneumonia. He had recently been diagnosed with HIV in 
Indonesia and his parents decided to take him to Perth. His condition was unstable. 
He had renal and liver impairment, severe immunosuppression, failure to thrive, 
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blood transfusion and nasogastric feeds. He also presented with spasticity in all 
limbs. Allergy/ADR history: nil. 
Current medications Discharge medications 
Fluconazole 125 mg OD IV Montelukast 4 mg nocte oral 
Tazocin
®
 (piperacillin + tazobactam) 1 g 
TDS IV 
Prednisolone 5 mg/mL 1.5 mL OD oral 
Aciclovir 259 mg 8-hourly IV Isoniazid 100 mg II mane oral 
Nilstat
®
 (nystatin) 1 mL QID oral Lamivudine 10 mg/mL 5 mL BD oral 
Montelukast 4 mg nocte oral Nevirapine 50 mg/5 mL 7 mL BD oral 
Ibuprofen 100 mg TDS oral PRN Clonidine 10 mcg/mL 1 mL QID oral 
Oxycodone 1 mg OD oral Rifampicin 100 mg/5 mL 7.5 mL nocte oral 
Paracetamol 150 mg 6-hourly oral PRN Moxifloxacin 400 mg ¼ tablet nocte oral 
Augmentin Duo
®
 (amoxycillin + 
clavulanic acid) 225 mg BD oral 
Ethambutol 100 mg II nocte oral 
Valganciclovir 200 mg OD IV Abacavir 100 mg/5 mL 4.25 mL BD oral 
Prednisolone 5 mg/mL 1.5 mL OD oral Captopril 5 mg/5 mL 1.5 mL TDS oral 
Isoniazid 100 mg II mane oral Frusemide 50 mg/5 mL 1 mL mane oral 
Lamivudine 10 mg/mL 5 mL BD oral Diazepam 10 mg/10 mL 1 mL TDS oral 
Nevirapine 50 mg/5 mL 7 mL BD oral Posaconazole 200 mg/5 mL 2.75 mL BD oral 
Clonidine 10 mcg/mL 1 mL QID oral Amphotericin lozenges QID 
Rifampicin 100 mg/5 mL 7.5 mL nocte 
oral 
  
Moxifloxacin 400 mg ¼ tablet nocte oral   
Ethambutol 100 mg II nocte oral   
Abacavir 100 mg/5 mL 4.25 mL BD oral   
Captopril 5 mg/5 mL 1.5 mL TDS oral   
Frusemide 50 mg/5 mL 1 mL mane oral   
Diazepam 10 mg/10 mL 1 mL TDS oral   
Posaconazole 200 mg/5 mL 2.75 mL BD 
oral 
  
Amphotericin lozenges QID   
During hospitalisation, he was prescribed fluconazole, which was charted twice for 
different routes of administration: intravenous and oral. The pharmacist spoke to the 
nurse and was informed that initially it was planned for intravenous use. As the line 
could not be found, the order was changed to oral. However, the intravenous order 
was not deleted. The pharmacist recommended the doctor cross out the intravenous 
fluconazole order. The recommendation was accepted. 
He was discharged 102 days after admission with monthly routine monitoring at the 
immunology clinic.  
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Case 6  
A 6-year-11-month-old female (weight: 28 kg) with a history of cystic fibrosis 
presented to hospital for elective admission for peripherally inserted central catheter 
insertion. Medical history: insignificant. Allergy/ADR history: nil. 
Medication on admission Current medications 
Augmentin Duo
®
 (amoxycillin + clavulanic 
acid) 6 mL BD oral 
Timentin
®
 (ticarcillin + clavulanic acid) 2.8 g 
TDS IV 
Ventolin
®
 (salbutamol) 1-2 puffs 2-4 hourly 
PRN 
Tobramycin 280 mg OD IV (10 mg/kg) 
Vit ABDECK
®
 (multivitamin) I OD oral Vit ABDECK® (multivitamin) I OD oral 
Salt solution 15 mL OD oral Salt solution 15 mL OD oral 
 Augmentin Duo
®
 (amoxycillin + clavulanic 
acid) 6 mL BD oral 
 Paracetamol 400 mg QID oral PRN 
 Ondansetron 3 mg QID oral PRN 
 Normal saline 5 mL IV PRN 
 Heparin saline 5 mL IV PRN 
Tobramycin AUC level was taken after the fourth dose and the level was lower 
(AUC: 35 mg/L/h) than the target level (target AUC: 70-100 mg/L/h). The 
pharmacist recommended the doctor increase the tobramycin dose from 280 mg to 
420 mg once daily IV and that 420 mg once daily IV (15 mg/kg/day) was the 
maximum dose for the patient. The recommendation was accepted. 
Case 7  
A 7-year-9-month-old male (weight: 30 kg) was transferred from another hospital 
with a 3-day history of right eye pain and swelling. He had been unwell for one week 
with fever and vomiting. He was diagnosed with right eye periorbital cellulitis and 
sinusitis. Medical history: severe atopic eczema. Regular medications: nil. 
Allergy/ADR history: peanut and bee string (may cause anaphylaxis), honey (airway 
swelling), egg (may cause rash and gastrointestinal reactions). Family medical 
history: allergic asthma and lactose intolerance (mother), hay fever (older brother), 
lactose intolerance and recurrent otitis (older sisters). 
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Current medications 
Day 
1 2 3 
Ceftriaxone 750 mg BD IV ✓ ✓ ✓ 
Flucloxacillin 1.5 g QID IV ✓ ✓ ✓ 
Vancomycin 450 mg OD IV ✓ ✓ x 
Paracetamol 500 mg QID oral ✓ ✓ ✓ 
Nasonex
®
 (mometasone furoate) spray topical II 
nocte ✓ ✓ ✓ 
Nurofen
®
 (ibuprofen) 200 mg TDS oral PRN ✓ ✓ x 
Heparinised saline 5 mL IV PRN ✓ ✓ ✓ 
Sinus rinse topical BD right eye ✓ ✓ ✓ 
Chloramphenicol eye drops topical I QID right 
eye ✓ ✓ ✓ 
Timolol drops 0.25% topical I OD right eye ✓ ✓ ✓ 
 
Discharge medications 
Amoxycillin/clavulanate 400 mg/57 mg per 5 
mL suspension 5 mL BD oral for 10 days 
Clindamycin 150 mg TDS oral for 10 days 
Mometasone furoate 50 mcg/dose nasal spray II 
spray each nostril nocte for 10 days 
Xylometazoline 0.05% nasal drops 2 drops each 
nostril QID for 5 days 
During hospitalisation, he was prescribed ceftriaxone 750 mg IV twice daily. 
According to the Paediatric Pharmacopoeia, the dose is 50 mg/kg 12-hourly = 1.5 g 
twice daily. The pharmacist recommended the ophthalmologist increase the dose. 
The recommendation was rejected because the patient was being discharged and the 
antibiotic would be ceased. 
Case 8  
A 5-year-2-month-old (weight: 16.7 kg) was admitted to a regional hospital on 25 
March 2012 because of fever and abdominal pain from suspected appendicitis. He 
had a one-week history of cough, fever (up to 39 degrees) and grunting. Chest X-ray 
showed pleural effusion. He was transferred from the regional hospital to Princesss 
Margaret Hospital on 26 March 2012.  
Medical history: eczema (2 months ago), facial and tooth injury after falling on 
paving (2008). Family medical history: brother had croup one week before. 
Allergies/ADR history: nil. Regular medications: nil. Other comorbidities: nil. 
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He was on 2 L oxygen via nasal prongs with soft grunting. He had bilateral crackles 
and a trial of salbutamol was not effective. He was diagnosed with right para-
pneumonic effusion and empyema (confirmed by chest X-ray). Microbiological 
culture and sensitivity test of pleural fluid (29 and 30 March) showed Staphylococcus 
aureus sensitive to flucloxacillin. Viral serology was negative.  
On 29 March, a right pigtail drain was inserted for drainage of empyema. Another 
chest X-ray (2 April) showed the empyema had reduced in size, although a 
considerable amount of right-sided pleural fluid remained. The mediastinum was 
displaced towards the left and there was underlying infiltrate in the right mid and 
lower zone. The left lung field and pleural space remained clear. 
Medications on admission 
Benzylpenicilin 600 mg QID IV (had received 5 doses) 
Azithromycin 170 mg OD oral (had received 1 dose) 
 
Current 
medications 
Day 
1 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
Azithromycin 170 
mg OD oral 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ceftriaxone 850 mg 
BD IV 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ x x x x x x x 
Lincomycin 250 mg 
TDS IV 
x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ x 
Teicoplanin 170 mg 
BD 3 doses and then 
170 mg OD IV 
x x x x x x x x ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Alteplase 1.6 mg 
once daily through 
chest drain for 2 days 
x x x x x ✓ ✓ x x x x x x x x 
Paracetamol 240 mg 
QID oral PRN 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ondansetron 2 mg 6-
hourly oral PRN 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Loratadine 5 mg OD 
oral PRN 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Oxycodone IR 1.5-3 
mg 4-hourly oral 
PRN 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ibuprofen 180 mg 
TDS oral PRN  
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
During hospitalisation, the patient slowly improved and the doctor decided to 
prescribe teicoplanin 170 mg IV twice daily. According to hospital policy, 
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teicoplanin is to be used 10 mg/kg/dose 12-hourly for 3 doses and then 6-10 mg/kg 
once daily (max dose 800 mg/day). As the patient had had received 3 doses, the 
pharmacist recommended the doctor reduce the frequency to once daily. The 
recommendation was accepted.  
The patient had slow resolution of symptoms and was discharged on 17 April with 
clindamycin 125 mg QID oral for 4 weeks and an outpatient appointment 1 week 
after discharge. 
GENERAL MEDICAL WARD FOR ADOLESCENTS 
Case 9 
A 16-year-old was admitted due to cerebral palsy-associated severe dystonia. Recent 
admission was 3 months previously for adjustment of medications and nasogastric 
(NG) rehydration. Allergy/ADR history: nil. Medication history: baclofen 10 mg 
TDS NG, tetrabenzine 12 mg BD NG, clonidine 50 mg TDS NG. 
Medications on admission  Current medications 
Diazepam 5 mg QID NG Diazepam 5 mg 3-hourly NG PRN 
Diazepam 3 mg NG PRN Benzhexol 2 mg BD NG 
 Melatonin 4 mg OD NG 
 Clonazepam 0.1 mg nocte NG 
 Ibuprofen 340 mg TDS NG PRN 
 Diazepam 5 mg QID NG 
 Paracetamol 500 mg TDS NG 
During hospitalisation, she was prescribed clonazepam 0.1 mg nocte via PEG. 
However, the medication had been left off when recharted. The pharmacist 
recommended the doctor represcribe it. The recommendation was accepted. 
Case 10 
An 18-year-old was admitted because of chronic lung disease. Medical history: 
scleroderma, chronic lung disease, inflammatory arthritis, blind, vasculitis, vocal 
cord palsy, recurrent cellulitis, recurrent pancreatitis, pneumonia and osteomyelitis. 
Allergy/ADR history: nil.  
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Medications on admission Current medications 
Omeprazole 20 mg BD oral Omeprazole 20 mg BD oral 
Vit E 1000 unit mane oral Vit E 1000 unit mane oral 
Aspirin 100 mg nocte oral Aspirin 100 mg nocte oral 
Amitriptyline 25 mg nocte oral Amitriptyline 25 mg nocte oral 
Caltrate
®
 (calcium) I OD oral Caltrate® (calcium) I OD oral 
Centrum
®
 (multivitamin) I mane oral Centrum® (multivitamin) I mane oral 
Flunarizine 10 mg nocte oral Flunarizine 10 mg nocte oral 
Folic acid 1 mg mane oral Folic acid 1 mg mane oral 
Methotrexate 5 mg weekly Paracetamol 1 g QID oral PRN 
Melatonin 20 mg nocte oral Oxycodone IR 5 mg 6-hourly oral PRN 
Metoclopramide 10 mg TDS oral  Flucloxacilin 2 g QID IV 
Hydroxychloroquine 200 mg OD oral Normal saline 5 mL QID IV PRN 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) 160 mg 3x/week oral 
Heparin saline 5 mL QID IV PRN 
Meloxicam 7.5 mg BD oral Ondansetron 4-8 mg 8-hourly IV PRN 
 Ibuprofen 400 mg 8-hourly oral PRN 
 Melatonin 20 mg nocte oral 
 Metoclopramide 10 mg TDS oral  
 Hydroxychloroquine 200 mg OD oral 
 Resprim
®
 (trimethoprim + sulfamethoxazole) 
160 mg 3x/week oral 
She had been taking meloxicam 7.5 mg twice daily regularly, which was not charted 
during hospitalisation. The pharmacist recommended the doctor prescribe 
meloxicam. The recommendation was accepted. 
Case 11  
An 18-year-old presented for elective admission for revision of rhinoplasty with 
castocartilageal graft. Medical history: Binder syndrome (rhinoplasty 2010). Regular 
medication: nil. Allergy/ADR history: morphine (itch and rash). 
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Current medications Discharge medications 
Diclofenac 50 mg TDS oral Diclofenac 50 mg TDS oral for 5 days 
Augmentin Duo Forte
®
 (amoxycillin + 
clavulanic acid) BD oral 
Augmentin Duo Forte 
®
 (amoxycillin + 
clavulanic acid) BD oral for 5 days 
Gabapentin 200 mg TDS oral Gabapentin 200 mg TDS oral for 2 weeks 
Paracetamol 1 g QID oral Paracetamol 1 g QID oral for 5 days 
Tramadol IR 100 mg 4-hourly oral PRN Tramadol IR 100 mg 4-hourly oral PRN 
Ibuprofen 400 mg TDS oral  
Timentin
®
 (ticarcillin + clavulanic acid) 3 g 
QID IV 
 
Tramadol SR 100 mg BD oral  
Oxycodone IR 6-12 mg 2-hourly oral PRN  
Ondansetron 4 mg 6-hourly IV PRN  
Metoclopramide 10 mg 6-hourly IV PRN  
Normal saline 5 mL IV PRN  
Oxycodone SR 10 mg BD oral  
Movicol
®
 (macrogol laxative) 1-2 sachet 
OD oral PRN 
 
Loratadine 10 mg OD oral PRN  
During hospitalisation, she was prescribed ibuprofen and diclofenac. Due to 
duplication of non-steroidal anti-inflammatory drugs, the pharmacist recommended 
the doctor cease one of the orders. The recommendation was accepted and ibuprofen 
was ceased. 
Case 12  
A 15-year-old patient was admitted due to cystic fibrosis-associated pulmonary 
exacerbation. Medical history: asthma. Allergy/ADR history: erythromycin, 
cephalexin, penicillin (rash and itch). 
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Medications on admission  Current medications 
Creon
®
 (pancreatic enzyme) 10,000 variable 
dose oral PRN 
Creon
®
 (pancreatic enzyme) 10,000 variable 
dose oral PRN 
Salbutamol inh 1-2 puffs 4-6-hourly PRN Salbutamol inh 1-2 puffs 4-6-hourly PRN 
Hypertonic saline neb PRN Hypertonic saline neb PRN 
Rifabutin 150 mg OD oral Rifabutin 150 mg OD oral 
Clarithromycin 500 mg OD oral Clarithromycin 500 mg OD oral 
Omeprazole 20 mg OD oral Omeprazole 20 mg OD oral 
Benefiber
®
 (fibre) 1 tablespoon OD oral Benefiber® (fibre) 1 tablespoon OD oral 
Melatonin 40 mg nocte oral Melatonin 40 mg nocte oral 
Vit ABDECK
®
 (multivitamin) II OD oral Vit ABDECK® (multivitamin) II OD oral 
Caltrate
®
 (calcium) I OD oral Caltrate® (calcium) I OD oral 
Ondansetron 4 mg QID oral PRN Ondansetron 4 mg QID oral PRN 
Lactulose 20 mL BD oral Lactulose 20 mL BD oral 
 Normal saline 5 mL IV PRN 
 Heparin saline 5 mL IV PRN 
 Xylocaine Viscous 10 mL oral PRN 
 Ceftazidime 2 g TDS IV 
 Moxifloxacin 400 mg OD IV 
 Paracetamol 750 mg QID oral  
 Amikacin 800 mg OD IV 
During hospitalisation, she was prescribed Xylocaine Viscous 10 mL PRN without 
frequency. The pharmacist recommended the doctor specify the frequency: every two 
hours. The recommendation was accepted. 
Case 13 
A 16-year-old female was admitted due to perianal celulitis. A perianal abscess had 
been present for one week. Patient complained of pain but no fever. She also had a 
skin rash that had started 3 weeks ago. Medical history: Crohn’s disease, Sweet’s 
syndrome, and abscess left inguinal region. Allergy/ADR history: nil. 
Medications on admission Current medications 
Mesalazine 1 g BD oral Mesalazine 1 g BD oral 
Azathioprine 100 mg mane oral Azathioprine 100 mg mane oral 
Adalimumab 40 mg SC fortnightly Adalimumab 40 mg orally fortnightly 
Multivitamin I OD oral Metronidazole 120 mg 8-hourly IV 
 Ciprofloxacin 500 mg BD oral 
 Paracetamol 1 g QID oral PRN 
 Ibuprofen 400 mg TDS oral PRN 
 Normal saline flush 5-10 mL QID IV PRN 
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During hospitalisation, she was charted for adalimumab 40 mg per oral. In Australia, 
adalimumab is only available as a subcutaneous injection. The pharmacist 
recommended the doctor change the route of administration from oral to 
subcutaneous. The recommendation was accepted. 
Case 14  
A 13-year-old male was admitted due to exacerbation of asthma. He had a one-day 
history of breathing difficulty and it was not improved after taking 3-hourly 
Ventolin® (salbutamol). His comorbidity included obesity. Allergy/ADR history: nil. 
Medications on admission Current medications 
Seretide
®
 (salmeterol) inh 125/25 2 puffs 
BD  
Seretide
®
 (salmeterol) inh 125/25 2 puffs 
BD  
Ventolin
®
 (salbutamol) inh 1-2 puffs 3-
hourly PRN 
Ventolin
®
 (salbutamol) inh 1-2 puffs 3-
hourly PRN 
 Tamiflu 75 mg OD oral for 5 days 
 Prednisolone 60 mg OD oral for 5 days 
 Paracetamol 1 g QID oral PRN 
 Normal saline 5-10 mL IV PRN 
During hospitalisation, he was prescribed Tamiflu 75 mg once daily oral for 
influenza prophylaxis. The lab result showed that the patient was positive for 
influenza virus. According to hospital policy and the Australian Medicines 
Handbook, the treatment regimen is Tamiflu 75 mg BD oral for 5 days. The 
pharmacist recommended the doctor change the regimen from prophylaxis (once 
daily) to treatment (twice daily). The recommendation was accepted. 
GENERAL SURGICAL WARD 
Case 15  
A 7-year-10-month-old was admitted due to sigmoid sinus thrombosis and 
mastoidectomy. Medical history: myringoplasty. Regular medications: nil. 
Allergy/ADR history: nil. 
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Current medications 
Paracetamol 500 mg QID oral 
Clexane
®
 (enoxaparin) 40 mg BD SC 
Ceftriaxone 1.95 g OD IV 
Vancomycin 900 mg QID IV 
Oxycodone IR 2-4 mg 4-hourly oral PRN 
Heparinised saline 5 mL IV PRN 
Ondansetron 5.94 mg QID oral PRN 
Ibuprofen 390 mg TDS oral PRN 
During hospitalisation, she was prescribed ondansetron 5.94 mg four times daily. As 
the dose is not easy to measure, the pharmacist recommended the doctor change the 
dose to one that is measurable (6 mg QID). The recommendation was accepted. 
Case 16  
A 11-year-old was admitted for bilateral reimplantation of ureter (bilateral grade IV 
vesicoureteral reflux). Allergy/ADR history: nil. 
Medications on admission Current medications 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 8 mL nocte oral 
Oxybutynin patch 10 mg for 3.5 days 
Oxybutynin 5 mg BD oral Ibuprofen 300 mg TDS oral PRN 
 Oxycodone IR 3-7 mg 3-hourly oral PRN 
 Promethazine 7 mg TDS IV PRN 
 Loratadine 10 mg OD oral PRN 
 Pethidine 35 mg 4-hourly IV PRN 
 Cephazolin 540 mg TDS IV 
 Cotrimoxazole
®
 (trimethoprim + 
sulfamethoxazole) 70 mg nocte oral 
 Paracetamol 500 mg QID oral 
During hospitalisation, she was prescribed oxybutynin patch 10 mg for 3.5 days. 
According to the Paediatric Pharmacopoeia and the Australian Medicines 
Handbook, the dose is 3.9 g/day or 13 mg for 3.5 days. The pharmacist 
recommended the doctor increase the dose. The recommendation was accepted. 
Case 17  
An 8-year-10-month-old (weight: 25 kg) was admitted for removal of a left ovary 
teratoma. She had a 6-day history of altered bowel habits with vomiting and urinary 
obstruction. The mother noticed a suprapubic mass which improved on opening 
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bowel/passing urine. After investigation, she was planned for teratoma hysterectomy. 
The left ovary teratoma was removed 3 days after admission. Medical history: 
unremarkable. Regular medications: nil. Allergy/ADR history: nil. 
Current medications Discharged medications 
Oxybutynin ½ patch every third day Oxycodone IR 2.5 mg 2-hourly oral PRN 
Paracetamol 400 mg QID oral Clindamycin 150 mg TDS oral for 4 days 
Cephazolin 300 mg TDS IV  
Lincomycin 390 mg TDS IV  
Lactulose 20 ml BD oral PRN  
Oxycodone IR 2.5 mg 2-hourly oral PRN  
Buscopan 10 mg TDS oral PRN  
Loratadine 10 mg OD oral  
During hospitalisation, she was prescribed oxycodone immediate release 2.5 mg 2-
hourly PRN. According to the Paediatric Pharmacopoeia, the oxycodone 
immediate-release dose for children is 0.1-0.2 kg/dose 4- to 6-hourly. The pharmacist 
recommended the doctor reduce the frequency to 4- to 6-hourly. The 
recommendation was accepted. 
Case 18  
A 10-year-old (weight: 76.14 kg, height: 160 cm) was transferred from a regional 
health clinic with abdominal pain, vomiting and fever for 2 days. On admission to 
Princess Margaret Hospital, he was diagnosed with appendicitis. Medical history: 
asthma, obesity (more than 9th centile), and eczema. He was on Seretide® 
(salmeterol) inhaler 125/25 BD and Ventolin® (salbutamol) inhaler PRN. 
Allergy/ADR history: peanut (may cause anaphylaxis), penicillin and grasses (may 
cause rash). 
On Day 1, he underwent a laproscopic appendicectomy and the result confirmed a 
perforated appendix with gangreneous inflammation. The other relevant results 
included: 
Peritoneal fluid microsopy – Streptococcus milleri (sensitive to penicillin) 
Stool specimen microsocpy: mucus (not seen), leukocytes (not seen), erythrocytes 
(not seen), yeast cell (moderate number) 
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Stool specimen-culture: Clostridium difficile toxin (not detected), Clostridium 
difficile (not isolated), Salmonella (not isolated), Shigella (not isolated), 
Campylobacter (not isolated). 
He was treated with intravenous triple antibiotics post operatively. He developed 
nausea and vomiting and explosive diarrhoea, as well as contact dermatitis on his left 
hip/buttock. 
Medications on admission  
Seretide
®
 (salmeterol) inhaler 125/25 BD 
Ventolin
®
 (salbutamol) inhaler 2 puffs 4-hourly 
PRN 
 
Current medications 
Day 
1 2 3 4 5 6 7 8 
Seretide
®
 (salmeterol) inh 125/25 BD ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ventolin
®
 (salbutamol) inh 1-2 puffs 4-
6-hourly PRN ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ceftriaxone 1 g BD IV ✓ ✓ ✓ ✓ ✓ ✓ ✓ x 
Metronidaxole 500 mg TDS IV ✓ ✓ ✓ ✓ x x x x 
Gentamicin 160 mg OD IV ✓ ✓ ✓ ✓ ✓ ✓ x x 
Paracetamol 1 g QID oral ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Oxycodone IR 5 mg 4-hourly oral PRN x x ✓ ✓ ✓ ✓ ✓ ✓ 
Ibuprofen 400 mg TDS oral PRN ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Tramadol 50 mg 4-hourly oral PRN ✓ x ✓ ✓ ✓ ✓ ✓ ✓ 
Morphine PCA 1 mg/ml lock out 5 
minutes 
x ✓ x x x x x x 
Ondansetron 4 mg BD oral PRN ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Metoclopramide 5 mg BD oral PRN ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Nilstat
®
 (nystatin) drops 1 ml QID oral x x ✓ ✓ ✓ ✓ ✓ ✓ 
According to the hospital antibiotic protocol for prophylaxis and treatment of 
appendiceal surgery with ruptured and gangrenous appendix for patients with non-
anaphylactic penicillin allergy, is two intravenous antibiotics: ceftriaxone 50 mg/kg 
(max 1 g) 6-hourly plus metronidazole 12.5 mg/kg IV (max 500 mg) 8-hourly for up 
to 5 days. It is common practice to add a third antibiotic: gentamicin 7 mg/kg once 
daily IV (max 500 mg/day). 
During hospitalisation, he was prescribed gentamicin 160 mg IV once daily. The 
patient was obese (BMI: 29.7 kg/m
2
) and his ideal body weight was 35 kg. The 
gentamicin dose is calculated using ideal body weight = 7 mg/kg/day (max 500 
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mg/day) = 245 mg IV once daily. One wrong dose had been given before the 
pharmacist recommended the doctor increase the dose to 245 mg once daily. The 
recommendation was accepted. 
The patient was also prescribed paracetamol 1 g QID oral. The paracetamol dose 
should be calculated using ideal body weight = 15 mg/kg /dose 4-6 hourly = 525 mg 
4-6 hourly ≈ 500 mg 4-6 hourly oral. Three wrong doses had been given before the 
pharmacist recommended the doctor reduce the dose to 500 mg QID oral. The 
recommendation was accepted. 
Case 19  
A 17-year-old presented for elective admission due to spina bifida for Mitrofanoff 
procedure and bladder augmentation. Medical history: spinal dysraphism. 
Allergy/ADR history: latex and IV contrast. 
Medications on admission Current medications 
Vesicare
®
 (solifenacin) 10 mg OD oral Vesicare® (solifenacin) 5 mg OD oral 
 Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 160/800 mg I OD oral 
 Paracetamol 1 g QID oral 
 Metronidazole 400 mg TDS oral 
 Loperamide I TDS oral 
 Oxycodone IR 5 mg 4-hourly oral PRN 
 Ondansetron 4 mg TDS SL PRN 
 Mucomyst
®
 (acetylcysteine) 1-5 mL PRN 
via catheter 
 Normal saline 5-10 mL PRN via catheter 
During hospitalisation, she was prescribed prophylaxis Bactrim® 160/800 mg once 
daily. According to the Therapeutic Guidelines, the prophylaxis 
trimethoprim+sulfamethoxazole dose is 80/400 mg-160/800 mg once daily, and for 
treatment 80/400 mg-160/800 mg 12-hourly. The pharmacist recommended the 
doctor change the dose to 80/400 mg once daily as it was for prophylaxis and not for 
treatment. The recommendation was accepted. 
The patient was discharged on loperamide, paracetamol and metronidazole. 
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Case 20  
An 8-year-8-month-old (weight: 33 kg) was admitted for pain management 
secondary to urine extravasation into abdominal wall tissue. He presented with 
abdominal pain and left flank and scrotal swelling four days after cystoscopy, 
nephrostomy and JJ stent insertion. He also had decreased urine output over time. 
Medical history: Vater syndrome, urinary incontinence secondary to Vater syndrome, 
Tetralogy of Fallot, anorectal malformation (repaired and closed), enuresis, faecal 
encoperesis, and solitary kidney. Allergy/ADR history: brown tape. 
Medications on admission Current medications 
Oxybutynin patch 1.95 mg every 3.5 days Oxybutynin patch 1.95 mg every 3.5 days 
 Paracetamol 500 mg QID oral PRN 
 Ondansetron 4 mg QID IV PRN 
 Oxycodone IR 5 mg 4-hourly oral PRN 
 Bactrim
®
 (trimethoprim + sulfamethoxazole) 
120 mg BD oral 
 Cephazolin 400 mg TDS IV 
 Tazocin
®
 (piperacillin + tazobactam) 2.9 g BD 
IV 
 Amoxycillin 600 mg TDS oral 
 Loperamide 2 mg mane oral 
During hospitalisation, he was prescribed oral Bactrim 120 mg twice daily. As the 
available formulation of Bactrim tablets was 80/400 mg, the pharmacist 
recommended the doctor reduce the dose to Bactrim 80 mg/400 mg one tablet 12-
hourly or change to liquid formulation with the dose of 0.5 mL/kg/dose 12-hourly = 
15 mL 12-hourly. The recommendation was rejected. 
Discharge medications 
Loperamide 2 mg mane oral 
Oxybutynin patch (3.9 mg/24 h) ½ patch/3.5 days 
Bactrim
®
 (trimethoprim + sulfamethoxazole) 200 
mg/400 mg 120 mg BD oral 
The patient was discharged with a clinic appointment within 3 weeks of discharge. 
He also needed repeat cystoscopy within 6 weeks post-discharge for stenosed urine 
output and redo reimplantation. 
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Case 21  
A 14-year-old was admitted due to multiple traumas following a quad bike accident. 
Computed tomography scan of abdomen in another hospital revealed significant 
intraabdominal trauma. On admission, he underwent surgery for splenectomy, left 
nephrectomy and insertion of intercostal catheter for drainage of left pneumothorax. 
His recovery was complicated by persistent hypertension. Medical history: attention 
deficit hyperactivity disorder (previously on Ritalin). Regular medication: nil. 
Allergy/ADR history: nil. 
Current medications 
Discharge medications with follow-up 
appointment for adjusting 
antihypertensives 
Omeprazole 20 mg OD oral Lisinopril 20 mg mane oral 
Metoclopramide 10 mg QID oral Lisinopril 10 mg nocte oral 
Domperidone 10 mg QID oral Ondansetron wafer 4 mg PRN 
Ondansetron 4 mg QID oral Phenoxymethylpenicilin 250 mg tablet II 
mane for 10 days 
Promethazine 12.5 mg TDS oral  
Hydralazine 15 mg 4-hourly IV  
Coloxyl with senna I BD oral  
Lactulose 30 mL BD oral  
Lisinopril 20 mg OD oral  
Oxycodone IR 5-10 mg 4-hourly oral PRN  
Paracetamol 1 g QID oral  
Timentin
®
 (ticarcillin + clavulanic acid) 3 g 
QID IV 
 
Clonidine 150 mg TDS IV  
Heparinised saline 5 mL OD IV   
Ibuprofen 400 mg QID oral PRN  
During hospitalisation, she was prescribed four antiemetics: metoclopramide 10 mg 
QID oral, domperidone 10 mg QID oral, ondansetron 4 mg QID oral and 
promethazine 12.5 mg TDS oral. As the patient’s nausea was not too bad, the 
pharmacist recommended the doctor change antiemetics from regular to if required. 
The recommendation was accepted and three antiemetics (metoclopramide, 
ondansetron and promethazine) were changed from regular to if required. 
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Case 22  
A 14-year-old male (weight: 80 kg) was admitted due to epiblepharon correction 
(bilateral upper eye lid repositioning). Medical history: obstructive sleep apnoea, 
mild asthma, Prader Willi syndrome (morbid obesity and day time somnolence) and 
bilateral cryptorchidism. Allergy/ADR history: nil. 
Medications on admission Current medications 
Concerta
®
 (methylphenidate) 36 mg OD 
oral 
Concerta
®
 (methylphenidate) 36 mg OD 
oral 
 Cephalexin 500 mg 8-hourly oral 
 Ibuprofen 400 mg TDS oral 
During hospitalisation, he was prescribed cephalexin 500 mg 8-hourly oral. 
According to the Paediatric Pharmacopoeia, the cephalexin dose for children is 
6.25-12.5 mg/kg 6-hourly. The pharmacist recommended the doctor increase the 
frequency to 6-hourly in order to achieve therapeutic level. The recommendation was 
accepted. 
Case 23 
A 5-year-1-month-old male (weight: 22 kg) was admitted due to a penetrating right 
eye injury. He had a sore right eye and yellowish discharge. He was referred by his 
general practitioner. Medical history: finger laceration in 2011 with plastic surgery. 
Regular medication: nil. Allergy/ADR history: nil. 
Current medications 
Ciprofloxacin 200 mg BD IV 
Metoclopramide 3.4 mg OD IV 
Paracetamol 140 mg QID oral PRN 
Ibuprofen 220 mg TDS oral PRN 
During hospitalisation, he was prescribed ciprofloxacin 200 mg BD IV. As 
ciprofloxacin IV was restricted in the hospital, the pharmacist recommended the 
doctor change the dose form to oral. The recommendation was rejected. 
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HAEMATOLOGY-ONCOLOGY WARD 
Case 24  
A 14-year-old female with newly diagnosed osteogenic sarcoma (September 2011) 
was admitted to receive her first chemotherapy cycle. Medical history: insignificant. 
Regular medication: nil. Allergy/ADR history: nil  
Current medications 
Cisplatin 102 mg IV over 4 hours 
Doxorubicin 64 mg IV over 15 minutes 
Flucloxacillin 1.4 g QID IV for 4 doses 
Dexamethasone 8 mg OD IV pre-chemotherapy for 2 days 
Dexamethasone 4 mg BD IV 
Paracetamol 1 g QID oral PRN 
Oxycodone IR 5-10 mg 2-hourly oral PRN 
Ondansetron 4 mg TDS IV PRN 
Metoclopramide 10 mg TDS oral PRN 
As the patient was still nauseated, the pharmacist recommended the doctor add 
lorazepam 1-2 mg 6-hourly oral PRN as antiemetic post-chemotherapy. The 
recommendation was accepted. 
Case 25 
A 17-year-old patient was hospitalised due to pain and electrolyte imbalance post 
bone marrow transplant. Medical history: sickle cell disease (bone marrow transplant 
14 months ago). Allergy/ADR history: nil. 
Current medications Current medications 
Gabapentin 300 mg TDS oral Oxycodone IR 5-10 mg 3-6-hourly oral PRN 
Sirolimus 2.1 mg OD oral Levetiracetam 500 mg BD oral 
Prednisolone 25 mg mane oral Lorazepam 1 mg nocte oral 
Prednisolone 12.5 mg nocte oral Posaconazole 200 mg TDS IV 
Omeprazole 40 mg OD oral Resprim® (trimethoprim + sulfamethoxazole) 
II BD 3 days/week 
Potassium chloride III BD oral Penicillin V 250 mg BD oral 
Ondansetron 8 mg TDS oral PRN Magnesium aspartate 500 mg BD oral 
Nifedipine 10 mg OD oral PRN Cholecalciferol 5000 unit OD oral 
Loratadine 10 mg OD oral PRN Sodium bicarbonate II TDS oral 
Loperamide I-II oral PRN Amphotericin lozenge I QID oral 
Budesonide 9 mg OD oral Budesonide 9 mg OD oral 
Enalapril 10 mg OD oral Vancomycin 760 mg TDS IV 
Valganciclovir 900 mg OD oral  
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During hospitalisation, she was prescribed posaconazole three times daily IV. When 
the pharmacist looked at administration record on the medication chart, it seemed 
that the medicine was given twice daily. The pharmacist reminded the nurse to give it 
three times daily instead of twice daily. 
 
Case 26  
A 9-year-old male (weight 26.7 kg) was admitted due to febrile neutropenia. Medical 
history: acute lymphoblastic leukaemia/ALL (consolidation phase diagnosed 3 
months ago) and seizure. Allergy/ADR history: vancomycin (Redman’s syndrome), 
ceclor (rash and diarrhoea). 
Medications on admission Current medications 
Mercaptopurine 75 mg oral on Sunday Mercaptopurine 75 mg oral on Sunday 
Mercaptopurine 50 mg OD oral except 
Sunday 
Mercaptopurine 50 mg OD oral except 
Sunday 
Fluconazole 200 mg nocte oral Fluconazole 200 mg nocte oral 
Levetiracetam 3 mL BD oral Levetiracetam 3 mL BD oral 
Resprim I BD 3 days/week oral Resprim® (trimethoprim + 
sulfamethoxazole) I BD 3 days/week oral 
Dexamethasone 3.4 mg mane oral Dexamethasone 3.4 mg mane oral 
Dexamethasone 3.3 mg nocte oral Dexamethasone 3.3 mg nocte oral 
 Vancomycin 2.1 g IV infusion over 24 hours 
He was prescribed vancomycin 2.1 g IV infusion but the dose was high. According 
to the hospital policy for febrile neutropenia, the vancomycin dose is 60-80 
mg/kg/day via continuous infusion. The pharmacist recommended the doctor reduce 
the dose to 1.6 g IV infusion over 24 hours. The recommendation was accepted. 
Case 27 
A 17-year-old female post bone marrow transplant was admitted due to pain and 
electrolyte imbalance. Medical history: sickle cell disease (bone marrow transplant 
14 months ago). Allergy/ADR history: nil 
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Current medications Current medications 
Gabapentin 300 mg TDS oral Oxycodone IR 5-10 mg 3-6 hourly oral PRN 
Sirolimus 2.1 mg OD oral Levetiracetam 500 mg BD oral 
Prednisolone 25 mg mane oral Lorazepam 1 mg nocte oral 
Prednisolone 12.5 mg nocte oral Posaconazole 200 mg TDS oral 
Omeprazole 40 mg OD oral Resprim® (trimethoprim + sulfamethoxazole) 
II BD 3 days/week 
Potassium chloride III BD oral Penicillin V 250 mg BD oral 
Ondansetron 8 mg TDS oral PRN Magnesium aspartate 500 mg BD oral 
Nifedipine 10 mg OD oral PRN Cholecalciferol 5000 unit OD oral 
Loratadine 10 mg OD oral PRN Sodium bicarbonate II TDS oral 
Loperamide I-II oral PRN Amphotericin lozenge I QID oral 
Budesonide 9 mg OD oral Budesonide 9 mg OD oral 
Enalapril 10 mg OD oral Vancomycin 960 mg TDS IV 
Valganciclovir 900 mg OD oral  
During hospitalisation, budesonide was charted twice. The pharmacist recommended 
the doctor cease one of the orders. The recommendation was accepted.  
Patient passed away the following month due to intracerebral haemorrhage and multi 
organ failure. 
Case 28  
A 14-year-old female with newly diagnosed osteogenic sarcoma (September 2011) 
was admitted to receive her chemotherapy cycle. Medical history: insignificant. 
Regular medication: nil. Allergy/ADR history: nil  
Medications on admission Current medications 
Bactrim 800 mg BD oral Ranitidine 150 mg BD oral 
Fluconazole 200 mg nocte oral Bactrim 800 mg BD oral 
 Fluconazole 200 mg nocte oral 
 Metoclopramide 10 mg TDS oral PRN 
 Lorazepam 1-2 mg BD oral PRN 
 Coloxyl II BD oral PRN 
 Parachoc 20 mL OD oral PRN 
 Ondansetron 8 mg TDS oral PRN 
 Methotrexate 20 g IV over 4 hours 
During hospitalisation, the patient received ondansetron as an antiemetic but 
continued to be nauseous. The pharmacist recommended the doctor change 
ondansetron to tropisetron 5 mg daily IV because tropisetron may be more effective 
in adolescents. The recommendation was accepted. 
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Case 29 
A 10 year-old male with osteosarcoma was admitted to receive his chemotherapy. He 
was diagnosed with osteosarcoma last month. Medical history: insignificant. 
Allergy/ADR history: nil. 
Medications on admission Current medications 
Fluconazole 100 mg OD oral Fluconazole 100 mg OD oral 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) I BD 3 days/week oral 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) I BD 3 days/week oral 
 Ondansetron 6 mg TDS oral PRN 
 Diphenhydramine 3 mg QID IV PRN 
 Dexamethasone 2 mg BD oral 
 High-dose methotrexate 1 g IV over 4 hours 
 Calcium folinate 18 mg QID IV (24 hours 
after high-dose methotrexate) 
 Doxorubicin 46 mg IV over 15 minutes 
 Cisplatin 73 mg IV over 4 hours 
The pharmacist recommended the doctor prescribe ondansetron and dexamethasone 
at discharge to overcome nausea and vomiting post chemotherapy. The 
recommendation was accepted. 
Case 30  
A 10-year-4-month-old male with osteosarcoma was admitted to receive his 
chemotherapy. He was diagnosed with osteosarcoma last month. Medical history: 
insignificant. Allergy/ADR history: nil. 
Medications on admission Current medications 
Fluconazole 100 mg OD oral Fluconazole 100 mg OD oral 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) I BD 3 days/week oral 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) I BD 3 days/week oral 
 Ondansetron 5 mg TDS IV 
 Diphenhydramine 3 mg QID IV PRN 
 Dexamethasone 2 mg BD oral 
 High-dose methotrexate 1 g IV over 4 hours 
 Calcium folinate 18 mg QID IV (24 hours 
after high-dose methotrexate) 
 Doxorubicin 46 mg IV over 15 minutes 
 Cisplatin 73 mg IV over 4 hours 
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At discharge, Resprim® was not highlighted as one of the discharge medications. The 
pharmacist recommended the doctor prescribe Resprim® at discharge in addition to 
fluconazole as the patient’s regular medications for antibacterial and antifungal 
prophylaxis, respectively. The recommendation was accepted. 
Case 31  
A 9-year-3-month-old male with newly diagnosed metastatic neuroblastoma 
(diagnosed one month ago) was admitted due to febrile neutropenia. Medical history: 
eczema. Allergy/ADR history: vancomycin (Redman’s syndrome). 
Medications on admission Current medications 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) I BD oral 3x/week 
Resprim
®
 (trimethoprim + sulfamethoxazole) 
I BD oral 3x/week 
Fluconazole 100 mg nocte oral Fluconazole 100 mg nocte oral 
 Movicol
®
 (macrogol laxative) Junior I BD 
oral 
 Lactulose 10 mL TDS oral 
 Ondansetron 4 mg TDS oral 
 Lugol’s iodine 0.2 mL TDS oral 
 Oxycodone SR 15 mg BD oral 
 Vancomycin 620 mg TDS IV 
 Tobramycin 340 mg OD IV 
 Tazocin
®
 (piperacillin + tazobactam) 3 g QID 
IV 
 Metoclopramide 4-5 mg TDS oral PRN 
 Loratadine 10 mg OD oral PRN 
 Paracetamol 500 mg QID oral PRN 
 Promethazine 5 mg QID oral PRN 
 Oxycodone IR 5 mg 6-hourly oral PRN 
The consultant decided to prescribe oxycodone SR 15 mg once daily after the ward 
meeting. During hospitalisation, the resident prescribed this medicine twice daily 
instead of once daily. The pharmacist recommended the resident reduce the 
frequency of oxycodone SR. The recommendation was accepted. 
Case 32  
A 3-year-2-month-old female with ALL was admitted due to back pain for 
investigation and neutropenia. Medical history: insignificant. Allergy/ADR history: 
nil. 
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Current medications 
Ranitidine 37.5 mg BD oral 
Parachoc
®
 (liquid paraffin) 10 mL OD oral 
Ondansetron 2 mg TDS oral PRN 
Oxycodone IR 2 mg QID oral PRN 
Paracetamol 180 mg QID oral PRN 
Patient had been neutropenic for a month and the high-dose methotrexate schedule 
had been withheld twice. However, during the neutropenic period, the patient was 
not on Bactrim as antibacterial prophylaxis. The pharmacist recommended the doctor 
prescribe Bactrim 3.5 mL bd oral three times weekly. The recommendation was 
accepted. 
Case 33  
A 4-year-old female with ALL (maintenance phase) was admitted due to fever. 
Medical history: duplex left kidney. Allergy/ADR history: vancomycin (Redman’s 
syndrome), tegaderm (rash). 
Medications on admission Current medications 
Mercaptopurine 50 mg OD oral 6 
days/week 
Mercaptopurine 50 mg OD 6 days/week 
Mercaptopurine 75 mg OD oral 1 
day/week 
Mercaptopurine 75 mg OD oral 1 day/week 
Methotrexate 15 mg weekly oral Methotrexate 15 mg weekly oral 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL BD oral 3 
days/week 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL BD oral 3 
days/week 
 Tazocin
®
 (piperacillin + tazobactam) 1.9 g 
QID IV 
 Movicol
®
 (macrogol) ½ sachet OD oral 
PRN 
 Parachoc
®
 (liquid paraffin) 10 mL BD oral 
PRN 
During hospitalisation, methotrexate oral was prescribed without a specific day for 
administration. According to the parent and oral chemotherapy diary, the patient took 
her oral chemotherapy every Friday. The pharmacist recommended the doctor 
specify the day on the medication chart because Resprim® and methotrexate should 
not be given on the same due to additive antifolate activity. The recommendation 
was accepted. 
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Case 34  
 A 4-year-old female with ALL (maintenance phase) admitted due  to fever. Medical 
history: duplex left kidney. Allergy/ADR history: vancomycin (Redman’s 
syndrome), tegaderm (rash) 
Medications on admission Current medications 
Mercaptopurine 50 mg OD oral 6 
days/week 
Mercaptopurine 50 mg OD oral 6 days/week 
Mercaptopurine 75 mg OD oral 1 
day/week 
Mercaptopurine 75 mg OD oral 1 day/week 
Methotrexate 15 mg weekly oral Methotrexate 15 mg weekly oral 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL BD oral 3 
days/week 
Resprim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL BD oral 3 
days/week 
 Tazocin
®
 (piperacillin + tazobactam) 1.9 g 
QID IV 
 Movicol
®
 (macrogol) ½ sachet OD oral 
PRN 
 Parachoc
®
 (liquid paraffin) 10 mL BD oral 
PRN 
During hospitalisation, no antiemetic was charted. The pharmacist recommended 
lorazepam 0.5 mg OD oral and ondansetron 3 mg TDS oral as antiemetics. The 
recommendation was accepted. 
Case 35 
A 1-year-10-month-old male with posterior fossa tumor was admitted for 
investigation. Medical history: hyperextension of lumbar spine, left sided corticolis, 
mesenteric adenitis and developmental delay. Allergy/ADR history: nil. 
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Medications on admission Current medications 
Glycopyrrolate 250 mcg BD NG Glycopyrrolate 250 mcg BD NG 
Domperidone 5.5 mg TDS NG Domperidone 5.5 mg TDS NG 
Hydrocortisone 15 mg QID NG Hydrocortisone 15 mg QID NG 
Lactulose 10 mL mane NG Lactulose 10 mL mane NG 
Levetiracetam 130 mg BD NG Levetiracetam 130 mg BD NG 
Sodium chloride 1 mL BD NG Sodium chloride 1 mL BD NG 
 Filgrastim 75 mg OD SC 
 Omeprazole 15 mg BD NG 
 Paracetamol 210 mg QID IV 
 Vincristine 0.9 mg IV over 10 minutes 
 Carboplatin 230 mg IV over 1 hour 
 Cyclophosphamide 600 mg IV over 1 hour 
 Mesna 120 mg IV over 15 minutes 
During hospitalisation, he was prescribed omeprazole. The pharmacist recommended 
the doctor cease omeprazole as it can affect the metabolism of most antineoplastic 
drugs. The recommendation was accepted. 
Case 36 
A 6-year-4-month-old male patient with T-cell ALL post consolidation phase 
(diagnosed last year) was admitted to receive his chemotherapy. Medical history: 
deep vein thrombosis (last year), urticarial rash, asthma. Allergy/ADR history: 
vancomycin (Redman’s syndrome), platelet (swelling, itch), ambisome (swelling, 
itch). 
Medications on admission Current medications 
Fluconazole 100 mg nocte oral Fluconazole 100 mg nocte oral 
Bactrim 6 mL BD oral 3x/week Bactrim 6 mL BD oral 
Ventolin neb 2.5 mg BD  Ventolin neb 2.5 mg BD  
Thioguanine 40 mg 5 days/week Thioguanine 40 mg 5 days/week 
Thioguanine 60 mg 2 days/week Thioguanine 60 mg 2 days/week 
 Ondansetron 3 mg TDS oral PRN 
 Methotrexate 120 mg IV over 25 minutes 
 Vincristine 1.1 mg IV over 2 hours 
During hospitalisation, he was prescribed daily Bactrim as bacterial infection 
prophylaxis. The pharmacist recommended the doctor change the regimen to three 
times/week since it was the standard dosing for this patients based on his treatment 
protocol. 
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Case 37  
A 16-year-old female with newly diagnosed osteogenic sarcoma (diagnosed 9 
months ago) was admitted to receive her chemotherapy. Medical history: 
insignificant. Regular medication: nil. Allergy/ADR history: nil  
Medications on admission Current medications 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 800 mg BD oral 
Ranitidine 150 mg BD oral 
Fluconazole 200 mg nocte oral Bactrim® (trimethoprim + 
sulfamethoxazole) 800 mg BD oral 
 Fluconazole 200 mg nocte oral 
 Metoclopramide 10 mg TDS oral PRN 
 Lorazepam 1-2 mg BD oral PRN 
 Coloxyl
®
 (poloxamer) II BD oral PRN 
 Parachoc
®
 (liquid paraffin) 20 mL OD oral 
PRN 
 Cisplatin 102 mg IV over 4 hours 
 Doxorubicin 64 mg IV over 15 minutes 
 Ondansetron 8 mg TDS oral PRN 
During the ward round, the doctor mentioned that the patient’s vitamin D level was 
low. The pharmacist recommended the doctor prescribe cholecalciferol. The 
recommendation was accepted. 
Case 38  
A 7-month-old male with newly diagnosed acute myelogenous leukaemia was 
admitted to receive his chemotherapy. Medical history: nil. Allergy/ADR history: nil. 
Medications on admission Current medications 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 2.5 mL BD oral 
3x/week 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 2.5 mL BD oral 3x/week 
Fluconazole 50 mg nocte oral Fluconazole 50 mg nocte oral 
 Ranitidine 20 mg BD oral 
 Heparin saline 5 mL IV PRN 
 Codeine 8 mg 4-6 hourly oral PRN 
 Paracetamol 80 mg QID oral PRN 
 Ondansetron 1.5 mg 8-hourly oral PRN 
 Cytarabine 280 mg IV over 1 hour 
 Bortezomib 0.5 mg IV push 
 Mitozantrone 3.4 mg IV over 30 minutes 
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Five days post chemotherapy ondansetron was still charted even though the patient 
was not nauseated anymore. The pharmacist recommended the doctor change 
ondansetron to if required. The recommendation was accepted. 
Case 39  
A 3-year-3-month-old male with newly diagnosed neuroblastoma was admitted due 
to fever, diarrhoea and vomiting. Medical history: tonsillectomy and adenoids. 
Allergy/ADR history: vancomycin (Redman’s syndrome), etoposide (anaphylaxis), 
lincomycin (rash). 
Medications on admission Current medications 
Fluconazole 90 mg nocte oral Fluconazole 90 mg nocte oral 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL BD oral 3x/week 
Rectinol
®
 (anorectal) ointment topical TDS 
 Flucloxacillin 340 mg QID IV for 4 doses 
 Ondansetron 2 mg TDS oral PRN 
 Codeine 7-14 mg 4-hourly oral PRN 
During hospitalisation, he was not prescribed Bactrim® as antibacterial prophylaxis. 
The pharmacist recommended the doctor to chart Bactrim® as it is supportive 
medication for haematology-oncology patients. The recommendation was accepted. 
HAEMATOLOGY-ONCOLOGY PHARMACY (DURING DISPENSING)  
Case 40  
A 6-year-6-month-old male with ALL-maintenance phase was admitted to the 
oncology clinic to receive chemotherapy. Medical history: insignificant. 
Allergy/ADR history: nil.  
Medications on 
admission 
Medications during clinic 
admission Discharge medications 
Resprim ½ tablet BD oral 
3 days/week 
Vincristine 1.3 mg in 60 mL 
N/S IV infusion over 5-15 
minutes 
Resprim ½ tablet BD oral 3 
days/week 
Mercaptopurine 50 mg OD 
oral 3 days/week 
 Mercaptopurine 50 mg OD 
oral 3 days/week 
Mercaptopurine 75 mg OD 
oral 4 days/week 
 Mercaptopurine 75 mg OD 
oral 4 days/week 
Methotrexate 25 mg 
weekly oral 
 Methotrexate 35 mg weekly 
oral 
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He was prescribed oral methotrexate 35 mg weekly (100% dose) at discharge. 
According to protocol, the patient should receive 75% dose (25 mg weekly). The 
pharmacist recommended the doctor reduce the dose. The recommendation was 
accepted. 
Case 41  
A 4-year-10-month-old female with newly diagnosed stage 4 neuroblastoma was 
admitted to the oncology clinic to receive chemotherapy (cyclophosphamide). 
Medical history: insignificant. Allergy/ADR history: nil.  
Medications on 
admission 
Medications during clinic 
admission Discharge medications 
Fluconazole 90 mg nocte 
oral 
Cyclophosphamide 260 mg 
in 84 mL N/S IV infusion 
over 30 minutes 
Fluconazole 90 mg nocte oral 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL 
BD oral 3 days/week 
Topotecan 0.8 mg in 57 mL 
N/S IV infusion over 30 
minutes 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 5 mL BD 
oral 3 days/week 
 Dexamethasone 2 mg TDS 
IV 
Ondansetron 2 mg TDS oral 
PRN 
 Ondansetron 2 mg stat IV 
pre-chemotherapy 
 
When the pharmacist was about to make cyclophosphamide, she noticed that the total 
volume printed on the label (by another pharmacist) was 80 mL instead of 84 mL 
according to the parenteral cytotoxic medication order (yellow sheet). The 
manufacturing pharmacist recommended the other pharmacist change the label. 
Case 42  
A 6-year-4-month-old male patient with ALL (maintenance phase) was admitted to 
the oncology clinic to receive chemotherapy. Medical history: insignificant. 
Allergy/ADR history: nil. 
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Medications on 
admission 
Medications during clinic 
admission Discharge medications 
Fluconazole 100 mg nocte 
oral 
Methotrexate 12 mg 
intrathecal push 
Fluconazole 100 mg nocte oral 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 6 ml 
BD oral 3 days/week 
Methotrexate 80 mg in 60 
mL N/S IV infusion over 
10-15 minutes 
Bactrim
®
 (trimethoprim + 
sulfamethoxazole) 6 mL BD 
oral 3 days/week 
Valaciclovir 50 mg OD 
oral 
Vincristine 1.1 mg in 60 
mL N/S IV infusion over 5-
15 minutes 
Valaciclovir 50 mg OD oral 
Thioguanine I oral 5 
days/week 
 Thioguanine I oral 5 
days/week 
  Ondansetron 3 mg TDS oral  
At discharge he was prescribed mercaptopurine oral with 50% dose at discharge. 
According to protocol, the patient was assigned to receive full dose. The pharmacist 
recommended the doctor increase the dose. The recommendation was accepted. 
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Appendix 7: Data Collection Form (Snapshot Periods) 
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Appendix 8: Participant Information Sheet (Focus Group Discussion) 
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Appendix 9: Participant Consent Form (Focus Group Discussion) 
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Appendix 10: Approval Letter from Curtin University Human Ethics 
Committee (Focus Group Discussion) 
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Appendix 11: Questionnaire for Root Cause Analysis 
 
MEDICATION ERRORS IN CHILDREN:  
ROOT-CAUSE ANALYSIS USING SIMULATED SCENARIOS 
 
 
Root cause analysis (RCA) is a systematic and comprehensive approach used to 
uncover the root of problems. It can be used to identify the gaps in hospital systems 
and processes of care that may not be immediately apparent and which may have 
contributed to the incident or near-miss (medication error). Some paediatric studies 
have reported that medication errors occur in nearly 6% of all medication orders. 
Despite the available literature on medication errors, less is known about such errors 
in children than adults.  
INSTRUCTIONS 
Please indicate your answer to each of the following questions by ticking the 
appropriate box(es) or entering your response in the space provided. The 
questionnaire should take about 30 minutes to complete. Please return the completed 
questionnaire by 17 October 2014 in the sealed envelope provided and mail it to the 
return address. Please retain the information sheet for future reference. 
 
1. Please indicate your age by ticking the relevant box: 
 21 – 30 years 
 31 – 40 years 
 41 – 50 years 
 >50 years 
2. What is your gender? 
 Female 
 Male 
  
SECTION 1: GENERAL INFORMATION, QUALIFICATIONS AND PROFESSIONAL 
EXPERIENCES 
Code:  
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3. What is your role? 
 Doctor → Go to question 3a 
 Nurse → Go to question 3b 
 Pharmacist → Go to question 3c 
3a. As a doctor, what position do you currently hold in the hospital?  
 Intern 
 Resident 
 Registrar 
 Consultant/specialist 
3b. As a nurse, what position do you currently hold in the hospital? 
 Registered nurse/midwife 
 Clinical nurse/clinical midwives/clinical development nurse 
 Clinical nurse consultant/clinical midwifery consultant 
 Clinical nurse specialist/clinical midwifery specialist 
 Nurse practitioner 
 Clinical nurse manager/clinical midwifery manager 
 Director of nursing/director of midwifery 
3c. As a pharmacist, what position do you currently hold in the hospital? 
 Intern pharmacist 
 Registered pharmacist (medication safety, clinical trial, manufacturing, 
inpatient/outpatient dispensary) 
 Clinical pharmacist 
 Senior clinical pharmacist 
 Pharmacy Director/Deputy Director 
4. How long have you been working as a health professional?  
 < 5 years 
 5-10 years 
 11-20 years 
 >20 years 
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5. How long have you been working in the area of paediatrics? 
 < 5 years 
 5-10 years 
 11-20 years 
 >20 years 
 
The goal of RCA is to find out: What happened? Why did it happen? What can be 
done to prevent it from happening again?. In this section, five simulated case studies 
are presented in paediatric patients. Each case study is followed by questions on the 
clinical significance of medication errors and the potential contributing factors of the 
error. You will be given an opportunity to give your opinion on how such errors may 
be prevented in the future.  
Please indicate your answer to each of the following questions by ticking inside the 
appropriate box(es) or entering your response in the space provided. 
 
A 6-month-old baby (weight: 8 kg) was admitted with a diagnosis of congestive heart 
failure and pneumonia. The main complaints on admission were 10-day history of 
increased respiration, wheezing, general agitation, and persistent vomiting. She was 
born full-term and had a history of cardiac abnormalities. Past surgeries included 
open heart surgery for repair of the congenital heart defect and gastrotomy tube 
replacement. There was no history of allergies or ADR.  
A resident who started his rotation in Paediatrics a week earlier prescribed the 
following medications without consulting the registrar, as he did not want to bother 
the registrar during the hectic morning.  
Benzylpenicillin 120 mg (15 mg/kg) q8h IV 
Normal saline 3 mL IV PRN 
Paracetamol 120 mg (15 mg/kg) q6h IV 
SECTION 2: CASE STUDY 1 (INAPPROPRIATE DOSE) 
SECTION 2: SCENARIOS AND ROOT CAUSE ANALYSIS 
245 
Frusemide 8 mg (1-2 mg/kg) q12h IV 
The resident also wrote up digoxin as per the National Inpatient Medication Chart 
(below). 
 
The orders were sent back to the ward along with the medications. The nurse 
believed all the orders to be correct, as the doctor and the pharmacist had checked 
them. He then administered the digoxin to the patient, who within 2 hours began 
vomiting and went into respiratory distress, with arrhythmias ranging from 
bradycardia to ventricular fibrillation, and subsequently went into cardiac arrest. The 
registrar requested the patient be transferred to the Intensive Care Unit. However, 12 
hours after her cardiac arrest, she again exhibited evidence of chronic heart failure 
with respiratory distress. She had low systolic blood pressure (75 mmHg), decreased 
breath sounds, and oxygen saturation readings of 74-78%. She went into cardiac 
arrest, and was pronounced dead an hour later due to the inappropriate dose of 
digoxin. 
1. From the case above, how do you rate the clinical significance of the medication 
error involved? (Please tick the most appropriate rating) 
(Medication error is any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of health 
professionals or patient or carer.)  
 Unsure 
 No clinical significance 
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 Minor: trivial error not expected to significantly alter hospital stay or clinical 
outcome 
 Moderate: the error reduces the effectiveness of drug therapy, producing 
minor reductions in patient morbidity 
 Major: the error results in a very serious drug related problem 
 Life threatening 
2. Which health professional(s) do you think were responsible for the error? 
 ------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
3. Having reviewed the case what do you believe may be contributing factors? Please 
complete the table below. 
3a. Were specific 
patient issues a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe the patient factors that 
may have contributed. 
Description:  
 
 
 
 
 
3b. Was dismissal of 
policies/procedure 
or guidelines a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Patient misidentification 
 Error/omission in medication 
reconciliation 
 Clinical guidelines 
 Coordination of care 
 Medical record documentation 
 Level and frequency of 
monitoring of patient 
Description:  
 
 
 
 
 
247 
3c. Were there issues 
related to human 
resources in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Staff workload and inadequate 
staffing 
 Recruitment 
 Staff training and competencies  
 Staff supervision  
Description: 
 
 
 
 
 
 
 
3d. Was 
miscommunication 
a factor in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe the perceived deficiency. 
 Miscommunication between 
staff 
 Miscommunication between 
staff and patient and/or family 
Description: 
 
 
 
 
 
 
 
3e. Was the physical 
environment of the 
health service a 
factor in this event?  
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Noise 
 Lighting 
 Space 
Description: 
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3f. Was 
control/provision of 
medication an issue 
in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Medication storage 
 Labelling 
 Documentation of 
administration 
 Internal transfer of medications 
Description: 
 
 
 
 
 
3g. Is there any other 
factor(s) that could 
have contributed to 
this error? 
 Yes 
 No 
 Unsure 
If yes, describe the other factors that 
may have contributed. 
Description: 
 
 
 
 
 
4. What are your suggestions to prevent the recurrence of the error? 
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------ 
------------------------ 
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A 7-year-old girl, who had been hospitalised for 4 days following seizures, was 
scheduled to be discharged in the afternoon. The ward pharmacist checked her 
discharge medication orders (one of the medications was primidone 250 mg twice 
daily) and found everything was correct. The pharmacist then sent the medication 
orders to the Pharmacy Department during lunch time. A locum pharmacist received 
the orders and dispensed the medications. The medications in the dispensary are 
arranged alphabetically by generic name and not by therapeutic class so primidone 
was located next to prednisolone 25 mg. The lighting in the dispensary was poor, and 
the pharmacist’s vision was reduced due to a cracked lens that he had not been able 
to replace. He picked prednisolone and dispensed a 1-month supply with her other 
antiepileptic medications. The other pharmacists were having lunch, so the 
medication orders were sent back to the ward without following the dispensary 
checking procedure. The nurse on the ward received the medications and gave them 
to patient’s mother. The nurse knew that the ward pharmacists had checked the 
discharge medication orders in the morning, and thought it unnecessary to check 
them again. The discharge procedure requires that nurses double-check the 
medications against the prescriptions. 
Two weeks later the patient was admitted to the ED due to lethargy, blurred vision, 
increased urination, thirst and dry mouth. Physical examiniation and laboratory 
results revealed that this patient was hyperglycaemic. After assessment of her 
medical condition and medication history, it was revealed that her condition was 
caused by a dispensing error by taking prednisolone instead of primidone to treat her 
seizures. 
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1. From the case above, how do you rate the clinical significance of the medication 
error involved? (Please tick the most appropriate rating) 
(Medication error any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of health 
professionals or patient or carer.)  
 Unsure 
 No clinical significance 
 Minor: trivial error not expected to significantly alter hospital stay or clinical 
outcome 
 Moderate: the error reduces the effectiveness of drug therapy, producing 
minor reductions in patient morbidity 
 Major: the error results in a very serious drug related problem 
 Life threatening 
2. Which health professional(s) do you think were responsible for the error? 
 ------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
3. Having reviewed the case what do you believe may be contributing factors? Please 
complete the table below. 
3a. Were specific 
patient issues a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe the patient factors that 
may have contributed. 
Description:  
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3b. Was dismissal of 
policies/procedure 
or guidelines a 
factor in this event 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Patient misidentification 
 Error/omission in medication 
reconciliation 
 Clinical guidelines 
 Coordination of care 
 Medical record documentation 
 Level and frequency of 
monitoring of patient 
Description:  
 
 
 
3c. Were there issues 
related to human 
resources in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Staff workload and inadequate 
staffing 
 Recruitment 
 Staff training and competencies  
 Staff supervision  
Description: 
 
 
 
 
3d. Was 
miscommunication 
a factor in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe the perceived deficiency. 
 Miscommunication between 
staff 
 Miscommunication between 
staff and patient and/or family 
Description: 
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3e. Was the physical 
environment of the 
health service a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Noise 
 Lighting 
 Space 
Description: 
 
 
 
 
 
3f. Was 
control/provision of 
medication an issue 
in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Medication storage 
 Labeling 
 Documentation of 
administration 
 Internal transfer of medications 
Description: 
 
 
 
 
 
3g. Is there any other 
factor(s) that could 
have contributed to 
this error? 
 Yes 
 No 
 Unsure 
If yes, describe the other factors that 
may have contributed. 
Description: 
 
 
 
 
4. What are your suggestions to prevent the recurrence of the error? 
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------ 
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A 15-year-old male was taken to the ED of a suburban hospital on Friday afternoon. 
He complained of difficulty breathing and wheezing history of asthma, long-standing 
history of a seizure disorder. His medications on presentation included sodium 
valproate, lamotrigine, levetiracetam, Ventolin (salbutamol) inhaler and Seretide 
(fluticasone/salmeterol) inhaler. The ED physician conducted a physical examination 
that revealed signs of an acute exacerbaton of his asthma. Chest X-ray did not show 
any sign of pneumonia. The patient was transferred to the ward and prescribed oral 
prednisolone 25 mg once daily, which resulted in a gradual improvement in his 
respiratory symptoms. He was also prescribed Ventolin (salbutamol) inhaler 2 puffs 
PRN, and Seretide (fluticasone/salmeterol) inhaler 125/25 2 puffs BD.  
 
At 11 pm on Saturday, one of the nurses found him convulsing on the floor of his 
room and called the overnight medical team. The team responded quickly and gave 
SECTION 2: CASE STUDY 3 (DRUG OMISSION) 
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him intravenous medications (diazepam 15 mg IV every 15-30 minutes and 
phenytoin 250 mg IV for 3 doses within 6 hours) to stop his seizure. After his mental 
status improved, the patient complained of pain in his left shoulder and elbow. An X-
ray of these joints showed evidence of traumatic fracture from his fall. On Sunday 
morning, the medical team reviewed the medication chart and the medication 
administration record and found that one of his seizure medications, levetiracetam, 
had not been given during his admission. There was a note in the medication 
administration chart from the daytime nurse indicating that levetiracetam was out of 
stock but the nurse did not notify the doctors, the pharmacy or the night shift nurse 
during handover. On Friday afternoon before the patient was admitted, the ward 
pharmacist noticed that the levetiracetam in the imprest room was low in stock, but 
the pharmacist was busy and forgot to notify the pharmacy assistant to restock the 
levetiracetam. The patient experienced the episode of seizure because of drug 
omission of one of his anticonvulsant medications, levetiracetam. 
1. From the case above, how do you rate the clinical significance of the medication 
error involved? (Please tick the most appropriate rating) 
(Medication error is any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of health 
professionals or patient or carer.)  
 Unsure 
 No clinical significance 
 Minor: trivial error not expected to significantly alter hospital stay or clinical 
outcome 
 Moderate: the error reduces the effectiveness of drug therapy, producing 
minor reductions in patient morbidity 
 Major: the error results in a very serious drug related problem 
 Life threatening 
2. Which health professional(s) do you think were responsible for the error? 
 ------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
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3. Having reviewed the case what do you believe may be contributing factors? Please 
complete the table below. 
3a. Were specific 
patient issues a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe the patient factors that 
may have contributed. 
Description :  
 
 
 
 
 
 
3b. Was dismissal of 
policies/procedure 
or guidelines a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Patient misidentification 
 Error/omission in medication 
reconciliation 
 Clinical guidelines 
 Coordination of care 
 Medical record documentation 
 Level and frequency of 
monitoring of patient 
Description:  
 
 
 
 
 
 
3c. Were there issues 
related to human 
resources in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Staff workload and inadequate 
staffing 
 Recruitment 
 Staff training and competencies  
 Staff supervision  
Description: 
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3d. Was 
miscommunication 
a factor in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe the perceived deficiency. 
 Miscommunication between 
staff 
 Miscommunication between 
staff and patient and/or family 
Description: 
 
 
 
 
 
3e. Was the physical 
environment of the 
health service a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Noise 
 Lighting 
 Space 
Description: 
 
 
 
 
 
3f. Was 
control/provision of 
medication an issue 
in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Medication storage 
 Labeling 
 Documentation of 
administration 
 Internal transfer of medications 
Description: 
 
 
 
 
 
3g. Is there any other 
factor(s) that could 
have contributed to 
this error? 
 Yes 
 No 
 Unsure 
If yes, describe the other factors that 
may have contributed. 
Description: 
 
 
 
 
 
257 
4. What are your suggestions to prevent the recurrence of the error? 
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
A 4-year-old female (weight: 15 kg) was referred by her GP with abdominal pain, 
vomiting and fever for 2 days. She was accompanied by her mother whose English 
was very poor. The patient’s family had migrated to Australia 6 months ago. Medical 
history: insignificant. Regular medications: nil. She was diagnosed with appendicitis, 
and scheduled for surgery the following morning. She was precribed paracetamol 
225 mg QID oral PRN, ibuprofen 150 mg TDS oral PRN, oxycodone immediate-
release 2.5 mg QID oral PRN and ondansetron 2 mg TDS oral PRN. In the morning, 
the pharmacist went to the ward to take the patient’s medication history and noticed a 
referral letter from the GP stating that the patient was allergic to penicillin, but there 
was no description of the reaction. The pharmacist tried to speak to the patient’s 
mother, but this was impeded by the language barrier. The pharmacist then 
telephoned the GP for more details about the patient’s allergy, but had to leave a 
message with the receptionist for the GP to return the call. In the meantime, the 
pharmacist annotated the chart with ‘penicillin allergy’ and attached an ADR sticker.  
In the afternoon, the doctor prescribed prophylaxis antibiotic before surgery. 
According to the hospital’s antibiotic protocol, prophylaxis for appendectomy in a 
patient with non-anaphylactic penicillin allergy is two intravenous antibiotics: 
cephazolin 25 mg/kg and metronidazole 12.5 mg/kg. The doctor was aware that the 
SECTION 2: CASE STUDY 4 (MONITORING ERROR-DOCUMENTED ALLERGY) 
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patient was allergic to penicillin, but did not check further as he thought the reaction 
was not serious. He presumed it was safe to prescribe cephazolin because the 
pharmacist had reviewed the patient. The next morning, one hour before surgery, the 
nurse administered cephazolin and metronidazole. Around five minutes after the 
antibiotics were administered, the patient became agitated and developed a diffuse 
erythematous rash across her chest and back. She also developed difficulty breathing 
and an audible wheeze. The patient was transferred to the Intensive Care Unit and 
treated with intravenous corticosteroid, antihistamine and nebulised salbutamol. The 
patient’s condition improved and she returned to the ward 2 days later and the 
surgery was rescheduled. The monitoring error had occurred as the patient had 
received penicillin although there was documentation of penicillin allergy. 
1. From the case above, how do you rate the clinical significance of the medication 
error involved? (Please tick the most appropriate rating) 
(Medication error is any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of health 
professionals or patient or carer.)  
 Unsure 
 No clinical significance 
 Minor: trivial error not expected to significantly alter hospital stay or clinical 
outcome 
 Moderate: the error reduces the effectiveness of drug therapy, producing 
minor reductions in patient morbidity 
 Major: the error results in a very serious drug related problem 
 Life threatening 
 
2. Which health professional(s) do you think were responsible for the error? 
 ------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
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3. Having reviewed the case what do you believe may be contributing factors? Please 
complete the table below. 
3a. Were specific patient 
issues a factor in this 
event? 
 Yes 
 No 
 Unsure 
If yes, describe the patient factors that 
may have contributed. 
Description :  
 
 
 
 
 
 
 
3b. Was dismissal of 
policies/procedure 
or guidelines a factor 
in this event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Patient misidentification 
 Error/omission in medication 
reconciliation 
 Clinical guidelines 
 Coordination of care 
 Medical record documentation 
 Level and frequency of 
monitoring of patient 
Description:  
 
 
 
 
 
 
3c. Were there issues 
related to human 
resources in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Staff workload and inadequate 
staffing 
 Recruitment 
 Staff training and competencies  
 Staff supervision  
Description: 
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3d. Was 
miscommunication a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe the perceived deficiency. 
 Miscommunication between 
staff 
 Miscommunication between 
staff and patient and/or family 
Description: 
 
 
 
 
 
3e. Was the physical 
environment of the 
health service a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Noise 
 Lighting 
 Space 
Description: 
 
 
 
 
 
3f. Was 
control/provision of 
medication an issue 
in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Medication storage 
 Labeling 
 Documentation of 
administration 
 Internal transfer of medications 
Description: 
 
 
 
 
 
3g. Is there any other 
factor(s) that could 
have contributed to 
this error? 
 Yes 
 No 
 Unsure 
If yes, describe the other factors that 
may have contributed. 
Description: 
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4. What are your suggestions to prevent the recurrence of the error? 
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------ 
 
A 7-month-old male (weight: 8 kg) with newly diagnosed acute myeloid leukaemia 
(AML) was admitted to the oncology ward to receive his first chemotherapy. 
Medical history: premature birth and seizures. Allergy/ADR history: nil. Post 
chemotherapy, the patient remained in hospital due to his low neutrophil level and 
severe vomiting. His condition improved slowly. During hospitalisation, he was 
prescribed the following medications: 
Trimethoprim-sulphametoxazole (40 mg-200 mg/5 mL) 2.5 mL BD 3 times/week 
Fluconazole 50 mg nocte oral  
Clonidine 20 mcg/mL 0.6 mL TDS oral 
Clonazepam 2.5 mg BD oral 
Levetiracetam 100 mg/mL 2.4 mL BD oral 
Paracetamol 120 mg QID oral 
Codeine 7.5 mg QID oral PRN 
Oxycodone IR 1 mg 1-hourly oral PRN 
Ranitidine 15 mg/mL 1 mL BD oral 
Ondansetron 1 mg TDS oral 
Hydrocortisone 2 mg TDS oral 
SECTION 2: CASE STUDY 5 (TRANSCRIBING ERROR) 
262 
One day before the start of the Christmas break, the doctor transcribed all the 
medication orders onto a new medication chart. The doctor was fatigued from 
writing discharge prescriptions, and did not notice that she had not written up the 
fluconazole (antifungal prophylaxis) on the new chart. The next day, the nurse 
administered the medications as charted. The nurse was not familiar with the 
oncology ward, as she was deployed from another ward due to staff shortages over 
the holiday period. She was not aware that one medication had been left off, and the 
ward pharmacist was only available on call. Consequently, the patient did not receive 
the antifungal. On the fourth day of not receiving fluconazole, the patient developed 
febrile neutropenia. The patient was prescribed intavenous antibiotics and an 
antifungal. His stay in the hospital was prolonged because of a transcribing error. 
1. From the case above, how do you rate the clinical significance of the medication 
error involved? (Please tick the most appropriate rating) 
(Medication error is any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of health 
professionals or patient or carer.)  
 Unsure 
 No clinical significance 
 Minor: trivial error not expected to significantly alter hospital stay or clinical 
outcome 
 Moderate: the error reduces the effectiveness of drug therapy, producing 
minor reductions in patient morbidity 
 Major: the error results in a very serious drug related problem 
 Life threatening 
2. Which health professional(s) do you think were responsible for the error? 
 ------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
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3. Having reviewed the case what do you believe may be contributing factors? Please 
complete the table below. 
3a. Were specific patient 
issues a factor in this 
event? 
 Yes 
 No 
 Unsure 
If yes, describe the patient factors that 
may have contributed. 
Description :  
 
 
 
 
 
3b. Was dismissal of 
policies/procedure 
or guidelines a factor 
in this event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Patient misidentification 
 Error/omission in medication 
reconciliation 
 Clinical guidelines 
 Coordination of care 
 Medical record documentation 
 Level and frequency of 
monitoring of patient 
Description:  
 
 
 
 
 
 
3c. Were there issues 
related to human 
resources in this 
event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe how it appeared to contribute. 
 Staff workload and inadequate 
staffing 
 Recruitment 
 Staff training and competencies  
 Staff supervision  
Description: 
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3d. Was 
miscommunication a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, tick the appropriate box(es) AND 
describe the perceived deficiency. 
 Miscommunication between 
staff 
 Miscommunication between 
staff and patient and/or family 
Description: 
 
 
 
 
 
 
 
 
3e. Was the physical 
environment of the 
health service a 
factor in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Noise 
 Lighting 
 Space 
Description: 
 
 
 
 
 
 
 
 
3f. Was 
control/provision of 
medication an issue 
in this event? 
 Yes 
 No 
 Unsure 
If yes, describe how it appeared to 
contribute. 
 Medication storage 
 Labeling 
 Documentation of 
administration 
 Internal transfer of medications 
Description: 
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3g. Is there any other 
factor(s) that could 
have contributed to 
this error? 
 Yes 
 No 
 Unsure 
If yes, describe the other factors that 
may have contributed. 
Description: 
 
 
 
 
4. What are your suggestions to prevent the recurrence of the error? 
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------- 
 THANK YOU FOR YOUR PARTICIPATION 
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Appendix 12: Participant Information Sheet (Root Cause Analysis) 
 
267 
 
 
 
 
268 
Appendix 13: Participant Consent Form (Root Cause Analysis) 
 
 
 
